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Abstract
In this study, the expression of several sensory neuron specific/predominant genes, 
and the effects o f neurotrophic factors upon them were studied in embryonic, 
postnatal and adult mouse sensory neurons.
In the embryonic mouse, NGF/TrkA signalling was shown to be essential for the 
expression of mRNAs encoding substance P and the sodium channels N avi.8 and 
N avi.9 in DRG and trigeminal ganglia. Differential regulation of the two isoforms of 
calcitonin gene related peptide (CGRP) mRNA was apparent in the DRG with a 
requirement o f NGF/TrkA signalling for expression of a , but not p CGRP. This was 
not reflected in the trigeminal ganglia.
Postnatally, experiments revealed that NGF/TrkA signalling within the DRG and 
trigeminal ganglia is 1) essential for expression of SP, aCGRP, pCGRP, N avi.8, 
Navi .9 mRNAs, 2) possibly required for expression of the neuropeptide galanin and 
the capsaicin receptor vanilloid receptor 1 (VR1) mRNAs, 3) not required for 
pituitary adenylate cyclase-activating peptide (PACAP) mRNA. Conversely, within 
the nodose ganglia, expression of N avi.8 and N avi.9 mRNAs did not require 
NGF/TrkA signalling. No regulation of all aforementioned genes by neurotrophin-3 
(NT-3) was observed in trigeminal, nodose or dorsal root ganglia.
In the adult mouse, DRG cultures were utilised to study gene regulation by the 
neurotrophic factors NGF, artemin and macrophage stimulating protein (MSP). 
Expression o f SP, aCGRP, pCGRP, N avi.8, N avi.9 and VR1 mRNAs all showed a 
decrease following 96 hours in culture that was inhibited by presence of MSP 
(50ng/ml), NGF (lOng/ml) or artemin (lOng/ml). PACAP, galanin, damage induced 
neuronal endopeptidase (DINE) and activating transcription factor 3 (ATF3) mRNAs 
increased over time, but neurotrophic factors could impede such increases. No 
axotomy or neurotrophic factor-induced effects were observed for P2X3, N avi.6 or 
Navi .7 mRNAs. Interestingly the additional presence of leukaemia inhibitory factor 
(LIF) opposed NGF, MSP and artemin-induced effects on PCGRP, SP, VR1 and 
galanin mRNAs, whilst enhancing effects on PACAP and DINE transcripts.
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Chapter 1 
General Introduction
This thesis concerns aspects o f the development o f the peripheral nervous system 
(PNS) and the regulation of gene expression in developing and mature PNS neurons 
in response to secreted signalling proteins. The PNS works alongside the central 
nervous system (CNS) with the primary function of ensuring the organism’s ultimate 
survival by enabling it to react to the internal and external environment, in the most 
appropriate or advantageous way. Not surprisingly, the most complex organ system 
in a vertebrate is its nervous system. The ubiquitous presence o f the system 
throughout the body, the diversity of neuronal type, and the intricate, yet precise, 
connectivity all contributes to its complexity. The development, maintenance and 
function o f the nervous system is precisely regulated by a range o f endogenous 
signalling proteins produced from a wide variety of cells within the nervous system 
and other tissues, at different times and by a number of different routes.
In this introductory chapter I will briefly review salient aspects o f the development of 
the nervous system, with particular emphasis on the PNS, and especially sensory 
neurons of the PNS, as these neurons have been extensively studied in this thesis. I 
will provide an overview o f functional aspects o f sensory neurons, especially in 
relation to pain transmission and painful states, as this is o f particular relevance to 
the work presented in the thesis. I will provide an overview of the neurotrophic 
hypothesis and the roles o f secreted signalling proteins like neurotrophic factors in 
neuronal development. Finally, I will describe relevant aspects o f the developmental 
and functional significance o f the various families of neurotrophic factors and their 
receptors in the nervous system.
1.1. Origins of the vertebrate nervous system
The vertebrate nervous system is divided into the central nervous system, made up of 
the brain and spinal cord, and the peripheral nervous system, consisting of the cranial
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and spinal nerves, and the autonomic nervous system. The function o f the central 
nervous system (CNS) is to interpret incoming nervous activity, process it and 
generate a response whilst the peripheral nervous system (PNS) acts as the bridge for 
nerve signals between the brain and spinal cord and the peripheral receptors and 
actuators.
The embryological development o f the nervous system begins with a process known 
as “gastrulation” when the blastula, which is made of a single layer o f cells, is 
transformed into a three-layered structure, consisting of endoderm, mesoderm and 
ectoderm. Each o f these layers eventually gives rise to specific systems and tissues. 
The innermost layer, the endoderm, develops into the epithelial components of the 
respiratory system, digestive system, pancreas, liver, urinary bladder, thyroid, 
parathyroids, tonsils and middle ear. The middle layer, the mesoderm, gives rise to 
muscles, connective tissue and the vascular and urogenital systems. The outermost 
layer, the ectoderm, develops into the skin and nervous system. Following 
gastrulation, “neural induction” occurs. In this process, the dorsal aspect of the 
ectoderm thickens and becomes what is referred to as the “neural plate”. The lateral 
edges o f the plate rise up whilst the midline sinks, folding the plate centrally to 
produce a canyon, the neural fold. The edges of the fold then grow together and fuse 
to produce a hollow tube, the ‘neural tube’, which runs along the dorsal midline of 
the developing embryo. The neural tube gives rise to the CNS, its hollow becoming 
the ventricular system while the epithelial walls become the neuronal and glial 
tissues.
The PNS is derived from a collection of “neural crest” (NC) cells. The crest (NC) 
develops from outer margins of the ectodermal neural tube. The NC cells detach 
from the dorsal aspect o f the neural tube and migrate through the mesoderm, 
following well-defined pathways. Differences in their environment and the inbuilt 
“drivers” lead the NC cells to migrate to specific regions of the developing embryo. 
Here these cells differentiate into the various cell types o f the PNS and a variety of 
other cell types. Those NC cells that migrate just beneath the surface of the ectoderm
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form pigment cells (melanocytes) of the skin, while the sensory ganglia are formed 
from those that take an intermediate pathway. The autonomic sympathetic and 
parasympathetic ganglia form from those that take a more medial pathway. Schwann 
cells and satellite cells are also o f neural crest origin (Jessen and Mirsky, 1998), as 
are the chromaffin cells o f the adrenal medulla and many o f the skeletal and 
connective tissue components of the head. The neurons of certain sensory cranial 
ganglia differentiate from another group of cells, the “neurogenic placodes”, which 
develop as thickenings of the rostral ectoderm (D’Amico-Martel and Noden 1983; Le 
Douarin, 1986).
In its development, there are a number of influences. These include two important 
classes o f proteins, the bone morphogenetic proteins (BMPs) (originating in the 
epidermal ectoderm) and the sonic hedgehog (SHh) morphogen, which is expressed 
in the axial mesoderm and stimulates vascular growth (Reviewed in Le Douarin and 
Dupin, 2003; Kandel, principles o f neuroscience 4th edition). Genes such as Mash1 
and ngns are important in specification of sensory and autonomic neurons. 
Endothelin-3 (ET3) and its receptor, the endothelin-B receptor (EDNRB) regulate the 
development o f melanocytes, the enteric nervous system and posterior enteric nerve 
plexuses (Nataf et al., 1996; Reviewed in Le Douarin and Dupin, 2003).
1.2. Development of the peripheral nervous system
The PNS is divided into the somatic and autonomic nervous systems. Somatic 
nerves, are those which link the CNS to systems which are under direct conscious 
control (movement o f the limbs, eyes, etc.) and convey sensory information that is 
generally consciously perceived, while the autonomic nerves link the CNS with 
systems which run (largely) without conscious control (e.g. motor activity in the gut, 
accommodation in the eye, etc.). The autonomic nerves may travel with or separately 
from the somatic nerves. In the PNS, the nerve cell bodies are gathered into groups,
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known as ganglia, but may also be found within neural plexuses. The main ganglia of 
these systems will be discussed briefly here.
1.2.1. Sensory ganglia of the peripheral nervous system
Sensory ganglia are subdivided into cranial ganglia and dorsal root ganglia (DRG). 
The DRG are located on the dorsal roots of the spinal nerves. Their neurons 
innervate sensory receptors in the skin, muscles and joints of the trunk. Cranial 
sensory ganglia innervate sensory receptors predominantly in the head and are 
located on five o f the twelve pairs o f cranial nerves. The location o f the twelve 
cranial nerves is shown in figure 1.1 and the main function of each nerve outlined in 
table 1.1. Neurons o f the trigeminal ganglion are located on cranial nerve V and 
innervate the mechanoreceptors, thermoreceptors and nociceptors o f the face and oral 
and nasal cavities. The geniculate ganglion, located upon cranial nerve VII, 
innervates anterior taste buds of the tongue. The vestibular and cochlear ganglia 
(cranial nerve VIII) are required for hearing and balance, with neurons innervating 
the hair cells in the cochlea, utricle, saccule and semicircular canals. The petrosal 
ganglion (glossopharyngeal nerve, IX) innervates posterior taste buds of the tongue 
and pharynx. Neurons o f the jugular (superior vagal) and nodose (inferior vagal) 
ganglia, (vagus nerve X) innervate the oro-pharynx, oesophagus and the gut in the 
chest and abdomen and the respiratory tract. Finally the superior glossopharyngeal 
ganglion, located on nerve IX, provides somatic sensory innervation to the tongue 
and throat and is important in swallowing reflexes.
The only neural crest-derived cranial sensory neurons found in a CNS site are those 
of the trigeminal mesencephalic nucleus (TMN), which is found in the midbrain. 
These neurons innervate stretch receptors in the muscles of mastication.
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The Cranial Nerves
wr /  4p i t u i t a r y  g l a n d
m e s e n c e p h a l o n
I /
p o n s --------------- 3
e x t e n t marrow
Figure 1.1. The location o f the 12 cranial nerves. Taken from
http://www.becomehealthvnow.com/images/organs/nervous/cranial nerves.jpg
CRANIAL NERVE: MAJOR FUNCTIONS:
I Olfactory • Smell
II Optic • Vision
III Oculomotor • Eyelid and eyeball movement
IV Trochlear
• Innervates superior oblique
• Turns eye downward and 
laterally
V Trigeminal • Chewing• Face & mouth touch & pain
VI Abducens • Turns eye laterally
VII Facial
• Controls most facial expressions
• Secretion o f tears & saliva
• Taste
VIII Vestibulocochlear 
(auditory)
• Hearing
• Equilibrium sensation
IX Glossopharyngeal • Taste
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• Senses carotid blood pressure |
X Vagus
• Senses aortic blood pressure I
• Slows heart rate I
• Stimulates digestive organs I
• Taste I
XI Spinal Accessory
• Controls trapezius & I 
sternocleidomastoid I
• Controls swallowing movements |
[XII Hypoglossal • Controls tongue movements |
Table 1.1. The main functions o f each o f the 12 cranial nerves.
Adapted from: http://www.gwc.maricopa.edu/class/bio201/cn/cranial.htm
1.2.2. Autonomic ganglia
The autonomic nervous system is divided into the sympathetic, parasympathetic 
systems and the enteric nervous system within the gut. The sympathetic and 
parasympathetic nervous systems control the gut, exocrine secretions (e.g. saliva) 
and the heart rate, allowing the body to react to environmental surroundings and 
prepare for ‘fight or flight’. The sympathetic ganglia are further subdivided into 
paravertebral and prevertebral ganglia. Paravertebral ganglia include the superior 
cervical ganglion (SCG), which innervates the salivary, lacrimal and sweat glands; 
the middle cervical ganglion and the stellate ganglion, which innervates heart, lungs 
and bronchi; and the sympathetic chain ganglion, which also contributes to the 
innervation o f the thoracic viscera, and neurons of the entire paravertebral chain 
innervate vascular smooth muscle throughout the body. Prevertebral sympathetic 
ganglia include the (abdominal) coeliac ganglion, which innervates oesophagus and 
stomach; aorticorenal ganglia, innervating the kidneys; the superior mesenteric 
ganglion, which innervates the small intestine; and the inferior mesenteric ganglion, 
which innervates the colon and pelvic organs. Parasympathetic ganglia include the 
ciliary ganglion, pterygopalatine ganglion, submandibular ganglion and otic 
ganglion, which innervate lachrymal, salivary and other glands. In addition, the 
terminal ganglion o f the vagus nerve and the pelvic plexus innervate the gut and 
areas of the uro-genital tract. The enteric nervous system is comprised of networks of 
sensory, intemeurons, motor neurons and astrocyte glia, which are divided into two
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separate groups, the myenteric (Auerbach’s) plexus and the submucosal (Meissner’s) 
plexus. Together these neuronal plexuses regulate and co-ordinate gut movement and 
intestinal exocrine secretions.
1.3. Origins of the peripheral nervous system
Sensory neurons differentiate from progenitor cells that are derived from two 
sources: the neural crest or the neurogenic placodes. Placodes are discrete regions of 
thickened ectoderm in the head. Neural crest (NC) cells are generated as a result of 
cell-cell interaction between the epidermis and neural plate, and they separate and 
migrate from the epidermis as the neural plate fuses to form the neural tube (Selleck 
and Bronner-Fraser, 1995). NC cells migrate through the mesoderm to specific 
regions o f the embryo where they differentiate into their destined cell type.
Detailed mapping experiments have determined the origins o f avian cranial sensory 
ganglia. The neural crest gives rise to neurons of the dorsomedial part o f the 
trigeminal ganglion, trigeminal mesencephalic nucleus, jugular ganglion, superior 
glossopharyngeal ganglion and the dorsal root ganglia (DRG), whilst neurons of the 
venterolateral part o f the trigeminal ganglion and the vestibulo-cochlear, geniculate, 
petrosal and nodose ganglia are derived from neurogenic trigeminal, epibranchial and 
otic placodes (Noden, 1978; D ’Amico-Martel, 1982; D’Amico-Martel and Noden, 
1983; Le Douarin, 1986; Le Douarin, 2004).
In the autonomic nervous system, the neurons of the parasympathetic and 
sympathetic ganglia are derived from neural crest cells of the entire trunk, whilst 
enteric nervous system neurons are derived from three distinct areas of the neuronal 
crest: the vagal, the sacral and the truncal regions (Epstein et al., 1994; Serbedzija et 
al., 1991; Le Douarin et al., 2004).
All Schwann cells and satellite cells o f the PNS are derived exclusively from the 
neural crest (D ’Amico-Martel and Noden, 1983).
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Transplantation experiments have revealed that both presumptative placodal 
ectoderm and premigratory neural crest cells are not predestined to particular cell 
types. Environmental cues and other external factors along their migratory track are 
responsible for designating a cell to a particular neuronal fate (Vogel and Davies, 
1993; Le Douarin et al., 2004).
1.4. The Mature PNS
1.4.1. Anatomy of the PNS
Mature peripheral nerves are composed o f myelinated and unmyelinated nerve fibres. 
Fibres surrounded by myelin sheaths have a greatly enhanced speed o f transmission. 
In the PNS, the myelin sheath o f the nerve fibre is formed from the encircling 
compressed layers o f  Schwann cell plasma membrane (see figure 1.2). Breaks in the 
myelin sheath (the node o f  Ranvier -  see figure 1.2) occur at intervals. Unmyelinated 
fibres are surrounded solely by Schwann cell cytoplasm. In the CNS, 
oligodendrocytes, rather than Schwann cells produce myelin sheaths.
A peripheral nerve is composed o f many nerve fibres. A nerve fibre bundle is known 
as a fascicle and is invested with connective tissue called endoneurium. Several 
smaller bundles o f  nerve fibres are enclosed in a connective tissue sheath known as
call mambrane 
Schwann call 
containing my*
Schwann call
Figure 1.2. Schwann cells in the PNS 
Taken from.
http://www.unis.org/UNIScienceNet/Schwann cell 800.html 
htto://www.infodotinc.com/corpsman/32.htm
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the perineurium, and the collections o f these larger nerve fibre bundles that make up 
the complete nerve fibre are in turn invested with a loose vascular connective tissue 
sheath known as the epineurium. Each nerve fibre can be thought o f as living inside 
its own protective pipe, a structure essential to assist in the accurate re-growth in the 
event o f fibre damage (see figure 1.3 and 1.4).
Interfascicular
epineurium
Nerve
Perineurium Endoneurium
Schwann cell
Axon
Figure 1.3. Composition o f a peripheral nerve. Taken from: 
http://www.backpain-guide.com/Chapter Fig folders/ChlO Recover Folder/ChlO-
1 NerveStruct.html
9
Epineurium
Vessel
Perineurium
Myetm
Nucleus of 
Schwann ceil
Endoneurlum 
Erythrocyte
Perineurium
B_________________________________________
Figure 1.4. (A). The main structures that make up a transected peripheral nerve as would be depicted 
by light microscopy. (B) Closer detail o f the transected nerve as observed in electron microscopy.
Taken from ‘Neuroanatomy’ Fitzgerald, 1992
1.4.2. Microanatomy of the PNS - Classification of mature 
peripheral neurons
Peripheral nerves can be classified on the basis of their fibres (rather than their cell 
bodies) with regards to myelination, diameter and conduction velocity. The Gasser 
and Erlanger system is one o f the most commonly used classification systems. In this 
system, nerves are categorised as A, B and C, with the A fibres further subdivided 
into A a, Ap, Ay and A8. (See table 1.2.)
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Unmyelinated
axon
FIBRE
GROUP
INNERVATION MYELINATION MEAN
DIAMETER
(pM)
MEAN
CONDUCTION
VELOCITY
(M/S)
A a Primary muscle 
spindle motor to 
skeletal muscle
Yes 15 100
Ap Cutaneous touch and 
pressure afferents
Yes 8 50
1 ^ Motor to muscle 
spindle
Yes 6 20
A8 Mechanoreceptors,
thermoceptors
Yes <3 15
B Sympathetic
preganglionic
Yes 3
7C Mechanoreceptors,
nociceptors,
sympathetic
postganglionic
No 1
Table 1.2. Gasser and Erlonger classification o f fibres in peripheral nerves. 
Adapted from  Ferrante, Postoperative pain management, 1993.
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1.4.3. Sensory neurons
This thesis concerns regards sensory neurons, in particular those o f the nodose 
ganglia, trigeminal ganglia and DRG. For this reason, the different subtypes o f 
sensory neurons will be discussed, followed by details o f the composition o f the 
sensory ganglia o f interest, and information on the proportions and biochemical 
properties o f relevant neuronal subpopulations.
The large diameter A a  and Ap fibres carry impulses from low threshold mechano­
receptors (LTM), and the nerve and receptor combined are often referred to as the 
low threshold mechanoreceptors (LTMs). They respond to low threshold non- 
noxious stimuli such as touch, pressure and proprioception (which enable the brain to 
establish its overall position in space). Many subtypes o f A a  and p LTMs exist. 
These include, the slowly adapting type 1 nerves with Merkel end organs that 
respond to pressure (figure 1.5A); slowly adapting type II type with Ruffini ending 
(figure 1.5B); Gj and G2 hair follicles which respond to hair movement; and rapidly 
adapting neurons, which respond to tapping and whose end organ is the Meissner 
corpuscle (figure 1.5C).
A. Merkel ending B. Ruffini ending C. Meissner
Capsule
Figure 1.5. The receptor endings o f LTMS
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In general non-nociceptive afferents have a lower threshold o f stimulation than 
nociceptive. However, a subpopulation of the small diameter A8 mechanoreceptive 
fibres, known as the high-threshold mechanoreceptors (HTM), become more 
sensitive over time so that small amounts o f non-damaging, but sustained, pressure 
cause pain.
Nociceptors (nociceptive neurons and their associated receptors) comprise small 
diameter A8 fibres and unmyelinated C fibres. A8 fibres are often referred to as 
mechano-heat fibres as respond to mechanical and thermal stimulus. They have 
restricted and small receptive fields. They respond to severe deformation of the skin, 
such as pinching. The pain sensation(s) they produce is one of sharpness and 
stinging. Thermoreceptive neurons are A8 fibres that sense cold and C fibres that 
sense heat.
C fibres are unmyelinated and of small diameter. As a result they the slowest of the 
small fibres. They have a wider receptive field and respond to noxious, mechanical, 
thermal and chemical stimuli. As a result, they are often referred to as “C-polymodal 
nociceptors” (C-PMN). C-PMNs “sensitise”, developing a lower threshold of 
stimulation with repetitive stimulation: they can develop an ongoing, continuous 
discharge. It is these nerve fibres that are responsible for the more prolonged intense 
aching or dull pain that experienced with inflammation or following nerve damage.
Subtypes o f neurons within mature DRG. trigeminal ganglia and nodose ganglia
Sensory neurons can be classified at a gross histological level into two broad groups. 
The first group consists o f small diameter nociceptive or thermal A8 or C fibres and 
are often referred to as ‘dark neurons’. The second group is made up of large 
diameter, A a  or p, mechanoreceptive ‘light’ neurons. Large light neurons bind the 
neurofilament antibody, RT97 (Lawson et al., 1984), whereas the majority of small, 
dark neurons can bind and transport the isolectin B4 (IB4) (Silvermann et al., 1988;
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Kitchener et al, 1993; Wang et al., 1994, 1998). These two markers can bind the 
majority (approximately 80%) of DRG neurons.
Neurons can also be categorised into smaller subpopulations based upon expression 
of neurotrophin receptors, (the receptor tyrosine kinase of the,= Trk family, and 
common receptor p75) and other sensory neuron specific genes. For example, in 
adult rats, approximately 40% of DRG neurons express the nerve growth factor 
(NGF) receptor tyrosine kinase TrkA (Verge et al., 1989, 1992). O f these, the 
majority (approximately 92%) co-express the neuropeptides “calcitonin gene related 
peptide” (CGRP) and substance P (SP), but not the genes somatostatin or thiamine 
monophosphatase (Verge et al., 1989; Averill et al., 1995). Only 18% of these TrkA- 
expressing neurons bind the marker o f large neurons, the neurofilament protein RT97 
(Averill et al., 1995). This proportion of TrkA expressing DRG neurons are, 
therefore, termed small diameter “peptidergic” neurons. A proportion o f adult rat 
DRG neurons do not express TrkA and are not labelled by neurofilament. These 
neurons comprise approximately 30% of DRG neurons and are unmyelinated small 
diameter neurons that also bind the isolectin B4 (Molliver et al., 1995; Averill et al.,
1995).
O f the other neurotrophin receptors, TrkC is expressed almost exclusively by large 
diameter sensory afferents o f the DRG (Mu et al., 1993; McMahon et al., 1994).
The low affinity common neurotrophin receptor, p75, is not expressed independently 
o f Trks and is found co-localised on the majority of TrkA and TrkB expressing 
neurons, but only on approximately 50% of TrkC neurons (Wright and Snider, 1995).
The “Sensory Neuron Specific” (SNS) “Tetrodotoxin Resistant” (TTX-r) sodium 
channels, N av i.8 and N avi.9, respectively, have specific expression profiles within 
adult rat DRG neurons. N avi.8 is found both in small diameter non-myelinated 
sensory neurons (C-fibres) and in 10% of large neurons with myelinated axons 
corresponding to A6 nociceptors (Sangameswaren et al., 1996; Amaya et al., 2000). 
The second TTX-R alpha subunit, N avi.9 (NaN/SNS2) is predominantly located in 
small diameter sensory neurons (Black et al., 1996; Dib-Hajj et al., 1998; Tate et al.,
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1998; reviewed in Lai et al, 2004), expressed specifically within C neurons, and is 
not detectable in neurons with myelinated axons (Amaya et al., 2000; Fang et al., 
2002).
In rat DRG, the capsaicin receptor, Vanilloid receptor 1 (VR1) is expressed by the 
TrkA- positive, peptidergic neurons, and the non-peptidergic IB-4 reactive 
population (Mantyh and Hunt, 1998; Michael and Priestly 1999; Guo et al., 1999). In 
contrast, in the mouse, only a small (2-3%) population of DRG neurons are both IB4 
and VR1 positive (Zwick et al., 2002), the majority of functional VR1 receptors 
being expressed by the TrkA expressing peptidergic neurons. This observation 
highlights the important fact that species differences occasionally occur.
In the adult rat, only 2% of intact DRG neurons are galanin mRNA positive (Xu et 
al., 1996; Ma et al., 1999). These neurons are predominantly small/medium sized 
peptidergic neurons and also express CGRP. However some expression in large size 
neurons has also been observed (Xu et al., 2000; Ma et al., 1999).
The trigeminal ganglia, which convey sensory information from the facial area have 
many similarities with DRG. It contains similar subpopulations of neurons and 
shows similar patterns o f expression of neurotrophin receptors and other sensory 
neuron specific genes (Matsumoto et al., 2001). The nodose ganglia, which are 
important for transmission o f cardiovascular, respiratory and gastrointestinal signals, 
shows some clear differences from DRG and trigeminal ganglia (Zhou et al., 1997). 
The nodose ganglia are derived from the neurogenic placode, and during 
development the neurons are reliant upon neurotrophic factors that differ from those 
o f the NC-derived DRG and trigeminal ganglia. Only approximately 5% of the 
nodose neurons express TrkA and 10% TrkC (Verge et al., 1992; Zhou and Helke
1996). Nevertheless, the mean density o f expression of p75 has been shown to be the 
same or higher than that o f the DRG or trigeminal ganglia (Verge et al., 1992). 
Expression o f other genes also differs. In the nodose ganglion, TrkB, rather than 
TrkA is co-localised withVRl mRNA (Michael and Priestly, 1999). This co­
expression o f VR1 and TrkB reflects the observation that BDNF, but not NGF, can
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regulate the capsaicin sensitivity of cultured adult rat nodose neurons (Winter 1998). 
Galanin immunoreactivity is detected in the nodose ganglia, but in contrast to 
trigeminal ganglia and DRG, it is expressed predominantly in large diameter neurons 
(Calingasan and Ritter, 1992). Expression of other genes in the rodent, including 
CGRP and SP mRNA are seen in similar populations and proportions o f nodose 
neurons to that o f the DRG and trigeminal (Helke and Hill 1988; Czyzyk-Krzeska et 
al., 1992; Stemini and Anderson, 1991).
1.4.4. Sensory neurons, insult, injury and the inflammatory 
response
Because this thesis focuses on sensory neurons of the PNS a brief overview of the 
involvement o f these neurons in pain states and diseases affecting these neurons in 
the adult is relevant.
1.4.4.1. Inflammation
Inflammation is characterised by four features “calor, rubor, dolor and tumor” -  heat, 
redness, pain and swelling. Heat and redness are due to capillary dilatation; swelling 
is due to extravasation o f protein-rich oedema fluid from the capillaries; pain occurs 
because o f swelling (stretching of tissues) and the presence of a host o f inflammatory 
mediators including prostaglandins. The inflammatory response has hallmarks 
similar to the “triple response” in which tissue injured by, for instance a scratch 
demonstrates the three features redness, flare and swelling.
The inflammatory stimulus is first sensed by polymodal nociceptors (C-fibres) in the 
deep epidermis. These receptors (Figure 1.6) subsequently transmit messages 
through to the CNS, and also stimulate the production of the neuropeptide Substance 
P (SP) from sensory nerves. SP is able bind to receptors on arterioles allowing 
arterial dilation and the characteristic ‘flare response’. SP is also able to bind to mast 
cells, stimulating the release of histamine and 5- hydroxytryptamine (5HT), which
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alters the permeability o f  capillaries, producing accumulation o f tissue fluid and the 
‘wheal response’.
Figure 1.6. Free epidermal nerve endings found in the deep layers o f  the epidermis
The release o f  SP in response to peripheral inflammation is well characterised 
(Duggan et al., 1987; Oku et al., 1987; Schaible et al., 1990), and is required for the 
development o f  the whole pattern o f inflammation and for the painful sensations with 
which it is accompanied. Intrathecal administration o f SP results in hyperalgesia 
(Moochhala et al., 1984). The application o f antagonists to the SP receptor, 
neurokinin 1 (NKj), results in a loss in the increased excitability in response to 
noxious thermal stimulation and also in a loss o f ‘wind-up’, (an increase in the 
response following repetitive stimuli o f equivalent strength so that the response to 
the last o f  the stimuli is much greater than that to the first stimulus, despite being the 
same strength) (Thompson et al., 1995; Radhakrishnan et al., 1998). Furthermore, 
ablation o f  SP neurons results in the loss o f response to capsaicin and a loss o f both 
thermal hyperalgesia and o f  mechanical allodynia1 which are normally associated 
with inflam m atory pain (Nichols et al., 1999; Khasabov et al., 2002).
In addition to the increased expression o f SP that follows inflammatory stimuli, 
alterations in other neuropeptides and sensory neuron specific genes are observed. 
These changes are also thought to be responsible for the subsequent inflammatory 
pain. For instance, an increase in the potent vasodilator “Calcitonin Gene Related
1 Allodynia refers to the feeling of pain from stimuli that are not normally painful e.g. touch of 
feather.
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Peptide” (CGRP) is also observed. CGRP potentiates the release o f SP (a positive 
feedback), thus enhancing the transmission of nociceptive information (Oku et al., 
1987; Brain et al., 1989). CGRP has also been shown to potentiate oedema formation 
when co-injected with histamine, a potent mediator o f vascular permeability that is 
released in the triple response. (Brain et al., 1992). Additionally, CGRP can affect 
the immune response to inflammation at the cellular level, where it can directly and 
indirectly affect production of chemotactic compounds from macrophages e.g. 
cytokines2. The presence of CGRP attenuates release o f the cytokine interleukin-1 
(IL-1), but produces an increase in production of the cytokine, interleukin- 10 (IL- 
10) (Torii et al., 1997). CGRP can also indirectly enhance lipopolysaccharide (LPS)3 
(also known as endotoxin) induced release of interleukin-6 (IL-6) from macrophages 
through induction o f nitric oxide (NO) (Tang et al., 1999).
Transcripts o f the neuropeptide, “Pituitary Adenylate Cyclase-Activating 
Polypeptide (PACAP) are increased in small-medium neurons following 
inflammatory stimulation, suggesting a role in inflammation and the associated 
inflammatory pain (Zhang et al., 1998; Jongsma-Wallin et al., 2003). Furthermore, 
Mabuchi et al., (Mabuchi et al., 2004) showed that PACAP*7' mice do not exhibit 
inflammatory pain induced by the injection of a carrageenan (a polysaccharide 
extracted from red seaweed).
An increased expression o f the capsaicin receptor, VR1, is also observed in the DRG 
following application o f the local irritant, Freund’s Complete Adjuvant (CFA) 
(Amaya et al., 2003; Ru-Rong et al., 2002). This increase is thought to play a role in 
the generation o f thermal hyperalgesia because mice lacking VR1 do not show this 
hypersensitivity effect following induction of inflammation (Caterina et al, 2000).
Following carrageenan injection (Colpaert, 1987; Butler et al., 1992; Ji et al., 1995) 
or administration o f CFA (Calza et al., 1998), decreases in both protein and mRNA
2 Cytokines are proteins produced by cells. They can effect cellular interaction/communication and 
can also affect cellular behaviour
3 Lipopolysaccharide (LPS) or endotoxins are structural components o f gram-negative bacteria,
mainly released when the bacteria are lysed. Endotoxins are pyrogens producing fever and can
activate inflam m ation
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expression o f the neuropeptide galanin are observed in the DRG, despite an increase 
in galanin immunoreactivity in the dorsal horn (Ji et al., 1995). Calza et al., (Calza et 
al., 1998) further monitored its expression following the onset of inflammation and 
found that galanin mRNA and peptide levels recovered to normal 5 days post­
injection. Interestingly, 21 days post-injection a significant increase from basal level 
was observed. It is thought that this increase in galanin expression could reflect 
neuronal damage, as discussed (above), and that the pain felt might therefore change 
from inflammatory to neuropathic pain (Calza et al. 1998).
One o f the adenosine triphosphate (ATP) receptors, the purigenic receptor P2X3, is 
also affected by inflammation. A low dose of ATP injected into rats skin previously 
inflamed with carrageenan produces an enhanced and greater pain response than in 
normal, untreated rats (Hamilton et al., 2001). This suggests that P2X receptors are 
sensitised by inflammation, and that the enhanced sensitivity may be due to 
mediators released as a result o f inflammatory stimulation. SP and bradykinin, which 
are both known to mediate pain perception, have both been shown to potentiate 
P2X3 and P2X2/3 heteromeric ion channels through phosphorylation. This suggests 
that such an action can subsequently sensitise nociceptors, producing an enhanced 
response to ATP (Paukert et al., 2001). CFA-induced inflammation also produces an 
increase in P2X3 protein in small-medium neurons of the rat DRG (Xu and Huang, 
2002).
Alterations in sodium channel expression also occur following inflammation. 
Carrageenan injection into adult rats leads to increased expression of two of the 
“Tetrodotoxin sensitive” (TTX-S) sodium channels N avi.3 and N avi.7 in DRG, 
producing an increase in TTX-S currents (Black et al., 2004). It was proposed that 
this increased sodium conductance contributes to the neuronal hyper-excitability and 
onset o f inflammatory pain. Additionally, the finding that application o f the “Cyclo- 
Oxygenase (COX) inhibitors, ibuprofen or NS-398 (a COX-2 specific inhibitor), 
prior to CFA injection, prevents the inflammation-induced up-regulation in N avi.7 
protein observed in adult rat DRG (Gould et al., 2004). These observations suggest 
that components o f the COX pathway are involved in the up-regulation of N avi.7.
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Alterations in the TTX-resistant (TTX-R) sodium channel N avi.8 are also observed 
in inflammation. Within 48 hours of CFA-induced inflammation in adult rats, there is 
a dramatic increase in N avi.8 protein in DRG neurons (Gould et al., 1998; Tanaka et 
al., 1998; Gould et al., 2004; Coggeshall et al., 2004). In small neurons, the 
inflammation-induced enhanced level o f N avi.8 persists and remains unchanged, 
while, as allodynia subsides, the expression of N avi.8 in the large neurons falls back 
to baseline (Gould et al., 2004). It was therefore proposed that the increased 
expression of Navi .8 in large neurons is responsible for the hyperalgesia observed in 
such inflammatory states, whilst the persistent up-regulation in small diameter 
neurons produces a prolonged increased sensitivity that could provide a protective 
role, to ensure the organism’s vigilance (and self protection) during healing (Gould et 
al., 2004). Further evidence o f Navi .8’s role in inflammatory pain has been provided 
by the use o f antisense oligonucleotides to attenuate Navi. 8 expression. Injection of 
these “anti-Navl.8” oligonucleotides into rats prevented PGE2-induced hyperalgesia 
and increased the threshold to mechanical nociceptive stimuli (Khasa et al., 1998).
1.4.4.2. Nerve injury and neuropathic pain
Following peripheral nerve damage or crush, in a process named Wallerian 
degeneration, axons degenerate distal to the lesion. During the first 48 hours 
following injury, lysosomal activity of Schwann cells breaks the myelin and axons 
into ‘ellipsoids’. Monocytes enter the nerve from the bloodstream through breaks in 
the endoneurium and begin to clear the debris. The end result o f the degenerative 
process is a shrunken nerve, but with intact endoneurium and a core o f functioning 
Schwann cells.
Unlike the neuronal damage in the CNS, neuronal regeneration in the PNS can occur, 
provided the cell body remains intact. Following a clean cut of a nerve fibre (or 
bundle) the process o f regeneration can begin within hours: the “clean up” process is 
localised and relatively quick. However, in crush or tear injuries, degeneration of
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axons is more widespread and so regeneration is delayed. The process o f 
regeneration begins with axonal sprouting from the distal nerve fibre stump, and the 
contact o f these sprouts with the local Schwann cells. Successful regeneration relies 
on this contact, without which regenerating axons become trapped. In this case, 
continued growth leads to the development of a tangled mass and the formation of a 
neuroma. Neuromas are frequently painful.
Successful axonal sproutings form growth cones, which produce fine “filopodia”
(fine precursors to the fibre) that can extend along the length o f the Schwann cell. 
They anchor temporarily to the basement membrane. Actin filaments within the 
filopodia are now able to attach to basement membrane receptors, and once firmly 
bound act as a platform for onward migration of the growth cone. Schwann cells then 
now begin myelination of the newly regenerating nerve. Complete regeneration is 
likely, provided the proximal and distal ends are aligned correctly, and the 
appropriate endoneurial tubes have been entered: sensory axons have the ability to 
regenerate along former motor tubes and vice versa. For this reason, injuries in which 
the endoneurium is preserved (for example a nerve crush), are likely to recover better 
than when a nerve is cut.
Nerve injury (crush or transection) may lead to the onset o f neuropathic pain. This 
has been found to be associated with alterations in the expression o f neuropeptides 
and other sensory neuron specific genes. However, these changes often differ from 
those observed in inflammation, and may serve to protect against or to contribute 
towards the onset o f neuropathic pain. Two genes, normally expressed at barely 
detectable levels in sensory neurons, are dramatically up-regulated following 
peripheral nerve injury. These are “Activating Transcription Factor-3” (ATF-3) and 
“Damage Induced Neuronal Endopeptidase” (DINE). ATF3 is markedly up-regulated 
following axotomy. In rats subject to sciatic nerve transection, 82% of L4 DRG 
neurons become immunoreactive for ATF3: control rats show no immunoreactivity 
(Averill et al., 2004). In a pattern similar to the neuropeptide galanin, DINE is also
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up-regulated in specifically IB4 negative and partly TrkA positive neurons (Kato et 
al., 2002).
In contrast to inflammation, peripheral nerve injury results in a decrease in the 
neuropeptides SP and CGRP. Transection of the rat sciatic nerve results in down- 
regulation o f SP peptide (Nielsch et al., 1987; Zhang et al., 1995; Sterne et al., 1998) 
and a decrease in expression of both iso forms of CGRP mRNA in DRG (Noguchi et 
al., 1990; Mulder et al., 1997; Sterne et al., 1998; Shi et al., 2001; Shadiack et al.,
2001). This has been proposed to result from a loss of retrograde transport of 
neurotrophic factors. This down-regulation o f SP and CGRP is not observed within 
the nodose ganglion following axotomy of the rat cervical vagus nerve (Helke et al., 
1991), suggesting that expression of these genes in this neuronal population is 
regulated in a different way from that in sensory neurons of the DRG.
PACAP is up-regulated in medium to large DRG neurons following either peripheral 
axotomy (Zhang et al., 1995; Zhang et al., 1996; Jongsma-Wallin et al., 2001; 
Armstrong et al., 2003) or nerve compression (Pettersson et al., 2004) in the rat. 
Mabuchi et al., (Mabuchi et al., 2004) showed that PACAP^' mice do not exhibit 
neuropathic pain following nerve transection, implicating PACAP up-regulation in 
the onset o f neuropathic pain.
In the rat, an increase in galanin transcripts and peptide is also observed following 
spinal nerve transection (Hokfelt et al., 1987; Villar et al., 1989; Noguchi et al.,
1993), chronic constriction injury (Nahin et al., 1994; Ma et al., 1997; Shi et al., 
1999) and spinal nerve ligation (Fukuoka et al., 1998). Following axotomy (Xu et al., 
1996; Shi et al., 1997) o f rat sciatic nerve, associated alterations in galanin receptors 
are also seen with a significant down-regulation of GAL-R1 and GAL-R2 in DRG 
neurons. Such an up-regulation of galanin would suggest a role in the production of 
neuropathic pain associated with such nerve injury. However, there are conflicting 
results showing both inhibitory (Wiesenfeld-Hallin et al., 1992; Hao et al., 1999; Yu 
et al., 1999; Liu and Hokfelt 2000) and stimulatory (Thompson et al., 1996;
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Thompson et al., 1998; Murphy et al., 1999; Kerr et al., 2000) effects o f galanin on 
pain transmission in the rodent. This is discussed in more detail in chapter 3.
A down-regulation in expression o f the capsaicin receptor VR1 is observed in adult 
DRG neurons following axotomy or nerve transection (Michael and Priestly, 1999; 
Michael and Priestly 2002; Fukuoka T et al., 2002). Conversely, expression of VR1 
in uninjured neurons appears to be differentially regulated. Following partial nerve 
injury o f rat DRG, expression of VR1 protein in those neurons remaining intact was 
increased (Hudson et al., 2001; Fukuoka et al., 2002), and may be crucial to the 
development o f neuropathic pain following axotomy.
Expression o f the ATP receptor P2X3 is up-regulated in small-medium neurons of 
the DRG following chronic constriction injury to the rat sciatic nerve (Novakovic et 
al., 1999). In the trigeminal ganglion, an increase in P2X3 immunoreactivity was 
also observed following ligation/section or chronic constriction of the inferior 
alveolar branch o f the mandibular nerve (Eriksson et al., 1998). Such an up- 
regulation would suggest a function following nerve damage. However other 
research has produced conflicting results. Fukuoka and colleagues (Fukuoka et al.,
2002) found no change in P2X3 immunoreactivity in the DRG following L5 spinal 
nerve ligation.
Injury related decreases have also been observed. Bradbury et al., (Bradbury et al.,
1998) found that following axotomy of the sciatic nerve, P2X3 immunoreactivity in 
the L4/L5 DR, decreased by 50%. A similar decrease was observed in lumbar DRG 
using a model o f spinal nerve ligation (Kage et al., 2002). These discrepancies might 
be due to differences in the models o f neuropathic pain but could also be a reflection 
of the differing mechanisms or types of regulation found in injured and in non­
injured neurons. Tsuzuki and colleagues (Tsuzuki et al., 2001) used ATF3 as the 
marker o f injured neurons to selectively study expression of P2X3 in injured neurons 
in the trigeminal ganglia and DRG following nerve transection. This study revealed a 
decrease in P2X3 mRNA in injured (ATF3-expressing) neurons, despite an overall 
increase in P2X3 mRNA expression throughout the ganglia. The increased 
expression o f P2X3 within intact neurons might play a role in the pathophysiology of
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nerve injury and the related neuropathic pain or may play a role in the regeneration 
of damaged neurons following injury. Further evidence supporting a role for P2X3 in 
injury-associated neuropathic pain was obtained using antisense oligonucleotides to 
downregulate P2X3 expression in a partial sciatic ligation model o f neuropathic pain 
(Barclay et al., 2002).
Following nerve damage and axotomy of peripheral DRG neurons, an increase in 
excitability and an enhancement of repetitive firing has been observed. This occurs 
alongside a reduction in action potential threshold (Zhang et al., 1997). This pattern 
of response is thought to underlie the generation o f the neuropathic pain associated 
with nerve injury. It has been attributed, at least partly, to alterations in sodium 
channel expression and conductance. An increased density in TTX-S channels 
following sciatic nerve axotomy is observed. This produces an increased sodium 
conductance within DRG, which is thought to contribute to the increased excitability 
in the axotomised neurons (Zhang et al., 1997; Black et al., 1999). This hyper­
excitability has been attributed to an up-regulation of the, normally silent, voltage 
gated sodium channel (VGSC) N avi.3 (Waxman et al., 1994; Cummins and 
Waxman, 1997, Sleeper et al., 2000). An up-regulation in N avi.3 mRNA has also 
been observed in medium to large size DRG neurons following spinal nerve ligation 
(SNL) in the rat (Kim et al., 2001; Abe et al., 2002; Chung et al., 2004). This up- 
regulation is maintained for at least 7 days post-procedure (Kim et al., 2001), and is 
associated with a more rapidly repriming TTX-S current. These axotomy/injury- 
induced changes in sodium channels are thought to alter neuronal excitability and 
contribute to the inappropriate firing observed following nerve damage. N avi.3 is 
also up-regulated in dorsal horn nociceptive neurons four weeks after rat spinal cord 
injury, coinciding with the onset of pain-related behaviours and neuronal 
hyperexcitability, implicating N avi.3 in the development of central neuropathic pain 
(Hains et al., 2003).
Despite these findings, a recent paper suggested that N avi.3 alone was not sufficient 
to account for the voltage-gated sodium channel dependent behavioural 
hypersensitivity that is associated with nerve injury (Lindia et al., 2005). It was
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found that following peripheral nerve lesion, only 18% of neurons expressing the 
injury factor ATF3 co-expressed N avi.3, which suggests that the up-regulation of 
Navi .3 observed following nerve injury was predominantly within intact neurons. 
Furthermore, although the use of the voltage-gated sodium channel blocking drugs, 
mexiletine and lamotrigine, partially alleviated mechanical allodynia, the use of 
antisense oligonucleotides specific for N avi.3 had no effect on the injury-induced 
mechanical and cold allodynia (Lindia et al., 2005).
Other sodium channels that may also contribute to changes in neuronal properties as 
a result o f injury are those belonging to the family o f TTX-R channels. Alongside 
alterations in TTX-S channels, changes in expression of the TTX-R channels are also 
observed following nerve damage. A decrease in expression o f both N avi.8 and 
N avi.9 is observed in small diameter DRG neurons following axotomy or sciatic 
nerve section (Okuse et al., 1997; Cummins et al., 1997; Tate et al., 1998; Dib-hajj et 
al., 1998; Novakovic et al., 1998 Sleeper et al., 2000; Decosterd et al., 2002). Such a 
down-regulation o f TTX-R channels is thought to contribute indirectly to the hyper­
excitability o f axotomised sensory neurons through the interaction of TTX-R 
currents with TTX-S sodium conductances (Zhang et al., 1997; Cummins et al.,
1997; Sleeper et al., 2000). The persistent TTX-R current carried by N avi.9 is 
thought to contribute a depolarising influence to the resting membrane potential of 
sensory axons (Cummins et al., 1999). The down-regulation of N avi.9 following 
injury would therefore produce a hyperpolarizing shift in resting membrane potential. 
This is proposed to relieve the inactivation of TTX-S channels, producing an increase 
in the TTX-S currents and neuronal excitability (Sleeper et al., 2000). In a computer 
model, the loss o f the slow inactivating TTX-R current carried by N avi.8 has also 
been shown to cause a lowering of action potential threshold and spontaneous, 
repetitive firing even in the absence of stimulation (Elliot, 1997; Schild and Kunze,
1997). A down-regulation in expression of both N avi.8 and N avi.9 is therefore 
implicated in the neuronal hyperexcitability that contributes to neuropathic pain 
following nerve damage. The down-regulation of N avi.9 mRNA has been observed 
in two radicular pain models and one peripheral neuropathic pain model (Abe et al.,
2002). A direct link between N avi.8 and neuropathic pain, has also been
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demonstrated by Lai et al., (Lai et al., 2002), who used antisense oligonucleotides to 
‘knock down’ the expression of N avi.8 in DRG of rats. In these rats neuropathic 
pain induced by spinal nerve injury was no longer observed, although the effects of 
acute pain and responses to non-noxious stimuli remained (Lai et al., 2002).
A number of other alterations in gene expression occur following nerve injury. For 
example, an increase in the enzyme neuronal nitric oxide synthase (NOS)4 is also 
observed in rat and monkey DRG following peripheral nerve lesion (Fiallos-Estrada 
et al., 1993; Verge et al., 1992; Zhang et al., 1993). This increase in NOS leads to 
increased production of the vasodilator nitric oxide (NO). However, the purpose of 
this increase is not known.
1.4.4.3. Peripheral neuropathies
If the cell body remains intact, PNS neurons have the ability to regenerate. In some 
neuropathies only the axon is damaged (“axonopathy”), while in most, both the nerve 
fibre and the cell body are damaged and die. Neuropathies may be generalised or 
focal. Focal neuropathies are usually a result of trauma or ischemia, whilst 
generalised lesions are usually caused by toxic effects (e.g. heavy metals and certain 
drugs), alterations in metabolism such as in diabetes, the genetically transmitted 
porphyria vitamin deficiencies (e.g., of the B vitamins thiamine and cobalamin). 
Other peripheral neuropathies, such as Guillain Barre syndrome, affect just the 
Schwann cells and hence lead to disorders in myelination, Guillain Barre syndrome 
(also known as acute inflammatory demyelinating polyneuropathy or Landry’s 
ascending paralysis) begins with a rapid onset o f weakness, with numbness or 
paralysis o f the feet and then legs, perhaps spreading to include the hands, then arms 
and finally face and breathing muscles. The cause is unknown. However in 50% of 
sufferers, it occurs following viral (cytomegalovirus, Epstein Barr) or bacterial 
infection e.g. Campylobacter. It is thought to be an autoimmune disorder in which
4 neuronal NOS is one o f  a family o f  several NOS’s. This family are responsible for the synthesis o f 
Nitric Oxide (NO). Three types o f NOS exist: neuronal NOS (nNOS), endothelialNOS (nNOS) and 
inducibleNOS (iNOS). nNOS produces NO in neuronal tissue o f both the CNS and PNS.
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the body’s own cellular defence mechanisms attack myelin sheaths preventing the 
fast transmission of peripheral information.
1.4.4.4. Post herpetic neuralgia
Herpes zoster virus causes pain and blistering of the skin supplied by a particular 
nerve root -  its dermatome. The illness is called “shingles”. Following apparent 
resolution o f the infection, a chronic pain, referred to as post-herpetic neuralgia 
(PHN) often develops. This is pain that persists after the pain associated with the 
viral infection has subsided. It is caused by the neuronal damage produced by the 
acute infection, in which inflammation and ischaemia cause necrotizing damage in 
the dorsal root, the DRG and the dorsal hom of the spinal cord. Predominantly large 
neurons are damaged leading to a relative increase in nociceptive transmission at the 
dorsal hom, and subsequent pain. This can be due to the reorganisation of central 
connections leading to enhanced spontaneous firing, but also as a result o f the loss of 
inhibitory signals transmitted by large diameter neurons. The elderly are particularly 
susceptible to PHN as they already have a reduced number o f large neurons.
1.4.4.5. Trigeminal neuralgia
The trigeminal nerve carries sensory information from the face, scalp, teeth and oral 
and nasal cavities, and is the motor nerve of the muscles involved in chewing. 
Trigeminal neuralgia - “tic douloureux” - is pain in one or more o f the three divisions 
o f the trigeminal nerve. It can be idiopathic (primary neuralgia), or be associated 
with another systemic disorder, such as compression by a tumour or central lesion, or 
demyelination as a result of multiple sclerosis (MS) (secondary neuralgia). Those 
with primary neuralgia have no abnormal physical signs, whilst those with secondary 
neuralgia may have sensory impairments (or other signs) as a result o f the secondary 
disorder. Symptoms common to both types include frontal or unilateral face pain, 
which is abrupt in onset and can last from a few seconds to two minutes. The pain is
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stereotypical to the patient and may be spontaneous or triggered by such things as 
chewing, talking or even a cold wind on the face. The pain felt is intense with a 
sharp/ stabbing quality that may be interspersed with dull aching pain.
1.5. Regulation of cell survival and neuronal number in the 
developing peripheral nervous system
1.5.1 The neurotrophic factor hypothesis
During the development o f the vertebrate nervous system neurons are produced in 
excess. A large proportion are lost during a period of developmentally programmed 
cell death. The target fields o f axons are thought to regulate this process by the 
production o f target derived survival factors, known as “neurotrophic factors”
(NTFs) (Levi-Montalcini, 1987, Farinas, 1999). These molecules are produced in 
limited quantities: the idea that innervating neurons compete for this limited supply 
is referred to as the ‘neurotrophic hypothesis*. Excess neurons and those forming 
inappropriate connections die by apoptosis, allowing the survival o f the appropriate 
number o f neurons.
Several lines o f research led to the formulation of this hypothesis. In vivo 
experiments involving sympathetic and sensory neurons, that are shown to be 
dependent upon Nerve Growth Factor (NGF) in vitro, illustrate that administration of 
anti-NGF antibodies during the time of target innervation results in a death of these 
neurons (Levi-Montalcini, 1987). Furthermore, addition of exogenous NGF allows 
survival o f neurons that would normally be lost, producing an excess o f neurons 
innervating their targets (Levi-Montalcini, 1987).
The use of transgenic mice illustrates and confirms these findings. Mice with 
targeted null mutations for NGF or its receptor tyrosine kinase TrkA have a loss of
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the same populations of peripheral neurons, whereas over-expressing NGF in target 
fields causes an excess o f neurons to survive and innervate their target fields (Lewin 
and Barde, 1996). Studies of the timing, location and level o f expression of NGF 
during development have reinforced this ‘neurotrophic hypothesis’. Target fields 
start producing NGF at a time coinciding with target field innervation (Davies et al., 
1987; Clegg et al., 1989), and the levels o f NGF produced are proportional to the 
number o f neurons innervating it (Harper and Davies, 1990). Target ablation 
experiments also confirm this, with increased cell death observed when specific 
developmental targets are removed (Caldero et al., 1998).
The neurotrophic hypothesis has become more elaborated in recent years with the 
recognition that survival and development of different subpopulations o f peripheral 
neurons are dependent upon the presence of a variety o f neurotrophic factors both 
before and after target field innervation. Sources of NTFs, other than targets, exist, 
with NTFs produced by cells along the route of axon extension or via autocrine 
pathways (Caldero et al., 1998; Maina et al., 1998; Wright et al., 1992; Robinson et 
al., 1996). Other work has shown that the particular NTF requirements o f certain 
neurons change during development (Davies et al., 1994, 1997; Buchman and 
Davies, 1993; Emfors et al., 1994a, 1994b; Francis et al., 1999; Zhou and Rush 
1995).
1.5.2. Roles of neurotrophic factors in the developing 
sensory neurons
This thesis focuses upon the sensory neuronal portion of the PNS, and, in particular, 
upon neurons o f the trigeminal ganglia, nodose ganglia and DRG. For this reason, 
the roles of various neurotrophic factors in the development o f these sensory ganglia 
will be briefly discussed.
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Trigeminal ganglia
Mouse trigeminal ganglia sensory neurons require several neurotrophic factors at 
different times through development. Initially when their axons are growing towards 
their targets, the neurons survive independently of neurotrophic factors. They 
become neurotrophin dependent following target innervation (Davies and Lumsden, 
1984; Vogel and Davies, 1991). Following sensory neuron target innervation, 
neurons are transiently supported by Brain Derived Neurotrophic Factor (BDNF) and 
Neurotrophin-3 (NT-3), before becoming dependent upon NGF at approximately 
embryonic day 13 (E13)5. Survival o f cultured embryonic day 10 (E10) trigeminal 
neurons is sustained and even increased in the presence o f NT-3 or BDNF for 48 
hours. However, this effect is not observed in cultured E l3 neurons, which show 
only 5% survival after 48 hours. At this stage, NGF has become essential for survival 
(Buchman and Davies, 1993; Buj-Bello et al., 1994). This suggests a transitory 
survival response to BDNF and NT-3 and a switch in neurotrophin dependence to 
NGF (Buchman and Davies, 1993), which was confirmed by following the 
neurotrophic factor requirements of BrdU-labelled subsets o f neurons in culture 
(Enokido et al., 1999). This change in dependence coincides with suitable alterations 
in Trk receptor expression, from initially high levels of TrkB (the preferred receptor 
for BDNF) and TrkC (the preferred receptor for NT-3), with low levels of TrkA to an 
increase in TrkA expression and a restriction of TrkB and TrkC in certain 
subpopulations (Arumae et al., 1993; Wyatt and Davies, 1993; Ninkina et al., 1996). 
The identity o f neurotrophin production from target tissues is also altered, showing 
neurons respond in sequence to target-derived NTFs (Buchman and Davies, 1993; 
Enokido et al., 1999; Davies et al., 1987). It is of note that “late bom” trigeminal 
neurons (those bom after target innervation) do not show this switch in 
responsiveness, and require NGF from the offset (Enokido et al., 1999; Huang et al., 
1999). The use o f transgenic mice also illustrates this switch from BDNF to NGF, 
with TrkB7' mice showing a loss in trigeminal neurons at much earlier stages than 
TrkA7' (Pinon et al., 1996).
5 Stages o f  em bryonic development. E l refers to embryonic day 1, the first day a vaginal plug is found 
indicating em bryonic conception.
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This early switch from BDNF and NT-3 to NGF is not the only switch that occurs 
during the development of trigeminal neurons. At late fetal stages and in the neonatal 
period, trigeminal neurons become responsive to members of other families of 
neurotrophic factors, such as macrophage stimulating protein (MSP) (Forgie et al.,
2003) and also the cytokine, ciliary neurotrophic factor (CNTF) (Horton et al., 1998). 
Additionally, it has been reported that mice with a null mutation in the gene encoding 
the Glial Cell Line-Derived Neurotrophic Factor (GDNF) family member neurturin 
(Neurturin'7' mice) have a reduced number of trigeminal ganglion neurons at 
postnatal ages. This suggests that neurturin is responsible for the normal 
development o f a subpopulation of trigeminal ganglia neurons at this late stage of 
development (Heuckeroth et al., 1999).
Nodose ganglia
Unlike trigeminal neurons, nodose neurons do not show an early developmental 
switch in neurotrophic factor requirements. These neurons depend mainly upon 
BDNF and to a lesser extent NT-3 during early embryonic development (Buj-Bello 
et al., 1994). A minor, subpopulation of nodose neurons are also dependent upon 
NGF for survival (Forgie et al., 2000).
Dorsal Root Ganglia
DRG contain subsets o f neurons that respond to and require NGF, BDNF and NT-3 
during embryonic development (Lindsay et al., 1985; Davies et al., 1986; Kalcheim 
et al., 1987). Experiments on chick sensory DRG neurons have also shown that 
BDNF produced by an autocrine route, is likely to allow maturation - but not survival 
of - early embryonic neurons prior to target innervation (Davies and Wright, 1995).
Following birth, a subpopulation of small diameter neurons, initially responsive to 
NGF, begin to down-regulate TrkA and become dependent upon GDNF family 
members in vivo (Tessarollo et al., 1993; Bennett et al., 1996; Molliver and Snider, 
1997; Molliver et al., 1997). This subpopulation is immunoreactive for the isolectin-
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B4 (I-B4) and thus is often referred to as the IB4 reactive subpopulation. By late 
post-natal ages, small diameter unmyelinated DRG neurons are categorised into two 
types: those with a high affinity for NGF and express TrkA, and those that are not 
NGF responsive and are characterised by an ability to bind the isolectin IB4. The 
neuropeptides CGRP and SP are expressed by the TrkA-positive neurons, whilst the 
1B4 reactive neurons express the neuropeptide somatostatin, the enzyme thiamine 
monophosphatase (TMPase), the P2X3 receptor and also the GDNF family receptor 
components: c-ret and GDNF Family Receptor a  (GFR) family members. Further 
research has shown that despite survival responses by GDNF family ligands only 
occurring postnatally, expression of GDNF family receptors occurs embryonically 
(Molliver et al., 1997; Baudet et al., 2000). It would, therefore, seem that 
neurotrophins are essential in embryonic development, although some 
subpopulations switch dependence to GDNF family members following birth.
By adulthood, sensory neurons can survive both in vitro and in vivo without the need 
for neurotrophic factor support (Lindsay, 1988). However, neurotrophic factors 
continue to have roles following neuronal insult by damage or disease. Roles include 
axonal regeneration and maintenance of neuronal phenotype. They can also alter the 
expression o f other sensory neuron specific genes in such conditions, producing 
neuroprotection or enhancing the associated hyperalgesia.
1.6. The biology of the neurotrophic factors
Since the discovery o f NGF and the elucidation of the neurotrophic factor 
hypothesis, several other neurotrophins -  “Brain-Derived Neurotrophic Factor” 
(BDNF), “Neurotrophin-3” (NT-3), “Neurotrophin-4/5” (NT-4/5), “Neurotrophin-6” 
(NT-6) and “Neurotrophin-7” (NT-7) - have been characterised. Other families of 
proteins with similar survival promoting effects have also been discovered. These 
molecules are collectively referred to as neurotrophic factors, although some were 
initially characterised for their regulatory properties in other systems, e.g. 
macrophage stimulating protein (MSP) and leukaemia inhibitory factor (LIF).
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The main families o f neurotrophic factors to date are the neurotrophins (NGF, 
BDNF, NT-3, NT-4/5, NT-6 and NT-7), the GDNF family (GDNF, persephin, 
neurturin and artemin), the neuropoietic cytokines (Ciliary neurotrophic factor, 
CNTF); leukaemia inhibitory factor, LIF; Oncostatin M, OsM; cardiotrophin-1, CT- 
1; interleukin-6, IL-6; interleukin-11, IL-11; cardiotrophin-like cytokine, CLC; 
neuropoietin) and two cytokine related factors, also known as plasminogen related 
growth factors (Hepatocyte Growth Factor, HGF, and Macrophage Stimulating 
Protein, MSP). These families, the individual members and their receptors are 
outlined in table 1.
1 FAMILY NEUROTROPHIC
FACTOR
ABBREVIATION RECEPTOR 
(NON­
PREFERRED IN 
BRACKETS)
NGF Nerve Growth 
Factor
NGF TrkA
Brain-Derived
Neurotrophic
Factor
BDNF TrkB
Neurotrophin-3 NT-3 TrkC (TrkA, TrkB)
N eurotrophin-4/5 NT-4/5 TrkB
Neurotrophin-6 NT-6 TrkA
Neurotrophin-7 NT-7 TrkA
GDNF Glial Cell Line 
Derived 
Neurotrophic 
Factor
GDNF G FR al (GFRa2)
Neurturin NTN GFRa2 (G FRal)
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Artemin GFRa3 (G FRal)
Persephin GFRa4
Plasminogen -  
Related Growth 
Factors
Macrophage 
Stimulating Protein 
/ Scatter Factor
MSP / SF STK/Ron
Hepatocyte growth 
factor
HGF Met
Neuropoietic
Cytokines
Ciliary
Neurotrophic
Factor
CNTF CNTFRa bound to 1 
heterodimer o f I 
LIFRp and gpl30
Leukemia 
Inhibitory Factor
LIF Heterodimer of 1 
LIFRp and gpl30
Oncostatin M OsM Heterodimer of 
OsMR and gpl30
Cardiotrophin-1 CT-1 As yet unknown a  
subunit, bound to 
heterodimer o f I 
LIFRP and gp 130 I
Cardiotrophin-
Like-Cytokine
CLC CNTFRa bound to 
heterodimer of 
LEFRp and gpl30
Interleukin-6 IL-6 IL6Ra bound to 
gp 130 homodimer
Interleukin-11 IL-11 IL1 IR a  bound to 
gp!30 homodimer
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neuropoietin CNTRa bound to
heterodimer of
LIFRP and gp 130
Table 1.3. The main neurotrophic factor families
As well as effects on neuronal survival, research has demonstrated numerous other 
roles for NTFs throughout development and in the adult. Effects on neurite 
outgrowth, regeneration, axonal branching, precursor proliferation, neuronal form 
and synaptic function have all been described, as well as effects on gene expression 
and maintenance of neuronal phenotype following neuronal damage. Effects in 
systems other than the nervous system have also been extensively documented.
The most relevant o f these factors and their receptors, their biology, expression 
patterns and regulation of expression will now be discussed.
1.6.1. The neurotrophins
The neurotrophin family of neurotrophic factors consists o f nerve growth factor 
(NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), 
neurotrophin-4/5 (NT-4/5) and the two fish neurotrophins neurotrophin-6 (NT-6) and 
neurotrophin-7 (NT-7). They are all produced as precursors which are proteolytically 
cleaved to produce the mature molecule, made up of a homodimer of approximately 
120 amino acid subunits. The family shares approximately 50% sequence similarity 
(Radziejewski et al., 1992). The crystal structures of the mature neurotrophins have 
been determined. They reveal a common tertiary fold and cysteine knot (McDonald 
et al., 1991; Fandl et al., 1994; Robinson et al., 1995; Butte et al., 1998; Robinson et 
al., 1999).
35
All neurotrophins have specific and essential roles in the survival, differentiation and 
gain of phenotype of particular subpopulations of neurons of the CNS and/or the 
PNS throughout development. Although adult neurons can survive independently of 
neurotrophic factor support, neurotrophins have been implicated in responses 
following injury or neuronal damage. They may act sequentially, in synergy or in 
opposition.
Initial efforts to isolate neurotrophin receptors led to the discovery o f the common 
neurotrophin receptor p75NTR. Initially, this receptor was thought specific for NGF, 
but further research by Rodriguez-Tebar et al., (Rodriguez-Tebar et al., 1991) 
revealed it could bind all of the neurotrophin ligands with similar affinity. Despite 
similar binding strength, the binding rate constants were found to be markedly 
different, suggesting that p75 may, to some extent, discriminate between ligands 
(Rodriguez-Tebar et al., 1992).
The Trk family o f tyrosine kinase neurotrophin receptors were discovered later. This 
family consists o f TrkA, TrkB and TrkC, with NGF, BDNF and NT-3 binding 
preferentially to TrkA (Cordon-Cardo et al., 1991; Kaplan et al., 1991, 1991b; Klein 
et al., 1991a) TrkB (Glass et al., 1991; Squinto et al., 1991; Klein et al., 1991b) and 
TrkC (Lamballe et al., 1991), respectively. Additionally, NT-3 can also bind, but 
with lower affinity, to TrkA and TrkB (Squinto et al., 1991; Klein et al., 1991b; 
Soppet et al., 1991), and NT-4, can also signal via TrkB (Klein et al., 1992; Conover 
et al., 1995). These binding patterns are illustrated in figure 1.7.
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Figure 1.7:
Binding o f neurotrophins to their preferred receptors (Bold arrows), and other ligand 
receptor interactions that can occur (dashed arrows). Taken from Barbacid M, 1994
Upon ligand binding, the Trk receptors form homodimers, allowing phosphorylation 
o f tyrosine residues within the receptor, leading to signal transduction. The Trk 
family and signalling will be discussed further following descriptions o f each 
neurotrophin.
1.6.1.1. Nerve growth factor (NGF)
The classic neurotrophic factor, NGF, was discovered by chance, when application 
o f a snake venom to chick sensory ganglia was shown to elicit neurite outgrowth 
(Cohen and M ontalcini, 1956). A non-dialyzable, heat labile protein responsible for 
this neurotrophic activity was purified from the fraction and was named nerve 
growth factor (Cohen et al., 1960). Angeletti and Bradshaw (Angeletti and 
Bradshaw, 1971) determined the amino acid sequence o f mouse NGF, and 
subsequently cDNAs o f  mouse, human, bovine and chick NGF have all been cloned 
(Scott et al., 1983; Ullrich et al., 1983; Meier et al., 1986; Ebendal et al., 1986). 
Mouse NGF is initially produced as a 307 amino acid precursor that is cleaved to 
leave the mature, 118 amino acid protein which contains the cysteine knot m otif 
characteristic o f  the neurotrophins (Berger and Shooter, 1977; Scott et al., 1983;
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Edwards et al., 1988). Dimerisation of this mature form produces biologically active 
NGF (McDonald et al., 1991).
In the rat nervous system, NGF is abundant in areas innervated by the magnocellular 
cholinergic neurons, namely, the hippocampus, olfactory bulb and cerebral cortex 
(Korsching et al., 1985; Whittemore et al., 1986; Maisonpierre et al., 1990). Regions 
containing the cell bodies of these neurons (septum, nucleus of the diagonal band of 
Broca and the nucleus basalis of Meynert) are also NGF immunoreactive (Korsching 
et al., 1985). Accordingly, NGF only supports the survival o f basal forebrain 
cholinergic neurons within the CNS (Chun and Patterson, 1977; Levi-Montalcini, 
1987; Hatanka et al., 1988; Hartikka and Hefti, 1988). Other areas o f the CNS also 
express NGF, but at much lower levels (Korsching et al., 1985; Whittemore et al., 
1986). Outside the CNS, NGF is expressed by the target tissues of NGF-responsive 
sensory and sympathetic neurons in proportion to their innervation density (Davies et 
al., 1987; Heumann et al., 1984; Korsching et al., 1985; Korsching and Thoenen, 
1983, 1988; Shelton and Reichardt, 1984; Harper and Davies, 1990).
Recent work has shown that the precursor to NGF, proNGF, selectively induces cell 
death through activation o f p75 by a mechanism that is dependent upon presence of 
the membrane protein sortolin (Lee et al., 2001; Ibanez, 2002; Nykjaer et al., 2004). 
This signalling pathway is thought to be important following neuronal injury when 
expression o f both p75 and proNGF are up-regulated (Beattie et al., 2002; Harrington 
et al., 2004). This pathway has been proposed as the route for elimination of 
damaged cells.
NGF binds not only to p75, the receptor common for all neurotrophins, but also to 
the receptor tyrosine kinase TrkA. TrkA was the first member o f the Trk family of 
neurotrophin receptors to be discovered. This 140 kDa protein has a restricted 
expression, only being detectable centrally in cholinergic neurons of the basal 
forebrain and the striatum (Vasquez and Ebendal 1991, Holtzman et al., 1992; Merlio 
et al., 1992; Steininger et al., 1993) and sympathetic neurons and the neurons of the
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DRG and cranial ganglia that that require NGF for survival (Martin-Zanca et al., 
1990; Tessarollo et al., 1993; Schropel et al., 1995). In the DRG of embryonic day 
17.5 (El 7.5) mice, the majority of neurons express TrkA (Tessarollo et al., 1993), 
but following birth, a subpopulation of small diameter DRG neurons down-regulate 
TrkA and become responsive to GDNF family ligands (Molliver et al., 1997). This 
subpopulation are also immunoreactive for the isolectin-B4 (I-B4), and are therefore 
often called the “IB4-reactive subpopulation”. Outside the nervous system, TrkA is 
expressed on T cells and monocytes (Ehrhard et al., 1993, 1993a).
Transgenic mice with null mutations in the TrkA and the NGF genes have facilitated 
a clearer understanding o f the biology of this signalling pathway. Both TrkA*7' and 
NGF*7* mice die shortly after birth with massive loss of sympathetic neurons and 
small diameter sensory neurons in DRG and trigeminal ganglia (Smeyne et al., 1994; 
Crowley et al., 1994). The small diameter sensory neurons that are lost are 
responsible for transmission of nociceptive information: this is indicated by a failure 
of both NGF'7* and TrkA*7* mice to respond to noxious stimuli (Smeyne et al., 1994; 
Crowley et al., 1994). The size of the other main population o f neurons that 
expresses TrkA, the basal forebrain cholinergic neurons o f the CNS, is unaffected in 
both null mutations. This would suggest that NGF/TrkA signalling is not required for 
the formation and survival o f these neurons,. However, there is a reduced expression 
of choline acetyltransferase (ChAT) in the basal forebrain cholinergic neurons in 
both NGF*7* mice, suggesting that although NGF might not be directly involved with 
cholinergic neuron survival, it may affect the function o f these neurons (Crowley et 
al., 1994). Because NGF*7* and TrkA*7' mice die shortly after birth, it is not possible 
to examine the importance of this ligand receptor system post-natally in these mice.
The expression o f TrkA by basal forebrain cholinergic neurons has raised the 
possibility that activation of NGF/TrkA signalling in neurodegenerative disorders 
associated with loss o f such neurons may be therapeutically valuable. The potential 
for NGF in the treatment o f Alzheimer’s disease (AD) was highlighted several years 
ago by grafts o f cells genetically engineered to produce NGF into the brain of
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primates. These grafts were shown to inhibit the cholinergic neuron degeneration that 
is associated with the onset o f AD (Tuszynski et al., 1996; Martinez-Serrano et al., 
1995). More recently, phase I clinical trials have been carried out. In these trials, 
fibroblasts, engineered to express NGF, were implanted into the brains of 8 patients 
with mild AD. No adverse effects due to the presence of NGF were found after 22 
months, and its presence led to a decline in the rate of cognitive degeneration 
(Tuszynski et al., 2005).
The expression o f TrkA in the small diameter nociceptive sensory neurons has 
implicated a role for NGF/TrkA signalling in nociception. In support o f this is the 
finding that NGF*7* and TrkA*7' mice fail to respond to noxious stimuli (Smeyne et al., 
1994; Crowley et al., 1994), and that direct administration of NGF leads to pain and 
hyperalgesia in human and rodents (Dyck et al., 1997; Lewin et al., 1993). 
Furthermore, in inflammatory conditions such as arthritis, an increase in NGF 
mRNA and NGF protein have been detected in the inflamed tissues (Aloe et al.,
1992; Aloe et al., 1993; Falcini et al., 1996; Halliday et al., 1998; Lowe et al., 1997; 
Miller et al., 2002). Additionally, application of inhibitors to NGF attenuates pain 
induced by the inflammatory agents CFA and carrageenan (Woolf et al., 1994; 
Safieh-Garabedian et al., 1995; McMahon et al., 1995; Dmitrieva et al., 1997; 
Delafoy et al., 2003). NGF is thought to contribute to the associated hyperalgesia 
through sensitisation of mast cells (Bischoff and Dahinden, 1992) and through 
increased production o f the neuropeptides CGRP and SP. NGF also potentiates 
nociceptive signalling pathways by regulating expression of the capsaicin receptor 
VR1 and the acid sensing ion channel 3 (ASIC3) (Ji et al., 2002; Amaya et al., 2004; 
Shu and Mendell, 1999; Mamet et al., 2003). In addition to its contribution to 
inflammatory pain, NGF has a role in promoting neuropathic pain in the chronic 
constriction injury (CCI) model of this kind of pain (Herzberg et al., 1997; Ro et al.,
1999). Taken together, the above findings suggest therapeutic roles for antagonists of 
NGF in the management of neuropathic and inflammatory pain.
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1.6.1.2. Brain-derived neurotrophic factor
BDNF was first isolated from pig brain using its ability to support survival of 
cultured chick embryonic sensory neurons as an assay (Barde et al., 1982). Survival 
in vivo was not demonstrated until 1988, when BDNF became accepted as a 
neurotrophic factor similar to NGF (Hofer and Barde, 1988). Porcine, human, mouse 
and rat BDNF have since been cloned and characterised (Leibrock et al., 1989; Hofer 
et al., 1990; Jones and Reichardt, 1990; Maisonpierre et al., 1991). Like NGF, BDNF 
is secreted as a precursor molecule which is proteolytically cleaved to produce the 
approximately 120 (13-14kDa) amino acid mature active protein (Leibrock et al., 
1989) which dimerizes to form a homodimer (Radziejewski et al., 1992). The mature 
form of BDNF shares approximately 50% homology with NGF (Maisonpierre et al., 
1991).
Expression o f BDNF is low early in CNS development, but increases with 
maturation, with notable expression in cortex, hippocampus and cerebellum of adult 
mice (Maisonpierre et al., 1990). It is also detected, at lower levels, in striatum, 
hindbrain, midbrain, olfactory bulb and spinal cord (Leibrock et al., 1989; Hofer et 
al., 1990). In the PNS, BDNF is expressed embryonically by sympathetic ganglia, 
and sensory ganglia including DRG and trigeminal ganglia (Schecterson and 
Bothwell, 1992). It is also expressed in target tissues of nodose ganglia and 
vestibular ganglia neurons during development (Robinson et al., 1996). Outwith the 
nervous system, BDNF mRNA transcripts are detectable in tissues innervated by 
BDNF responsive neurons, namely those of the heart, lung and skeletal muscle 
(Maisonpierre et al., 1990, 1991; Buchman and Davies, 1993).
BDNF can support survival o f retinal ganglion cells (Johnson et al., 1986; Thanos et 
al., 1989), basal forebrain cholinergic neurons (Alderson et al., 1990; Knusel et al., 
1991) and prevent axotomy-induced degeneration of postnatal rat motor neurons 
(Sendtner et al., 1992; Koliatsos et al., 1993). It can also promote survival of 
dopaminergic neurons o f the substantia nigra (Hyman et al., 1991; Knusel et al.,
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1991; Altar et al., 1992), which would implicate this neurotrophin in the therapeutic 
treatment of Parkinson’s disease. This will be discussed later.
In the PNS, target-derived BDNF has been shown to promote survival o f neural crest 
derived DRG (Lindsay et al., 1995; Davies et al., 1986; Kalcheim et al., 1987) and 
also populations of sensory neurons insensitive to NGF, i.e. those o f the placode- 
derived nodose ganglia (Davies et al., 1986; Lindsay et al., 1985; Buj-bello et al.,
1994).
Experiments on early chick DRG neurons have also shown that BDNF produced by 
an autocrine route is likely to allow maturation, but not survival, o f these neurons 
prior to target innervation (Davies and Wright, 1995). This autocrine route of BDNF 
production may also occur in adult DRG neurons for survival purposes (Acheson et 
al., 1997). Adult mouse DRG neurons can survive in culture independently of 
exogenous NTFs. However application of antisense oligonucleotides to BDNF, 
which inhibit expression of BDNF, results in a dramatic loss o f neurons (Acheson et 
al., 1997). This loss could be reversed by application of BDNF but not by any other 
NTF. Recent work has shown that in the same way as proNGF, proBDNF, the 
precursor o f BDNF, also affects neuronal survival, inducing neuronal apoptosis in 
cells co-expressing p75 and a co-receptor sortolin (Teng et al., 2005).
Analysis o f the product o f the trkb gene, gpl45trkB in NIH 3T3 cells, found that it 
could be phosphorylated by BDNF (Soppet et al., 1991), indicating that this receptor 
was the high affinity BDNF receptor. Other groups have confirmed or shown BDNF 
affinity and signalling for TrkB (Squinto et al., 1991; Soppet et al., 1991; Glass et 
al., 1991; Klein 1991b). NT-3 can also activate TrkB as well as its preferred receptor 
TrkC (Klein et al., 1991, 1992; Soppet et al., 1991).
TrkB is a 145kDa protein that shares approximately 69% homology with TrkA 
(Klein et al., 1989). TrkB can be detected within the mouse embryo at E9.5 (Klein et 
al., 1990), and unlike the restricted expression profile o f TrkA, TrkB shows 
widespread expression in the CNS, with expression being particularly notable in 
tissues o f the hippocampus, hypothalamus, brainstem, cerebellum and spinal cord
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motor neurons (Klein et al., 1989; Merlio et al., 1992). In the PNS, TrkB is also 
widely expressed, being detectable in almost every peripheral ganglion (Klein et al., 
1989; Ninkina et al., 1996; Carroll et al., 1992; Tessarollo et al., 1993; Lamballe et 
al., 1994). TrkB is also found in Schwann cells (Carroll et al., 1992) and is observed 
outside the nervous system in lung, muscle and ovaries (Klein et al., 1989).
The importance o f BDNF in neuronal development is highlighted by the phenotype 
of BDNF'7' mice. The majority of BDNF*7' mice die shortly after birth (Emfors et al., 
1994; Jones et al., 1994). Such mice have severe deficits o f co-ordination and 
balance due to the loss of the majority o f vestibular sensory neurons (rather than 
cerebellar dysfunction). They also have reduced numbers o f other cranial and DRG 
sensory neurons. Detailed analysis has shown that there are no defects in motor or 
sympathetic neurons (Emfors et al., 1994; Jones et al., 1994). Research using mice 
with either a conditional mutation in the BDNF gene or who carry a deletion in one 
copy of the BDNF gene shows that these mice have impaired learning abilities, 
suggesting a role for BDNF in learning and memory, possibly through effects on 
long term potentiation (LTP)6 (Linarsson et al., 1997; Minichello et al., 1999). Mice 
with a disruption in the TrkB gene, can survive up to birth. However feeding 
mechanisms are absent and so most die by Postnatal day 1 (PI) (Klein et al., 1993). 
The observation that the phenotype of TrkB*7' mice is more drastically affected than 
BDNF'7' mice is consistent with the finding that NT-4/5 and NT-3 can also signal via 
this receptor (Conover et al., 1995; Soppet et al., 1991; Klein et al., 1991, 1992).
The effects o f BDNF on motor neurons following spinal nerve injury have also been 
observed in mature adult mice. In this model, application of BDNF following the 
axotomy o f spinal motor neurons attenuated injury-induced alterations in neuronal 
phenotype (Friedman et al., 1995). BDNF has also been shown to have important 
effects on neuro-regeneration in adult neurons. When fetal spinal cord was 
transferred into rat spinal cord following complete spinal cord transection, it was 
found that addition o f exogenous BDNF (or NT-3) promoted axonal growth, 
allowing some functional restoration of anatomical connections (Coumans et al.,
6 LTP is the process in which a synapse can be strengthened (or potentiated) by repetitive stimulation. 
It is thought to contribute to synaptic plasticity producing an adaptable nervous system.
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2001). Furthermore, addition of antibodies against BDNF following peripheral nerve 
injury significantly attenuated the length of the regenerated nerve by 24% and 
produced abnormalities in the lamellar layers of the myelin sheath (Zhang et al.,
2000).
BDNF also has a nociceptive role, regulating spinal cord excitation. Following 
inflammatory stimulus and nerve injury, an increase in BDNF contributes to the 
associated central sensitisation of spinal processing and subsequent hyperalgesia 
(Chao et al., 1997a, b; Tonra et al., 1998; Michael et al., 1999; Kerr et al., 1999; Ha 
et al., 2001; Yajima et al., 2002). Evidence has suggested that it may act as a 
neurotransmitter in the pain pathway of adult animals (Thompson et al., 1999). 
Antagonists o f BDNF might therefore be of therapeutic use in the treatment of 
hyperalgesia associated with persistent inflammatory states or following nerve 
damage.
Parkinson’s disease (PD) is a neurological disorder associated with the progressive 
loss o f dopaminergic neurons from the substantia nigra pars compacta (SNc). Current 
treatments involve administration of levadopa (L-Dopa), which aims to replenish the 
diminishing levels o f dopamine, but produces significant, distressing side-effects and 
ultimately does not address the neuronal degeneration at the route of the disorder.
The discovery that BDNF can exert neurotrophic factor effects on dopaminergic 
neurons (Hyman et al., 1991; Knusel et al., 1991; Altar et al., 1992; Klein et al.,
1999), associated with a down-regulation of BDNF mRNA and protein in substantia 
nigra of sufferers o f PD (Mogi et al., 1999; Howells et al., 2000), raised the 
possibility that BDNF might have a role in the treatment of this disorder. Gene 
transfer o f BDNF into rat nigrostriatal neurons, prior to 6-hydroxydopamine (6- 
OHDA)7 lesion, led to significant reduction in the degeneration of dopaminergic 
neurons and also corrected behavioural deficits (Sun et al., 2005; Mohapel et al., 
2005). Research by Guillin et al., (Guillin et al., 2001, 2003) also showed that TrkB 
was co-expressed with the D3 dopamine receptor and that BDNF produced by 
dopaminergic neurons stimulates the production of D3 receptors in the nucleus
7 6-hydroxydopamine (6-OHDA) is a neurotoxin used to specifically kill dopaminergic and 
noradrenegic neurons
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accumbens during development and maintains its expression in the adult. Agonists of 
the D3 receptor have been shown to inhibit the L-dopa induced dyskinesia, without 
affecting the beneficial therapeutic effects of this drug (Guillin et al., 2003). BDNF 
has also been shown to augment effects of levodopa. It is thus clear that BDNF, 
through regulation of D3 receptor production, is of potential therapeutic use, 
enhancing the effects of L-Dopa treatment, whilst attenuating troublesome side 
effects.
1.6.1.3. Neurotrophin-3
NT-3 was the third neurotrophin discovered. The gene encoding it was cloned 
following comparisons o f sequence homologies of BDNF and NGF and the design of 
oligonucleotides complimentary to regions of such homology (Emfors et al., 1990; 
Maisonpierre et al., 1990; Hohn et al., 1990; Rosenthal et al., 1990). Like NGF and 
BDNF, NT-3 is synthesized as a precursor which is cleaved to generate a mature 
active protein of 119 amino acids (approximately 13.6kd) with 57.6% and 55.6% 
sequence identity to NGF and BDNF, respectively (Rosenthal et al., 1990). The 
mature form exists as a homodimer (Radziejewski et al., 1992). In the developing 
embryo, NT-3 is expressed very early, peaking at E4.5 and declining steadily 
thereafter. It is broadly expressed, detectable in peripheral tissues including heart, 
liver, spleen, kidney and lung. In the CNS, it is expressed at greatest concentrations 
in the hippocampus and cerebellum (Emfors et al., 1990; Hohn et al., 1990; 
Maisonpierre et al., 1990; Rosenthal et al., 1990). Expression of NT-3 is initially 
high in regions o f developing CNS, but levels decrease as maturation progresses 
(Maisonpierre et al., 1990).
NT-3 has neurotrophic factor activity in many of the neuronal populations of the 
CNS. Embryonic noradrenergic neurons of the locus coeruleus (LC) can be 
supported in culture by NT-3, while in adult neurones, its presence can prevent 6- 
OHDA-induced degeneration of such neurons (Arenas and Persson, 1994). NT-3 can 
support survival o f embryonic rat motor neurons (Henderson et al., 1993), but cannot 
rescue postnatal motor neurons from axotomy-induced degeneration (Sendtner et al.,
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1992; Koliatsos et al., 1993). It is also essential for the survival and differentiation of 
oligodendrocyte precursors (Barres et al., 1993, 1994; Rubio et al., 2004).
In the PNS, NT-3 is important in initial survival of NC-derived trigeminal sensory 
ganglia just after target innervation and prior to a switch in responsiveness to NGF 
(Buchman and Davies, 1993; Buj-bello et al., 1994; Wilkinson et al., 1996) (see 
1.5.2.). NT-3 can also promote survival of other sensory neuronal containing ganglia 
including the DRG, parts of the trigeminal mesencephalic nucleus and also the, 
placode-derived nodose sensory ganglia (Rosenthal et al., 1990; Emfors et al., 1990; 
Maisonpierre et al., 1990; Hohn et al., 1990; Wilkinson et al., 1996). Other PNS 
neurons responsive to NT-3 include the sympathetic ganglia o f the paravertebral 
chain (Zhou and Rush, 1995; Maisonpierre et al., 1990).
NT-3 also influences the development of PNS neuronal precursors, inducing their 
survival, differentiation and proliferation (Kalcheim et al., 1992; Pinco et al., 1993; 
DiCicco-Bloom et al., 1993; Verdi and Anderson, 1994; Karavanov et al., 1995; 
Memberg and Hall, 1995; Elshamy and Emfors, 1996; Elshamy et al., 1996). NT-3 
has also been suggested as having a role very early in PNS neuronal development, 
contributing to initial ganglia formation (Ockel et al., 1996).
Lamballe et al. (Lamballe et al., 1991) discovered the 145kDa protein receptor,
TrkC, by screening a mouse brain cDNA library using the gene encoding TrkA as a 
probe. TrkC is first detected in the mouse embryo at E9.5 (Lamballe et al., 1991) and 
shows widespread expression, both throughout development and in the adult, being 
detectable in similar tissues as its ligand, NT-3 (Lamballe et al., 1994). Like TrkB, 
TrkC is widely distributed in the brain, with high expression in neocortex, caudate, 
putamen, brainstem, hypothalamus, hippocampus, cerebellum, and spinal cord motor 
neurons (Merlio et al., 1992; Tessarollo et al., 1993). Some tissues co-express TrkB 
and TrkC (Tessarollo et al., 1993). However, although general tissue expression is 
similar, the two receptors show distinct patterns of expression on specific
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subpopulations of neurons, which suggests different survival roles for NT-3 and 
BDNF (Merlio et al., 1992).
Broad expression of TrkC is also observed in the PNS, detectable to some extent in 
most ganglia and also within migratory cells of the neural crest (Tessarollo et al., 
1993). Expression of TrkC is also observed in the enteric nervous system and in non­
neuronal tissues, including the vibrissae and dental papillae, the submandibular 
gland, the wall o f the aorta and the brown adipose tissue surrounding the cervical 
spinal cord (Tessarollo et al., 1993; Lamballe et al., 1994). The distribution is similar 
to that o f its ligand NT-3.
As stated earlier, NT-3 can also bind to TrkA and TrkB (Soppet et al., 1991; Klein et 
al., 1991b; Cordon-Cardo et al., 1991; Glass et al., 1991; Ip et al., 1993), albeit with 
lower affinity than their preferred ligands NGF and BDNF, and can also signal via 
these receptors. NT-3’s effects on survival and neurite outgrowth of sympathetic 
neurons are mediated through TrkA rather than TrkC (Belliveau et al., 1997).
Mice with a null mutation in the gene encoding NT-3 die within a few weeks of birth 
and suffer from abnormal limb movement most likely due to a lack o f muscle 
afferent projections to the spinal cord (Farinas et al., 1993; Emfors et al., 1994). No 
defects in enteric or motor neurons are apparent, but affected animals show much 
loss o f sensory neuron populations (Liebl et al., 1997). Disruption o f the TrkC gene 
to remove the catalytic portion of the receptor also produces mice with severe 
proprioceptive sensory neuron loss (Klein et al., 1994). Unlike NT-37'mice, some 
TrkC7' mice can survive for long periods following birth, and only show 30% loss of 
sensory neurons rather than the 70% deficit of the NT-37' mice (Liebl et al., 1997). 
This probably illustrates the ability of NT-3 to signal through other Trks. NT-3 
supports the survival of both cultured trigeminal and nodose ganglion neurons from 
TrkC7' mice, to an extent comparable to NGF and BDNF, respectively (Davies et al.,
1995). This suggests that NT-3 can also signal via TrkA and TrkB in the absence of 
its preferred Trk receptor, TrkC. This has been further confirmed using studies of 
NIH 3T3 cells expressing various Trks, which illustrate that NT-3 can bind and
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signal via TrkA and TrkB, although with lower potency than via TrkC (Cordon- 
Cardo et al., 1991; Glass et al., 1991; Ip et al., 1993) and by the observation that NT- 
3 can displace NGF from its preferred receptor (Emfors et al., 1990).
In the adult, NT-3 has a number of effects following neuronal injury or insult. Thus, 
the presence o f NT-3 has been shown to increase numbers of oligodendrocytes and 
thus enhance CNS myelin repair following chemical demyelination of CNS neurons 
(Jean et al., 2003). This action would suggest a potential therapeutic role for NT-3 in 
the treatment o f the debilitating demyelination disorders such as MS. Additionally 
following injury, NT-3 acts in an antagonistic fashion to the pro-hyperalgesic effects 
of NGF (Wilson-Gerwing et al., 2005) by competition for TrkA binding sites (Gratto 
and Verge, 2003) and by decreasing the levels of BDNF (Karchewski, et al., 2002), 
SP and CGRP (Jongsma Wallin, 2001).
1.6.1.4. Neurotrophin-4/5
A fourth neurotrophic factor, was discovered by polymerase chain reaction (PCR) 
techniques, using oligonucleotides designed to contain regions conserved in NGF, 
BDNF and NT-3 (Berkemeier et al., 1991; Hallbook et al., 1991; Ip et al., 1991). 
This neurotrophin was originally identified in Xenopus oocytes (Hallbook et al., 
1991) and named neurotrophin-4 (NT-4). Rat and human forms encoding a similar 
receptor were discovered shortly after but were named neurotrophin-5 (NT-5) 
(Hallbook et al., 1991; Ip et al., 1992). With approximately 65% identity, it was 
thought that NT-4 and NT-5 (Berkemeier et al., 1991; Ip et al., 1992), were likely to 
be identical: the factor is now referred to as NT-4/5. Like other neurotrophin family 
members, NT-4/5 is secreted as a precursor, although the pro-region o f NT-4 is 
significantly shorter (approximately 60 amino acids) than NGF, BDNF and NT-3 
(Berkemeier et al., 1991; Ip et al., 1992). The precursor is cleaved to produce mature 
active NT-4/5, which shares 50%, 56% and 55% homology to NGF, BDNF and NT- 
3 respectively (Berkemeier et al., 1991).
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Rat NT-4 is widespread, detected in lung, thymus, muscle, ovary, heart and stomach 
both in the adult and in development (Berkemeier et al., 1991; Ip et al., 1992; 
Timmusk et al., 1993). Within the brain it is detected in many areas including cortex, 
pons, cerebellum, hippocampus, olfactory bulb and hypothalamus (Timmusk et al., 
1993).
NT-4/5 has been shown to bind to (Klein et al., 1992) and signal (Ip et al., 1992) via 
TrkB. Weak tyrosine phosphorylation of TrkA was also observed for NT-4/5 in 
studies using NIH 3T3 cells (Ip et al., 1992).
NT-4/5 exerts neurotrophic factor effects on many subpopulations of neurons. In the 
CNS, it can promote survival and neurite outgrowth of cultured adult retinal ganglia 
cells (Cohen et al., 1995). It can also enhance ChAT activity in cultured embryonic 
cholinergic neurons of the basal forebrain and locus coeruleus (LC), and enhance 
their survival (Friedman et al., 1993). Effects on motor neurons have also been 
observed. NT-4/5 can promote survival of cultured corticospinal motor neurons from 
the neonatal rat (Junger et al., 1997) and rescue injury-induced loss of facial motor 
neurons in vivo (Koliatsos et al., 1994). Application to embryonic motor neurons can 
also stimulate differentiation to the cholinergic phenotype by up-regulation of 
(ChAT) (Wong et al., 1995). In the PNS, NT-4/5 can promote survival and neurite 
outgrowth o f embryonic mouse trigeminal neurons in vitro at a time coinciding with 
early stages o f target field innervation (Davies et al., 1993; Ibanez et al., 1993). 
Potent survival effects are also observed for NT-4/5 on cultured embryonic chick 
DRG neurons (Berkemeier et al., 1991; Ip et al., 1992) and for mouse, but not chick, 
nodose neurons at a time coinciding with naturally occurring cell death (Davies et al., 
1993). Species differences in NT-4 effects are thus apparent, and suggest that NT-4 
is not well conserved between mammals and birds (Davies et al., 1993). Additionally 
NT-4/5 can promote survival and neurite outgrowth of embryonic sympathetic 
ganglia neurons, but with low potency (Berkemeier et al., 1991; Hallbook et al., 
1991).
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In the adult, NT-4 is a potent stimulus to axon outgrowth in explanted mouse nodose 
ganglia (Wiklund et al., 2000). These effects on axonal outgrowth suggest a role for 
NT-4/5 in regeneration of neurons following injury (Blesch et al., 2004). After 
thoracic spinal cord injury in rats, application of NT-4/5 significantly improved 
axonal regrowth of motor axons, coerulospinal, reticulospinal, and propriospinal 
neurons (Blesch et al., 2004). Positive effects of NT-4/5 on nerve regeneration were 
also observed following sciatic nerve transection (Yin et al., 2001; Simon et al.,
2003). NT-4/5 regulation of gene expression following injury is also notable in the 
adult rat. NT-4/5 can prevent axotomy-induced changes in neuronal phenotype 
following axotomy of spinal motor nerves (Friedman et al., 1995) and also 
cholinergic hypoglossal motor neurons (Tuszynski et al., 1996)
Mice with a null mutation in the NT-4/5 gene reveal an essential role for NT-4/5 in 
development o f a specific subpopulation of sensory neurons (Conover et al., 1995; 
Liu et al., 1995). NT-4/57* mice are viable and fertile and have a milder neurological 
phenotype than other neurotrophin knockouts. They have a reduced number of 
nodose sensory neurons in comparison to wild-type mice (Conover et al., 1995; Liu 
et al., 1995). NT-4/5'/_ mice have abnormal and enlarged neuromuscular junctions 
with disassembled expression of the acetylcholine receptor (AChR), suggesting a 
role for NT-4/5 in the maintenance of neuromuscular connections (Belluardo et al.,
2001).
1.6.1.5. Neurotrophin-6 and neurotrophin-7
The most recently described neurotrophins, NT-6 and NT-7, are exclusively present 
in fish. Compared with mammalian neurotrophins, they share greatest similarity with 
NGF and signal exclusively via TrkA (Lai et al., 1998; Nilsson et al., 1998). In some 
fish species (pufferfish and salmon) only one NT-6/7 like protein can be found 
(Dethleffsen et al., 2003). NT-6 and NT-7 have been distinguished as separate factors 
in other fish species, as they share relatively low sequence similarity (63%) (Nilsson 
et al., 1998) and their expression patterns are different (Gotz et al., 1994; Lai et al., 
1998; Dethleffsen et a., 2003).
50
NT-6 was isolated from the teleost fish Xiphophorus and is expressed as early as 
stage 13 o f embryonic development (Gotz et al., 1994). Although it has not been 
found in mammals, recombinant purified NT-6 has been shown to act in a similar 
fashion to NGF, promoting both neurite outgrowth and survival o f chick sensory 
DRG explants, but with a much lower potency (Li et al., 1997). NT-6 differs from 
other neurotrophin family members in being glycosylated (Li et al., 1997). The 
biological significance of this glycosylation is yet to be determined.
The fish neurotrophin NT-7 was isolated from both carp (Lai et al., 1998) and 
zebrafish (Nilsson et al., 1998). Like NT-6, NT-7 is most similar to NGF (with 65% 
sequence identity) and acts exclusively via TrkA (Lai et al., 1998; Nilsson et al.,
1998).
1.6.1.6 Neurotrophin receptors
Neurotrophins signal via two types of receptor: the common receptor p75, and the 
ligand specific Trk neurotrophin receptors. These receptors have been mentioned 
briefly whilst discussing the individual neurotrophins. More information about 
structure, signalling pathways, and splice variants follows in this section.
P 7 5 NTR
The p75NTR receptor was the first neurotrophin receptor discovered. p75NTR has been 
isolated in rat, chicken and human, with all forms showing significant homology 
(Chao et al., 1986; Johnson et al., 1986; Radeke et al., 1987). Initially, p75NTR was 
thought to be a specific NGF receptor, but was later shown to bind NGF, BDNF and 
NT-3 with equal affinity (Rodriguez-Tebar et al., 1991). p75 NTR is a distant member 
of the tumour necrosis factor (TNF) receptor family, containing the characteristic 
cysteine repeats in the extra-cellular domain. It is approximately 75kDa (Johnson et
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al., 1987; Radeke et al., 1987) and contains 4 cysteine residues important for ligand 
binding (Welcher et al., 1991; Yan and Chao, 1991).
p75 NTR is widely expressed throughout the chick and rat brain both during 
development and in the adult, with highest levels in the cerebellum and septum 
(Emfors et al., 1988; Buck et al 1988; Yan and Johnson, 1989). In the PNS of the 
chick, p75 NIR is present in embryonic premigratory neural cells and all the 
sympathetic, parasympathetic and sensory tissues derived from them (Heuer et al., 
1990; Hallbook et al., 1990; Wyatt et al., 1990). Moreover, in chick sensory ganglia, 
p75 NTR expression is increased during development as the first axons reach their 
targets. It continues to increase throughout target innervation, plateauing when all 
neurons have reached their target field (Wyatt et al., 1990).
v j 'r n
The role o f p75 is controversial and complex. In addition to regulating Trks
signalling and neuronal responsiveness to neurotrophins, p75 NTR can also directly act 
as both an inhibitor and promoter of apoptosis, dependent upon presence and/or 
absence o f neurotrophin ligands. The complex balance between concentration of 
Trks and p75 NTR, their direct and indirect actions and the presence and absence of 
endogenous or exogenous ligands, determine the cellular outcome of neurotrophin 
binding at different developmental stages. These factors will be discussed briefly 
here
p75 NTR as a regulator of Trk responsiveness
p75 NTR has been shown to alter responsiveness to neurotrophins. Studies using 
transgenic mice show that NT-3- induced survival of sympathetic neurons via TrkA, 
is more effective in the absence of p75 NTR (Brennan et al., 1999). Such an inhibitory 
effect on NT-3/TrkA mediated neurite outgrowth was also observed in vitro in 
cultured PC 12 cells8 (Benedetti et al., 1993; Clary and Reichardt, 1994). Conversely 
cultured embryonic DRG and SCG neurons from p757' mice show a decreased
8 PC 12 cells are sympathetic neurons.
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response to NGF, suggesting p75 NTR enhances NGF-induced TrkA signalling (Lee et 
al., 1994).
p75 NIR, a promoter of survival or anoptosis
As well as regulating Trk signalling, p75 NTR is able to regulate cellular survival in 
the absence of Trks. p75 NTR appears to both promote survival and apoptosis, 
depending upon the subpopulation of neurons. In the CNS, p75 NTR has been shown 
to promote death of chick retinal cells (Frade et al., 1996; Frade and Barde, 1998), 
spinal motor neurons (Frade and Barde, 1999), oligodendrocytes (Casaccia-Bonnefil 
et al., 1996) and basal forebrain cholinergic neurons of the mouse (Van der zee et al., 
1996; Yeo et al., 1997), whilst enhancing cell survival of rat hippocampal neurons in 
the presence o f glutamate (Bui et al., 2002). In the PNS, p75 NTR promotes apoptosis 
of chick trigeminal neurons (Davey and Davies, 1998) and mouse sympathetic 
neurons o f the SCG (Majdan et al., 2001), whilst enhancing survival of mouse 
sensory neurons of the DRG in the absence of trophic support (Barrett and Barlett, 
1994; Longo et al., 1997).
Several signalling pathways have been implicated in the mediation of the effects of 
p75 NTR. Survival effects are thought to be mediated by the transcription factor NFkB 
(Carter et al., 1996; Hamanoue et al., 1999; Foehr et al., 2000; Gentry et al., 2000), 
whilst c-Jun N-terminal kinase (JNK) pathways have been implicated in pro- 
apoptotic effects (Cassaccia-Bonnefil et al., 1996; Yoon et al., 1998; Harrington et 
al., 2002). Induction of the intracellular mediator, ceramide, through hydrolysis of 
sphingomyelin (Dobrowsky et al. 1994,1995) has also been shown to occur
N T Rfollowing p75 activation.
Binding o f the zinc finger protein, neurotrophin receptor interacting factor (NRIF) 
has been shown to play a role in p75 NTR -induced apoptosis (Bamji et al., 1998; 
Casedemunt et al., 1999). Tumor Necrosis Factor Receptor Associated Factor-6
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(TRAF-6)9 has also been shown to mediate p75 NTR signalling via NFkB and INK 
signalling (Foehr et al., 2000; Yeiser et al., 2004).
The effects o f p75 NTR in certain cell types also vary depending on the presence or 
absence of neurotrophin ligands. In PC 12 cells, p75 NTR was shown to enhance 
apoptosis in the absence of NGF (Rabizadeh et al., 1993), but in the presence of 
NGF, cell death by p75 NTR was inhibited (Rabizadeh et al., 1993). The use of 
antisense oligonucleotides against p75 NTR show that the survival response o f early 
DRG neurons (E l2 -E l5) to NGF is lost in the absence of p75 NTR. However, by E l9 
-  P2, the absence of p75 NTR enhances the survival o f DRG neurons in the absence of 
NGF (Barrett and Bartlett, 1994). These results not only highlight the effects of 
ligand upon p75 NTR - induced apoptosis, but also detail a developmental switch in 
sensory neurons of the role of p75 NTR as an inhibitor o f apoptosis to one of 
promotion.. This role in apoptotis for p75 NTR could be important during the 
developmental periods of naturally occurring cell death that occur within both the 
PNS and CNS (Bamji et al., 1998; Casedemunt et al., 1999).
Mice with a null mutation in the gene encoding the p75 NTR receptor are viable and 
fertile. However, sensory deficits due to defective innervation of TrkA expressing 
peptidergic sensory neurons lead to an impaired response to heat and noxious stimuli 
(Lee et al., 1992; Stucky and Koltzenberg, 1997; Bergmann et al., 1997). This could 
be due to alterations in the response to neurotrophins in the absence o f p75 NTR, 
mentioned previously. It would seem that p75 NTR plays an essential part of the 
functional development of, and not just survival of, sensory neurons.
NTR •Regulation o f p75 expression
Several factors, most notably the neurotrophin NGF, have been shown to contribute 
to the regulation o f p75 NTR expression. In cultured embryonic and adult sensory 
neurons, NGF promotes an increase in p75 NTR mRNA expression (Wyatt et al., 
1993).: Lindsay et al., 1990; Verge et al., 1992). Likewise, NGF enhances p75 NTR
9 Tumour Necrosis Factor (TNF) is a cytokine with a number o f proinflammatory actions. TRAF-6 is 
a protein that can associate with TNF receptor to modify its action.
54
mRNA expression in neonatal and adult sympathetic neurons both in vitro and in 
vivo (Doherty et al., 1988; Miller et al., 1991, 1994; Verge et al., 1992). However, 
mice with a null mutation in the NGF gene show no alterations in p75 NTR expression 
within trigeminal ganglia (Davies et al., 1995), illustrating that the normal 
developmental expression pattern of p75 NTR is not dependent upon endogenous 
NGF.
p75 NTR expression on Schwann cells increases following nerve transection (King et 
al., 2000), and the number of myelinated axons and thickness of myelin is 
significantly reduced in p75'/'mice following sciatic nerve injury, suggesting a role
KJTp
for p75 in remyelination following peripheral nerve injury (Song et al., 2006). 
BDNF and NT-3 increase in p75 on Schwann cells at the lesion site (King et al., 
2000), and a role for BDNF in the successful regeneration and remyelination of 
axons following nerve injury has been suggested previously (Zhang et al., 2000;
Song et al., 2006). It is possible that these effects of BDNF are thus mediated 
through p75 NTR signalling on Schwann cells.
The Trk family
The second class o f neurotrophin receptors, the Trk (tropomyosin kinase) family, 
were discovered after p75 NTR. This family has of three members: TrkA, TrkB and 
TrkC, with each member displaying several characteristic features. On the 
extracellular portion, three leucine repeat motifs are flanked by cysteine rich clusters. 
Two immunoglobulin (IgG)-like domains, adjacent to the transmembrane region are 
responsible for neurotrophin binding (Martin-Zanca et al., 1989; Perez et al., 1995) 
and an intracellular tyrosine kinase domain provides catalytic effects.
The trk proto-oncogene was first isolated from a human colon carcinoma biopsy 
(Martin-Zanca et al., 1989). This 140kDa glycoprotein was referred to as “gpl40trk” 
and subsequently “TrkA”. Other trk-related transcripts were isolated by screening a 
mouse brain cDNA library using a human trk probe under relaxed hybridisation
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conditions. This led to the discovery of the 145kDa (approximately) TrkB (Klein et 
al., 1989) and TrkC (Lamballe et al., 1991) receptors.
Splice variants
Several splice variants o f the Trk receptors have been characterised. Two isoforms of 
TrkA exist, TrkAI and TrkAII, which differ by the insertion of a 6 amino acid insert 
into the extracellular domain (Barker et al., 1993). The presence of the insertion 
(TrkAII) appears to have no effect on either affinity of ligand binding or on receptor 
signalling. In the rat and human, only the TrkAII form is expressed in neuronal 
tissues at appreciable levels. TrkAI expression is found in non-neuronal cells such as 
mast cells (Barker et al., 1993; Horigome et al., 1993).
Two truncated TrkB transcripts, TrkB.Tl and TrkB.T2, have been observed. They 
are identical to the 9kb (145kDa) TrkB protein, but lack the cytoplasmic region 
containing the catalytic tyrosine kinase domain (Klein et al., 1990; Ninkina et al., 
1996; Middlemas et al., 1991). This renders these isoforms catalytically inactive. 
Other isoforms, which contain deletions in the leucine-rich motifs o f the extracellular 
domain, also exist (Ninkina et al., 1997).
The truncated ‘inactive’ forms of TrkB receptors appear later in development than 
the complete form (Escandon et al., 1994). The physiological role o f these receptors 
is unsure. Experimental studies have shown that presence o f the truncated forms can 
attenuate the survival response of BDNF, acting via catalytic TrkB. This could be 
due to competitive effects of two splice variants for BDNF binding, or be due to 
formation of inactive receptor heterodimers (Eide et al., 1996; Ninkina et al., 1996). 
Due to the location of the truncated versions on the choroidal plexus and ependymal 
linings of the cerebral ventricles, it has been proposed that they may mediate the 
active transfer o f the ligand BDNF (or even NT-4/5) around the brain and might aid 
transfer across the blood brain barrier (Klein et al., 1990). Other suggestions include 
a role in the recruitment of ligand for the catalytic form of the TrkB receptor, or that 
these truncated versions are not receptors at all, but may function as cell adhesion
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molecules, or ligands for an, as yet, unknown receptor (Klein et al., 1990; Middlemas 
et al., 1991).
At least four isoforms of the TrkC receptor have been identified. Three contain an 
insert into the kinase domain, while one is truncated and lacks the intracellular 
catalytic kinase domain (Tsoulfas et al., 1993; Valenzuela et al., 1993). Insertion of 
the TrkC iso forms into PC 12 cells, reveal that those containing an insert in the kinase 
domain can still autophosphorylate in response to NT-3. However, it is unable 
promote neurite outgrowth (Tsoulfas et al., 1993; Valenzuela et al., 1993; Guiton et 
al., 1995). It is o f note that truncated TrkC is the only isoform found in astrocytes 
and non-neuronal cells (Valenzuela et al., 1993).
Neurotrophin Receptor signalling:
When Trk receptors bind with ligands they form homodimers. As a result, the 
autophosphorylation o f specific tyrosine residues on the intracellular portion of the 
receptor can occur (reviewed in Kaplan and Stephens, 1994). The phosphorylated 
residues act as docking sites for intracellular signalling proteins that carry Src 
homology-2 (SH-2) domains or phosphotyrosine-binding (PTB) motifs. These 
adaptor molecules link Trks to signalling pathways, which include the 
phosphatidylinositol-‘3 kinase (PI3-K)/Akt kinase, the ras/ERK (extracellular signal- 
regulated kinase) pathway and the phospholipase C y (PLC y) pathways. Activation 
of these pathways ultimately leads to regulation of gene expression by stimulation of 
transcription factors.
Mutational studies have shown that the She family o f proteins are important adaptor 
molecules for neurotrophin signalling and activation of the ras/ERK pathways 
(Minichello et al., 1998). The She family consists of ShcA, ShcB/SCK and the most 
recently discovered neuronal She (n-Shc) also known as “ShcC” (Nakamura et al., 
1996). The neuronal form is active in the CNS, while other members have signalling 
roles in non-neuronal tissues. n-Shc binds to phosphotyrosine residues on Trks via 
two domains, either the Src homology domain-2 (SH-2) domain or the
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phosphotyrosine binding domain (PTB) (Kavanaugh and Williams, 1994). This 
allows phosphorylation o f tyrosine residues and subsequent binding to the Grb2 
(Growth factor receptor bound protein 2) adaptor protein. Activation o f the 
MAPK/ERK signalling pathway then ensues. This pathway involves activation o f the 
G protein “ras” , the serine/threonine kinase “r a f ’, mitogen and extracellular 
regulated kinase (MEK) and the extracellular signal-regulated kinase (ERK) 
(Obermeier et al., 1994; Stephens et al., 1994; Marshall et al., 1995). Activated 
ERKs can then regulate gene expression via activation o f specific transcription 
factors and produce effects on neurite outgrowth (Vambutas et al., 1995). This is 
illustrated more clearly in figure 1.8.
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Figure 1.8. Signalling via the ras/ERK pathway. Taken from 
http://fbspcuO 1 .leeds.ac.uk/users/bmbatrl/apoptosis 13 .gif
Two o f the key phosphotyrosine residues required for activation o f Ras/ERK 
signalling cascades were determined using PC 12 cells carrying TrkA receptors with
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mutations at phosphotyrosine sites Y490 and Y785 (Stephens et al., 1994; Obermeier 
et al., 1994). Mutation of tyrosine residues individually had no effect, but the 
combined mutation of both resulted in lack of activation of ERK and attenuation of 
the subsequent neurite outgrowth. This would indicate that phosphorylation of both 
Y490 and Y785 is important in activating the Ras/ERK pathway in PC 12 cells.
Another adaptor protein, the 90kDa Sue 1-associated tyrosine phosphatase-1 (SHP-1) 
or fibroblast growth factor receptor substrate-2 (FRS), is phosphorylated following 
neurotrophin binding. It is thought to be of importance in neurotrophin signalling via 
the ERK/MAPK pathway (Rabin et al., 1993; Ong et al., 1996). SHP-1 competes 
with SHC for phospho-Y490 on activated TrkA (Meakin et al., 1999).
Phosphorylated SHP-1 is then able to bind to other adaptor proteins, including Grb2 
(Growth factor receptor bound protein 2) (Califano et al., 2000), Crk and the 
phosphatase SH-PTP-2 (Meakin et al., 1999). This ultimately results in activation of 
the ERK/MAPK signalling pathway, with effects on differentiation and survival 
(Meakin et al., 1999). SHP-1 thus provides an alternative to SHC for activation of the 
ERK/MAPK pathway.
As discussed earlier, Trk activation also activates other signalling pathways 
including the PI3-K (phosphatidylinositol-‘3 kinase) pathway. She proteins mediate 
activation of the PI3-K pathway through recruitment of the adaptor protein Grb2 that 
can then bind to Gabl (Grb-2 associated binder-1), which in turn binds to and 
activates PI3-K. Activation of the enzyme PI3-K results in stimulation of the serine 
threonine kinase Aktl which can exert inhibitory or excitatory effects on a number of 
other proteins, including the transcription factor forkhead, the pro-apoptotic proteins 
BAD and p53 and activation of the NFkB signalling pathway. PI3-K signalling 
produces effects on cell survival and gene transcription with a cascade of other 
effects (Reviewed in Huang and Reichardt 2001).
Phospholipase Cyl (PLC-yl) signalling pathways begin with binding of PLC-yl 
directly to phosphorylated Y785 on activated TrkA (Vetter et al., 1991; Stephens et 
al., 1994). This leads to the generation of the second messengers inositol tris-
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phosphate (IP3) and diacylglycerol (DAG). The increased level of EP3 mobilises 
Ca2+ from storage organelles causing an increase in intracellular Ca2+. This allows 
activation of Ca2+ dependent enzymes including Ca2+ regulated forms of protein 
kinase C (PKC) and Ca2+ calmodulin dependent kinases and phosphatases. DAG also 
stimulates activation of PKC iso forms, including PKC8, which can induce neurite 
outgrowth in PC 12 cells and can also activate the ERK cascade (Corbit et al., 1999).
A more in-depth look at the functional outcome of each signalling pathways 
associated with NGF-induced growth and differentiation during development has 
been studied using mice in which the gene encoding the pro-apoptotic protein Bax 
has been knocked out (Markus et al., 2002). Neurons from these mice can grow in 
culture in the absence of NGF, allowing effects of exogenous signalling mediators to 
be observed. Experimental studies have found that Raf-Erk signalling can mediate 
axon elongation, whilst PI3K/Akt pathways influence other aspects such as axon 
branching (Markus et al., 2002).
1.6.2. The GDNF family
The GDNF family of neurotrophic factors are distant members of the transforming 
growth factor beta (TGFP) superfamily, with all members containing the seven 
cysteine residues in the same spacing (cysteine knot), characteristic of this family. 
The GDNF family contains glial cell line-derived neurotrophic factor (GDNF), 
persephin, neurturin and the most recently discovered artemin. Unlike other TGFp 
family members, the GDNF family signals via a receptor tyrosine kinase called Ret 
(Jing et al., 1996; Treanor et al., 1996) rather than the typical serine/threonine 
kinases utilised by other members of the TGFp family. Receptors for the GDNF 
ligands (GDNFLs) are multicomponent (Treanor et al., 1996) consisting of the 
common signalling receptor tyrosine kinase Ret, and a member o f the GFRa family: 
G FR al, 2, 3 or 4 which confers ligand specificity (Jing et al., 1996; Treanor et al., 
1996; Trupp et al., 1996). The GFRa protein is activated by binding of the correct 
homodimeric GDNF family ligand. It can then form a homodimeric complex that
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binds to ret, leading to its dimerisation, phosphorylation and ultimately intracellular 
signalling (illustrated in figure 1.9).
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Figure 1.9. GDNF family signalling. A homodimer of the GDNF family ligand binds to its preferred 
GFRa protein, leading to its dimerisation and binding to ret. Ret now dimerises, leading to 
autophosphorylation o f its tyrosine residues and subsequent signalling. Taken from Sariola and
Saarma, 2003.
Preferentially, GDNF binds to G FR al (Jing et al., 1996, 1997; Treanor et al., 1996), 
neurturin to G FR a2 (Baloh et al., 1997; Buj-Bello et al., 1997; Klein et al., 1997; 
Sanicola et al., 1997), artemin to GFRa3 (Baloh et al., 1998a) and persephin to 
G FRa4 (Masure et al., 2000; Enokido et al., 1998), although some receptor 
promiscuity has been observed. Neuronal cultures have revealed that GDNF can also 
signal through G FR a2 (Sanicola et al., 1997; Jing et al., 1997), neurturin through 
G F R al and 4 (Creedon et al., 1997; Jing et al., 1997) and artemin can also bind to 
G F R al (Baloh et al., 1998b). It is o f note that persephin only binds to G FRa4 
(Enokido et al., 1998; Lindahl et al., 2000). These binding affinities are illustrated in
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figure 1.10. Despite such receptor cross-talk apparent in vitro, analysis o f knockout 
mice has revealed that in vivo, each ligand shows a more specific role, binding to its 
preferential receptor complex.
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Figure 1.10.
GDNF family ligand binding to preferred GFRa family members (shown in bold arrows). Other 
ligand/receptor interactions are also shown (dashed arrows). Taken from Sariola and Saarma, 2003.
Following ret phosphorylation, several intracellular signalling pathways are 
activated. M ost o f  these pathways are similar to those activated by neurotrophin/Trk 
binding mentioned previously. Phosphorylation o f ret on specific tyrosine residues 
(Y905, Y1015, Y1062, Y1096) allows the binding o f proteins to PTB or SH2 
domains on ret (Asai et al., 1996; Arighi et al., 1997; Tsui-Pierchala et al., 2002). 
These molecules include the she family, Grb proteins, and the adaptor proteins Crk 
and Nek (Pandey et al., 1995, 1996; Bocciardi et al., 1997; De Falco et al., 2005). 
These proteins act as signalling intermediates, and upon binding activate several 
intracellular signalling pathways such as the MAPK/Akt, PI3K and JNK pathways.
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Activation of She and Grb2 leads to stimulation of both MAPK/Akt and the PI3K 
pathways, which are important in neurite outgrowth and survival (Kaplan and Miller, 
2000; Encinas et al., 2001; Murakami et al., 1999). Ret signalling via PI3K also 
stimulates activation of several focal adhesion proteins important in survival 
signalling, such as focal adhesion kinase (FAK), paxillin and pl30Cas (Murikami et 
al., 1999). PLCy can also bind to phosphorylated tyrosine residues of ret (Borrello et 
al., 1996). Activation of PLCy subsequently regulates intracellular calcium via an 
increase in inositol trisphosphate. This pathway also mediates the oncogenic activity 
of GDNF ligands (Borrello et al., 1996).
Two splice variants o f ret exist: a short iso form of 1072 amino acids, known as ret9, 
and a long iso form of 1114 amino acids, ret 51. Mice lacking the ret51 type are 
normal. On the other hand, mice lacking the short isoform suffer from renal 
abnormalities and enteric aganglionesis (Srinivas et al., 1999), which suggests a role 
for ret9 in kidney development. The two isoforms differ in binding sites for she 
proteins, with ret51 only containing the SH2 binding site, but the short isoform 
having both SH2 and PTB (Ohiwa et al., 1997; Lorenzo et al., 1997; Tsui-Pierchala 
et al., 2002). These isoforms can therefore form different signalling complexes 
explaining their differing cellular actions. ret51 can associate more strongly than ret9 
with the ubiquitin ligase Cbl, allowing faster turnover. Furthermore, it can bind to 
Crkl allowing activation of Erkl and Erk2 (Scott et al., 2005).
GFRa (GDNF family receptor) family members are bound to the outer leaflet of the 
plasma membrane via a GPI anchor (as shown in figure 1.9.). Such a location 
suggests the ability to recruit and signal via the cholesterol rich microdomains, 
known as lipid rafts. Research on GDNF and GFRal signalling has shown that 
G FRal recruits ret to lipid rafts, where it can then bind to adaptor proteins and other 
signalling molecules such as src kinases within or outwith the raft (Tansey et al., 
2000; Encinas et al., 2001; Paratcha et al., 2001). The formation of lipid rafts is 
essential for GDNF-induced signalling, differentiation and neuronal survival (Tansey 
et al., 2000). However, GFRa4, the receptor component binding persephin, does not
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have the ability to recruit ret to lipid rafts (Yang et al., 2004). It is o f interest that 
following GDNF activation, ret preferentially associates with She outside of lipid 
rafts, leading to activation of MAPK/Akt pathways. However, within the rafts, She 
binds with FGF ,FRS2, suggesting that GDNF signalling through ret inside and 
outside of rafts can produce different responses (Paratcha and Ibanez, 2002)
GFL signalling via such GFRa/ret complexes is fairly well characterised. However, 
expression of GFRa family members is more widespread than that of ret, suggesting 
that GFLs may be able to signal via another receptor type (Trupp et al., 1997; Golden 
et al., 1998; Kokaia et al., 1999). It has been shown that in the absence of ret, GDNF 
family members can signal via the neural cell adhesion molecule (NCAM) in various 
parts o f the nervous system (Paratcha et al., 2003; Enomoto et al., 2004). In the 
absence of ret, G FR al is able to bind to NCAM, which facilitates binding of the 
GDNF ligand to NCAM and subsequent activation of the cytoplasmic kinases, Fyn 
and focal adhesion kinase (FAK) (Paratcha et al., 2003).
1.6.2.1. Glial cell line derived neurotrophic factor
GDNF was initially characterised as a neurotrophic factor for embryonic midbrain 
dopaminergic neurons, supporting survival and differentiation as well as promoting 
increased dopamine uptake (Lin et al., 1993). GDNF has since been shown to exert 
effects on several other CNS neurons including spinal cord motor neurons 
(Henderson et al., 1994; Oppenheim et al., 1995), facial motor neurons (Yan et al.,
1995), central adrenergic neurons (Arenas et al., 1995), cerebellar Purkinje neurons 
(Mount et al., 1995) and cholinergic neurons of the basal forebrain (Williams et al., 
1996; Golden et al., 2003). In the PNS, GDNF supports the survival of cranial 
parasympathetic neurons and sensory neurons of the nodose ganglia, DRG and 
trigeminal ganglia (Trupp et al., 1995; Ebendal et al., 1995; Hashino et al., 2001; 
Forgie et al., 1999; Enomoto et al., 2000; Hashino et al., 2001). GDNF can also 
promote cell survival and neurite outgrowth from PC 12 cells (Chen et al., 2001) via 
PI3K and MAPK dependent mechanisms, respectively (Chen et al., 2001; Encinas et
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al., 2001). GDNF can also support neurons of the enteric nervous system (Hearn et 
al., 1998; Heuckeroth et al., 1998).
Consistent with these effects, GDNF mRNA is detectable in various areas of the rat 
brain and developing spinal cord (Schaar et al., 1993; Trupp et al., 1995; Golden et 
al., 1998). Outside the nervous system, GDNF mRNA expression is detected in 
developing skin, kidney, bladder, stomach and testis with a lower expression in 
developing skeletal muscle, lung, ovary and adrenal gland (Trupp et al., 1995; 
Golden et al., 1998; 1999; Kawakami et al., 2003). Such a high expression in non­
neuronal tissues might suggest other important functions for GDNF, as confirmed by 
studies of the phenotype of mice lacking GDNF or G FRal (Moore et al., 1996; 
Sanchez et al., 1996; Pichel et al., 1996; Cacalano et al., 1998; Enomoto et al., 1998). 
In both GDNF’7' and G F R al'7’ mice, the enteric nervous system is absent and ureters 
and kidneys do not develop.. It is of interest that mice with a null mutation in the 
gene encoding ret show a similar phenotype. Mice homozygous for the mutation die 
shortly after birth with renal agensis or severe dysgenesis. The enteric nervous 
system is also undeveloped (Schuchardt et al., 1994).
The preferential ligand-binding component for GDNF is G FRal (Jing et al., 1996; 
Treanor et al., 1996), although GDNF can also bind with lower affinity to GFRa2 
(Sanicola et al., 1997; Jing et al., 1997). GFRal (Jing et al., 1996; Treanor et al.,
1996) is widely expressed throughout the body and in the nervous system of 
embryonic and adult mice (Golden et al., 1998; 1999; Kawakami et al., 2003), 
although not always co-localised with ret.
Studies of GDNF'7' and GFRal*7' mice have permitted further characterisation of the 
effects o f GDNF/GFRal signalling in the nervous system. GDNF'7* mice have 
reduced numbers o f neurons in the DRG, nodose ganglia and sympathetic neurons, 
but display normal development of hindbrain, noradrenergic, midbrain dopaminergic 
neurons and motor neurons (Moore et al., 1996; Sanchez et al., 1996). However, 
more recent studies using in vivo transgenic approaches and also in vitro experiments 
using neuronal cultures gave differing results, which are discussed here.
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GDNF regulation of motor neuron number has been extensively studied. A reduction 
in the majority of spinal and cranial motor neurons has been observed in GDNF7* and 
G F R al7' mice (Oppenheim et al., 2000; Garces et al., 2000; Cacalano et al., 1998). 
This role for GDNF in motor neuron development was also reflected in GDNF over­
expressing mice, which display enhanced motor neuron survival (Oppenheim et al., 
2000). Furthermore, in vitro studies using embryonic cultures of mammalian and 
avian motor neurons found that GDNF could support survival (Henderson et al., 
1994; Oppenheim et al., 1995; Soler et al., 1999) by a PI3K dependent pathway 
(Soler et al., 1999).
Survival o f DRG sensory neurons was found to be unaffected in GDNF7', G FR al7' 
and GDNF over-expressing mice (Oppenheim et al., 2000). A study of GFRal 
deficient mice showed no neuronal losses within peripheral ganglia, including SCG 
and nodose (Enomoto et al., 1998). On the other hand, in vitro experiments have 
shown a role for GDNF in the survival of a specific subpopulation of developing 
sensory neurons after birth. GDNF was found to only support the survival o f 10% of 
cultured rat embryonic DRG neurons (Kotzbauer et al., 1996; Matheson et al., 1997). 
However, a much greater proportion were rescued in cultured DRG neurons from 
newborn rats (Matheson et al., 1997; Bennett et al., 1998), which illustrates the 
switch in dependence from neurotrophins to GDNF ligands which occurs postnatally 
for a subpopulation of nociceptive neurons (Molliver et al. 1997; Baudet et al.,
2000). There was an additive effect of NTN and GDNF on the number o f surviving 
neurons, but no additive effect for cultures containing either o f these neurotrophic 
factors and artemin. This suggests that GFRal is expressed by a subpopulation of 
neurons distinct from those expressing the neurturin receptor component GFRa2, 
and that GFRa3 is expressed by both GFRal and GFRa2 expressing neurons 
(Baudet et al., 2000).
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1.6.2.2 Neurturin
The second member of the GDNF family, neurturin (NTN), was originally identified 
as a survival factor for cultured sympathetic neurons (Kotzbauer et al., 1996). It has 
since been shown to act as a neurotrophic factor for other populations o f neurons 
including sensory neurons of nodose and DRG (Kotzbauer et al., 1996; Forgie et al.,
1999), cranial parasympathetic neurons (Forgie et al., 1999; Hashino et al., 2001), 
spinal motor neurons (Klein et al., 1997), embryonic and adult dopaminergic neurons 
(Horger et al., 1998; Tseng et al., 1998) embryonic basal forebrain cholinergic 
neurons (Golden et al., 2003) and enteric neurons and glia (Heuckeroth et al., 1998). 
Like GDNF, active NTN is produced by cleavage of the 195 amino acid precursor 
molecule, preproNTN. The amino acid sequence of the, 100 amino acid, mature 
NTN, shares 42% similarity with GDNF (Kotzbauer et al., 1996).
NTN transcripts are detectable in the cerebral cortex, striatum, brain stem and pineal 
gland of the developing nervous system (Widenfalk et al., 1997). It is widely 
expressed in other areas of the body. Throughout development, high levels of NTN 
mRNA are detectable in pituitary, bladder, intestine and testis, and moderate levels in 
adrenal gland, kidney, ovary, thyroid and spleen. This would suggest that NTN might 
be involved in the maintenance of these peripheral organs, as well as a target derived 
neurotrophic factor for innervating neurons (Golden et al., 1999; Xian et al., 1999; 
Kawakami et al., 2003). In the adult, expression is much less widespread, being 
detected predominantly in the gut, testis and oviduct (Golden et al., 1999).
GFRa2 is the preferred ligand-binding portion of the NTN receptor. Mammalian 
GFRa2 was isolated by several groups (Baloh et al., 1997; Buj-Bello et al., 1997; 
Klein et al., 1997; Sanicola et al., 1997; Widenfalk et al., 1997). Expression is more 
widespread than NTN throughout the nervous system. GFRa2 is detectable in both 
the developing and the adult nervous system in areas of cortex, cerebellum, thalamus, 
hypothalamus and brain stem. In peripheral sensory neurons, GFRa2 is expressed
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predominantly in 80% of IB4 reactive small diameter neurons (Bennett et al., 1998), 
but is barely detectable in TrkA-expressing nociceptors. At various stages of 
development, GFRa2 is also present in other tissues, including bladder, heart, 
digestive tract, respiratory system, skin, bone and endocrine glands (Golden et al., 
1999; Kawakami et al., 2003).
Although neurturin preferentially signals via GFRa2, it can also to bind to GFRal 
and GFRa4 (Creedon et al., 1997; Jing et al., 1997). The recent identification of a 
cell-line, NG108-15, that endogenously expresses ret and G FR al, but not GFRa2 or 
GFRa4 has proved useful in the elucidation of the individual effects of NTN on 
G FRal (Lee et al., 2006). It has been demonstrated that application of GDNF, but 
not NTN could promote survival of NG108-15 cells through a MAPK signalling 
pathway. However NTN, but not GDNF was shown to promote neurite outgrowth 
(Lee et al., 2006). It appears that NTN and GDNF have differential effects via the 
G FRal-ret complex and the biological responses that occur are determined by ligand 
concentration and receptor availability.
Mice with null mutations in the neurturin or GFRa2 genes are viable and fertile, but 
show defects in parasympathetic cholinergic neurons, with poor innervation in the 
lacrimal and salivary glands (Heuckeroth et al., 1999; Rossi et al., 1999). Noxious 
heat transduction is also lost in this null mutant due to loss of IB-4 reactive 
nociceptive neurons (Stucky et al., 2002).
In culture, parasympathetic neurons are initially dependent upon GDNF for survival, 
but switch to NTN at a later stage of embryonic development (Forgie et al., 1999; 
Enomoto et al., 2000; Hashino et al., 2001). In developing DRG neurons, NTN is 
able to promote survival and enhance neurite outgrowth (Kotzbaur et al., 1996; Yan 
et al., 2003). Additionally, NTN can stimulate axon outgrowth from DRG of young 
adult mice (Paveliev et al., 2004).
Outside the nervous system, a role for NTN in the immune system has been 
suggested by the discovery that T cells, B cells and monocytes can all produce NTN
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(Vargas-Leal et al., 2005). Quantitative PCR also reveals that these cells express 
significant levels of GFRa2 transcripts (Vargas-Leal et al., 2005).
1.6.2.3. Persephin
Persephin (PSP), the third member of the GDNF family discovered, is cleaved from 
the 156 amino acid precursor, preproPSP (Milbrandt et al., 1998). The mature 
cleaved form has only 96 amino acids and shares 40% identity with GDNF and NTN. 
It is ubiquitously expressed throughout the CNS, but at very low levels (Milbrandt et 
al., 1998; Jaszai et al., 1998).
Culture studies have shown that PSP is able to promote survival and differentiation 
of embryonic basal forebrain cholinergic neurons, with an efficacy comparable with 
NGF (Golden et al., 2003). This suggests a role for PSP in the development of such 
neurons and thus in normal cognitive function. No survival effects on peripheral 
neurons have been observed.
GFRa4 comprises the ligand-binding portion of the PSP receptor. Mammalian 
GFRa4 (Masure et al., 2000; Lindahl et al., 2000) was isolated following earlier 
characterisation of the avian form (Enokido et al., 1998; Thompson et al., 1998). 
Mammalian GFRa4 has a markedly different sequence from the rest of the GFRa 
family and also lacks the first cysteine rich domain observed in G F R al-3. It also 
shares only 37% sequence similarity with the avian form (Masure et al., 2000). 
Unlike other GFRa family members, it does not recruit ret into lipid rafts upon 
ligand binding (Yang et al., 2004). The mammalian form is detected in both the 
developing and mature nervous system, and in testis and thyroid gland. It is also 
expressed at very low levels in developing and adult kidney, muscle spleen and liver 
(Lindahl et al., 2000; Masure et al., 2000). It is alternatively spliced in a tissue 
dependent fashion with a GPI linked isoform being exclusively expressed in juvenile 
thyroid C cells and parathyroid gland, but another transmembrane, non-GPI anchored 
form is present in new bom and adult thyroid, parathyroid pituitary and adrenal gland
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(Lindahl et al., 2000). In the peripheral nervous system, GFRa4 mRNA expression 
has been noted within the sympathetic chain ganglia and SCG and also in sensory 
neurons of the trigeminal ganglia and DRG (Lindahl et al., 2000). In adult DRG, 
transcripts do not encode the GPI anchored form (Paveliev et al., 2004).
Much evidence indicates the potential for PSP in the treatment o f Parkinson’s disease 
through protection of dopaminergic neurons. PSP is also able to support survival of 
cultured midbrain dopaminergic neurons to an extent comparable with GDNF 
(Akerud et al., 2002). In vivo, PSP is localised to nigrostriatal dopamine neurons and 
its receptor, GFRa4 is detected in midbrain dopaminergic neurons (Akerud et al., 
2002). Moreover, two weeks following 6-OHDA-induced injury, an increase in PSP 
mRNA is observed in the ipsilateral striatum. (Zhou et al., 2000). The use o f rodent 
models o f PD has further indicated therapeutic potential for PSP. In one study, neural 
stem cells were genetically engineered to over-express PSP and were grafted into the 
striatum of a rodent model of PD (Akerud et al., 2002). Within the first month, PSP 
dispersed successfully throughout the striatum, and in mice injured by 6-OHDA 
injections, the loss in dopamine neurons and behavioural impairment was prevented 
(Akerud et al., 2002). Furthermore in mice subject to OHDA lesioning, enhanced 
dopamine dependent behaviour was observed. The ability o f PSP to act only via one 
receptor, GFRa4, combined with its slightly more restricted expression pattern in 
comparison to other GDNF family members, might make it a more attractive 
candidate for the treatment of this neurodegenerative disorder than other members of 
the GDNF family.
Studies on PSP7' mice have indicated a role for PSP in neuroprotection following 
ischaemic insult. Phenotypically, PSP7' mice seem normal. They are viable, healthy 
and display no behavioural or developmental impairments. However, following focal 
ischaemia, the mice show increased cerebral infarction when compared with wild- 
type litter-mates (Tomac et al., 2002). Such effects could be attributed to the loss of 
regulatory effects o f PSP on glutamate-induced Ca2+ influx. Without regulation, a 
dramatic influx in Ca2+ could lead to neuronal damage.
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Mutations in the GFRa4 gene have recently been implicated in the rare inherited 
cancer syndrome, multiple endocrine neoplasia 2 (MEN2) also known as Sipple’s 
syndrome). It leads to medullary carcinoma of the thyroid gland and 
phaeochromocytoma (neuroendocrine tumour of the adrenal gland resulting in 
excessive secretion of catecholamines). This disorder has been attributed in part to 
mutations in the ret receptor gene. However the phenotypic variability in MEN2 
sufferers who carry the same ret mutation, combined with the finding that a small 
minority o f patients do not have mutations in the ret gene, suggest that other factors 
are involved. The GFRa4 gene has been implicated by the overlapping expression of 
ret and GFRa4 (but not other GFRa family members), in normal and malignant 
thyroid medullary cells (Lindahl et al., 2001). Two particular mutations were found 
in patients suffering from this disorder. The first was a single base substitution 
upstream of the coding region, altering the reading frame of the receptor. The 
second, was a 7 base pair insert that would alter the formation of ret signalling 
complexes through a shift in membrane binding (Vanhome et al., 2005). It is thought 
that these mutations might contribute to MEN2 in the absence of a ret mutation, or 
that they might alter the ret mutation phenotype (Vanhome et al., 2005).
1.6.2.4. Artemin
The 113 amino acid mature protein, artemin (ART) was the last of the GDNF family 
to be cloned (Baloh et al., 1998b; Masure et al., 1999). The rodent form was cloned 
by exploring DNA databases using NTN as a query (Baloh et al., 1998b). Masure et 
al., (Masure et al., 1999) isolated and characterised the human form of artemin and 
subsequently named it “enovin”. For the purpose of this thesis however, the rodent 
form will be discussed. Artemin has 45% sequence identity with NTN and PSP, and 
slightly less similarity (36%) with GDNF. It was first isolated for its ability to 
support the survival of sympathetic and sensory neurons in culture, but has also been 
shown to promote survival of dopaminergic neurons signalling via the GFRal-Ret 
receptor (Baloh et al., 1998b). This highlights the cross talk between receptor types. 
Artemin mRNA is present at low levels in fetal and adult brain. In the CNS, artemin 
transcripts are detectable in basal ganglia and thalamus. Its expression in non­
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neuronal tissues is observed in pituitary gland, placenta and trachea o f the adult and 
in the kidney and lung of the fetus (Baloh et al., 1998).
Only artemin can bind to GFRa3, with no other GFLs having this affinity. The 
amino acid sequence of GFRa3 is 32% identical with GFRal and 37% identical 
with GFRa2 (Naveilhan et al., 1998; Baloh et al., 1998a; Widenfalk et al., 1998; 
Worby et al., 1998). Unlike GFRal and GFRa2, whose expression is found in 
overlapping populations of the adult rodent CNS, expression of GFRa3 is primarily 
in the PNS. It is predominantly expressed by small diameter nociceptive sensory 
neurons, the majority co-expressing TrkA, CGRP and VR1. A significant proportion 
are IB4 reactive (Baloh et al., 1998a; Naveilhan et al., 1998; Widenfalk et al., 1998; 
Worby et al., 1998; Orozco et al., 2001). GFRa3 immunoreactivity is barely 
detectable in the adult, although during development prominent expression can be 
detected in the DRG and trigeminal sensory ganglia where it is found on a mixed 
subpopulation of neurons that also express GFRal or GFRa2 (Baloh et al., 1998a; 
Naveilhan et al., 1998; Widenfalk et al., 1998; Worby et al., 1998; Baudet et al.,
2000). It is also expressed on sympathetic neurons (Baloh et al., 1998a; Widenfalk et 
al., 1998; Worby et al., 1998), and on non-neuronal immature Schwann cells 
(Widenfalk et al., 1998).
Prominent expression during development and production of artemin by Schwann 
cells suggest that artemin influences the development of PNS neurons (Baloh et al., 
1998b). Artemin expression is detectable in blood vessels embryonically, at a time 
when sympathetic neurons are using blood vessels as the pathway to reach their final 
target tissues (Enomoto et al., 2001). Study of ret7'mice, artemin7' mice and GFRa3' 
A mice reveal defects in sympathetic neuron migration, axonal outgrowth and 
neuronal survival (Nishino et al., 1999; Enomoto et al., 2001; Honma et al., 2002; 
Andres et al., 2001). Furthermore, in vitro, early embryonic SCG cultures show 
enhanced neurite outgrowth in the presence of artemin (Yan et al., 2003). Artemin 
also promotes proliferation of sympathetic neuroblasts (Andres et al., 2001).
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Artemin is also important in the development of sensory neurons, but at slightly later 
stages. It can support the survival of a proportion of cultured sensory DRG neurons 
at early postnatal stages and also enhance neurite outgrowth (Yan et al., 2003). 
Neurons rescued correspond to the IB4 reactive population of neurons 
(approximately 35% of total DRG) that switch dependence from NGF to GDNF 
family ligands after birth (Baloh et al., 1998b; Widenfalk et al., 1998). It is of 
particular interest that by late postnatal ages, artemin signalling is able to inhibit 
survival effects of other GDNF family members. Experiments by Baudet et al., 
(Baudet et al., 2000) using cultures of PI 5 DRG neurons demonstrated that artemin, 
in combination with GDNF and/or neurturin, supported the survival o f significantly 
fewer neurons than with either factor alone. It is unclear why this effect is observed 
at these ages, but it has been postulated that possible formation of heterodimeric 
complexes might prevent receptor binding, or, that artemin might possibly signal via 
another receptor in order to promote inhibitory effects (Baudet et al., 2000).
In the adult, it has been suggested that artemin might have a role following neuronal 
injury. Following sciatic nerve axotomy, a dramatic increase in GFRa3 expression in 
DRG neurons occurs such that all small diameter DRG neurons were found to be 
GFRa3 immuno-reactive (Bennett et al., 2000). An increase in artemin production 
from Schwann cells was also apparent (Baloh et al., 1998b). These findings suggest a 
possible role for artemin in injury associated neuropathic pain. This is supported by 
the observation that administration of artemin following SNL leads to a reversal of 
nerve-injury related pain behaviour and the associated alterations in biochemical 
phenotype (Gardell et al., 2003). Artemin antagonists are therefore of potential 
therapeutic benefit in the treatment of neuropathic pain. A role for artemin following 
neuronal trauma and in nerve regeneration is also implicated following the 
observation that it is able to stimulate axon outgrowth in cultured DRG neurons 
taken from the young adult mouse (Paveliev et al., 2004). It is thus of potential 
therapeutic benefit following neuronal trauma.
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1.6.3. The plasminogen-related growth factors
Plasminogen-related growth factors (or cytokine-related factors) are a new family of 
growth factors related to the blood proteinase plasminogen. This family contains just 
two factors: hepatocyte growth factor/scatter factor/plasminogen-related growth 
factor 1 (HGF/SF/PRGF1) and macrophage stimulating protein/plasminogen-related 
growth factor 2 (MSP/PRGF2). These factors will be referred to as “HGF” and 
“MSP”.
Both of these factors have evolved from the same ancestral gene as plasminogen and 
apolipoprotein that consisted of an N-terminal corresponding to the plasminogen 
activation peptide (PAP), at least 3 copies of the kringle domain10 and a serine 
protease domain (Donate et al., 1994). It is of interest that activation of plasminogen 
and apolipoprotein requires cleavage o f the N terminal domain. This does not occur 
for HGF and MSP, suggesting that this portion is important for their function 
(Matsumoto et al., 1991; Okigaki et al., 1992; Donate et al., 1994). Like other 
members of the family, HGF and MSP are secreted as inactive single chain 
precursors (pro-MSP and pro-HGF). These precursors are cleaved by trypsin-like 
serine proteases to produce the biologically active molecules (Naldini et al., 1992). 
Proteolysis produces a disulphide linked otp chain heterodimer, the a  chain 
containing the kringle subunit (62 kDa for HGF and 53kDa for MSP) and the P chain 
forming the serine proteinase-like subunit (32kDa for HGF and 62kDa for MSP) 
(Skeel et al., 1991). This is shown for MSP in figure 1.11. (taken from Leonard and 
Danilkovitch, 2000). Unlike plasminogen and apolipoprotein, MSP and HGF have no 
enzymatic activity due to amino acid substitutions in catalytic triad of the p subunit 
(Yoshimura et al., 1993).
10 Kringle domain -  a conserved sequence in a triple disulphide loop structure
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Figure 1.11 The cleavage o f  MSP from  its precursor pro-M SP by trypsin-like serine proteases (Taken
from Leonard and Danilkovitch, 2000)
1.6.3.1. Hepatocyte growth factor
Hepatocyte growth factor (HGF), also known as scatter factor (SF), is a pleiotropic 
factor which was discovered independently by several groups as a molecule that was 
able to trigger motility, proliferation and morphogenesis in a variety o f epithelial and 
other cells (Ebens et al., 1996; Montesano et al., 1991; Shima et al., 1991; Weidner et 
al., 1991; Gheradi et al., 1989; Nakamura et al., 1989; Miyazawa et al., 1989; Rubin 
et al., 1989; Stoker et al., 1987). HGF has since been found to have a wide variety of 
roles. Thus during embryogenesis, HGF is required for development o f many organs 
and tissues including liver, kidney, lung, gut, skeletal muscle and placenta 
(Matsumoto et al., 1996; reviewed in Birchmeier and Gherardi, 1998). In the adult, it 
supports the regeneration of organs such as liver, lung and kidney (Ueki et al., 1999; 
Matsumoto et al., 1996).
HGF is found in both the developing and mature CNS and PNS where it displays 
neurotrophic factor-like activity (Thompson et al., 2004; Hamanoue et al., 1996;
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Maina et al., 1997; Maina and Klein, 1999; Davey et al., 2000; Ebens et al., 1996; 
Wong et al., 1997; Yamamoto et al., 1997). It is localised both in neurons and in non­
neuronal cells including Schwann cells, for which it is a mitogen (Krasnoselsky et 
al., 1994), and microglia (Hamanoue et al., 1996). Thus, HGF may affect neurons 
both directly, through receptors on neurons, and indirectly, through actions on non­
neuronal cells. It would seem, for example, that survival and maturation of 
embryonic rat dopaminergic mesencephalic neurons is promoted by HGF secreted 
from microglia (Hamanoue et al., 1996). During development, HGF itself can 
directly support the survival of a subpopulation of motoneurons of a similar size to 
that supported by either BDNF or CNTF (Ebens et al., 1996; Wong et al., 1997; 
Yamamoto et al., 1997).
In the PNS, HGF has no effect on sensory neurons on its own, but enhances 
neurotrophic factor effects of NGF and CNTF on differentiation, axonal outgrowth 
and survival in vitro (Maina et al., 1997; Maina and Klein, 1999; Davey et al., 2000). 
Mice which carry a signalling defect in the HGF receptor (met) gene have 
intercostal nerves that are significantly shorter and contain less branching than their 
wild type litter mates, further suggesting that HGF signalling is important in the 
development of sensory neuronal populations (Maina et al., 1997). HGF is also 
important in development of other peripheral neurons. It can promote survival and 
neurite outgrowth of mature sympathetic neurons in vitro (Thompson et al., 2004) 
and also enhance in vitro effects of NGF-induced neurite outgrowth (Maina et al.,
1998). The use of pharmacological inhibitors has shown that effects on survival and 
growth of sympathetic neurons are actioned through PI-3 kinase and MAP kinase 
dependent mechanisms (Thompson et al., 2004).
The HGF receptor is encoded by the c-met proto-oncogene, a transmembrane protein 
with tyrosine kinase activity. This oncogene was identified by immunoblot analysis 
(Bottaro et al., 1991) and confirmed as the receptor for HGF/SF by further 
experiments, which included ligand induced tyrosine phosphorylation of the p 
subunit and co-precipitation (Naldini et al., 1991).
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The importance of HGF signalling has been highlighted by the generation of mice 
with a null mutation in the gene encoding HGF. HGF'A mice die as embryos, 
suggesting an essential role for HGF signalling in development (Schmidt et al., 1995; 
Uehara et al., 1995). Livers from embryos are much reduced in size. Embryos also 
lack muscles of the forelimbs and diaphragm, confirming an important role for HGF 
in organogenesis and tissue development. Furthermore, placental function is severely 
impaired, so that it is unable to invade maternal uterine tissue in order to expand the 
placenta, implicating HGF in placental invasive growth. The early lethality of this 
defect in these mice prevents the investigation into roles for HGF in the adult.
1.6.3.2. Macrophage stimulating protein
Macrophage stimulating protein (MSP) was originally characterised as a chemotactic 
factor for macrophages (Leonard and Skeel, 1978). It has since been isolated from 
human blood plasma. Cloning (Skeel et al., 1991;Yoshimura et al., 1993) has 
allowed further characterisation and the identification of additional functions. MSP 
has been shown to modulate the growth of various cell types, including the 
enhancing of proliferation of keratinocytes (Wang et al., 1996); the growth of bone 
marrow megakaryocytes (Banu et al., 1996) and resorption of bone by osteoclasts 
(Kurihara et al., 1996; Kurihara et al., 1998).
MSP has 45% sequence identity with HGF. As a result, it is often termed “HGF-like 
protein”. MSP exerts its effects via the tyrosine kinase receptor recepteur d ’origine 
nantis (Ron), also known in the mouse as stem cell derived tyrosine kinase (STK). 
The cDNA encoding human Ron was first isolated from a transformed foreskin 
keratinocyte cell line (Ronsin et al., 1993). The murine form, STK was later isolated 
from hematopoietic stem cells (Iwama et al., 1994). For the purpose of this study, 
Ron/STK will be referred to only as “Ron”. Ron is structurally related to the HGF 
receptor, c-Met proto-oncogene, displaying 63% sequence identity in the intracellular 
region (Ronsin et al., 1993). In the adult, Ron transcripts have been shown to be 
detectable in almost all tissues with the exception of spleen and heart (Guadino et al., 
1995). During development Ron can be detected in liver, lung, kidney bone, adrenal
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glands, digestive tract, testis and the brain (Quantin et al., 1995; Guadino et al.,
1995). This widespread expression would suggest an important role for Ron 
signalling in the development of many tissues. In the immune system, Ron 
expression is tightly restricted to certain types of macrophages. Peritoneal, skin, liver 
and bone macrophages have all been found to express the receptor (Iwama et al., 
1995; Kurihara et al., 1996; Nanney et al., 1998). However macrophages from the 
lung, spleen or bone marrow show no expression (Iwama et al., 1995). Additionally, 
blood monocytes, neutrophils and lymphocytes all do not express this receptor 
(Iwama et al., 1995). During late development, in the mouse, the Ron receptor is 
detectable at particularly high levels in the trigeminal ganglia and hypoglossal 
nucleus (Gaudino et al., 1995; Quantin et al., 1995).
In the nervous system MSP has been shown to act as a neurotrophic factor for many 
populations of neurons. MSP exerts neurotrophic factor-like effects on motor 
neurons promoting both survival and neurite outgrowth in cultured embryonic chick 
hypoglossal motor neurons (Schmidt et al., 2002). In the PNS, MSP can support the 
in-vitro survival of sensory neurons from the mouse (Forgie et al., 2002). This 
survival effect has also been observed for early embryonic sympathetic neurons in 
vitro. However this effect is lost by birth, coinciding with a decrease in Ron mRNA 
in sympathetic targets (Forgie et al., 2003). In adult mouse hypoglossal neurons,
MSP has also been shown to prevent motor neuron atrophy following axotomy 
(Stella et al., 2001). No studies on other populations of adult neurons have been 
done.
Mice with a null mutation in the MSP gene have been found to develop normally and 
are viable. They suffer from liver abnormalities, shown by lipid containing vacuoles 
present in the cytoplasm of hepatocytes. However hepatic function is unaffected and 
mice can still survive into adulthood (Bezzera et al., 1998). Ron/STK'7’ mice show 
different effects. Mice carrying a homologous mutation die embryonically, which has 
confirmed an essential role for Ron signalling in the development of numerous 
tissues and organs. In order to facilitate further study, mice in which the tyrosine 
kinase portion of the receptor had been removed, were generated. These knockout
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mice were viable and appeared healthy. However, they displayed enhanced tissue 
damage in response to acute and cell-mediated inflammation (Waltz et al., 2000; 
reviewed in Wang et al., 2002). In addition, peritoneal macrophages produced 
enhanced levels of nitric oxide (NO) in response to the inflammatory mediator, 
interferon (IFN)-gamma, but levels of pro-inflammatory cytokines were unaffected 
(Correll et al., 1997). A significant increase in inducible -nitric oxide synthase 
(iNOS)11 within the ovary was also observed, producing higher levels of NO, which 
led to a decrease in ovulation rate (Hess et al., 2003).
These observations indicate a normally inhibitory effect of MSP/Ron signalling on 
NO production, allowing regular ovulation rates and also an attenuation of the 
harmful effects of the cellular immune response that can lead to tissue damage. This 
effect has also been observed in vitro. In this study, physiological concentrations of 
MSP, applied to mouse peritoneal macrophages, were found to inhibit 
lipopolysaccharide-(LPS)-induced production of inducibleNOS (iNOS) and 
subsequent NO production (Wang et al., 1994; Chen et al., 1998). Expression of 
other pro-inflammatory molecules has also been found to be negatively regulated by 
MSP/Ron signalling. Cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) are 
both produced from macrophages to enhance pathophysiological effects of 
inflammation. MSP has been found to inhibit the LPS-induced production of both 
COX-2 and PGE2 from macrophages (Zhou et al., 2002).
More recent studies have revealed that expression of Ron is also regulated by 
inflammation. Levels of Ron have been found to be decreased by the inflammatory 
mediators’ lipopolysaccharide (LPS) and IFNy (Wang et al., 2000). Further 
investigation has revealed that these inflammatory mediators stimulated NO 
production, which subsequently attenuated Ron expression via suppression of the 
Ron gene promoter activities (Wang et al., 2000). Taken together, these results
11 iNOS -  inducible Nitric Oxide Synthase is one o f a family o f several N O S’s. As mentioned 
previously, this family are responsible for the synthesis o f Nitric Oxide (NO). iNOS is found 
predominantly in the immune system, where it is used by macrophages to defend the body from 
pathogens.
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would therefore suggest that cytoplasmic signalling via the Ron receptor is important 
for inflammatory responses, but is not essential for survival.
Genetically modified mice, which over-express Ron, have also highlighted additional
effects of this receptor. Over-expression of Ron in lung epithelia, which normally
show barely detectable levels, resulted in the formation of multiple pulmonary
cctiv* »t <M«t ftfHHN VhWh ill alii v m m m h m  uriMm him
also been shown in colon (Chen et al., 2000), breast (Maggiora et al., 1998) and
ovarian (Maggiora et al., 2003) tumours. Epithelial cells from such tissues normally 
show barely detectable levels of this receptor. It is thought the abnormal up- 
regulation of this receptor and the increased signalling can enhance invasive activity 
of cells and protect them from apoptosis. A role for Ron in the progression of 
carcinomas to the invasive metatastic phenotype is thus suggested and provides a 
possible therapeutic target for the treatment of such carcinomas.
1.6.4. The neuropoietic cytokines
The neuropoietic cytokine family (also known as gpl30 cytokines or the interleukin- 
6 family of cytokines) contains ciliary neurotrophic factor (CNTF), leukaemia 
inhibitory factor (LIF), oncostatin M (OsM), cardiotrophin-1 (CT-1), interleukin-6 
(IL-6), interleukin-11 (IL-11), cardiotrophin-like cytokine (CLC) and neuropoietin. 
All members of the family share low sequence homology. However, a similar tertiary 
structure has suggested a possible common ancestral gene (Bazan et al., 1991; Bruce 
et al., 1992). With the exception of LIF, which is introduced in a small section of 
chapter four, this family is not studied in this thesis. Only brief information will 
therefore be provided about each factor, with an outline of the receptor complex. LIF 
is discussed in more depth in the introduction to Chapter Four.
The neuropoietic cytokines are often referred to as the gpl30 family, because all 
utilise the common receptor signalling subunit, gpl30. gpl30 then forms hetero- or 
homo-dimers with additional a  and/or p receptor subunits dependent upon the ligand 
involved. The two interleukins, IL-11 and IL-6 form homodimers o f gpl30 following
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binding of their own supplementary subunits, IL6 R a and IL1 IR a (Barton et al., 
2000; Murakami et al., 1993). CNTF, LIF, CT-1, CLC and neuropoietin form 
heterodimers comprising of gpl30 and the p receptor subunit (LIFR) (Gearing et al., 
1991). CNTF, CLC and neuropoietin must also firstly bind to the a  subunit, 
CNTFRa, which allows the formation of the high affinity complex with LIFRp and 
gpl30 (Davis et al., 1991, 1993; Gearing et al., 1991; Ip et al., 1993; Stahl and 
Yancopoulos, 1994; Elson et al., 2000). CT-1 also requires an alpha subunit, but this 
protein is yet to be identified (Pennica et al., 1995a; Pennica et al., 1996a). The OSM 
ligand binds to the heterodimeric complex of the OSM receptor subunit, OSMR and 
gpl30, without the need for LIFRp (Ichihara et al., 1997; Lindberg et al., 1998; 
Heinrich et al., 2003)
Neither gpl30 nor LIFR contain tyrosine kinase activity, so in order for the receptor 
complex to become active, membrane bound j anus kinases (JAKs) must 
phosphorylate tyrosine residues in the cytoplasmic region of gpl30. Signal 
transducers and activators of transcription (STAT) family members can then bind to 
these phosphorylated residues via their SH2 domain. Phosphorylated ST AT dimers 
are then translocated to the nucleus where they initiate transcription of target genes 
(reviewed in Heinrich et al., 1998). gpl30 cytokine family members show many 
neurotrophic factor-like effects, promoting survival of both embryonic sensory 
neurons (Horton et al., 1998; Their et al., 1999) and motor neurons (Arce et al.,
1999).
1.6.4.1. Ciliary neurotrophic factor
CNTF was originally discovered as a trophic factor that promotes the survival of 
chicken embryo ciliary ganglion neurons (Adler et al., 1979). It has since been 
shown to promote survival of a range of neurons including certain chick and rodent 
sympathetic and sensory neurons (Barbin et al., 1984; Horton et al., 1996) and chick 
embryonic motor neurons (Arakawa et al., 1990). CNTF can also regulate 
differentiation of sympathetic neurons. The presence of CNTF can induce ChAT 
expression in primary cultures of rat sympathetic neurons, together with a reduction
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in tyrosine hydroxylase (TH) 12 levels, promoting differentiation to a cholinergic 
phenotype (Saadat et al., 1989). CNTF mRNA is present at high levels within the 
sciatic nerve, spinal cord, optic nerve and olfactory bulb, with lower expression in 
other brain areas (Stockli et al., 1991; Dobrea et al., 1992).
1.6.4.2. Leukaemia inhibitory factor
Leukaemia inhibitory factor (LIF) (also known as cholinergic differentiation factor, 
CDF), is widely expressed throughout the mammalian nervous system and has 
pleiotropic activity in several adult and embryonic systems. In the hematopoietic 
system, LIF induces the proliferation of hematopoietic stem cells (Fletcher at al., 
1990; Leary et al., 1990) as well as the differentiation of leukaemic cells (Tomida et 
al., 1984) and megakaryocyte progenitor cells (Metcalf et al., 1990). LIF affects bone 
resorption (Abe et al., 1986) and also inhibits adipogenesis by negative regulation of 
lipoprotein lipase (Mori et al., 1989). Other inhibitory effects on cell differentiation 
are observed for kidney epithelial cells (Tomida et al., 1990) and also for embryonic 
stem cells, where the inhibitory effects of LIF has been shown to maintain their 
developmental potential (Smith et al., 1988; Williams et al., 1988). In the nervous 
system, LIF displays neurotrophic factor-like activity with effects on both nerve 
differentiation and survival on several subpopulations of neurons (Yamamori et al., 
1989; Murphy et al., 1991; Murphy et al., 1993). Other effects and regulation of LIF 
will be discussed in more depth in chapter four.
1.6.4.3. Oncostatin M
Oncostatin M (OsM) was originally isolated as an inhibitor of tumour progression 
(Zarling et al., 1986). However, it has since been shown to have neurotrophic factor 
effects in the nervous system. OsM can promote the survival and differentiation of 
oligodendrocytes (Vos et al., 1996), while in the PNS it can support the survival of 
certain subpopulations of sensory neurons (Horton et al., 1996). This survival role is
12 TH is an enzyme used in the body in the manufacture o f adrenaline. It catalyses the conversion o f 
L-tyrosine, to the dopamine precurose, dihydroxyphenylalanine (DOPA).
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further shown in a study of OsM_/* mice, which display a loss in a subpopulation of 
VR1 and P2X3 expressing DRG neurons in comparison to wild-type litter-mates 
(Morikawa et al., 2004). OsM has also been shown to affect neuronal differentiation 
of PNS neurons, enhancing ChAT activity in sympathetic neurons, and promoting 
differentiation towards a cholinergic phenotype (Rao et al., 1992).
1.6.4.4. Cardiotrophin-1
Cardiotrophin-l (CT-1) was originally cloned from mouse embryoid body cDNA 
library (Pennica et al., 1995, 1996). The human form has also been identified and 
shares 80% identity (Pennica et al., 1996b). CT-1 is found predominantly in the 
heart, although is also expressed in many other areas including fetal kidney and lung 
and in adult skeletal muscle, prostate and ovary (Pennica et al., 1995b, 1996b). CT-1 
was originally identified as a factor that induces cardiac myocyte hypertrophy 
(Pennica et al., 1995). It can also promote survival and differentiation of several 
populations of neurons including rat dopaminergic neurons, chick ciliary neurons 
(Pennica et al., 1995b), motor neurons (Arce et al., 1998) and sensory neurons of the 
nodose and trigeminal ganglion (Horton et al., 1998).
1.6.4.5. Interleukin-6
Interleukin- 6  (IL-6 ) (also known as B cell stimulating factor-2 (BSF-2)) was 
discovered in 1986 as factor that regulates immunoglobulin production from B 
lymphocytes (Hirano et al., 1986). IL- 6  can also support survival of several 
subpopulations of neurons including sensory neurons (Horton et al., 1996), 
catecholaminergic neurons from both fetal and postnatal rats and also postnatal 
cholinergic neurons (Kushiman et al., 1992a, 1992b, Hama et al., 1989). Additionally 
it can enhance ChAT activity in cholinergic neurons.
1.6.4.6. Interleukin-11
Interleukin-11 (IL-11) was cloned in 1990 (Paul et al., 1990) and initially considered 
a hematopoietic cytokine. It can also affect non-hematopoietic systems stimulating
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osteoclasts, megakaryocyte maturation, platelet maturation and inhibition of 
adipogenesis (Teramura et al., 1992; Yang et al., 1993; Keller et al., 1993; Girasole 
et al., 1994). IL-11 transcripts have been found in a wide range of tissues, but highest 
levels are observed in the testis and brain, particularly the hippocampus (Du et al., 
1996). The high expression in hippocampus concurs with its ability to stimulate 
proliferation of a hippocampal neuronal progenitor cell line in vitro (Du et al., 1996). 
Also in the nervous system, IL-11 enhances the in vitro survival o f rat postnatal DRG 
but only in the presence of its soluble receptor component ILRa (Their et al., 1998).
1.6.4.7. Cardiotrophin-like cytokine
Cardiotrophin-like cytokine (CLC) (also named novel neurotrophin-l/B cell- 
stimulating factor-3 (NN1/BSF-3)) was originally identified as a protein with the 
capacity to bind to gpl30 and for its ability to stimulate B-cells (Shi et al., 1999; 
Senaldi et al., 1999). Highest expression of CLC has been found in the spleen and 
lymph node (Shi et al., 1999; Senaldi et al., 1999), but it is also detectable in a 
variety of other tissues including thymus, lung, uterus, ovary and testis (Senaldi et 
al., 1999). It has been found to have highest homology to CNTF and CT-1, and to 
show similar activities to other family members, including an ability to promote 
survival of chick embryo motor and sympathetic neurons (Senaldi et al., 1999). CLC 
has also been shown to stimulate differentiation of astrocytes (Uemura et al., 2002).
1.6.4.8. Neuropoietin
The remaining member o f the family, neuropoietin, has only been recently 
discovered, following a structural profile-based computational screen (Derouet et al., 
2004). It has been shown to share similarities with CNTF, CT-1 and CLC. It is not 
expressed in adult tissues, but high specific expression is found in embryonic 
neuroepithelia (Derouet et al., 2004). Neuropoeitin has been found to support 
survival of embryonic motor neurons and to stimulate the proliferation of neural 
precursors in vitro when associated with epidermal growth factor (EGF) and 
fibroblast growth factor-2 (FGF-2) (Derouet et al., 2004). This effect, when
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combined with the specific embryonic expression, would implicate an important role 
for neuropoietin in the development of the nervous system.
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1.7 Aims and Objectives
In this study the neurotrophic factor regulation of genes within mouse sensory 
neurons is to be studied at various ages. The thesis thus falls neatly into three 
chapters which explore expression at a) embryonic ages (chapter 2 ), b) postnatal 
ages (chapter 3) and in c) the adult (chapter 4).
Several genes have been chosen that are required for a number o f key functional 
properties o f subsets of sensory neurons, and in this study I hope to gain more 
knowledge about their regulation and patterns of expression at various stages of 
development.
Previous work on expression of the selected genes has largely focused on the adult 
and postnatal DRG, therefore I want to initially determine if regulation of expression 
by neurotrophic factors differs in the embryonic mouse and also to explore 
expression within other sensory neuronal ganglia.
In the embryonic mouse those genes chosen are important in determining the 
functional characteristics o f sensory neurons. Although work on the regulation of 
expression of these genes has been explored in postnatal and adult mice, I want to 
identify if the initial induction o f  expression of such genes at early embryonic stages 
is regulated by neurotrophic factors. Knockout mice in which genes encoding 
neurotrophic factor receptors or the neurotrophic factors themselves have been 
chosen as a suitable and reliable method for this work, and due to the low levels of 
RNA available for study at this young age the highly sensitive methods of 
competitive RT-PCR and also real-time QPCR were chosen as the most suitable 
techniques for quantification o f gene expression.
Postnatally, as mentioned, research has focussed on expression of genes within the 
DRG. In this chapter, as well as reconfirming previous published findings, I wanted 
to explore gene expression and neurotrophic factor regulation in other sensory 
neuronal ganglia. To date very little has been known about the regulation of
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expression of nociceptive neurons markers in the, neurogenic placode-derived, 
nodose ganglion, either under normal conditions or following nerve lesion/trauma so 
in this chapter I wanted to explore how expression and regulation of genes differed in 
this ganglia from regulation in neural crest derived trigeminal and dorsal root 
ganglia. Once again I chose to use knockout mice, however neurotrophin and 
neurotrophin receptor knockout mice do not survive to postnatal ages, so the use of 
double knockout mice in which the proaptotic gene Bax had also been removed was 
employed. In vitro cultures were also set up for comparison and the sensitive and 
efficient method of real-time QPCR was, once again, chosen for quantification.
In the final chapter I wanted to explore gene expression in adult sensory neurons and 
in addition to the mRNAs examined in previous chapters, I wanted to also examine 
the transcriptional regulation of a number of other genes that may play important 
roles both in determining normal nociceptive thresholds, and in the generation of 
inflammatory and neuropathic pain conditions.
Since all the genes selected have important roles in determining nociceptive 
thresholds, it seems important to establish the neurotrophic growth factor, or 
combination of growth factors, that set these steady state expression levels. This is 
o f particular importance, since changes in the expression of these genes, that occur 
during inflammation and following nerve trauma, and which may be causally related 
to pathological pain conditions, are likely to be driven, at least in part, by a change in 
the availability of neurotrophic factors that normally regulate their steady state levels 
in the “normal” adult. Since adult rodent DRG neurons can survive in culture 
independently of neurotrophic factors (Lindsay, 1988), they allow a direct 
comparison of the effects of specific neurotrophic factors on regulating gene 
expression as a true ‘no neurotrophic factors control’ can be set up without the need 
for caspase inhibitors to prevent apoptosis.
In many respects, culturing neurons can be regarded as a model of axotomy and/or 
peripheral nerve injury. Indeed, adult DRG cultures have been extensively used in 
the fields of inflammatory and neuropathic pain research to examine the regulation of
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a number of genes that have previously been implicated in the aetiology of 
neuropathic pain following in-vivo nerve lesion/axotomy/crush models. As such my 
results may provide an insight into alterations in gene expression occurring in 
situations of nerve injury and the neurotrophic factor regulation that can enhance or 
attenuate such effects. This work would therefore be of potential therapeutic benefit, 
providing further background to research in the fields of nerve injury and 
neuropathic pain.
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Chapter 2
Nerve growth factor regulation of the early induction of sensory neuron gene 
expression in the developing mouse embryo
2.1. Introduction
It has previously been demonstrated that NGF/TrkA signalling is necessary to 
maintain the expression of several sensory neuron specific genes (e.g. CGRP, SP, 
N avi.8 , N avi.9), within mouse DRG neurons, normally in the neonatal period and 
also following neuronal damage, axotomy or inflammation in the adult (Patel et al., 
2000; Dib-Hajj et al., 1998; D’Arcangelo G et al., 1993). However, whether 
NGF/TrkA signalling is required for the initial induction of expression of these genes 
is unclear. In addition, few studies have addressed the role of NGF/TrkA signalling 
in the regulation of gene expression in other sensory populations, such as those 
within the nodose ganglia or trigeminal ganglia. In this chapter the role of NGF and 
TrkA signalling in the initial induction of expression of the neuropeptides Calcitonin 
Gene Related Peptide (CGRP) and Substance P (SP), and the sensory neuron 
specific, tetrodotoxin resistant (TTX-R) sodium channels N avi . 8  and N avi.9, in 
trigeminal ganglia and DRG, will be explored.
2.1.1. Calcitonin gene related peptide (CGRP)
Calcitonin gene related peptide (CGRP) is a 37 amino-acid neuropeptide that is 
expressed throughout the peripheral and central nervous system (Amara et al., 1992; 
Rosenfeld et al., 1993; reviewed in Ishida-Yamamoto and Tohyama, 1989). It is 
predominantly located in small sensory unmyelinated, C and myelinated A8  fibres in 
the periphery, often colocalised in C fibres with the tachykinin peptides, SP and 
neurokinin A (Lundberg et al., 1985; Lee et al., 1985; Skofitsch et al., 1985). CGRP 
is usually located in nerves closely associated with blood vessels, suggestive of a 
cardiovascular role, which will be discussed later (Sexton et al., 1991; Brain et al., 
1996; Wimalawansa et al., 1997). It belongs to the calcitonin family of peptides that
89
consists o f calcitonin (CT), adrenomedullin (AM), amylin (AMY) and the two 
isoforms of CGRP, a-CGRP and p-CGRP. Although primary sequence homology 
between peptides is weak, they do show significant similarities at the secondary 
structure level. They all have a six amino acid ring structure at the N termini and are 
amidated at the C terminal. A region of potential amphipathic a  helix also lies 
adjacent to the N terminal (Reviewed in Breiner et al., 1988; Poyner et al., 2004).
a-CGRP is the product o f a calcitonin/a-CGRP transcript (CALC1) that is 
alternatively spliced to allow tissue specific production of either CT or a-CGRP 
(Amara et al., 1982; Rosenfeld et al., 1983). Calcitonin is a potent inhibitor of bone 
resorption and is produced in abundance in parafollicular C-cells (Amara et al., 1982; 
Rosenfeld et al., 1983). a-CGRP peptide and transcripts are widely distributed 
throughout both the CNS and PNS. (Amara et al., 1992; Rosenfeld et al., 1993; 
reviewed in Ishida-Yamamoto and Tohyama, 1989).
P-CGRP was isolated later, and found to differ from the a  iso form by just one amino 
acid in the rat (Amara et al., 1995), and three amino acids in the mouse (Thomas et 
al, 2001). This high degree of sequence homology is observed at both the nucleotide 
and amino-acid levels, but despite the similarity, p-CGRP is the product of a separate 
gene that lacks the exon encoding CT and is thought to have arisen by partial gene 
duplication.
Despite almost perfect sequence homology, the two CGRP isoforms show different 
expression profiles. The isoforms do coexist in many tissues, however a-CGRP is 
found predominantly in the CNS and PNS (Amara et al., 1995), whilst p-CGRP 
predominates in the enteric nervous system (Mulderry et al., 1988; Schutz et al.,
2004) and pituitary gland (Jonas et al., 1985; Petermann et al.,1987).
Developmental switches in expression also occur. In adult rats, a-CGRP is the 
abundant isoform in both DRG neurons and motor neurons of the spinal cord (Amara 
et al. 1985, Gibson et al., 1988), however, during embryonic development, 
transcripts of the p- isoform are initially predominant, with a switch during perinatal
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stages (Terrado et al., 1999). Using in-situ hybridization, Terrado et al. found that, p- 
CGRP mRNA, but not a-CGRP mRNA was expressed in cells o f both trigeminal 
ganglia and DRG at E l4. a-CGRP mRNA was not co-expressed with p-CGRP 
mRNA, until E l 6 .
The recent sequencing of the mouse P- isoform (Thomas et al, 2001) and the 
production of mice that lack a functional a-CGRP gene has led to further 
investigation into the distinct expression of both a - and p- iso forms in the mouse. 
Homozygous a-CGRP knockout mice are viable and fertile, with no obvious 
abnormalities (Lu et al., 1999). In DRG of the adult a-CGRP*7* mouse, little or no 
CGRP transcript (due to P-CGRP) was observed in comparison to wild-type (Zhang 
et al., 2001; Schutz et al., 2004), suggesting a predominance of the a - isoform in 
accordance with the data from rat.
Receptors
CGRP receptors are divided into two categories CGRPi and CGRP2 . Differentiation 
between the subtypes was permitted by the discovery of the receptor antagonist 
CGRPi2-37 and the receptor agonists [Cys(ACM)2,7]haCGRP and 
[Cys(Et)2.7]haCGRP (Dennis et al., 1989; Dennis et al., 1990; Dumont et al., 1997). 
CGRPi receptors show more sensitivity to CGRP 12-37 than CGRP2 receptors (Dennis 
et al., 1989; Dennis et al. 1990), whilst CGRP agonists are more potent at CGRP2 
receptors. Although this classification still exists, it is not universally accepted with 
many still questioning the selectivity of the CGRP agonist, [Cys(ACM)2,]haCGRP 
(Poyner and Marshall, 2001).
A breakthrough in the structure determination of these receptors was made following 
the discovery o f the rat calcitonin like receptor (CL) (Njuki et al., 1993), and two 
years later human CL (Fluhmann et al., 1995). These receptors could not bind CGRP 
and were deemed orphan receptors. However the cloning of the human CGRPi 
receptor (Aiyar et al., 1996), which showed high sequence homology with CL,
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combined with work by McLatchie et al (McLatchie et al.,1998) led to the realisation 
that CL must be combined with a receptor activity-modifying protein (RAMP) in 
order to produce a functional CGRP receptor.
The RAMPS are a family of single transmembrane domain proteins that consist of 
RAMP1, RAMP2 and RAMP3 (McLatchie et al., 1998). CL is a seven- 
transmembrane spanning G protein coupled protein which, when combined with 
RAMP1 , produces a CGRP receptor that is antagonised by CGRPg-37 (CGRPI). 
Combined with RAMP2 it produces an amylin receptor and with RAMP3 another 
AM receptor, that may also have the ability to bind PCGRP (Reviewed in Poyner et 
al., 2 0 0 2 ).
Physiological Role
As few studies have discriminated between isoforms, the subsequent background 
information provided here will refer to both isoforms, a- and P-, as CGRP, unless 
otherwise mentioned. CGRP is distributed widely throughout the CNS and PNS, 
regulating the biological function of tissues including those of the gastrointestinal 
(GI), respiratory, endocrine and CNS. CGRP has a number of physiological roles 
within the body most notably with regards to its cardiovascular effects, hence the 
wide expression in nerves closely associated with blood vessels. Both isoforms of 
CGRP are potent arterial and venous vasodilators through activation of the CGRPi 
receptor (Brain et al. 1986). At the cellular level effects via two pathways have been 
suggested. The first is endothelium dependent and the second, endothelium 
independent.
In the endothelium independent pathway has CGRP produces an increase in cAMP 
via adenyl cyclase. This stimulates the production o f protein kinase A (PKA), which 
can open K+ channels, in turn activating Ca2+ sequesteration and producing the 
relaxation of smooth muscle (Crossman et al., 1990; Hirata et al., 1988; Nelson et al.,
1990). The majority o f tissues appear to use this endothelium dependent pathway, 
including rat perfused mesentery (Han et al., 1990), cat cerebral artery (Edvinsson et
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al., 1985) and porcine coronary artery (Yoshimoto et al., 1998). Exceptions however 
do exist which require the presence of endothelium and activation of the smooth 
muscle relaxant, nitric oxide (NO). In this model, CGRP once again activates PKA 
through increases in adenyl cyclase and cAMP. PKA activates endothelial nitric 
oxide synthase (eNOS), stimulating the production of NO, which produces 
subsequent muscle relaxation through guanylate cyclase and accumulation of cGMP 
(Brain et al., 1985; Gray and Marshall, 1992a, 1992b).
The intravenous administration of CGRP and use of antagonists have shown that 
CGRP is associated with hypotension, as a result of such vasorelaxant effects. It has 
also been found to promote positive effects on the force o f muscular contractions and 
the rate of heart contraction (Ando et al., 1990; Gardiner et al., 1991; Bell and 
McDermoot, 1994). In contrast intracerebroventricular administration increases 
blood pressure in rats due to actions on sympathetic nerves and the release of 
norepinepherine (Fisher et al., 1983). These general effects of CGRP will be 
discussed here with regards to effects in other tissues.
CGRP and blood pressure
Studies o f the role of CGRP in maintenance of basal blood pressure have produced 
conflicting results. Intravenous injection of the CGRP antagonist into adult rodents 
or dog has shown no effect on resting blood pressure (Gardiner et al., 1989; Shen et 
al., 2001), however studies in transgenic mice have produced varying results. Lu et 
al., (Lu et al., 1999) found no change in basal blood pressure in aCGRP'A, however 
mice in which the gene encoding both aCGRP and calcitonin is knocked out, show 
an increase in both systolic and mean arterial pressure (Gangula et al., 2000). This 
was originally thought to be due to effects of additionally removing calcitonin, 
however other studies by Oh-hashi et al., (Oh-hashi et al., 2001) in which solely 
aCGRP is knocked out, show an increase in mean arterial pressure and heart rate.
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CGRP and migraine
A role for CGRP in the onset of migraine and also cluster headache was suggested as 
in both conditions an increased release of CGRP into cranial circulation is observed 
(Goadsby et al., 1990, 1994). Furthermore, addition of exogenous CGRP induces 
delayed migraine like headache in sufferers (Lassen et al., 2002). It is proposed that 
CGRP promotes vasodilation of cerebral blood vessels, which allows stimulation of 
perivascular sensory nociceptive nerve fibres producing the subsequent pain 
(Goadsby et al., 2000). The use of CGRP antagonists in the treatment of migraine has 
much therapeutic potential and has been shown to be clinically effective (Brain et al., 
2004; Goadsby et al., 2005).
Protective effects of CGRP in heart conditions
The heart is innervated by CGRP containing fibres (Gulbenkian et al., 1993; Sun et 
al., 1993), and the local production of CGRP has been shown to be protective in 
many heart conditions. Indeed an increase in CGRP immunoreactivity is observed 
following myocardial infarction, suggesting release as a protective mechanism 
(Preibisz et al., 1993; Roudenok et al., 2001). In patients with congestive heart 
failure, infusion of CGRP can produce an increase in cardiac output and a decrease in 
blood pressure through vasodilation (Gennari et al., 1990; Shekhar et al., 1991). 
Additionally effects o f CGRP are useful in patients suffering from angina, a 
condition in which coronary arteries are narrowed by several factors including stress 
or fatty deposits, resulting in severe chest pain in situations when the heart rate is 
increased. The use o f CGRP was illustrated by clinical trial, in which CGRP was 
administered to exercising angina sufferers. CGRP produced dilation of coronary 
arteries, which delayed the onset of myocardial ischemia induced by the exercise 
(Uren et al., 1993).
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Pulmonary hypertension
Constriction of lung arterioles leads to pulmonary hypertension and is caused by a 
misbalance in endogenous vasodilators and constrictors. Indeed a decrease in blood 
CGRP was observed in a rat model of pulmonary hypertension (Keith et al., 2000). 
Exogenous CGRP has also been shown to prevent development of pulmonary 
hypertension (Tjen et al., 1992, 1998) and to relax precontracted pulmonary arteries 
in vitro (Martling et al., 1990).
CGRP and blushing
Blushing, such as that observed in menopausal women, is believed to be due to a 
release of CGRP and its subsequent vasodilatory effects in skin arterioles. Indeed 
elevated levels of CGRP were noted in serum and urine during attacks of hot flushes 
and sweating in menopausal women (Wyon et al., 1998, 2000).
CGRP. inflammation and hyperalgesia
The distribution o f CGRP on small diameter nociceptive neurons of the PNS 
(Molliver et al., 1997; Snider and McMahon, 1998; Lewin et al., 2004; Lewin and 
Moshourab, 2004; Green et al., 2004) suggests a role for CGRP in pain. An increase 
in CGRP is observed in primary sensory neurons following application of 
inflammatory stimuli such as complete Freud’s adjuvant (CFA), suggesting a role for 
CGRP in inflammation (Donaldson et al., 1992; Donnerer et al., 1992; Woolf et al., 
1994). Experiments have revealed roles in both the immune response to 
inflammation and also within the associated hyperalgesia.
Vasodilator effects of CGRP allow enhanced activities of inflammatory cells, 
through increased blood flow, and thus circulating cells such as neutrophils, to the 
area (Buckley et al., 1991). It can also directly and indirectly affect production of 
chemotactic compounds from macrophages. The presence of CGRP attenuates
release o f interleukin-1 (IL-1), but produces an increase in production of IL-10 (Torii 
et al., 1997). It can also indirectly enhance LPS induced release o f IL- 6  from 
macrophages through induction of NO (Tang et al., 1999). As well as macrophages 
CGRP has been shown to be chemotactic for human T lymphoctes (Foster et al.,
1999) and can also attenuate lymphocyte activity (McGillis et al., 2002). A role for 
CGRP in the cellular response to inflammation is thus likely.
Studies o f mice with null mutations in the a-CGRP gene have illustrated a role for 
CGRP in the inflammation-associated hyperalgesia. CGRP'7' mice, in which the gene 
encoding both a-CGRP and calcitonin has been disrupted, are less sensitive to 
thermal hyperalgesia, failing to develop secondary hyperalgesia following knee joint 
inflammation (Zhang et al., 2001). Mice, in which a-CGRP, specifically, is knocked 
out, show a decrease in response to inflammatory stimuli including capsaicin, 
formalin and carrageenan (Salmon et al., 2001).
Additionally CGRP has also been shown to potentiate oedema formation when co­
injected with histamine, a potent mediator of vascular permeability that is released 
following application of inflammatory stimuli (brain et al., 1992). It also enhances 
the release of SP, thus promoting the inflammatory response and associated 
hyperalgesia (Oku et al., 1987; Brain et al., 1989).
Nerve damage and neuropathic pain
In contrast to inflammatory stimuli, following axotomy or transection of sciatic nerve 
a decrease in expression of both isoforms of CGRP peptide and transcripts is 
observed in adult lumbar DRG (Noguchi et al., 1990; Mulder et al., 1997; Sterne et 
al., 1998; Shi et al., 2001; Shadiack et al., 2001). Interestingly axotomy of the 
cervical vagus to identify alterations within nodose ganglia, showed no difference in 
CGRP immunoreactivity (Helke et al., 1995). This illustrates how the sensory 
neurons from different populations are phenotypically different and often regulated 
by different factors.
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Neurotrophic Regulation
The regulation of CGRP mRNA and peptide expression in sensory neurons of the 
DRG, by NGF has previously been studied in adult and neonatal rodents.
As mentioned, sciatic nerve axotomy or transection in adult rats results in the loss of 
target field trophic support and a massive decrease in CGRP mRNA and peptide.
This decrease in CGRP expression can be prevented by application of exogenous 
NGF, both in-vivo and in-vitro when cultured neurons can be used as a model of 
axotomy (Lindsay et al., 1989; Verge et al., 1995; Jiang and Smith, 1995; Price et al,
2005). Sequestering endogenous NGF with anti-NGF antibodies or TrkA IgG also 
reduces CGRP expression, inducing axotomy like changes (Shadiack et al, 2001; 
Christensen and Hulsebosch, 1997; McMahon et al, 1995). The addition of 
exogenous NGF or NGF over expression has also been shown to stimulate the 
expression of CGRP in intact and capsaicin lesioned DRG neurons of the adult 
rodent (Ma et al, 1995; Schuligoi and Amann, 1998; Schicho et al, 1999; Tandrup et 
al., 1999; Price et al., 2005) and cause a prolonged hyperalgesia (Lewin and Mendell, 
1993). All of the above studies only measured the expression of the aCGRP isoform.
NGF regulation of CGRP has also been shown postnatally by the use of anti-NGF 
antiserum and TrkA/Bax and NGF/Bax double knockout mice (Tonra and Mendell, 
1998; Patel et al, 2000). TrkA and NGF single knockout mice have a dramatic 
phenotype, with massive sympathetic and sensory neuronal loss resulting in death 
shortly after birth (Smeyne et al., 1994; Crowley et al., 1994). By additionally 
knocking out the gene that encodes the pro-apoptotic protein Bax, Patel et al., found 
that cells normally lost in the single knockout survive. These surviving neurons are 
also phenotypically identical to those that would be lost (Patel et al, 2000). 
Postnatally, the expression of CGRP and SP was dramatically reduced in DRG of 
TrkA/Bax and NGF/Bax null mutant mice (Patel et al.2000). However the study of 
alpha and beta isoforms individually was not addressed in this publication.
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Effects of the GDNF neurotrophic factor family member, artemin on CGRP 
expression have been observed in a model of neuropathic pain. Following sciatic 
nerve ligation, the associated down-regulation in CGRP mRNA observed in rat 
DRGs was partially reversed by the presence of artemin (Gardell et al., 2003). 
Additionally, in uninjured neurons, intrathecal administration of GDNF produced an 
increase in CGRP immunoreactivity in the GDNF receptor expressing proportion of 
DRG neurons (Ramer et al., 2003).
Fibroblast growth factor 2 (FGF2) can also regulate CGRP expression in sensory and 
motor neurons. Analysis o f mice carrying null mutations in FGF2 gene and also in its 
receptor, FGFR3, showed a decrease in the loss of CGRP normally observed 
following injury (Jungnickel et al., 2005). Within motor neurons, an increase in 
CGRP is observed following lesion. This can be abolished upon application of bFGF 
(Piehl et al., 1995, 1998).
In this chapter TrkA and NGF knockout mice were used to study the regulation of a- 
and P- CGRP mRNA expression by NGF in both DRG and trigeminal ganglion 
neurons during embryonic development rather than postnatally or in the adult
The arrival of new Real-time PCR technology in the lab allowed me to extend this 
study further. Real-time PCR is a highly sensitive and fast form o f quantitative PCR 
(QPCR) and the computer package Beacon Designer permitted the production of 
more efficient and specific PCR primers that could distinguish between the two 
closely related CGRP isoforms, allowing me to look at the expression of alpha and 
beta CGRP separately, alongside studying the expression of other interesting sensory 
neuron specific genes. Any competitive data produced for CGRP could also be 
reconfirmed.
2.1.2. Substance P (SP)
Substance P (SP) is an 11 amino acid neuropeptide of the tachykinin family. It was 
first synthesised by Susan Leeman and colleagues back in 1971 (Chang et al., 1971),
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following deduction of the amino acid sequence as Arg-Pro-Lys-Pro-Gln-Gln-Phe- 
Phe-Gly-Leu-Met.NH2 (Tregear et al., 1971). Expression studies revealed that SP is 
confined to the CNS and PNS, where it is localised in cell bodies and nerve terminals 
(Hokfelt et al., 1975; Cuello et al., 1978). Predominant expression is within sensory 
nuclei particularly within small diameter non-myelinated sensory neurons and thinly 
myelinated A-delta nociceptive neurons that express TrkA and are NGF responsive 
(Hokfelt et al., 1975; Cuello et al., 1978; Skofitsch and Jacobowitz, 1985; Lee et al.,
1985). Within the CNS it is also detected at high levels in the thalamus, 
hypothalamus and extrapyramidal system and at lower levels in the spinal root 
ganglia, caudoputamen and globus pallidus, but is not detectable in the majority of 
the cortex (Cuello et al., 1978). The expression pattern corresponds with a role as a 
widespread neurotransmitter and this was confirmed by work of Otsuka and Konishi 
who illustrated SP release into the spinal cord after application of electrical stimuli 
(Otsuka and Konishi, 1976).
SP belongs to a family of small, biologically active, peptides collectively called 
tachykinins. SP is the most widely characterised member of this peptide family, 
however other members include Neurokinin A (NKA) and Neurokinin B (NKB). SP, 
NKA and NKB are all produced by alternative splicing of a precursor gene. SP and 
NKA are derived from the same precursor gene, preprotachykinin (PPT)-A, whilst 
NKB is generated from a separate gene PPT-B. Both PPT-A and PPT-B originate 
from the same common ancestral gene by duplication (Carter et al., 1990). 
Alternative splicing of the PPT-A gene (Figure 2.1.) generates four transcripts a , p, 8  
and y PPT-A mRNAs (Carter et al., 1990). The sequence for SP is present in all four, 
however the sequence for NKA is only present in p and y splice forms (Carter et al., 
1990; Holzer and Holzer-Petsche, 1997).
The cloning of the first neuropeptide receptor, that of Substance K, by Masu et al., 
(Masu et al., 1987) was a breakthrough, allowing the subsequent cloning of many 
more neuropeptide receptors, including those of SP and the other tachykinins, 
namely the neurokinin (NK) receptors. The family of NK receptors consist of NKi, 
NK2 and NK3 , which bind preferentially to SP, NKA and NKB (Regoli et al., 1987;
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Maggi et al., 1987). Ligand promiscuity does occur however dependent upon ligand 
concentration and receptor availability. The preferred SP receptor, NK] is located 
throughout the CNS with highest levels in olfactory bulb, hippocampus, striatum and 
superior colliculous. It is also detected to a lesser extent in areas including the 
substantia nigra, cerebral cortex and within the dorsal horn o f the spinal cord (Shults 
et al., 1984; Dam et al., 1986)
Because o f  the small size o f SP, amplification via PCR is impossible. In this study, 
part o f  the precursor PPT-A was amplified instead. Primers were designed that 
detected only p and y PPT-A mRNA in the portion that encodes the active SP 
peptide. They did however also span the region encoding NKA. The product 
produced is therefore representative o f the precursor for both these neuropeptides and 
not a true representation o f SP mRNA expression alone
PPT-A gene
Exon I Exon II Exon III Exon IV ExonV Exon VI Fxon VII
—n — m — — ■ —  — qp— w s m s —
encoding SP encoding NKA
Figure 2.1 Diagram to represent the organization o f  the PPT-A gene with its seven exons.
Exon III encodes SP and exon VI encodes NKA. There are 4 splice variants produced from this gene. 
aPPT-A has all exons except VI, p contains all exons, the 5 transcript is missing exons IV and VI and 
the y form is missing exon IV. Taken from Qian et al., 2001.
Substance P knockout
Mice with null mutations in the tachykinin 1, preprotachykinin gene and also in the 
NKi receptor gene are all viable and fertile, but have defects in nociceptive 
transmission and cellular responses to inflammatory stimuli (Cao et al., 1998; De- 
Felipe et al., 1998; Zimmer et al., 1998; Ahluwalia et al., 1999; Mansikka et al.,
1999; Bester et al., 2001; Kidd et al., 2003). This suggests a role for SP in 
transmission o f nociceptive information particularly following inflammatory stimuli.
100
This will be discussed whilst examining the physiological roles of this neuropeptide 
and its effects in peripheral tissues.
Physiological roles
SP and neurogenic inflammation
SP is a sensory neurotransmitter that is produced particularly following inflammatory 
stimulation (Donaldson et al., 1992; Donnerer et al., 1992; Woolf et al., 1994), and 
effects produced by release of SP from nerve endings of capsaicin-sensitive sensory 
neurons is referred to as ‘neurogenic inflammation’. The released SP causes 
vasodilation of arterioles and plasma protein extravasation (Ferrante and 
VadeBoncouer, 1993). It also has many tissue specific effects including smooth 
muscle contraction/relaxation in iris and bladder and bronchoconstriction of the 
airways. Such effects suggest many roles for SP in the GI tract, genitourinary 
disorders, migraine and asthma.
Nociception
SP is synthesised and located in a subpopulation of small diameter DRG neurons, 
implicating a nociceptive role. It is released from sensory neurons in response to 
inflammatory stimuli (Duggan et al., 1987; Oku et al., 1987; Schaible et al., 1990), 
alongside an increase in transcripts of its preferential receptor NK]t within the 
superficial dorsal horn (Krause et al., 1995). It is thus implicated in nociceptive 
transmission and the hyperalgesia associated with application of inflammatory 
stimuli (Hokfelt et al., 1975). An increase in SP production is also observed in 
diseases of chronic inflammation (Oku et al., 1987; Krause et al., 1995).
Much evidence implicates a role for SP in the hyperalgesia associated with 
inflammation. Intrathecal administration of SP results in hyperalgesia (Moochhala et 
al., 1984). Application of NKj antagonists results in a loss in the increased
1 0 1
excitability in response to noxious thermal stimulation and also in a loss of ‘wind­
up*, (a concept in which following repetitive stimulation, the response will increase 
markedly, so that the response to the last stimuli is much greater than that to the first 
stimuli, despite being the same strength) (Thompson et al., 1995; Radhakrishnan et 
al., 1998). Furthermore ablation of SP neurons results in a loss of capsaicin 
responsiveness and the thermal hyperalgesia and mechanical allodynia associated 
with neuropathic or inflammatory pain (Nichols et al., 1999; Khasabov et al., 2002).
Further information on the functional role for SP in peripheral inflammation has been 
gained following the generation of mice with a null mutations in the NKi receptor 
and the PPT gene. In both N K f7' and PPT*7* mice, hyperalgesia develops normally 
(De Felipe et al., 1998; Cao et al., 1998; Zimmer et al., 1998; King et al., 2003), 
however NKi7' mice display a loss of hyperalgesia in response to more chronic 
phases of inflammatory disease (Kidd et al., 2003). Furthermore such mice show a 
loss of response to noxious chemical signalling (Laird et al., 1998; Mansikka et al.,
1999), and also display a loss of intensity coding of nociceptive stimuli and a 
decrease in ‘wind-up’, alongside a decrease in stress-induced analgesia (De-Felipe et 
al., 1998; Bester et al., 2001).
Migraine
SP is present in cerebral arteries o f several species (Edvinsson et al., 1983). Upon 
release it can produce arterial relaxation and plasma extravasation, suggestive that SP 
signalling contributes to the onset of migraine (Moskowitz et al., 1992; Moussaoui et 
al., 1993). Such effects are proposed to be mediated by NKi receptors, as SP-induced 
plasma extravasation in cerebral arteries of the rat and guinea pig can be prevented 
by application of antagonists to NKi, but not NK2 (Mousanni et al., 1993; 
O’Shaughnessy et al., 1994).
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Asthma and chronic bronchitis
A role for SP in the inflammation of the airways associated with asthma and chronic 
bronchitis has been suggested. Neurogenic inflammation of the airways leads to 
bronchoconstriction and in some cases bronchorelaxation (Figini et al., 1996), as 
well as secretion from secromucous glands (Geppetti et al., 1993) and release of 
mediators from the epithelium such as prostaglandins and NO. It is proposed that SP 
and neurogenic inflammation produce the airway hyperresponsiveness following 
allergen challenge (Bertrand et al., 1996). Application of NKi antagonists abolishes 
hyperresponsiveness and microvascular permeability in animal models (Mashito et 
al., 1999; Schuiling et al., 1999). Analysis of autopsy, biopsy and bronchoscopy 
tissue samples from asthmatics support such a role for SP in development of 
bronchial hyperresponsiveness. A decrease in SP immunoreactivity in tracheal (Lilly 
et al., 1995) and lung (Howarth et al., 1991) tissue of asthmatic illustrates an 
enhanced release of SP, which is reflected by the observation of an increase in SP 
immunoreactivity in sputum collected from asthmatics following antigen challenge 
(Nieber et al., 1992).
Gastrointestinal (GI) tract
The gut is innervated by extrinsic and intrinsic enteric neurons, which regulate 
motility and fluid secretion. These neurons are likely to contain SP (Costa et al.,
1986). SP has been shown to contract all parts of the GI tract in all mammals 
including man, despite regional variations in SP expression between species 
(reviewed in Bartho and Holzer, 1994; Bartho et al., 1995). It can also stimulate 
plasma extravasation in post capillary venules of stomach, small and large intestines 
and pancreas, via NKi, in mouse (Figini et al. 1997) and in stomach, small intestine 
and pancreas of the rat (Nicolau et al., 1993). Such effects, illustrate the role of SP 
and regulation of neurogenic inflammation in the GI tract.
Alterations in SP signalling have been postulated to contribute to diseases of the GI 
tract. An increase in NKi receptor sites is observed in inflammatory bowel disease
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(Holzer, 1998), Crohns disease and ulcerative colitis (Mantyh et al., 1988). Studies of 
NKI-/- mice also suggest a role for SP signalling via NKi in proinflammation and 
severity of pancreitis (Saluja et al., 1999; Grady et al., 2000).
Genitourinary tract
SP immunoreactive fibres are present in the bladder (Maggi et al., 1988). SP 
increases motility and plasma extravasation in the genitourinary tract (Hua et al., 
1987; Maggi et al., 1987; Maggi et al., 1988) and is thought to contribute to cystitis.
In interstitial cystitis the number of NKi receptors around small blood vessels is 
increased alongside NKi receptor transcripts within the bladder endothelium 
(Marchand et al., 1998; Buffington et al., 1998). Furthermore, NKi receptor 
antagonists inhibit the onset of the early phase of plasma extravasation in xylene- 
induced cystitis (Maggi et al., 1988b).
Immune System
SP can regulate activity o f many cells of the immune system affecting the cellular 
response to inflammation. SP can stimulate interleukin- 8  (IL-8 ) synthesis and release 
(Serra et al., 1994); is chemotactic for neutrophils and eosinophils in vitro (Cazlan et 
al., 1993; Roch-Arveiller et al., 1986); is required for IL-lbeta induced neutrophil 
accumulation in response to inflammation (Ahluwalia et al., 1999) and can contribute 
to antibody dependent cell mediated toxicity (Wozniak et al., 1993). Additionally it 
has indirect effects on cells of the immune system, producing a priming effect on 
responses mediated by other molecules such as platelet activating factor (PAF) and 
recombinant human interleukin 5 (rhIL-5) (El-Shazly et al., 1996; Wiedermann et al.,
1991).
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SP. nerve injury and neuropathic pain
Transection of the sciatic nerve results in a down-regulation of SP expression within 
DRG (Nielsch et al., 1987; Zhang et al., 1995; Sterne et al., 1998). Such a down- 
regulation is not observed within the nodose following axotomy of cervical vagus 
(Helke et al., 1995), suggesting that SP expression in this neuronal population is 
regulated differently from that in sensory neurons of the DRG. Additionally the 
inflammation induced increase in SP observed in DRG of a mouse model of arthritis, 
is also attenuated following nerve section (Ahmed et al., 1995). Such effects are 
thought to be due to a loss of target derived factors such as NGF which regulate 
expression of SP.
Neurotrophic factor regulation
SP is co-expressed with CGRP in the same subpopulation of sensory neurons, and 
both neuropeptides appear to be regulated by NGF. Exogenous NGF stimulates the 
expression of SP and CGRP in intact DRG of the rat (Schuligoi and Amann, 1998; 
Tandrup et al., 1999). and both neuropeptides are massively down-regulated in 
TrkA'^/Bax7' and NGF^'/Bax'7' mice (Patel et al., 2000). The axotomy-induced 
decrease in SP in wild-type mice can also be prevented by NGF administration 
(Lindsay et al., 1989; Zhang et al., 1995).
2.1.3. Voltage gated sodium channels (VGSC), Nav1.8 and 
Navi .9
Sodium channels allow the generation and propagation of the compound action 
potential in electrically excitable tissues such as nerve, muscle and the heart. 
Depolarisation of tissues is caused by Na+ ion diffusion through voltage gated 
sodium channels (VGSCs).
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Sodium channel structure
Mammalian VGSCs are multimers, composed of a central pore forming a  subunit 
(approx 260kDa) and auxilliary p subunits. The alpha subunit forms the ion pore and 
is responsible for voltage sensing of the channel. Multiple isoforms of the alpha 
subunit exist in different regions of the brain and peripheral nervous system. These 
are outlined in figure 2.2. Isoforms differ in their kinetic properties and expression 
pattern. Sensitivity to the neurotoxin, tetrodotoxin (TTX), a toxin from the puffer 
fish, is used to pharmacologically distinguish between a  subunits. Only three of the 
subunits show TTX resistance (TTX-R), N avi.5, N avi . 8  and N avi.9, the remaining 
channels are TTX sensitive (TTXS) (Black et al., 1996; Akopian et al., 1996; 
Sangameswaren et al., 1996; Dib-Hajj et al., 1998; Tate et al., 1998; Plummer and 
Meisler, 1999). Interestingly the genes encoding these three TTX-R subunits all exist 
on the same chromosome (Chromosome 3p21-24 in mice), suggesting an 
evolutionary link between these channels (Plummer and Heisler, 1999 and Goldin et 
al., 2000). Future references to sodium channels will be referred to as the gene (e.g. 
SCN10A) or the new nomenclature (e.g. N avi.8 ).
p subunits act as accessory subunits, modulating the channel kinetics and membrane 
localisation (Catterall., 1992; Isom et al., 1994; Kazen-Gillespie et al., 1999; Isom et 
al., 2001). Three such subunits have been identified, these are p i (SCN1B, 36kDA), 
p2 (SCN2B, 33kDa) (Isom et al., 1994; Catterall., 1992) and the most recently 
discovered p3 (Morgan et al., 2000).
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Table 1. Mammalian Sodium Channel a  8ubunit»
Chromosomal
Type Former Name Qenbank Number* Gene 8ymbol Location 8p«oe Variants Primary Tissues
Na,1.1 rat 1 X03638 ft) 8CN1A Mouse 2 Navi .1 a CNS
HBSCI XB5362 (h) Human 2q24 PN8
QPBI AF003372(gp)
SCN1A
Navi .2 rat II
HBSCII
HBA
X03639 (r) 
X81149 (r) 
X85361 (h) 
M94056 (h)
8CN2A Mouse 2 
Human 2q23-24
Nav1.2a CN8
Nay1.3 rat III YQ0766 (f) SCN3A Mouse 2 
Human 2q24
N%1.3a 
Nayl .3b
CNS
Nav1.4 SkM1. M20643 (r) 
M81758 (h)
SCN4A Mouse 11 
Human 17q23-25
sk. muscle
Nay1.5 SkM2 M27902 (r) SCN6A Mouse 9 Uninnervated sk.
H1 M77235 (h) Human 3p21 muscle, heart
Navi .6 NaChfi
PN4
Scn8a
Cerill
L39018 (r)
AF049239 (r) 
AF049240 (r) 
U26707(m) 
AF049617 (m) 
AF060738 (h) 
AF225988 (h) 
AF003373(gp)
8CN8A Mouse 15 
Human 12q13
Na«1.ea CN8, PNS
Nav1.7 NaS U35238 (rb) SCN9A Mouse 2 PNS
hNE-Na X82836 (h) Human 2q24 Schwann cels
PN1 079688 (r) 
AF000368 (r)
Na«1 -8 SNS
PN3
NaNQ
X92164 (r) 
U53833 (r) 
Y09108 (m) 
U60600 (d)
8CN10A Mouse 9 
Human 3p22-24
DRG
Navi .9 NaN
SNS2
PN8
NaT
SCN12A
AF069030 (i) 
AJ237862 (i) 
AF118044 (m) 
AB031389 (m) 
AF126739 |h) 
AF188679 (h) 
AF109737 (h) 
AF150882(h)
SCN11A Mouse 9 
Human 3p21>24
Nav1.9a PNS
Na, Nay2.1 M91566(h) SCN7A Mouse 2 heart, uterus,
Na-G M96678 (r) SCN6A* Human 2q21 -23 sk. muscle
SCL11 Y09164 (r) astrocytes,
Nar2.3 L38179 (m) DRG
* The letter In parentheses after each accession number indicates the species of origin for the sequence, as follows: h, human; r, rat; rfe, 
rabbit; m, mouse; gp, guinea pig; d, dog.
6 This gene was originally assigned symbols SCN6A and SCN7A, which were mapped in human and mouse, respectively. The two most likely 
represent the sam e gene, and the SC NBA symbol w tt probably be deleted.
Figure 2.2. Nomenclature and location o f  mammalian sodium channel alpha subunits. 
Taken from Goldin et al., 2000
The use of in situ hybridization and RT-PCR has revealed that nine of the ten alpha 
subtypes and all three of the beta subtypes are present in sensory neurons (Black et 
al., 1996; Renganathan et al., 2002; reviewed in Lai et al., 2004). Expression profiles 
of different subunits vary considerably. Of the TTXR channels, N avi . 8  is highly 
expressed in small diameter neurons, with some expression in medium and large 
neurons, whist N avi.9 is only expressed only in small diameter neurons (Black et al., 
1996). The remaining TTX-R channel, N avi.5, is predominantly a cardiac channel, 
however some expression has been observed in embryonic DRG (Renganathan et al., 
2002). TTX-S channels in sensory neurons include N avi . 6  and N avi.7 whose 
expression is detectable to some extent in all sensory neurons (Tzoumaka et al.,
2000). N avi.2 can be found in all sensory neurons, but at barely detectable levels. 
Other sodium channels have a more restricted expression profile (Black et al., 1996). 
N avl.l is preferentially expressed in large diameter neurons and N avi.3 is 
developmentally regulated, showing high expression embryonically, but very low 
expression in the adult rat (Waxman et al., 1994).
These voltage gated sodium channels collectively, are responsible for the current 
flow required within sensory neurons to propagate the compound action potential. 
Electrophysiological results indicate that there are two general sodium currents in 
DRG, one sensitive to TTX (TTX-S), and one unaffected by TTX (TTX-R) (Kostyuk 
et al., 1981; Cafffey et al., 1992; Roy and Narahashi, 1992). The TTX-S current is 
predominant in large sensory neurons, however small neurons additionally contain 
the TTX-R component, which compliments the restricted expression profiles of the 
TTX-R channels, N avi . 8  and N avi.9 in small diameter neurons (Roy and Narahashi 
1992; Rush et al., 1998). Additionally, more in-depth, work has recently shown that 
within small diameter sensory neurons TTX has no effect on sodium currents in IB4 
positive neurons, but can inhibit AP generation in approximately 50% IB4 negative 
neurons (Wu et al., 2004). This provides more information of the distinct expression 
of TTX-S and TTX-R channels within subclasses of small diameter sensory neurons, 
peptidergic neurons containing a compliment of both TTX-S and TTX-R, but IB4 
reactive small diameter neurons containing just TTX-R channels. The presence of the
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TTX-R current only in a sub-population of small sensory neurons suggests a function 
for TTX-R VGSCs in nociception. This will be discussed further later.
Information on the discrete functions of each VGSC, within sensory neurons, has 
been hindered by the lack of specific channel blockers. Some insight has been gained 
using novel approaches and pharmacological techniques. Most of the VGSCs giving 
rise to the TTX-S current have a low activation threshold (in the region of -50mv and 
-40mV) with fast activation and inactivation. The application of TTX to distal axons, 
blocks nerve impulse conduction, evidence that TTX-S channels are required to 
mediate action potential generation in both myelinated and unmyelinated axons 
(Brock et al., 1998; Gold et al., 2003).
Several subtypes of the TTX-R current exist within the DRG, these are termed TTX- 
Rl,2 and 3. TTX-R1 has a high threshold for activation (approximately -36mV) and 
steady state inactivation. It activates and inactivates relatively slowly, but recovers 
from inactivation rapidly such that when other channel subtypes are inactivated by 
depolarisation, low levels of activity can be sustained by this current (Ogata et al., 
1993; Elliott et al., 1993 Rush et al., 1998). There is evidence to suggest that N avi . 8  
is the sodium channel underlying this current. Injection of N avi . 8  into N avl.8 7' mice 
produces a TTX-R current with characteristics identical to this TTX-R 1 (Akopian et 
al., 1999). These null mutant mice also no longer display the all-or-nothing action 
potentials characteristic o f such neurons, suggesting a role for TTX-R1 and N avi . 8  
in action potential generation electrogenesis (Renganathan et al., 2001).
TTX-R2 has unique biophysical properties with slow activation kinetics and a 
persistent nature with very low threshold for inactivation (between -70mV and -  
90mv) (Cummins et al., 1999). The properties of this current suggest that it is 
unlikely to contribute to the action potential upswing. However, its slow inactivation 
and its regenerative properties suggest a role in determination of membrane resting 
potential (Cummins et al., 1999; Herzog et al., 2001; Baker et al., 2003). The finding 
that this current still persists in N avl.8 'A, and indeed is further enhanced following 
GDNF infusion in the null mouse indicates that another TTX-R channel underlies
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this current (Cummins et al., 1999; Cummins et al., 2000). This is most likely 
Navi.9, due to its similar activation kinetics (Baker et al., 2003; Priest et al., 2005; 
Reviewed in Wood et al., 2004).
The TTX-R3 current has very similar kinetics to that of the TTX-S current, with 
low threshold of activation, combined with rapid rates of activation and inactivation 
(Rush et al., 1998). The physiological and pharmacological profile of this current 
suggests that the predominantly cardiac channel, N avi.5 carries it (Renganathan et 
al., 2002). N avi.5 is developmentally regulated, suggesting this current is only seen 
within DRG embryonically.
In this thesis it was decided to initially focus on the expression of the two sensory 
neuronal predominant TTX-R VGSCs, N avi . 8  (also known as SNS/PN3) and 
Navi.9 (also known as NaN).
Expression
N avi . 8  (SNS/PN3) was cloned from rat DRG, and shown to display 65% identity to 
the rat cardiac TTX-R channel, N avi.5 (Sangameswaran et al., 1996; Akopian et al., 
1996). It is encoded from the gene ScnlOa and is sensory neuron specific. It is found 
both in small diameter non-myelinated sensory neurons (C-fibres) and in 10% of 
small diameter myelinated axons corresponding to A-delta nociceptors 
(Sangameswaren et al., 1996; Amaya et al., 2000). Of such small diameter 
unmyelinated neurons, N avi . 8  is expressed equally in the peptidergic TrkA positive 
population and in the IB4 reactive populations (Benn et al., 2001).
The second TTX-R alpha subunit, Navi.9 (NaN/SNS2) is encoded from the Scnl la 
gene (Dib-Hajj et al., 1998). It exhibits only 42-53% similarity to N avi.8 . Navi.9 is 
predominantly located in small diameter sensory neurons, but is also expressed at 
low levels within the CNS (Black et al., 1996; Dib-Hajj et al., 1998; Tate et al., 1998; 
reviewed in Lai et al, 2004). Within sensory neurons, Navi.9 is expressed 
specifically within unmyelinated small C fibres that are peptidergic and
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immunoreactive for TrkA. It is not detectable in neurons with myelinated axons 
(Amaya et al., 2000; Benn et al., 2001; Fang et al., 2002). Such a specific expression 
within the unmyelinated nociceptive neurons is suggestive of a role for Navi .9 in 
pain. This will be discussed later.
Physiological function
Both channels are resistant to TTX and are important in the TTX-R currents within 
sensory neurons. As discussed, Navi.9 is implicated to underlie the persistent TTX- 
R2 current that is thought to play a role in determination of membrane resting 
potential. N avi.8 is responsible for the TTX-R1 current that has been implicated in 
action potential generation within nociceptive neurons of the DRG (Reneganathan et 
al., 2001). Working in conjunction with TTX-S channels, N avi.8 produces the 
characteristic shape of the nociceptive action potential, which displays a rapid 
depolarisation with a prominent shoulder during the falling phase. The upstroke of 
the nociceptor action potential is produced by an influx of positive charge through 
both TTX-R channels (Approximately 58%) and TTX-S channels (approximately 
40%), with a small contribution (2%) from Calcium channels. TTX-S channels then 
rapidly inactivate, but the TTX-R 1 current remains to sustain low levels of activity 
(Ogata et al., 1993; Elliott et al., 1993 Rush et al., 1998). This, in combination with 
Ca2+ influx, produces the characteristic nociceptor AP shoulder.
Navi .8. Navi .9 and pain
Both Navi .8 and Navi .9 are strongly implicated in the molecular mechanisms of 
nociception, as discussed above. In the following section I will discuss in turn the 
roles of these channels in neuropathic pain as a result of neuronal injury and in 
inflammatory pain.
Following nerve damage and axotomy of peripheral DRG neurons, an increase in 
excitability and enhanced repetitive firing has been observed, alongside a reduction 
in action potential threshold (Zhang et al., 1997). Such effects are thought to underlie
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the neuropathic pain associated with nerve injury and have been attributed partly to 
alterations in sodium channel expression and conductance. An increased density in 
TTX-S channels following axotomy is observed, producing an increased sodium 
conductance within DRG thought to contribute to the increased excitability in the 
axotomised neurons (Zhang et al., 1997; Black et al., 1999). This has been attributed 
to an up-regulation of the normally silent VGSC N avi.3, and is discussed further in 
chapter 4 (Waxman et al., 1994; Cummins and Waxman, 1997, Sleeper et al., 2000).
Alongside alterations in TTX-S channels, alterations in the TTX-R channels Navi.8 
and Navi.9 are also observed. In contrast, expression of these channels is decreased 
within small diameter neurons of the DRG following peripheral axotomy or sciatic 
nerve section (Okuse et al., 1997; Cummins et al., 1997; Tate et al., 1998; Dib-hajj et 
al., 1998; Novakovic et al., 1998 Sleeper et al., 2000; Decosterd et al., 2002). Such a 
down-regulation of TTX-R channels is thought to contribute indirectly to the hyper­
excitability of sensory neurons, following axotomy, through the interaction of TTX- 
R currents with TTX-S sodium conductances (Zhang et al., 1997; Cummins et al., 
1997; Sleeper et al., 2000). The persistent TTX-R current carried by Navi .9, is 
thought to contribute a depolarising influence to the resting membrane potential of 
sensory axons (Cummins et al., 1999). The down-regulation of N avi.9 following 
injury would therefore produce a hyperpolarizing shift in resting membrane potential. 
This shift is proposed to relieve the inactivation of TTX-S channels, resulting in an 
increase in TTX-S currents and subsequent neuronal excitability (Sleeper et al.,
2000). Loss o f the slow inactivating TTX-R current carried by Navi .8 has also been 
illustrated, by computer simulation, to result in a lowered AP threshold and 
spontaneous/repetitive firing in the absence of stimulation (Elliot, 1997; Schild and 
Kunze, 1997). Down-regulation of both N avi.8 and N avi.9 channels is therefore 
implicated in the neuronal hyperexcitability that contributes to neuropathic pain 
following nerve damage.
A direct link between Navi .8 and neuropathic pain, was demonstrated by Lai et al., 
(Lai et al., 2002), who used antisense oligonucleotides to ‘knock down’ the 
expression of Navi .8. In such mice, neuropathic pain induced by spinal nerve injury
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was no longer observed, but effects of acute pain and responses to non-noxious 
stimuli remained (Lai et al., 2002). A down-regulation of N avi.9 mRNA is also 
observed in three separate models of neuropathic pain (Abe et al., 2002).
Of therapeutic interest were results following experiments to study the 
electrophysiological properties of Navi. 8 by cloning this channel into xenopus 
oocytes (Chevrier et al., 2004). The local anaesthetic, lidocaine was found to have a 
strong affinity for N avi.8, binding to the slow inactivated state of the VGSC, where 
it is thought to block nociceptor firing and prevent the proposed positive effects of 
N avi.8 on neuropathic pain. Such LA sensitivity was not observed for other 
channels, namely N avi.7 (Chevrier et al., 2004), which correlates with results of Roy 
and Narahashi (Roy and Narahashi, 1992) who found that TTX-R currents were 
more sensitive to lidocaine than TTX-s channels in native DRG neurons. These 
results suggest the TTX-R channels, particularly Navi.8, are suitable targets for the 
development of drugs to treat neuropathic pain. Despite such findings, recent work 
by Nassar et al., (Nassar et al., 2005) shows conflicting results. In this study cre-lox 
transgenic mice, in which N avi.8 and N avi.7 are both specifically knocked out in 
nociceptive neurons, show normal generation of neuropathic pain, despite a lack of 
inflammatory pain symptoms.
A role for TTX-R channels in inflammatory pain has also been investigated. The 
generation of mice with null mutations in sodium channel genes has been useful in 
further characterising such a role. Navl.8'7' mice appear normal, and are viable and 
fertile, however, behaviourally such mice display a pronounced analgesia to noxious 
mechanical stimuli, have small deficits in noxious thermoception and show a delayed 
development o f inflammatory hyperalgesia (Akopian et al., 1999; Ogata et al., 2001). 
Such mice also display an increase in current densities of TTX-S channels, 
implicating an up-regulation of TTX-S currents within the DRG to compensate for 
the loss of TTX-R flow (Akopian et al., 1999; Ogata et al., 2001). Such an up- 
regulation in TTX-S currents was also observed following the down regulation of
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TTX-R channels in models of nerve damage and neuropathic pain, as mentioned 
previously.
Inflammatory pain caused, for example, by CFA injection into adult rat skin, 
produces a dramatic increase in N avi.8 protein expression in DRG ;within 48 hours 
(Gould et al., 1998; Tanaka et al., 1998; Gould et al., 2004; Coggeshall et al., 2004). 
This is observed in both small and large neurons, and both myelinated and 
unmyelinated axons (Gould et al., 2004; Coggeshall et al., 2004). The inflammation- 
induced, enhanced level in small neurons persists. However as allodynia subsides, 
the expression of N avi.8 within large neurons decreases back to baseline (Gould et 
al., 2004). It has been proposed that the increase in Navi .8 in larger neurons is likely 
to be responsible for the hyperalgesia observed in such inflammatory states. The 
persistent up-regulation in small diameter neurons is proposed to produce prolonged 
increased sensitivity that could provide a protective role, to ensure vigilance during 
healing (Gould et al., 2004). Further evidence of a role in inflammatory pain was 
provided by the use of antisense oligonucleotides to attenuate Navi. 8 expression. 
Injection of such oligonucleotides into rats, prevented PGE2 induced hyperalgesia 
and increased the threshold to mechanical nociceptive stimuli (Khasa et al., 1998). 
Interestingly no increase was observed in N avi.9 in inflammatory states, suggesting 
that unlike N avi.8, Navi .9 plays no role in the peripheral sensitisation early in 
inflammation (Coggeshall et al., 2004).
The dynamic alteration in Sodium channel levels in response to injury or 
inflammation is suggestive of a role in the associated neuropathic/inflammatory pain. 
A TTX-R current only found in small nociceptive neurons also would indicate a role 
in nociceptive transmission. The precise mechanisms by which such channels could 
mediate effects are yet to be elucidated. However the limited expression of the 
sodium channels, N avi.8 and Navi.9 to sensory neurons, provides strong therapeutic 
potential, allowing the manipulation of specific subpopulations of sensory neurons.
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Regulation of Na channel expression bv neurotrophic factors
The increase in NGF released in vivo as part of the inflammatory response is thought 
to mediate such increases in N avi.8 in small DRG neurons. Indeed, administration of 
NGF has been shown to increase N avi.8 protein expression in DRG and produce a 
decrease in paw withdrawal latencies characteristic of hyperalgesia. Furthermore pre­
blocking NGF with anti-NGF antibodies prevented the NGF-induced effects on paw 
withdrawal latencies and significantly reduced expression of N avi.8 protein (Gould 
et al., 2000).
In addition to altering expression of Navi.8 in response to inflammation, NGF also 
regulates the TTX-R current and TTX-R sodium channel expression following 
axotomy of adult DRG neurons. As mentioned, axotomy of DRG neurons produces a 
decrease in TTX-R currents (Cummins and Waxman, 1997; Sleeper et al., 2000) in 
response to a decrease in expression of the sodium channels N avi.8 (Dib-Hajj et al., 
1996; Okuse et al., 1997) and N avi.9 (Dib-Hajj et al., 1998a; Tate et al., 1998). 
Following axotomy of DRG neurons, retrograde transport of NGF from peripheral 
targets is prevented. This reduction of NGF at the site of injury is thought to be 
responsible for several of the axotomy related phenotypic changes in DRG neurons, 
including the reduction in TTX-R current and channels. Much evidence supports this. 
NGF has been shown to restore the down-regulation of TTX-R currents following 
axotomy of DRG neurons in vitro (Aguayo and White, 1992; Black et al., 1997; Fjell 
et al., 1999) and in vivo (Dib-Hajj et al., 1998), attributable to positive effects of 
NGF on TTX-R channel expression (Black et al., 1997; Dib-Hajj et al., 1998).
GDNF has also been shown to promote similar effects following axotomy both in 
vivo and in vitro (Fjell et al., 1999; Cummins et al., 2000). GDNF treatment of 
cultured rat DRG produced an up-regulation in levels of both Navi. 8 and Navi.9 
mRNAs, alongside increasing both the slowly inactivating and the persistent TTX-R 
currents (Cummins et al., 2000). In vivo, infusion of GDNF to axotomised DRG 
neurons also resulted in an increase in N avi.8 and Navi.9 protein levels and an up- 
regulation in TTX-R currents (Cummins et al., 2000). Another GDNF family
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member, artemin, has also been shown to reduce the SNL-induced down-regulation 
of N avi.8 protein in a rat model of experimental neuropathy (Gardell et al., 2003). 
NGF, GDNF and artemin therefore all prevent axotomy/nerve damage induced 
changes in sodium channel expression, which are thought to contribute to the onset 
of neuropathic pain. A clearer understanding of the role and pathways involved with 
such neurotrophic factor effects would therefore be of interest for the design of novel 
drugs in the treatment of neuropathic pain.
Neurotrophic factor-induced regulation of Navi.9 has also been observed in other 
populations of neurons. BDNF has been shown to evoke TTX-R currents in 
hippocampal neurons mediated by Navi.9 (Blum et al., 2002), and it is proposed that 
such currents play a role in long term potentiation (LTP) (Kovalchuck et al., 2002). 
Interestingly these N avi.9 generated currents differ from those seen in sensory 
neurons being smaller; readily blocked by the neurotoxin, saxitoxin; and only 
observed in TrkB positive neurons (Blum et al., 2002). Furthermore HEK293 cells 
transfected using cDNA clones encoding Navi .9 with or without TrkB, showed 
characteristics of both types of current (Blum et al., 2002). The ability of Navi.9 to 
mediate a different current according to cell type could be attributable to post- 
transcriptional regulatory steps, for example trans-splicing (Akopian et al., 1999); 
post-translational modulation of alpha subunits e.g. phosphorylation by PKA (Gold 
et al., 1999); or through modulation by accessory p subunits (Isom et al., 2001, 
reviewed in Wood et al., 2004).
Little has been done on the effects of neurotrophic factors on TTX-R channels in 
development. In cultured embryonic DRG neurons it was found that the expression 
of both N avi.8 and N avi.9 mRNA was decreased following NGF withdrawal, 
suggesting NGF is required for their expression (Zur et al., 1995; Klein et al, 2003). 
However, the interpretation of findings is complicated by the fact that the neurons 
are dependent on NGF for survival and that NGF withdrawal of NGF leads to the 
death of these neurons.
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Other functions
Despite the generally healthy and viable phenotype of the N avi.8 null mutant, a 
surprising role for incorrect expression of Navi. 8 has been found in sufferers of 
multiple sclerosis (MS). N avi.8 is normally expressed within the PNS, but not in the 
brain, however in a mouse model of MS, Navi.8 mRNA and protein were expressed 
in cerebellar Purkinje cells (Black et al., 2001). This was also found in post-mortem 
tissue from patients with MS, but not in control tissue from subjects with no 
neurological disorders. These results suggest that expression of Navi. 8 is altered 
within neurons in the brain of MS sufferers. This abnormal expression may 
contribute to characteristic traits of the disorder, such as ataxia (Black et al., 2001)
2.1.4. NGF and TrkA knockout mice
In this chapter gene regulation by NGF was explored using mice with null mutations 
in the NGF gene. TrkA'7' mice were also used to to investigate NGF signalling via 
this receptor tyrosine kinase. Homologous recombination methods in embryonic 
stem cells allowed the generation of mice with a deletion in the coding sequence of 
the NGF gene (Crowley et al., 1994) and the TrkA gene (Smeyne et al., 1994). 
Histological analysis of mice homozygous for NGF disruption revealed a severe cell 
loss in both sensory and sympathetic ganglia, alongside an inability to respond to 
noxious mechanical stimuli (Crowley et al., 1994). Similarly, TrkA knockout mice 
had severe sensory and sympathetic neuropathies, most dying within one month of 
birth (Smeyne et al., 1994). Because of this drastic phenotype, I studied gene 
expression in these mice at embryonic stages before the onset of excessive neuronal 
cell death and after normal expression of TrkA and NGF occurs. A small time 
window between E l2 and E l6 was possible for these experiments.
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2.2. Materials and methods
2.2.1. Transgenic mice
The TrkA and NGF knockout mice used were those originally generated by 
homologous recombination by Smeyne et al., 1994 and Crowley et al, 1994.
Embryos of the required stage were obtained from overnight matings of TrkA and 
NGF heterozyote mice. The date of identification of vaginal plug was set to be 
embryonic day 1. Pregnant females were killed by carbon dioxide asphyxiation 
followed by cervical dislocation at 13, 14, and 15 days of gestation. Embryos were 
carefully removed from the amniotic sac and the precise stage of development was 
determined by the criteria of Theiler (Theiler K, 1972).
2.2.2. Dissections
Dissections of trigeminal, nodose and DRG from staged embryos were performed 
under a stereo-microscope, using a fibre-optic light source that allows illumination of 
specimens without overheating. Dissections were carried out in filter sterilised 
Liebowitz-15 (L-15) medium (pH 7.3) supplemented with penicillin (60mg/l) and 
streptomycin (100mg/l).
Dissections were carried out using forceps and scissors (E l5) followed by tungsten 
needles to remove adherent connective tissue. For younger ages (E l3, E l4), tungsten 
needles were used for the whole dissection. Tungsten needles were made from 
0.5mm diameter tungsten wire electrolytically sharpened in 1M KOH whilst being 
held in chuck-grip platinum wire holders (Davies AM, 1988). All tools were flamed 
with alcohol to sterilise prior to dissection.
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Dorsal Root Ganglia (DRG) Dissection
The head and tail of the embryo were severed so just the trunk region remained. Skin 
and internal organs were then removed to leave just the spinal column. Cuts were 
made along the length of the spinal column by inserting one blade of the scissor (or 
one needle) inside the column and cutting along the ventral aspect. This was done on 
either side to allow the removal of the ventral section of the spinal column. The DRG 
were now visible in gaps between where ribs were to form. Ganglia were gently 
isolated, and any adherent nerves and connective tissue cut off using needles. A 
Pasteur pipette was used to transfer collected ganglia to 1.5ml micro-centrifuge 
tubes. Ganglia were stored at -80°C until genotyping was complete.
Trigeminal Dissection
The dissection of these ganglia varied with the age of the mouse. From embryonic 
day 15, the top of the skull was removed using fine scissors and the brain gently 
removed using forceps. The two trigeminal ganglia were now visible on either side 
of the midbone at the base of the skull. The ganglia were removed using forceps and 
tungsten needles were used to clean them of any adherent connective tissue. At 
younger ages (E l4 and below) the dissection was carried out by initially using 
tungsten needles (E l3) or scissors (E l4) to make two coronal incisions between the 
maxillary and mandibular processes of the first brachial arch, one just above the eye 
and the second below the eye. The opaque structures of the two trigeminal ganglia 
were now visible just behind either eye in this tissue slice. They were freed from this 
tissue slice by slowly removing the surrounding tissue with tungsten needles. See 
figure 2.3.
Both types of ganglia were dissected from each individual mouse, collected in 1.5ml 
micro-centrifuge tubes and stored at -80°C until genotyping was complete.
Following genotyping, ganglia from knockout and wild-type mice had RNA 
extracted from them prior to RT-QPCR analysis of gene expression.
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Figure 2.3 : Dissection o f  the trigeminal ganglia
A: The lateral aspect o f El 1 mouse head. Dotted likes represent the location o f the transverse 
incisions that are made to obtain a tissue slice containg the trigeminal ganglia (TG), B: The 
rostral aspect o f the tissue slicecontaining the TG.
(Mx - Maxillary process; Mn - Mandibuar process; IV - fourth ventricle.
Taken from Davies, 1995
2.2.3. Genotyping
Genotyping was used to determine whether dissected mice were knockout, wild-type 
or heterozygote for the gene of interest. To avoid contamination, all DNA extractions 
and Polymerase Chain Reactions (PCRs) were carried out in a DNA free 
environment, following standard procedures to minimise exposure to DNases and 
contaminating DNA species.
DNA Extraction
DNA was extracted from a small amount of the remaining tissue of each dissected 
embryo using a Nucleospin Tissue DNA extraction kit (Macherey-Nagal, Germany), 
following the manufacturers protocol. In brief, tissue was broken down by overnight 
incubation at 56°C in a micro-centrifuge tube containing lysis buffer and 25 pg/ml 
proteinase K. The following day, tubes were centrifuged at 10,000RPM for 5 
minutes, to pellet the undigested tissue and 200pl of the supernatant was transferred 
to a fresh 1.5 ml micro-centrifuge tube along with an equal volume of dt^O. 200pl 
of this diluted solution was added to an equal volume of buffer B3 and the samples 
were incubated at 70°C for lOmins. Samples were centrifuged again, at 10,000rpm 
for lOmins, and the supernatant transferred to a spin tube with a DNA binding filter. 
Bound DNA was washed to remove contaminating proteins and salts, using an 
ethanol based solution and centrifugation. Finally, the DNA was eluted from the 
membrane by the addition of 120pl of low ionic-strength elution buffer (supplied by 
the manufacturer) that had been pre-heated to 70°C. Extracted DNA was stored at -  
20C whilst awaiting genotyping by PCR.
PCR
PCR reactions were designed to distinguish whether individual embryos from 
heterozygote X heterozygote crosses contained just knockout alleles, just wild type 
alleles or were heterozygous for both. PCR reactions were performed in duplicate 
from the DNA sample of each mouse. Details of reaction conditions and primer
1 2 1
sequences are outlined below. A master mix was made up for each reaction, 19pl of 
which was added to 1 pi DNA. Mastermix recipes are outlined below.
NGF TRKA
1 Ox hot taq buffer (GeneSys Ltd) 2 pi 2pl
5mM dNTPs (Promega) 1 pi lpl
WT primers (MWG) 0.34pl 0.2pl
KO Primers (MWG) 0.67 pi 0.2pl
Common Primers (MWG) 0.5pl 0.23pl
Hot Start Taq (GeneSys Ltd.) 0.13pl 0.2pl
25mM MgCL (GeneSys Ltd.) 4pl lpl
Mr solution (GeneSys Ltd.) 6.61 pi -
dH20  (GIBCO) 6.61 pi 13.167pl
Table 2.1 Reaction mix for genotyping reactions
The combination of 3 primers could potentially produce 2 products, one for the wild 
type allele and one for the knockout allele. DNA from Heterozygote animals 
contained both products.
Primer sequences are outlined below
TrkA:
P095-4 (wild type): 5’-CGG ACC TCA GTG TTG GAG AGC TGG-3’
P096-0 (mutant): 5’-CAC CCT GCA CTG TCG AGT TTG C-3’
P097-0 (common): 5 ’-GCT CCC GAT TCG CAG CGC ATC G-3 ’
NGF:
NGF1 (wild-type) 5’-ACA GAT AGC AAT GTC CCA G-3’
NGF 2 (mutant) 5’-TCT GGA TTC ATC GAC TGT G-3’
NGF C (common) 5 ’-GGT GCT GAA CAG CAC ACG-3 ’
1 2 2
Two drops of mineral oil were layered on top of each PCR reaction to prevent 
evaporation of reagents during thermocycling. The Taq polymerase used for 
genotyping had been genetically altered to be inactive unless heated at 95 °C for 15 
minutes. Such “hot start” polymerases reduce the amount of mispriming in the first 
PCR cycle and, therefore, give cleaner, more efficient PCR reactions. Initially 
samples were heated to 95°C for 15 minutes to activate taq. A variable number of 
PCR cycles were then performed to amplify the product, the exact number of cycles 
depending on the concentration of the DNA and the amplification efficiency of the 
primer sets used. Each cycle followed the same general pattern. First, tubes were 
heated to 95°C to denature secondary structure in the DNA, and separate double­
stranded DNA into single-stranded DNA. Next, the reaction was cooled to the 
specific annealing temperature of the primer set, to allow primers to anneal. The 
annealing temperature was determined according to primer sequence and size. 
Finally, the reaction was heated to 72°C to allow the taq DNA polymerase to extend 
primers and synthesize a complementary copy of the single stranded DNA template. 
Following cycling, samples were heated to 72°C for lOmins for a final extension step 
to ensure all products of the PCR reaction were full length.
Reaction conditions for both knockout strains are outlined below.
NGF TRKA
Denaturation 95°C 15mins 95°C 15mins
Denaturation 95°C 40s 95°C 40s
Annealing 55°C lmin 10s 65°C lmin 10s
Extension 72°C lmin 50s 72°C lmin 40s
No. Cycles 45 38
Final Extension 72°C 72°C
Hold 4°C 4°C
Table 2.2 Reaction conditions for genotyping reactions
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Visualisation o f  Products
Once the PCR reaction was completed, the PCR products were visualised by adding 
4ul o f 6X loading dye (0.25% bromophenol blue, 0.25% xylene cyanol FF, 15% 
Ficoll in dH20) and runninglOpl on a 2% agarose gel, made with TAE buffer and 
containing 1 pg/ml ethidium bromide (Sigma).
The wild type lower band and knockout upper band could be visualised in the gel 
using a UV gel documentation system (Biogene). Figures 2.4. and figure. 2.5. show 
representative gels o f genotyping products from NGF and TrkA mice, respectively. 
Expected PCR product sizes are outlined below
NGF TRKA
Wt band size 190 400
KO band size 610 800
Table 2.3 Band sizes fo r  genotyping reactions
NGF
1 2 3 4 5 6 7 8 9  10
Figure 2.4: Genotyping gel showing the three possible genotypes o f  embryos from  NGF+A crosses.
Lanes 1, 2, 5 and 6 show the PCR product from the wild-type DNA. Lanes 3, 4, 9 
and 10 show the PCR product from the knockout DNA. Lanes 7 and 8 show the 
products from the heterozygote DNA. The size o f the products is shown with respect 
to a 1 kb ladder. (N.B. -C  shows the negative controls in which DNA extractions 
were done with no tissue. +C is a positive control using DNA shown to be 
heterozygote previously).
124
TrkA
1 2 3 4  5 6 7 8 9  10
Figure 2.5: Genotyping gel showing the three possible genotypes o f  embryos from  TrkA +A crosses. 
Lanes 1 and 2 show the PCR product from the knockout DNA. Lanes 3, 4, 5, 6, 7 and 8 show the PCR 
product from the heterozygote DNA. Lanes 9 and 10 show the products from the wild-type DNA.
The size of the products is shown with respect to a 1 kb ladder.
As the expression o f the genes investigated in this chapter is low in young embryos, 
knockout and wild-type ganglia were pooled separately to give a more concentrated 
RNA sample following RNA extraction. 6 ganglia per replicate were pooled for E l3, 
4 for E l4 and 3 or 4 ganglia for E l5. 3 or 4 replicates were collected for each type of 
ganglia at each age (n = 3-4).
2.2.4. RNA extraction
RNA from collected ganglia was extracted using a phenol-based method described 
by Chomcynski and Sacchi (Chomcynski and Sacchi, 1987). 500pl o f Solution D 
lysis buffer (4M guanidine thiocyanate, 25mM tri-sodium citrate pH 7.0, 0.5% N- 
lauroylsarcosine, 0.1M p mercaptoethanol), was added to each tube containing 
ganglia, and the ganglia were homogenized by passing up and down through a 25 
gauge needle. The following was then added sequentially to the lysed cell solution: 
lp l lOmg/ml E-coli transfer-RNA (Sigma); 50pl sodium acetate, pH 4.4; 500pl 
water-saturated acidic phenol (Sigma); 150pl o f 25:1 chloroform: isoamyl alcohol 
(Sigma). The solution was mixed vigorously and tubes left on ice for 1-5 minutes 
before centrifugation at 13,000rpm for 20 minutes. Following centrifugation the 
RNA solution had separated into two layers, the upper aqueous phase containing 
total RNA. This top layer, approx. 450pl, was transferred to a clean 1.5ml micro­
centrifuge tube and twice the volume of 100% ethanol (AnalR grade) was added. The
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samples were vortexed and put at -20°C overnight to allow precipitation of total 
RNA.
The following day, samples were centrifuged at 13,000 rpm for 20 minutes, the 
supernatant discarded and the compact white pellet formed washed in 70% ethanol. 
The pellet was allowed to air-dry before the addition of a DNase solution. (N.B In 
order to prevent false-positive results following RT-PCR, the samples were 
extensively DNased to remove any contaminating genomic DNA). 50pl of the 
following DNase solution was added to each pellet: lOmM Tris pH 7.5 (Sigma),
6mM MgCh (Promega), 20mM Vanadyl-ribonucloeside complex (VRC, an RNase 
inhibitor) (Sigma), and 5pl of 7,500 units/ml RNase-ffee DNase I (Pharmacia). The 
samples were then put in a 37°C water bath for 2-3 hours to allow degradation of any 
contaminating genomic DNA. Following the DNase step an RNA extraction kit was 
used to purify the RNA further (RNaid kit from BIO 101). 180pl binding solution 
(3M NaClOa) and 20-30pl, dependent of the amount of starting tissue, RNA binding 
(RNaid) matrix was added to samples. Tubes were incubated at room temperature for 
10-25 minutes, with occasional shaking to allow RNA to bind to the matrix. The 
matrix containing bound RNA was then sedimented by brief centrifugation at 
13,000rpm and the supernatant was discarded. The matrix was washed with 700pl 
wash solution (RNaid kit, Amersham), centrifuged, the supernatant discarded and the 
wash step repeated. The RNA was then eluted by addition of 30-1 OOjlxI DEPC-treated 
dH20 and heating the samples to 65°C for 2-3 minutes. Samples were centrifuged at 
13,000rpm for 1 minute, to sediment the matrix, and the supernatant containing the 
RNA was pipetted off carefully into new RNase-ffee micro-centrifuge tubes and 
stored at -80°C until required.
2.2.5. Competitive RT- PCR
RT-PCR is a sensitive method of detecting rare mRNAs in small amounts of tissue. 
The method of competitive RT- PCR described below allows the expression levels of 
specific mRNAs to be accurately quantified. The technique involves spiking the RT 
reaction with a known concentration of a synthetic competitor cRNA, which is
1 2 6
identical to a portion of the mRNA that is being quantified, but with the addition of 
3-4bp between the PCR primer binding sites. The mRNA and competitor cRNA are 
both converted to cDNA with equal efficiency in the same reverse transcription (RT) 
reaction. During the subsequent PCR reaction, competitor cDNA and cDNA from the 
endogenous target mRNA are amplified with the same primers. Because the 
competitor cDNA and cDNA from the endogenous target are virtually identical they 
are amplified with equal efficiency. For this reason, the ratio between the RT- PCR 
products of the cRNA and mRNA at the end of the PCR reaction, observed by 
separating them on a polyacrylamide gel, staining with SYBR Gold and viewing 
under UV, accurately reflects the ratio of cRNA competitor and endogenous mRNA 
before the RT reaction. If the amount of the cRNA added to each RT reaction at the 
beginning of the RT-PCR assay is known and an imaging system is used to quantify 
the ratio between the SYBR Gold stained RT-PCR products, then the initial amount 
of mRNA can be easily calculated. This use of competitor cRNAs rather than 
competitor cDNAs makes a more accurate and reliable assay, since it takes account 
of variation in the efficiency of reverse transcription between individual reactions.
2.2.5.1. Production of competitors
The cRNA competitors used to assay GADPH and CGRP mRNAs were transcribed 
in-vitro from a competitor cDNA that had been constructed from a cDNA clone of a 
portion of CGRP and GAPDH mRNAs.
General Method
RT-PCR to clone the competitor
The cDNA clones were made by RT-PCR amplification of E14 mouse trigeminal 
ganglia total RNA, with GAPDH or CGRP specific primers.
8pl of E14 mouse trigeminal RNA was reverse transcribed in a 40pl mixture below:
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REAGENT VOLUME
5x RT Superscript buffer (Gibco) 8 pi
5mM dNTPs (MBI Fermentas) 4pl
lOOpM Random Hexanucleotides 4pl
0.1MDTT 4pl
dH20 12pl
Table 2.4 Reverse Transcription reaction for producing cDNA clones.
The reaction mix was heated for 2 minutes at 90°C followed by addition of 2ju,l 
Superscript reverse transcriptase. Samples were incubated for 90 minutes at 37°C 
and then the temperature increased to 95°C for 6 minutes to stop the reaction and 
degrade the RNA template.
PCR was used to amplify cDNAs of interest. Primer sequences were based on 
published sequence information and were selected carefully to ensure amplification 
of a region between 400 -  800bp. Primer sequences are shown in table 2.5.
GENE PRIMERS FRAGMENT SIZE
GAPDH Forward: 5’-CTT CAT TGA CCT CAA CTA 
CAT G-3’
Reverse: 5’-GGC ATG GAC TGT GGT CAT-3’
401 bp
CGRP Forward: 5’-AAG AGT CAC CGC TTC GCA 
AGC A-3’
Reverse: 5’-AGC TCC TGT CAA AGG GAG 
AAG-3’
628bp
Table 2.5 Primer sets and fragment sizes for cDNA fragments to produce competitor species
1 2 8
50pl reactions were set up comprising of:
REAGENT VOLUME
Reverse Transcription Product 5 pi
lOx Hot Start Taq buffer (Gibco) 4.5pl
5mM dNTPs (MBI Fermentas) 2pl
50pmoles primers (MWG-Biotech) 5 pi
Hot Start Taq polymerase (Gibco) 0.5pl
dH20 33pl
Table 2.6 PCR reaction reagents for amplification o f DNA fragments
3 drops of mineral oil was layered on the top of each reaction and the tubes 
transferred to the heating block of a PCR machine.
The following protocol was run:
STEP TEMPERATURE TIME
Activation of Taq 95°C 10 minutes
Annealing at 55°C (for both GAPDH and CGRP 55°C 60 seconds
Synthesis 72°C 90 seconds
Extension 72°C 10 minutes
Table 2.7 PCR protocol for amplification o f cDNA clones
Products were run on a 1% agarose gel and the band of interest cut out using a razor 
blade. Purification of the gel fragment was done using the Gene Clean®II kit and 
DNA recovered in 20pl dtkO.
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The cDNA fragment generated was cloned into pGEM T-vector (Promega) following 
the manufacturers protocol. This ligation mixture was then used to transform 
competent E.coli XLI cells (Stratagene).
Transformation of Competent Cells
1/10 volume of the ligation mixture was added to competent cells and left on ice for 
lhour. Cells were then heat-shocked by placing in a 42°C waterbath for 90 seconds, 
before returning to ice for 5 minutes. 800pl LB broth was added to cells and tubes 
incubated at 37°C for 1 hour, before plating onto LB agar (Gibco) dishes. The LB 
agar contained lOOmg/ml ampicillin; hence only colonies containing the transformed 
vector with ampicillin resistance will grow. Dishes were placed at 37°C overnight to 
facilitate growth.
Analysis of Transformants
Single colonies were picked from plates and used to inoculate 3ml LB broth 
containing lOOmg/ml ampicillin. Tubes were placed in a shaking incubator overnight 
at 37°C. Plasmid DNA was now extracted from the resulting bacterial suspension 
using a QLAprep Spin Miniprep kit (Qiagen) and eluted in 50pl dH20 . To check for 
presence of the insert, 5 pi of plasmid DNA was digested with appropriate restriction 
enzyme for 1 hour in a 20pl reaction. The digest was run on a 1 % agarose gel to 
ensure products of the correct size had been generated.
Modification of Cloned DNA to Produce Competitor DNA
40pl of remaining plasmid DNA was cut at a certain unique restriction site by 
incubation overnight with specific restriction endonuclease, Hindlll for GAPDH and 
BAMHI for CGRP. The reaction contained 5pi lOx buffer (chosen according to the 
restriction enzyme being used), 2pl dH20  and 3 pi restriction enzyme. The restriction
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enzyme was chosen for each reaction to allow a single cut in cDNA that leaves a 4-5 
bp 5’ overhang.
Following digestion, plasmids were purified using the Gene Clean ® II kit. The 
overhang was now filled in and blunt ended by the use o f Klenow polymerase (see 
figure 2.6). A 20pl reaction was set-up containing 15pl plasmid DNA 2pl lOx 
klenow buffer and 3pi 5mM dNTPs. After mixing, lp l o f  Klenow enzyme was 
added, and the reaction incubated at room temperature for 5 minutes. The reaction 
was stopped by the addition o f Nal from the Geneclean® II kit and the DNA was 
purified again.
Figure 2.6: The use o f  klenow polymerase to fill in missing base pairs o f  a DNA overhang.
Taken from Bowen, 1999
The blunt ends were then re-ligated using the reagents o f p-GEM T-vector kit. 9pl of 
the newly filled-in DNA were incubated overnight at 4°C with lOpl 2x ligase buffer 
and lp l o f 400u/pl T4 DNA ligase. Following ligation, the Gene Clean®II kit was 
used to remove DNA ligase and T4 ligase buffer and the DNA was recovered in 20pl 
dH20. This resulted in a competitor cDNA that was 3-4bp longer than the original 
native cDNA.
Linearisation and Purification
To produce cRNA from the competitor cDNA, the plasmid was first linearised at the 
3’ end o f the inserted DNA by overnight digestion with an appropriate restriction 
endonuclease (Sal I for gapdh and Nco I for CGRP). Enzymes were chosen for their 
ability to produce blunt ends, or 5’ overhangs and to cut only once, as far away from 
the insert site as possible. Gel electrophoresis was used to visualise the digest to 
ensure complete linearisation. The DNA band corresponding to the linearised cDNA
5  * A -G -G -C -f i-G  
3* T -C “ C ~G ~T -C ~C ~T “ A-G
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was then cut out of the gel with a razor blade and purified using the Gene Clean®II 
kit following the manufacturers protocol.
In-Vitro Transcription
cRNA was transcribed in-vitro from the linearised competitor cDNA using T7 RNA 
polymerase (Promega). 2x50pl reaction mixtures were set up containing the 
following, added sequentially:
REAGENT VOLUME
5x Transcription Buffer (Promega) lOpl
lOOmM ATP (Promega) 5 pi
lOOmM CTP (Promega) 5 pi
lOOmM GTP (Promega) 5 pi
lOOmM UTP (Promega) 5 pi
lOOmM DTT (Promega) 5 pi
RNAguard (Pharmacia) 2 pi
dH20 6pl
Plasmid DNA (l-5pg) 7 pi
30-50u T7/SP6 RNA polymerase (Promega) 2pl
FM mng-minCTW TT—FT —     Bgg
Table 2.8 Reagents for In- Vitro Transcription o f competitor cDNAs
After thorough mixing, the reaction was incubated for 1 hour at 37°C. After this time 
2pl more of T7/SP6 polymerase was added to the reaction, which was then incubated 
for a further hour. The remaining plasmid DNA was now degraded by the addition of 
2pi VRC and 5pi of 7,500u/ml DNase I, and incubation for 2 hours at 37°C.
The RNA transcripts were then purified, as previously, using the RNaid kit (Bio 101) 
(See 2.2.3) and eluted in lOOpl DEPC water. The integrity and approximate size of 
the purified cRNA was determined by gel electrophoresis on a 1 % agarose DEPC 
treated gel in a DEPC treated gel tank (DEPC (di-ethyl-pyrocarbonate) treatment
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effectively removes contaminating RNases). Next, a spectrophotometer was used to 
determine the concentration. The remaining RNA was then diluted with water and 
precipitated at a concentration of lng/pl by the addition of an appropriate volume of 
water, 0.1 volume of 3M sodium acetate (pH5.5), 3 volumes of ethanol and 20ng 
E.coli tRNA for every lng of transcript. The ethanol-precipitated transcript was 
stored at -20°C until use.
2.2.5.2 The competitive RT-PCR assay
Reverse Transcription (RT)
Initially total RNA was reverse transcribed to cDNA. Competitor cRNAs were 
included in the reverse transcription reaction along with the competitor for the 
housekeeping gene GAPDH.
The protocol used for reverse transcription is outlined below. To lp l of RNA sample 
the following was added:
REAGENT VOLUME FOR 1 
REACTION
5x buffer (GIBCO, included in superscript kit) 8 pi
lOOpM Random Hexanucleotides (RH) (Pharmacia, 
Amersham)
4pl
5mM dNTPs (Fermentas) 4pl
0.1M DTT (GIBCO, included in superscript kit) 4pl
Competitor RNA lpl
GAPDH competitor RNA lpl
dH20 16pl
Table 2.9 Reverse transcription reaction reagents for competitive PCR
The mixture was heated to 90°C for 2 minutes to allow any secondary structures 
within the RNA to be broken down. After rapid cooling on ice, 1 pi of Superscript
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reverse transcriptase (GIBCO) was added to all samples, excluding those samples 
that were to serve as no RT negative controls (these samples contained everything 
but enzyme, and were used to check for the presence of contaminating genomic 
DNA). Immediately after the addition of enzyme, samples were incubated at 37°C 
for lhour, and finally the reaction was halted by heating the sample to 95°C for 6 
minutes, resulting in denaturation of the reverse transcriptase and degradation of the 
RNA template.
Polymerase Chain Reaction (PCR)
PCR reactions were carried out for CGRP and GAPDH separately. 5 pi cDNA was 
used in a 40pl reaction as below.
A mastermix was made up using the following protocol:
REAGENT VOLUME
lOx buffer (Helena biosciences) 4pl
Primers 1:1 ratio of forward and reverse 50pmoles (MWG) 4pl
5mM dNTPs lp l
Taq polymerase, 5U/pl (Helena Biosciences) 0.125pl
dH20 30.875pl
Table 2.10 PCR reagents for competitive PCR
After mixing, mineral oil was layered on the top of each sample and tubes transferred 
to the heating block of a PCR machine. Samples were initially denatured by heating 
to 95°C for 1 minute, followed by annealing (53°C GAPDH, 59°C CGRP) for 60 
seconds and then synthesis at 68°C for 60seconds. Annealing and synthesis steps 
were then repeated (24 cycles for GAPDH and 32 cycles for CGRP) before a final 
extension step at 68°C for lOmins.
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Primers used were designed to span the region of the competitor insert so that two 
separate products would be produced, the product from the cRNA being 4bp bigger 
than that of the native product. The primers are shown below:
Calcitonin Gene Related Peptide (CGRP):
Forward: 5’-TCT GCT GAG CAG ATC AGG AG-3’
Reverse: 5’-GGG CTG TTA TCT GTT CAG GC-3’
GAPDH:
Forward: 5’-TCC AGT ATG ACT CCA CTC AC-3’
Reverse: 5’-TCC TGG AAG ATG GTG ATG G-3’
Electrophoresis of Products
PCR products were run on an 8% (29:1) polyacrylamide gel to allow the very small 
differences in size of product and competitor cDNA to be visualised. Following 
electrophoresis, gels were stained for 15 minutes in the dark with SYBR Gold 
solution at a 10,000 x dilution (molecular probes). SYBR Gold is a non-isotopic UV- 
sensitive dye that intercalates between double stranded DNA, allowing PCR products 
to be visualised under UV light. PCR product bands were visualised using a UV 
video imaging system (Biogene) and the intensity of the adjacent bands were 
compared via densiometry using phoretix ID quantifier software. As the 
concentration of competitor added to the reaction was known, the amount of mRNA 
in samples could be calculated by the ratio of the intensity of the competitor RT-PCR 
product band compared to the mRNA RT-PCR product band. This value was then 
normalised against GAPDH to account for any differences in starting levels of total 
RNA between different RT-PCR reactions.
Initially, a competitor titration reaction was carried out to determine the optimum 
amount (fg) of each competitor species to use in the PCR reaction (CGRP and 
GAPDH). Ideally, an approximately equal amount of competitor and target product
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should be amplified, as would be shown by 2 bands o f similar intensity on the gel. 
Such titration results are shown in figure.2.7. More than a five-fold difference in 
amplified product to amplified competitor cannot be detected accurately by the 
imaging software.
Figure 2.7. Titration reactions to determine levels o f  CGRP competitor species to use in RT-PCR 
reactions.
0.5fg to 50pg of CGRP competitor was used to determine the most suitable amount to use with E14 
trigeminal RNA samples (A) and E14 DRG samples (B). The RT-PCR product of the competitor is 
the higher molecular weight band at the top and the RT-PCR product o f the CGRP mRNA is the 
lower band. 50fg was the most suitable competitor concentration to use for trigeminal RNA and 5fg 
for DRG RNA, as at these competitor concentrations both competitor and mRNA RT-PCR products 
have a similar intensity.
2.2.6. Real t im e quan t i ta t ive  PCR -  S t r a t a g e n e  
MX3000P
A new Q-PCR machine, Stratagene's MX3000P, was acquired in the lab allowing 
validation o f previous competitive RT-PCR results and also enabled quantitative
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study o f expression levels o f additional mRNAs using a method that has a broader 
dynamic range and is quicker to optimise reactions for new mRNAs. Additionally, 
reactions are set-up and run in a 96-well format and PCR products do not have to be 
resolved by gel electrophoresis, making it significantly faster than competitive RT- 
PCR.
Unlike competitive RT- PCR used previously, real-time PCR monitors the progress 
o f the PCR reaction continuously through the use o f dual-labelled fluorescent probes, 
single labelled hybridisation probes or, as in the majority o f the reactions performed 
in this project, a dye (SYBR green) that fluoresces upon binding to double-stranded 
DNA. SYBR green generation o f fluorescence is significantly cheaper and more 
sensitive than probe systems, but is not specific to any one PCR product (see figure 
2.8). SYBR green is a double stranded (ds) DNA-binding dye. It is thought to bind in 
the minor groove o f double-stranded DNA and upon binding its fluorescence 
increases over a hundred-fold.
SYBR Green
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Figure 2.8.: SYBR green is a non-specific fluorescent dye that, upon binding to any double-stranded 
DNA, fluoresces.
Taken from Rasmussen, 2001
After each PCR cycle the fluorescence, and hence product accumulation, is recorded 
and represented graphically on a PC attached to the PCR machine. A sigmoidal curve 
illustrates the reaction. It shows the initial build up o f the product followed by the 
exponential amplification, and then the plateau when either one or all reagents are 
used up or become limiting, or single stranded template re-annealing becomes the 
dominant kinetic process (figure 2.9A). By monitoring the number o f cycles required
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to produce a threshold amount of product, the relative quantity of mRNA of interest 
within a sample can be calculated. The process is outlined in more detail below.
2.2.6.1 Reverse transcription
For reactions on the Stratagene MX3000P, cDNA was produced using a Stratagene 
reverse transcription enzyme, Stratascript, rather than the GIBCO Superscript used 
previously. In initial pilot studies, Stratascript was found to produce consistently 
higher yields of cDNA than Superscript and was found to be significantly more cost 
effective. In addition, the amount of cDNA produced shows a stronger linear 
relationship with reference to the amount of input total RNA than with Superscript. 
Importantly, active Superscript that carries over into the QPCR reaction was found to 
inhibit QPCR much more strongly than Stratascript (data not shown).
5 pi RNA was transcribed to cDNA using Stratascript reverse transcriptase 
(Stratagene) in the following 40pl reaction.
REAGENT VOLUME
10x buffer (Stratagene) 4pl
Random Hexanucleotides lOpM (Pharmacia) 2pl
dNTPs, lOOmM (Stratagene) 2 pi
Stratascript Enzyme (Stratagene) 0.4pl
dH20  (GIBCO) 31.6pl
Table 2.11 Reaction mix fo r  Stratagene Reverse Transcription
Samples were incubated at 37°C for 1 hr 15 minutes. Unlike previous reverse 
transcription reactions for competitive RT-PCR, a final 95°C step was not included 
because the QPCR enzyme used was a “hot start” enzyme and required 10 mins at 
95°C as the first step of the PCR reaction.
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2.2.6.2 Real-time quantitative PCR
Real time QPCR was carried out using the Stratagenes’ MX3000P. A mastermix was 
set up and 22.5pl added to 2.5pl of cDNA.
Per sample:
REAGENT VOLUME
lOx buffer (stratagene) 2.5pl
MgCl2 20mM (stratagene) 1.5pl, 2pl or 2.5pl to give a final 
concentration of 3mM, 4mM or 5mM 
respectively.
15pM forward and reverse primer mix 
(MWG)
0.5pl
Rox reference dye at a dilution of 1/500 
in dH20  (Stratagene)
0.4jil
SYBR Green at a dilution of 
l/4000(Molecular Probes)
0.25pl
dNTPs 20mM (Stratagene) lpl
Taq (Stratagene) 0.33pl
dH20 15.8pl, 15.3pl or 14.8pl (volume 
dependent on MgCl2 concentration
Table 2.12 Reaction mix fo r  Real-Time PCR
Samples were initially heated to 95°C for 10 minutes to denature DNA secondary 
structure, degrade Stratascript and RNA and activate the “hot start” taq. The cycling 
stage now began with samples being heated to 95°C, cooled to the primer annealing 
temperature (determined by the primer sequence being used), and then heated back 
up to 72°C to allow the DNA polymerase to extend the primers and synthesize a copy 
of the template DNA. This cycle was repeated 40 times to ensure ample fluorescent 
product build up. A fluorescence measurement was taken from all wells at the end of 
each annealing step
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As SYBR green can bind to all double-stranded DNA, the specific product, non­
specific products and primer dimers are all detected equally well. This problem can 
be ameliorated by using a “hot start” taq polymerase and careful primer design. For 
this project ‘Beacon Designer’ software (Biosoft International) was used for primer 
design. Following cycling, due to the non-specificity of SYBR green, it was 
important to include a melting curve to ensure that only the correct product had been 
amplified The samples were gradually heated from 65°C to 95°C at 1 ° C per minute 
with continuous monitoring of fluorescence. A rapid drop in fluorescence is recorded 
at the temperature that the PCR products separate or melt. If the rate of change of 
fluorescence is plotted against temperature a sharp peak is obtained at the melting 
temperature of each PCR product. A good PCR reaction will have only one clean 
peak at the expected melting temperature of the correct PCR products (as determined 
by computer software) and no additional peaks at lower temperature corresponding 
to primer artefacts (see figure 2.9B). Reactions that did not show a melting curve 
with these characteristics were not used for data analysis.
The concentration of SYBR green added to the reaction was optimised in a series of 
pilot experiments as preliminary experiments showed that at lower SYBR green 
concentrations insufficient fluorescence is emitted, but at higher concentrations, the 
PCR reaction was inhibited. A 1/4000 dilution seemed to produce optimum results 
(data not shown).
In some cases, when primer artefacts confounded obtaining good quantitative data, 
specific Molecular Beacon probes were used in place of SYBR Green. Such 
Molecular Beacons are designed so that they only bind to the specific amplified 
product of the gene of interest. In this case no melting curve was required. A probe 
for beta CGRP was often used. The sequence for this probe is given below, designed 
on Beacon Designer and produced by Biosearch Technologies, Inc.
5’Quasar 670 d(CGC GAT AAA TAT GAT GGT GTC TCC CAC TGG ATC GCG) 
BHQ-2 3’
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Figure 2.9. Real time PCR
A) After each cycle the level of fluorescence emitted is recorded. This represents the amount 
of PCR product present, which builds up to produce a sigmoidal shaped curve. Each coloured 
line represents a different cDNA sample. B) Melting curve of samples. After the PCR reaction 
is complete, samples are heated gradually to determine the melting temperature o f the product 
and to check for primer dimers or other contaminating products. Only one peak should be seen
For all the mRNAs assayed by RT followed by QPCR, the reaction was run using the 
protocol outlined below with the only variation being the annealing temperature. The 
melt was also not included when using molecular probes, rather than S YBR green.
STEP CONDITIONS
Denaturation 95°C 15mins
Denaturation 95°C 30s
Annealing X°C 30s
Extension 72°C 30s
No. Cycles 40
Melt Heated up to 95°C by 1°C per minute
Table 2.13 Reaction Conditions for Quantitative Real-Time PCR
QPCR - Further reaction optimisation
For each gene the primers used were designed on ‘Beacon Designer’ computer 
software, to ensure the utmost efficiency and specificity and the minimum of 
primer/primer interactions.
The reaction for each mRNA was optimised to determine the optimum MgC^ 
concentration and annealing temperature required to produce the most efficient 
reaction (as determined by the slope of a standard curve (see below)), but with a 
clean single product of the correct melting temperature and no primer artefacts. 
Reactions were always run for 40 cycles to ensure ample product amplification. For 
real time PCR the actual cycle number used is less important than with semi- 
quantitative PCR, as analysis of product concentration is done during the exponential 
phase of the reaction, and not after the reaction has approached the plateau phase..
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Standard Curve
Real-time PCR is a relative quantitative method for measuring gene expression. The 
reaction is monitored constantly throughout the reaction and the product build-up is 
illustrated by a sigmoidal curve (see figure 2.10A). The principal behind 
quantification is due to the inverse correlation between cycle number and product 
concentration. In general, the lower the cycle number required to amplify the 
product, the higher the concentration, and vice versa. Some standards, which contain 
known concentrations of cDNA are therefore required. These samples can then be 
used to determine the relative concentration of mRNA within an unknown sample
To this end, in each run, samples were included to allow production of a standard 
curve. These samples contained cDNA diluted lx, 1/3, 1/9 and 1/27 and were 
referred to as 27, 9, 3 and 1 arbitrary units respectively. For accuracy, a serial 
dilution was set up using an RT mix to dilute the samples. This RT mix was 
produced by carrying out a reverse transcription reaction, as before, with all reagents 
except the RNA template. If the standard curve was diluted in water, a linear 
standard curve was not produced. This is because reagents in the RT mix (most 
notably the RT enzyme and random hexamers) inhibit the QPCR reaction strongly; 
therefore at each dilution with water the QPCR reaction becomes more efficient.
The standards were run alongside the other unknown samples in the PCR reaction. 
See figure 2.10A for a graphical representation and note that the sigmoidal curves, 
representing product build up, are equidistant apart for each step up in concentration, 
resulting in a linear standard curve (figure 2.10A and C). From data like this the 
computer could produce a standard curve plotting cycle number to threshold vs. 
arbitrary concentration. An example standard curve is shown in Figure 2.IOC. The 
standard curve should have an RSq value as close tol as possible. RSq values of less 
than 0.95 were deemed unsatisfactory and results were not calculated from these data 
sets. The efficiency of the PCR reaction was calculated from the slope of the 
standard curve by the MX300P software. 100% efficiency corresponds to a doubling 
of product at each PCR cycle. For most mRNAs, efficiencies of 80-100% were
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obtained after reaction optimisation. In the case where reactions generated a lot of 
false products and primer artefacts, as determined by melting curve analysis, the 
PCR reaction efficiency was often seen to be over 100%. In these cases the data was 
rejected.
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Figure 2.10. Production o f  standard curve.
Samples o f a serial dilution of cDNA are included in each PCR run. 3 replicates of lx, 1/3, 1/9 and 1/27 
are shown as they amplify (A). They all have the correct melting temperature (B) and produce a 
standard cure with RSq just below 1.
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Figure 2.11. Quantification o f  data.
A) PCR product builds up exponentially the number o f cycles required to produce a threshold 
amount o f product is recorded (x) and extrapolated onto the standard curve (B) to determine 
the relative concentration o f mRNA in that sample (arbitrary units).
The standard curve generated in each reaction was used to determine the relative 
level of mRNA in the unknown samples by identifying the number of cycles required 
to produce a threshold amount of product, and extrapolating it on the calibration 
curve as shown in figure 2.11.
Reaction conditions and primer sequences for all reactions are outlined as below:
GENE PRIMER SEQUENCES m g c l 2
CONCN.
(MM)
ANNEALING 
TEMP. (°C)
a-CGRP Forward:
5’-AAG AAA GGC TGA 
AAG ACA-3’
Reverse:
5’-GGA TAC AGA GTC 
AC A TAC AAC AC-3’
5 51
P-CGRP Forward:
5’-GAG TTA ATT CTG 
TGT TTG TTT GC-3’ 
Reverse:
5’-TTG GCT GGA TGG 
CTC TTG-3’
5 51
Substance P (SP) Forward:
5’-CCC AAG CCT CAG 
CAG TTC-3’
Reverse:
5’-GCC CAT TAG TCC 
AAC AAA GG-3’
5 51
Sodium channel Nav1.8 Forward:
5’-AGG CTG GAT GGA
4 51
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CAT TAT G-3’
Reverse:
5’-TGA AGA CGA AGT 
ATA GG-3’
Sodium channel Nav1.9 Forward:
5’-CCT TCC GAG TGT 
TGA GAG-3’
Reverse:
5’-AAA GAG AGT GAG 
GAC CAT C-3’
5 51
Gapdh Forward:
5’-TCC CAC TCT ACC 
TTC-3’
Reverse:
5’-CTG TAG CCG TAT 
TCA TTG TC-3’
3 51
Table 2.14 Primer Sequences, MgCU concentration and annealing temperature fo r  all 
genes
a- and p-CGRP mRNAs are almost identical in sequence and are the products of two 
separate genes. The competitive RT-PCR initially used to analyse CGRP expression 
could not distinguish between the two different CGRP mRNAs. However, careful 
primer design generated specific QPCR reactions for a- and p-CGRP.
148
2.3. Results
2.3.1. NGF/TrkA signalling is not required for initial induction 
of CGRP mRNA expression in early embryonic mouse 
sensory neurons.
Initially, the expression of CGRP mRNA was studied in TrkA and NGF knockout 
mice using a quantitative form of RT-PCR, competitive PCR. In these experiments 
primers were unable to distinguish between the two isoforms of CGRP.
Trigeminal and DRG were dissected from TrkA7' and NGF7' and their wild-type 
littermates. Ganglia were pooled, as expression of the genes of interest is low at 
young ages. Total RNA was extracted using a phenol based method and reverse 
transcribed. Expression of CGRP was quantified using competitive PCR. Primers 
used here allowed amplification of both transcripts equally.
Competitive PCR involved the use of a synthetic RNA competitor (cRNA) that 
differed from the amplified product by just 3-4bp. Both competitor and RNA were 
reverse transcribed and amplified together. Due to their similarities, they compete for 
primer binding and subsequent amplification. The two amplified products could be 
distinguished on an acrylamide gel. As the concentration of competitor added to the 
reactions was known, the relative concentration of native product could be 
determined from band intensity. The housekeeping gene GAPDH was also amplified 
within each sample and used to normalise results to account for any differences in 
starting RNA. Expression of CGRP was studied in both trigeminal and DRG from 
E13-E15.
In this chapter, data was statistically analysed by use of the t-test. The t-test was 
chosen as only two sets of data were being compared (knockout vs wildtype) and the 
data would be expected to fit into the following criteria:
• Both sets of data are normally distributed
• The variances of the samples are similar to each other
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This test is also used in the following chapter (chapter 3), as once again only two sets 
of data are being compared (knockout mouse vs wild-type mouse or 0 hours vs 96 
hours). An unpaired t-test was used in all cases since experiments being compared 
were independent of each other. The t-test compares the mean of each data set, whilst 
taking into account the variance of the results (the spread of results around the 
mean). Thus the formula for the t-test (see below) is a ratio - the top part being the 
difference between the two means or averages, whilst the bottom part illustrates the 
variance of the results (standard error of difference).
The significance levels in this thesis are when p <0.05 ( *) and when p<0.001 (**) 
i.e. results are classed as ‘significantly different’ when confidence levels reach 95% 
that the results are not different just due to random chance (or there is only 5% 
chance that you find the results as significantly different when they are not (i.e by 
random chance)).
Trigeminal ganglion
In the trigeminal ganglion, the expression of CGRP did not differ between wild-type 
and NGF'7' or TrkA'7', as shown in figure 2.12. This would suggest that in the 
trigeminal ganglion, the onset of CGRP expression does not require NGF/TrkA 
signalling.
CGRP mRNA was found to be expressed at lower average levels in DRG than in 
trigeminal ganglia (figure 2.13, note scale change), suggesting it is either expressed
t
DRG
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in a larger sub-population of trigeminal ganglia neurons compared to DRG neurons, 
the levels of CGRP mRNA per neuron are higher in the trigeminal ganglia than in the 
DRG or that trigeminal ganglia are developmentally more advanced at these ages 
than DRG. The expression of CGRP mRNA normalised to the levels of GAPDH 
mRNA is shown in figure 2.13 for both the TrkA'7' (A) and the NGF'7' (B) mice in 
comparison to their wild-type littermates at ages between E l3 and E l5. In TrkA'7' 
mice CGRP mRNA levels in DRG are comparable to those in wild-type mice (figure 
2.13 A), as was seen in trigeminal ganglia. Although there is a lower level of CGRP 
mRNA expression in the null mutant at E l5 compared to wild type mice (Figure 
2.13B), this reduction in expression is not statistically significant.
It is worth mentioning that NT-3 signalling via TrkA will also be lost in TrkA'7' 
mice. NT-3 is important during the early embryonic development of sensory neurons 
(Buchman and Davies, 1993). As well as signalling via its preferred receptor TrkC, 
NT-3 can also bind to TrkA (Soppet et al., 1991; Klein et al., 1991b; Cordon-Cardo 
et al., 1991; Glass et al., 1991; Ip et al., 1993) and signal via this receptor. NT-3 was 
shown to support the survival of cultured trigeminal ganglia from TrkC'7' mice to an 
extent comparable to NGF (Davies et al., 1995). This suggests that NT-3 can also 
signal via TrkA. This has been further confirmed through the observation that NT-3 
can displace NGF from its preferred receptor (Emfors et al., 1990). It is quite 
possible that following the additional loss of NT-3 signalling via TrkA in TrkA'7' 
mice, neurons that do survive and differentiate have a slightly different phenotype 
from those of the NGF'7' mice. NT-3 can also regulate PNS neuronal precursors, 
inducing survival, differentiation and proliferation of a wide range of cell types, 
including NC precursors, sympathetic neuroblasts and trigeminal progenitor cells 
(Kalcheim et al., 1992; Pinco et al., 1993; DiCicco-Bloom et al., 1993; Verdi and 
Anderson, 1994; Karavanov et al., 1995; Memberg and Hall, 1995; Elshamy and 
Emfors, 1996; Elshamy et al., 1996). Some of these effects could also be mediated 
by TrkA and thus neuronal phenotype may be altered in these TrkA'7' mice. Indeed 
CGRP levels appear lower in the TrkA'7' than in the NGF"7' (figure 2.12 and 2.13) this 
could be a reflection of the differences in the phenotype of surviving neurons.
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Trigeminal TrkA-'-
Trigeminal A/GPA ;
Figure 2.12. Expression o f  CGRP in trigeminal o f  TrkA"/* and NGF"A ra/ce.
Trigeminal ganglia were dissected from E l3 -  E l5 null mutant and wild-type mice and the 
expression of CGRP mRNA quantified by competitive RT-PCR. Expression o f CGRP in 
trigeminal of TrkA_/* (A) and NGF_/' (B) is shown in comparison to their wild-type 
littermates. All data is normalised with respect to GAPDH mRNA.
Error bars +/- standard error, n = 3-4. * = p = <0.05, ** = p = <0.0las determined by two- 
tailed unpaired t-test.
Figure 2.13. Expression o f  CGRP in DRG o f  TrkA A and NGFL/_ mice.
DRG were dissected from E l3 -  E l5 null mutant and wild-type mice and the expression 
of CGRP mRNA quantified by competitive RT-PCR. Expression of CGRP in DRG of 
TrkA-7' (A) and NGF'7' (B) is shown in comparison to their wild-type littermates. All 
data is normalised with respect to GAPDH mRNA.
Error bars +/- standard error, n = 3-4. * = p = <0.05, ** = p = <0.0las determined by 
two-tailed unpaired t-test.
Non-normalised data
Embryonic day 13-15 mice were chosen specifically for this study so that cell death 
in the absence of NGF/TrkA signalling would not confound the results. However, to 
confirm that loss in cell survival was not affecting results, the level of mRNA for the 
housekeeping protein, GAPDH was plotted for each ganglia at each age studied. The 
non-normalised levels of CGRP mRNA were also plotted for each ganglia at each 
age studied. Results are shown in figures 2.14-2.17
Trigeminal ganglia
In the trigeminal ganglia of both TrkA'7' and NGF'7' mice the expression of GAPDH 
mRNA is constant and at a similar level to that seen in wild-type mice (figure 2.14), 
suggesting no significant cell death occurs in the trigeminal ganglia of these null 
mutant mice up to E l5. There is also no significant difference in CGRP mRNA 
levels between wild-type and TrkA'7' or NGF'7' mice (Figure 2.15), in agreement with 
normalised data (Figure 2.12).
DRG
Non-normalised data from the DRG is shown in figures 2.16 and 2.17. The levels of 
GAPDH mRNA are also fairly constant and there is no significant difference in 
GAPDH mRNA levels between TrkA'7' mice or NGF'7' mice and their wild-type 
littermates as determined by two-tailed t-test (figure 2.16), although a slightly lower 
GAPDH mRNA level is apparent at E l5 in DRG from the NGF null mutant (2.16B). 
This data could reflect some cell death, which could possibly account for the 
difference in expression of CGRP mRNA in the normalised data at El 5 (Figure 
2.13B). However, as results were normalised against this GAPDH data to take into 
account such a loss, it is unlikely. On the whole GAPDH mRNA levels are 
unaffected suggesting little cell death.
Non-normalised CGRP mRNA levels are shown in DRG from TrkA'7' and NGF'7' 
mice (figure 2.17). The non-normalised data appear to show a significant difference
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in CGRP mRNA expression at E l5 in DRG from NGF'7' mice compared to wild-type 
mice, which is not seen in DRG from TrkA'7'mice. This seems to reflect observations 
in normalised data in which DRG of NGF'7'mice show a decreased expression 
(figure 2.13).
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Figure 2.14. Expression o f  GAPDH per ganglia in trigeminal o f  TrkA-'' and NGF'- mice prior 
to normalisation..
Trigeminal were dissected from E l3 -  E l5 null mutant and wild-type mice and the expression 
of GAPDH mRNA quantified by competitive RT-PCR. Expression o f GAPDH mRNA per 
ganglia in TrkA'7' (A) and NGF'7* (B) is shown in comparison to their wild-type littermates.
Error bars +/- standard error, n = 3-4. * = p = <0.05, ** = p = <0.0las determined by two-tailed 
unpaired t-test.
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Figure 2.15. Expression o f CGRP per ganglia in trigeminal o f  TrkA'1' and NGF'1' mice prior 
to normalisation..
Trigeminal were dissected from E l3 -  El 5 null mutant and wild-type mice and the 
expression of CGRP mRNA quantified by competitive RT-PCR. Expression of CGRP 
mRNA per ganglia in TrkA'7' (A) and NGF'7' (B) is shown in comparison to their wild-type 
littermates.
Error bars +/- standard error, n = 3-4. * = p = <0.05, ** = p = <0.01 as determined by two- 
tailed unpaired t-test.
DRG TrkA-'-
0.9 
0.8 
J  0.7O)|  0.6
1 °'5 
% 0.4
§> 0.3
■  wt
■ T rkA ko
E13 E14 E15
B
DRG N
NGF ko
E13 E14 E15
Figure 2.16. Expression o f  GAPDH per ganglia in DRG o f  TrkA"A and NGF1' mice prior to 
normalisation..
DRG were dissected from E l3 -  E15 null mutant and wild-type mice and the expression of 
GAPDH mRNA quantified by competitive RT-PCR. Expression of GAPDH mRNA per ganglia 
in TrkA'7' (A) and NGF"7' (B) is shown in comparison to their wild-type littermates.
Error bars +/- standard error, n = 3-4. * = p = <0.05, ** = p = <0.0las determined by two-tailed 
unpaired t-test.
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Figure 2.17. Expression o f CGRP per ganglia in DRG o f TrkA A and NGF~A mice prior to 
normalisation..
DRG were dissected from E l3 -  E l5 null mutant and wild-type mice and the expression of 
CGRP mRNA quantified by competitive RT-PCR. Expression of CGRP mRNA per ganglia 
TrkA'7" (A) and NGF'7' (B) is shown in comparison to their wild-type littermates.
Error bars +/- standard error, n = 3-4. * = p = <0.05, ** = p = <0.0las determined by two- 
tailed unpaired t-test.
2.3.2. Alpha and beta transcripts of CGRP may be 
differentially regulated in the early embryonic mouse
The arrival of new technologies in the lab allowed the analysis of CGRP mRNA 
expression in absence of NGF/TrkA signalling to be extended further. Real-time 
PCR (QPCR) is a very sensitive and fast form of quantitative PCR, which allowed 
me to look at the expression of other genes and also reconfirm competitive data for 
CGRP. The computer program ‘Beacon Designer’ also allowed the production of 
more specific and efficient primers.
Primers used earlier in this chapter for competitive PCR did not distinguish between 
the mRNAs for the a- and P-CGRP peptides. Data presented in figures 2.12 to 2.17, 
therefore represent the combined expression of both mRNAs. The recent sequencing 
of both isoforms of CGRP in the mouse, and the subsequent design of new primers 
permitted the amplification of the two isoforms separately.
RNA extracted previously for competitive RT-PCR studies was used in this study. 
However, Stratscript reverse transcription enzyme, and real-time PCR was used to 
quantify gene expression (See materials and methods 2.2.5). Results were normalised 
against GAPDH, to account for any discrepancies in initial RNA levels between 
samples. Transcripts for both CGRP isoforms appear to be expressed to a similar 
extent in both DRG and trigeminal ganglia of the developing mouse (figures 2.18 -  
2.21). Once again, the expression of CGRP mRNAs in trigeminal ganglia was visibly 
higher than in DRG.
q-CGRP
In the DRG, as was indicated by the competitive data, there was a marked decrease 
in a-CGRP mRNA expression in NGF7' mice compared to NGF+/+ mice, becoming 
significant by E l5 (figure 2.18B). This was once again not reflected in the TrkA7* 
mouse (figure 2.18A). This could suggest a role for NGF signalling via p75 rather
1 6 1
than TrkA in the onset of a-CGRP expression or it could be a reflection of the loss of 
NT-3/TrkA signalling that could affect the phenotype of neurons in these TrkA7' 
mice.
In the trigeminal ganglia the expression of a-CGRP mRNA was not diminished in 
either NGF7' or TrkA7' mice compared to wild type mice (figure 2.19A and B), 
suggesting that in the trigeminal ganglia NGF and TrkA signalling are not required 
for the onset of expression of the a  isoform.
B-CGRP
Unlike a-CGRP mRNA, there is no significant difference in P-CGRP mRNA levels 
in TrkA7' or NGF7' DRG in comparison to wild-type (figure 2.20.A and B). In the 
trigeminal ganglia, the same result as for a-CGRP mRNA is observed, with no 
difference in expression of P-CGRP between either null mutants in comparison to 
wild-type (figure 2.21. A and B)
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Figure 2.18. Expression o f alpha CGRP mRNA in DRG o f TrkA1' and NGF ^  mice.
DRG were dissected from El 3-El 5 null mutant and wild-type mice and the expression of alpha 
CGRP mRNA quantified via real-time QPCR. Expression of alpha CGRP mRNA in the DRG of 
TrkA '^A) and NGF*/_(B) mice is shown in comparison to their wild-type litter mates.
Error bars +/- standard error. * = p =<0.05, ** = p = <0.01 as determined by two-tailed unpaired 
t-test, n = 3-4
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Figure 2.19. Expression o f alpha CGRP mRNA in trigeminal ganglia o f TrkA*A and NGF-/- mice. 
Trigeminal ganglia were dissected from El 3-El 5 null mutant and wild-type mice and the 
expression o f alpha CGRP mRNA quantified via real-time QPCR. Expression o f alpha CGRP 
mRNA in the trigeminal ganglia of TrkA'/_(A) and NGF A(B) mice is shown in comparison to 
their wild-type litter mates.
Error bars +/- standard error. * = p =<0.05, ** = p = <0.001 as determined by two-tailed unpaired 
t-test, n = 3-4
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Figure 2.20. Expression ofbeta-CGRP mRNA in DRG o f TrkA'A and NGFL/mice.
DRG were dissected from El 3-El 5 null mutant and wild-type mice and the expression ofbeta- 
CGRP mRNA quantified via real-time QPCR. Expression of beta CGRP mRNA in the DRG of 
TrkA'^A) and NGF'7'(B) mice is shown, in comparison to their wild-type litter mates.
Error bars +/- standard error. * = p =<0.05, ** = P = <0.01 as determined by two-tailed unpaired t- 
test, n = 3-4
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Figure 2.21. Expression o f beta CGRP mRNA in trigeminal ganglia o f TrkA'A and NGFL/'. 
Trigeminal ganglia were dissected from El 3-E l5 null mutant and wild-type mice and the 
expression o f beta CGRP mRNA quantified via real-time QPCR. Expression of beta CGRP 
mRNAin the trigeminal ganglia of TrkA '^A) and NGF'/_(B) mice is shown in comparison to their 
wild-type litter mates.
Error bars +/- standard error. * = p =<0.05, ** = p = <0.001 as determined by two-tailed unpaired 
t-test, n = 3-4
These results parallel those obtained by competitive RT-PCR where a decrease in 
CGRP mRNA in the DRG of NGF7' mice was observed, but was not significant, in 
comparison to wild type mice. This lack of significance could be due to the 
additional detection of the p- isoform by the non-specific competitive primers. P- 
CGRP mRNA was not found to be down-regulated in NGF7* mice(figure 2.20B), so 
any real decrease in a-CGRP mRNA may have been masked.
A table to summarise the regulation of both CGRP mRNA isoforms in DRG and 
trigeminal ganglia is shown below.
ALPHA CGRP BETA CGRP
NGF TrkA NGF TrkA
DRG X X X
Trigeminal X X X X
Table 2.10 Summary ofNGF/TrkA signalling required for expression o f  a  and f3 CGRP transcripts, in 
embryonic (E l3-E l5) mouse DRG and trigeminal.
S  = required, x = not required.
2.3.3. Differential regulation of substance P in trigeminal 
ganglia and DRG
SP is largely co-expressed with CGRP in the same subpopulation of sensory neurons 
in the adult (Lee et al., 1985; Skofitsch et al., 1985; Lundberg et al., 1985). To 
investigate whether the expression pattern of SP parallels that of CGRP throughout 
development and if there is comparable neurotrophic factor regulation during 
development, the expression of the SP precursor mRNA was quantified in embryonic 
trigeminal ganglia in TrkA7' and NGF7' mice and their wild type littermates using
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reverse transcription followed by real-time PCR. SP is only 12 amino acids long, and 
because of its small size was difficult to detect via PCR. Instead the mRNA for the 
PPTA precursor was reverse transcribed and amplified at the portion that is cleaved 
to produce SP (see figure 2.1.). Because the expression levels of SP precursor mRNA 
at early ages is low and very difficult to detect in DRG, since they are smaller than 
trigeminal ganglia and yield less purified RNA, only results for the trigeminal 
ganglia were obtained (figure 2.22).
In trigeminal ganglia of both TrkA'7' and NGF'7' mice there is a decrease in the 
expression of SP precursor mRNA in comparison to wild-type mice at both E14 and 
E l5. This reduction is significant at E l5 in both null mutants and also at E l4 in 
NGF'7* mice. This would suggest that NGF and TrkA expression are both required at 
least in part for the onset of SP precursor mRNA expression in developing trigeminal 
ganglia. The expression of SP precursor mRNA at El 3 was very low, but still 
detectable, suggesting that the onset of SP precursor mRNA expression may occur at 
this age.
These data for SP differ from those of both isoforms of CGRP mRNAs. Neither C o ­
nor p-CGRP mRNAs showed an apparent requirement for NGF/TrkA signalling for 
initial induction of expression in the trigeminal ganglia (figures 2.19 and 2.21).
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Figure 2.22. Expression o f SP mRNA in sensory neurons o f TrkA'A and NGF~\
Trigeminal ganglia were dissected from El 3-El 5 null mutant and wild-type mice and the expression 
of SP mRNA quantified via real-time QPCR. Expression of SP mRNA in the trigeminal ganglia of 
TrkA_/‘(A) and NGF'^fB) mice is shown in comparison to their wild-type litter mates.
Error bars +/- standard error. * = p =<0.05, ** = p = <0.01 as determined by two-tailed unpaired t- 
test, n = 3-4
2.3.4. Initial induction of mRNA expression of the 
Tetrodotoxin (TTX) resistant sodium channels Nav1.8 and 
Nav1.9 is reliant upon NGF/TrkA signalling
The role that NGF/TrkA signalling plays in regulating the expression of Navi.8 and 
Navi.9 mRNAs in developing trigeminal ganglia and DRG was examined by 
measuring the expression of both mRNAs by RT-QPCR in ganglia from NGF and 
TrkA null mutants and their wild type littermates. The two genes ScnlOa and Scnl la 
are transcribed to produce the functional proteins Navi.8 and Navi.9 respectively. 
Primers were designed to allow amplification of Navi.8 and Navi.9 mRNAs using 
reverse transcription followed by real time Q-PCR RNA samples from TrkA and 
NGF null mutants that had been collected previously and used for the competitive 
RT-PCR and real time-QPCR studies of CGRP and SP mRNA expression were used 
to determine the expression of sodium channel mRNAs.
Figure 2.23 shows the expression levels of Navi.8 mRNA in DRG of TrkA'7' (A) and 
NGF'7' (B) mice and figure 2.24 show expression in the trigeminal ganglia of TrkA'7' 
(A) and NGF'7'(B) mice compared to that of their wild-type littermates. Nav 1.8 
mRNA expression is just detectable at E l3 in DRG, more noticeably so in trigeminal 
ganglia. Nav 1.8 mRNA is therefore detectable at a younger age than Navi .8 protein, 
which cannot be detected until E l5 (Benn et al., 2001), as would probably be 
expected given the high sensitivity of this method of RT-QPCR. Nav 1.8 mRNA 
levels are similar in both trigeminal ganglia and DRG, unlike CGRP isoforms 
mRNA, whose expression is greater in trigeminal ganglia than in DRG .
The data in figures 2.23 and 2.24 suggest that the initial induction of expression of 
Navi.8 mRNA is regulated to some extent by TrkA/NGF signalling. In both DRG 
and trigeminal ganglia there is a large, often significant reduction in expression of 
Navi.8 mRNA in both TrkA'7' and NGF'7' mice compared to wild type mice (figures 
2.23 and 2.24). This is observed from E14 in DRG and from E l3 in trigeminal
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ganglia, suggesting that TrkA/NGF signalling is required for the initial onset of 
Navi. 8  expression.
Data showing the expression of Navi.9 mRNA in DRG and trigeminal ganglia from 
E13 to E15 is plotted in figures 2.215 and 2.26. Navi.9 mRNA was not detectable at 
El 3, but was apparent by E14. This later expression of Navi.9 than N avi . 8  follows 
the expression pattern at the protein level where Navi . 8  is detectable at E l5, whereas 
Navi.9, is below the limits of detection until E17 (Benn et al., 2001). Navi.9 mRNA 
is expressed at similar levels in DRG and trigeminal ganglia. Like Navi.8 , 
NGF/TrkA signalling seems to be required for the onset of Navi.9 mRNA 
expression in both ganglia, with mRNA levels being significantly diminished in 
DRG and trigeminal ganglia from both null mutants at E l5 compared to ganglia from 
wild type mice (figures 2.25 and 2.26).
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Figure 2.23. Expression o f Nav 1.8 mRNA in DRG o f TrkA'A and NGFA.
DRG were dissected from El 3-El 5 null mutant and wild-type mice and the expression o f Nav 1.8 
mRNA quantified via real-time QPCR. Expression o f N avi.8 mRNA in the DRG of TrkA_/'(A) and 
NGF /'(B) mice is shown, in comparison to their wild-type littermates.
Error bars = +/- standard error. * = p =<0.05 and ** = p =<0.01 as determined by two-tailed, 
unpaired t-test, n = 3-4
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Figure 2.24. Expression o f Nav 1.8 mRNA in trigeminal ganglia o f TrkAA and NGFL/‘.
Trigeminal ganglia were dissected from El 3-El 5 null mutant and wild-type mice and the 
expression o f Navi .8 mRNA quantified via real-time QPCR. Expression o f Navi .8 mRNA in the 
trigeminal ganglia o f TrkA'A(A) and NGF' '(B) mice is shown in comparison to their wild-type 
litter mates.
Error bars +/- standard error. * = p =<0.05, ** = p = <0.01 as determined by two-tailed unpaired 
t-test, n = 3-4
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Figure 2.25. Expression o f Nav 1.9 mRNA in DRG o f TrkA-'- and NGF-'-.
DRG were dissected from El 3-El 5 null mutant and wild-type mice and the expression of Nav 1.9 
mRNA quantified via real-time QPCR. Expression of N avi.9 mRNA in the DRG ofTrkA '/_(A) 
and NGF'/_(B) mice is shown, in comparison to their wild-type litter-mates.
Error bars +/- standard error. * = p =<0.05 and ** = p=<0.01 as determined by two-tailed 
unpaired t-test, n = 3-4
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Figure 2.26. Expression o f Nav 1.9 mRNA in trigeminal ganglia o f TrkA A and NGFL/'.
DRG and Trigeminal ganglia were dissected from El 3-El 5 null mutant and wild-type mice and 
the expression of N avi.9 mRNA quantified via real-time QPCR. Expression of Nav 1.9 mRNA in 
the trigeminal ganglia o f TrkA'^A) and NGF'A(B) mice is shown, in comparison to their wild- 
type litter-mates.
Error bars +/- standard error. * = p =<0.05 and ** = p=<0.01 as determined by two-tailed 
unpaired t-test, n = 3-4
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2.3.5 All PCR reactions are highly efficient
To check the reliability and specificity of the QPCR reactions for a- and p-CGRP, 
SP, N avi . 8  and Navi.9, RT-QPCR reactions were run using RNA extracted from 
tissue that should not express any of these mRNAs mouse liver was chosen for this 
purpose. Mouse Liver RNA (Ambion) was reverse transcribed, as described 
previously. Mouse trigeminal RNA was also transcribed alongside liver RNA, to act 
as a positive control and ensure efficient transcription. No expression of a-CGRP, p- 
CGRP, SP, N avi . 8  and Navi.9 mRNAs could be detected in liver RNA. Any 
amplification (as observed by increasing fluorescence with increasing PCR cycle 
number) occurring in these QPCR reactions was due to primer artefacts or 
amplification of non-specific products (figure 2.27). GAPDH mRNA was present in 
both liver and trigeminal, acting as a positive control (figure 2.27).
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Figure 2.27. Expression o f genes o f interest in Liver RNA.
To check the ‘Leakiness’ o f the PCR reactions, reactions were run for all genes using RNA from Liver. No gene expression 
of any genes under test was observed in liver, with the exception of GAPDH.
A and B show expression o f GAPDH clearly present. C and D show the absence of a  CGRP mRNA expression. N.B. 
Although some amplification is seen late on (C) the product produced is not the correct one, as illustrated by the melting 
curve (D).
2.4. Discussion
The highly sensitive, quantitative methods of competitive RT-PCR and, more 
recently, real time-QPCR, have allowed investigation into the developmental 
expression of several genes that are important in determining the functional 
characteristics of sensory neurons. The use of embryonic transgenic mice allowed the 
effects of NGF and TrkA signalling on the developmental expression of these genes 
to be studied. This helped to ascertain if NGF and TrkA signalling are required for 
the initial induction of transcripts for these genes in the different sensory ganglia of 
the embryonic mouse.
Whilst interpreting results, one important caveat should be bom in mind. The Real 
time Q-PCR technique used in this thesis allows relative quantification of mRNA 
levels i.e. comparisons are made between samples after normalising for differences 
in sample concentration and loading. Normalisation is necessary to control for the 
numerous errors associated with such experiments, including the inherent variability 
of RNA, the variability of extraction protocols and the differences in efficiencies 
between reverse transcription and PCR. However, despite its necessity, normalisation 
remains one of the main problems and drawbacks of real-time QPCR at present.
Several methods of normalisation exist. Two such techniques are: a) Ensuring similar 
sample sizes are initially obtained prior to RNA extraction and b) Normalising 
results to total RNA within the sample. Neither of these methods however control for 
errors that occur at the reverse transcription or PCR stages. To this end, the most 
popular method of normalisation employed tends to be the use of a reference gene. In 
this method an internal control is amplified, in the PCR reaction, alongside the gene 
of interest. This method is particularly advantageous as the internal control is subject 
to the same conditions as the mRNA of interest, and it was this method that was used 
in this thesis.
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The identity of the most reliable internal control is still a controversial and much 
debated topic. The ideal RNA species for an ‘internal control’ should be expressed at 
a constant level throughout the tissue in question and should not be regulated by the 
experimental conditions. Unfortunately, there is no single RNA which can fulfil such 
criteria at present, with most being altered through the course of the experiment. The 
most popular internal controls used experimentally include p actin, Glyceraldehyde - 
3-phosphate-dehydrogenase (GAPDH), hypoxanthine-guanine phosphoribosyl 
transferase (HPRT) and 18s ribosomal RNA. Despite all being used frequently, as 
illustrated in numerous published papers, they all have drawbacks. Levels of 
GAPDH and p-actin have been shown to vary over certain conditions, however 
because of its abundance the use of 18S rRNA impedes the detection of the PCR 
product of rare messages.
Throughout this thesis Glyceraldehyde -3-phosphate-dehydrogenase (GAPDH) was 
chosen as internal control. The mRNA encoding GAPDH is moderately expressed in 
many tissues including neuronal cells, and has been used as an internal control in 
many similar experiments. As mentioned briefly, GAPDH levels can vary with 
developmental stage and so its use may not provide the accurate results sought. This 
possibility should be borne in mind when intertpreting results.
A round-table debate on the limitations of the use of such internal controls was 
published in the journal of leukaemia in 1997-1998, and is still of debate to this day. 
There is a thought that perhaps an ‘alien RNA’ molecule that could be synthesised 
and added in accurate quantities prior to RNA extraction could solve most problems, 
however until such a molecule is created researchers must continue to debate the pros 
and cons of the ‘classic’ housekeeping genes to make their, albeit not 1 0 0 % 
foolproof, decision as to which will be the gene of choice in their laboratory.
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Table 2.11 summarises findings.
ALPHA
CGRP
BETA
CGRP
SP NAVI . 8 NAV 1.9
NGF TrkA NGF TrkA NGF TrkA NGF TrkA NGF TrkA
DRG X X X - - ✓ V /
Trigeminal X X X X S
Table 2.11 Summary o f  NGF/TrkA signalling required fo r  expression o f  sensory neuron predominant 
genes, in embryonic (El 3-El 5) mouse DRG and trigeminal.
S  = required, x = not required. - = not carried out
Initially, the investigation of the neuropeptide CGRP was studied using competitive 
PCR to quantify mRNA expression in DRG and trigeminal ganglia of TrkA'7’ and 
NGF'7' mice in comparison to wild-type littermates. The development of real-time 
QPCR in the laboratory allowed me to extend this analysis. This method of PCR was 
favoured due to its efficiency and flexibility. In particular, time did not have to be 
spent in the manufacture of competitors for each gene, gels did not need to be run 
and reactions could be set-up in a high-throughput 96-well format. In addition,
QPCR has the advantage that it has a much wider dynamic range than competitive 
RT-PCR, allowing the direct comparison of samples that have greatly differing levels 
of target mRNA expression. Although QPCR is not as accurate or reproducible as 
competitive PCR, performing more replicates can compensate for this drawback and 
the advantages of the system far outweigh the disadvantages.
The introduction of QPCR and a more efficient primer design package, allowed me 
to design primers and set up reactions that allowed both isoforms of CGRP to be 
studied separately. Little research thus far has been done on the mouse (3-CGRP 
isoform for several reasons. First, high sequence homology between the two isoforms 
has led to a practical difficulty in discriminating between them. Secondly, little has 
been done in the mouse, as until recently both genes were not sequenced in this
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species (Thomas et al., 2001). Finally the a- transcript is usually considered the more 
abundant of the two, at least in the adult (Amara et al. 1985, Gibson et al., 1988), so 
research has tended to focus on this isoform. Throughout development, however, p- 
CGRP has been shown to be the predominant form in many areas of the nervous 
system, suggesting a strong developmental role (Terrado et al., 1999). My results do 
show that p-CGRP is indeed expressed to a similar extent to the a  isoform in both 
trigeminal and DRG at these early stages of development. Although no statistical 
comparisons have been made, the pattern of P-CGRP mRNA expression in 
trigeminal ganglia of wildtype mice (figure 2 .2 1 ) is indeed comparable to that of a- 
CGRP mRNA (figure 2.19). In trigeminal ganglia of wild-type mice from TrkA7' 
litters i.e. TrkA+/+ mice, expression of both a  and p CGRP mRNA is similar at El 3. 
Levels of both then double from El 3 -  El 4 before dropping back to approximately 
El 3 levels by El 5 (figures 2.19A and 2.21 A). In trigeminal ganglia of wildtype mice 
from NGF7' litters i.e. NGF+/+, a similar mRNA level for a  and p CGRP is found 
once again at E l3. A two-fold increase in expression is then observed in both 
isoforms between E13 and E14 (figure 2.19B and 2.21B), and this increase is 
maintained until El 5. This maintenance in expression between El 4-El 5 in 
trigeminal of NGF+/+mice is in contrast to the dip observed in TrkA+/+ mice. Such 
discrepancies between TrkA+/+ and NGF+/+ are odd since both of these phenotypes 
are essentially wild-type. However it could be due to experimental issues, or down to 
differences in the strain or background of the mice. In the DRG, a-CGRP mRNA 
was also expressed to a similar extent to P-CGRP mRNA. In TrkA+/+mice 
expression of both isoforms increased in DRG from El 3 -  El 5 (figure 2.18A and 
2.20A). In DRG of NGF+/+mice, levels of a-CGRP mRNA were initially higher than 
those of the p isoform, however by El 5 both isoforms were detectable at comparable 
levels (figure 2.18B and 2.20B). These results would indicate that P-CGRP is 
expressed as abundantly as the a- isoform, at least in some sensory neuronal 
populations of the developing mouse. A possible role for p-CGRP in development 
of such neuronal subpopulations is therefore indicated.
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Despite a high sequence homology between the CGRP isoforms, the two peptides are 
transcribed from separate genes that most probably arose as a result of gene 
duplication. The difference in expression patterns in development, and their 
production from distinct genes would therefore suggest functionally different roles 
for a- and p-CGRP in the young embryo, and possible differential regulation by 
trophic factors. My results showed that mRNAs for both a- and P- transcripts are 
present at a similar level in both sensory ganglia studied from E l3 up to El 5. Both 
transcripts are expressed more highly in the trigeminal ganglia than in the DRG. In 
embryonic trigeminal ganglia, no significant difference between the expression of the 
a- and P- transcripts was observed between wild-type and TrkA and NGF null 
mutant mice from E13 to E15 (figures 2.19 and 2.21). This suggests no regulation of 
expression of either a- or p- CGRP mRNA by NGF or TrkA signalling in the 
embryonic trigeminal ganglia at these ages. This demonstrates that NGF/TrkA 
signalling is not required for the induction of a- and P- CGRP expression in 
trigeminal neurons. In the DRG, however, NGF may play a role in regulating the 
expression of a-CGRP mRNA, but not the mRNA for the p- isoform. No difference 
was seen in the expression of a-CGRP mRNA in the DRG of TrkA7' mice compared 
to TrkA+/+ mice, however, in NGF7' mice there was a notable decrease in the 
expression of the a  transcript compared to wild-type mice. This was seen in real-time 
data (figure 2.18) and also suggested in competitive data (figure 2.13.) p-CGRP 
mRNA was conversely expressed at similar levels in DRG from TrkA and NGF null 
mutants and wild type mice (figure 2.20). It is therefore apparent that despite high 
sequence homology, the two CGRP transcripts are regulated differentially in the 
DRG of the developing mouse. This suggests that not all subpopulations of sensory 
neurons require NGF/TrkA signalling for the induction of CGRP expression, as has 
been thought previously from a much less extensive study of developing sensory 
neurons (Patel et al., 2000).
It is curious that a-CGRP mRNA induction and maintenance of expression between 
E l4 to El 5 is independent of TrkA signalling in developing DRG, but appears to 
require NGF signalling. One possibility is that NGF regulated induction and intial 
up-regulation of a-CGRP mRNA expression is affected entirely through signalling
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through the common p75 neurotrophin receptor. Analysis of the expression of a- 
CGRP mRNA in the DRG of p75 knockout mice would address this possibility. 
Another possibility is that the TrkA and NGF mouse colonies show subtle inherent 
strain differences in the timing of sensory neuron loss in the absence of functional 
TrkA/NGF signalling. The neurotrophin NT-3 can also signal through TrkA (Soppet 
et al., 1991; Klein et al., 1991b; Cordon-Cardo et al., 1991; Glass et al., 1991; Ip et 
al., 1993). NT-3 is required for the correct timing of neuroblast differentiation 
(Kalcheim et al., 1992; Pinco et al., 1993; Elshamy and Emfors, 1996), and mice 
deficient in NT-3 show a perturbation in sensory neuron differentiation and a 
subsequent loss of post-mitotic neurons (Liebl et al., 1997). Much of the effects of 
NT-3 on survival and differentiation of sensory neurons are proposed to be via 
receptors other than its preferred receptor TrkC, since NT-3’7' mice show 70% loss in 
sensory neurons, a much greater proportion than the 30% loss observed in TrkC'7' 
mice (Liebl et al., 1997). It is possible that TrkA*7' mice suffer a loss of functional 
NT-3/TrkA signalling as well as NGF/TrkA signalling during the period E l3 to E l5 
with concomitant derangement of normal neuronal differentiation that may lead to 
DRG with different proportions of different neuronal sub-types (CGRP mRNA 
expressing or non-expressing) and different numbers of neurons at El 5 compared to 
wild-type mice or NGF'7' mice.
It is noteworthy that figure 2.13 shows that the timing of CGRP mRNA up- 
regulation from basal levels is different in DRG of wild type mice from the TrkA and 
NGF colonies. In the TrkA colony, CGRP mRNA increases in the DRG of wild type 
mice from E l4 to E l5, but this is not the case in wild-type mice from the NGF 
colony. Similar differences between strains are also shown for a-CGRP mRNA in 
figure in 2.18, and in trigeminal ganglion in figure 2.12. Perhaps both strains show 
subtle differences in the timing of the induction and up-regulation of CGRP mRNA 
and/or the requirement for NGF/TrkA signalling to up-regulate CGRP mRNA from 
the basal levels expressed immediately after initial induction. This could be 
responsible for the data, suggesting that NGF but not TrkA signalling is required for 
the up-regulation of a-CGRP mRNA expression between E l4 and El 5 in DRG. This 
hypothesis is supported by the observation that both TrkA and NGF are necessary for
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the up-regulation of CGRP expression in the late embryonic period and the 
maintenance of expression in the neonatal period (Patel et al, 2000).
The neuropeptide SP is expressed in the same subpopulation of neurons as CGRP. 
However, as revealed by my studies, its regulation by NGF/TrkA signalling is 
different from that of CGRP. In particular, SP does require TrkA/NGF signalling for 
the onset of expression in the trigeminal ganglion, unlike a- or P- CGRP. In both 
null mutants there was a decreased expression of SP mRNA in comparison to wild­
type (figure 2.22). This decrease was significant at E l4 in NGF'7' mice and at E l5 in 
both TrkA*7* and NGF'7' mice. SP mRNA was expressed at lower levels than CGRP 
mRNA in trigeminal ganglia at all ages studied but could not be detected in the early 
DRG, possibly because it is not expressed at this young age or because levels are too 
low to detect because the smaller size of the DRG compared to the trigeminal 
ganglion may result in a lower concentration of total RNA in DRG samples. Taken 
together, these results indicate that the induction of expression and up-regulation of 
SP mRNA from E l3 to E l5 is largely dependent on NGF acting via its receptor 
tyrosine kinase TrkA in trigeminal sensory neurons.
The expression of the two TTX resistant sodium channels Nav 1.8 and Nav 1.9 was 
also investigated. Previous research has identified that NGF and GDNF regulate the 
expression of both channels in adult DRG (Fjell et al., 1999), but the regulation of 
these sodium channel mRNAs in sensory neurons during embryonic development 
has not been previously addressed. Throughout embryonic development GDNF will 
no doubt have little effect on the expression of either channel as the majority of 
sensory neurons don’t respond to this factor until after birth, when approximately 
half of small diameter neurons down-regulate TrkA and up-regulate receptors for 
members of the GDNF family of neurotrophic factors (Molliver and Snider, 1997; 
Molliver et al., 1997; Baudet et al., 2000). My results have shown that NGF does 
play a role in onset of expression and intial developmental up-regulation of these 
channels in sensory neurons during embryonic development. In both trigeminal 
ganglia and DRG of TrkA and NGF null mutant mice there was a large reduction in 
Navi. 8  mRNA levels in comparison to wild-type mice, at all ages studied, this
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suggests a critical role for NGF/TrkA signalling in regulating the expression of this 
sodium channel in embryonic sensory neurons. The onset of expression of Nav 1.9 
mRNA in sensory neurons was later than that for Navi .8 , as Navi .9 mRNA was not 
detectable in E l3 mice in either DRG or trigeminal ganglia. This is in accordance 
with sodium channel protein expression patterns. Benn et al. (Benn et al., 2001) 
showed N avi . 8  protein was detectable at E l5 whilst Navi.9 protein was not 
detectable until E l7 in mouse DRG. At E l5 the induction and developmental up- 
regulation of Navi.9 mRNA, like Navi . 8  mRNA, showed a distinct requirement for 
NGF/TrkA signalling with a significant reduction in Nav 1.9 mRNA in both DRG 
and trigeminal ganglia of NGF'7' and TrkA'7' mice in comparison to wild-type mice.
Summary
In this chapter the expression of several genes that are required for a number of key 
functional properties of subsets of sensory neurons have been studied in the DRG 
and trigeminal ganglia during the early stages of sensory neuron development. 
Previous work on the expression of these genes has largely focused on the adult and 
postnatal DRG. In contrast to these earlier studies, which have concluded that NGF 
positively regulates the expression of all of these genes, my results have revealed that 
the expression of only some of these genes is regulated by endogenous NGF and 
TrkA signalling during the earlier stages of development. This was true for Navi . 8  
and Navi.9. mRNAs whose levels were significantly decreased in sensory neurons of 
TrkA'7' and NGF'7' mice in comparison to wild type mice. Likewise, the expression of 
SP is highly dependent on NGF/TrkA signalling for initial induction and up- 
regulation in the trigeminal ganglia. Despite the co-expression of CGRP and SP in 
subsets of sensory neurons and the previous demonstration of co-regulation by NGF 
(Lundberg et al., 1985; Donaldson et al., 1992; Donnerer et al., 1992; Woolfe et al., 
1994; Jiang and Smith, 1995; Verge et al., 1995; Shadiack et al., 2001; Gardell et al.,
2003), the expression of CGRP is more complex than was previously thought. It 
seems that mRNAs for the two isoforms of CGRP, a- and p-, are regulated 
differentially in the DRG developmentally, but neither have a requirement for 
NGF/TrkA signalling in the trigeminal ganglia. This contradicts the previous
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hypothesis that NGF and TrkA signalling was imperative for the induction and initial 
up-regulation of expression of CGRP mRNA in sensory neurons of the developing 
mouse (Patel et al., 2000). In the DRG, P-CGRP mRNA expression also showed no 
requirement for NGF/TrkA signalling. Of interest was the finding that a-CGRP 
mRNA expression does seem to be dependent upon NGF signalling within the DRG, 
but not on TrkA signalling. This suggests either that NGF may regulate the 
expression of the a  isoform solely through the common neurotrophin receptor p75 at 
these early stages of DRG development or that subtle strain differences exist between 
the timing of CGRP mRNA expression and the requirement for NGF/TrkA signalling 
for its up-regulation between the TrkA mouse line and the NGF mouse line. 
Alternatively, the timing of neuronal cell death in sensory ganglia in the absence of 
functional TrkA signalling may be different to that in the absence of NGF, since the 
neurotrophin NT-3 can also signal through TrkA.
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2.5. Results in Brief
As discussed, this chapter explored the expression of several mRNAs of interest, and 
their regulation by neurotrophic factors, in embryonic mice (E l3-E l5). Results and 
findings can be summarised as below:
CGRP:
• a- and p-CGRP mRNAs appear to show differing regulation in embryonic 
DRG. Results suggest that NGF signalling (through TrkA/p75?) may be 
required for initial induction of a  CGRP mRNA expression, but not for p 
CGRP mRNA.
• Expression of both a  and p CGRP mRNA seems to be independent of 
TrkA/NGF signalling within the trigeminal ganglia.
• Differences in results in the DRG vs the trigeminal ganglia show that not all 
genes are regulated in a similar fashion in all sensory neuronal ganglia, a- 
CGRP mRNA seems dependent upon NGF/TrkA signalling within the DRG, 
but not in the trigeminal ganglia.
SP:
• In trigeminal ganglia, initial induction of SP mRNA requires NGF/TrkA 
signalling, despite the finding that a  and p CGRP mRNAs do not. This is of 
interest since SP and CGRP are predominantly co-localised and usually 
regulated in a similar fashion.
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Nav1.8 and Nav1.9:
• NGF/TrkA signalling is required for initial induction of expression of both 
N avi . 8  and Navi.9 mRNAs in both trigeminal and dorsal root ganglia at 
embryonic ages.
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Chapter 3
The role of NGF and NT-3 in the regulation of gene 
expression in sensory neurons of the early postnatal mouse
3.1 Introduction
In the previous chapter the effects of NGF/TrkA signalling on sensory neuron gene 
expression were explored in the mouse embryo. The results showed that NGF 
signalling, via TrkA, has distinctive effects on the expression of SP, CGRP, N avi . 8  
and Navi .9 mRNAs in embryonic DRG and trigeminal sensory ganglia. In the 
current chapter, the previous study was extended to analyse the role that neurotrophin 
signalling plays in regulating the mRNA expression of these genes in sensory 
neurons later in development. Expression was additionally studied in another sensory 
neuronal ganglion, the nodose ganglion (or inferior vagal ganglia). The majority of 
nodose neurons express TrkB rather than TrkA, making them predominantly 
dependent upon BDNF for survival during development. However, since a small 
population of nodose neurons are NGF dependent during the late embryonic period 
(Forgie et al., 1999), the effect of NGF/TrkA signalling on nodose neuron gene 
expression was investigated. In addition, the effects of NGF on the expression of 
some other important sensory neuron genes was studied alongside those mRNAs 
investigated in chapter 2 .
In the current chapter, the effects of NT-3 on sensory neuron gene expression were 
also investigated. NT-3, like NGF, is highly important throughout development both 
with regards to neuronal survival and determination of neuronal phenotype. 
Embryonic sensory neuron survival is influenced by both factors, as is illustrated 
through study of transgenic mice with null mutations in the genes encoding these 
neurotrophic factors and their preferred receptors. Both TrkA'7' and NGF'7* mice die 
shortly after birth and show a massive loss of small diameter sensory neurons of the
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DRG and trigeminal ganglia (Smeyne et al., 1994; Crowley et al., 1994). The small 
diameter sensory neurons lost are responsible for transmission of nociceptive 
information. This is reflected by a failure of both NGF'7' and TrkA'7' mice to respond 
to noxious stimuli (Smeyne et al., 1994; Crowley et al., 1994). Mice with a null 
mutation in the gene encoding NT-3 die within a few weeks of birth and suffer from 
abnormal limb movement, most likely due to a lack of muscle afferent projections to 
the spinal cord (Farinas et al., 1993; Emfors et al., 1994). Disruption of the TrkC 
gene to remove the catalytic portion of the expressed receptor also produces mice 
with severe proprioceptive sensory neuron loss (Klein et al., 1994). These results 
highlight the essential role for NGF in the development of small nociceptive neurons 
and NT-3 in the development and maintenance of large proprioceptive neurons.
TrkA is the preferred receptor for NGF and TrkC the preferred receptor for NT-3, 
and both ligands additionally bind to the common neurotrophin receptor p75. 
Although NGF specifically binds to TrkA (Cordon-Cardo et al., 1991; Kaplan et al., 
1991, 1991b; Klein et al., 1991a), NT-3 can also signal through other Trk receptors, 
binding to TrkA and TrkB, as well as its preferred receptor, TrkC (Lamballe et al., 
1991; Squinto et al., 1991; Klein et al., 1991b; Soppet et al., 1991). Because of this, 
NT-3 may not only exert effects on gene expression in large TrkC expressing 
neurons, but also upon genes present in the small, peptidergic, TrkA-positive and low 
threshold mechanoreceptor, TrkB-positive sub-populations of trigeminal and dorsal 
root ganglia neurons. In addition, NT-3 may possibly regulate gene expression in 
TrkB responsive nodose neurons as well as the small sub-population of NGF 
responsive nodose neurons. Indeed, both mid-embryonic nodose and trigeminal 
neurons from TrkC kinase domain knockout mice survive in-vitro in the presence of 
NT-3, despite the lack of its preferred receptor (Davies et al., 1995). This TrkC 
knockout shows a decrease in 6-22% of trigeminal neurons (Pinon et al., 1996), 
which is significantly less than the 70% neuronal deficit in the NT-3 knockout 
(Wilkinson et al., 1996; Elshamy and Emfors, 1996; Liebl et al., 1997), a clear 
indication that NT-3 activation of TrkA and TrkB is highly important throughout 
development. Indeed, few mid-embryonic trigeminal neurons survive with NT-3 
when they lack functional TrkA expression. Likewise, loss of functional TrkB
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prevents NT-3 from promoting the survival of a large proportion of mid-embryonic 
nodose neurons (Davies et al., 1995).
Interestingly, NT-3 has also been shown to regulate expression of TrkA, in the adult. 
Exogenous NT-3 down-regulates the expression of TrkA at the protein and mRNA 
level in nociceptive adult DRG neurons in-vivo (Gratto and Verge, 2003). Such 
regulation of TrkA receptors could have effects on gene expression and the 
nociceptive phenotype associated with TrkA expression in small nociceptive neurons 
(Gratto and Verge, 2003; Wilson-Gerwing et al., 2005). It is proposed therefore, that 
NT-3 may not only have effects on gene expression through activation of TrkC 
receptors present on large proprioceptive neurons. It may also have direct actions on 
non-preferred Trk receptors, and the subsequent alteration of mRNA levels in small 
peptidergic nociceptive sensory neurons and medium sized mechanoreceptive 
sensory neurons. Moreover, NT-3 may modulate NGF mediated gene expression 
through alterations in TrkA receptor availability.
The effects of both NT-3 and NGF on the expression of sensory neuron genes is 
therefore of interest. This will be addressed in this chapter. Real time QPCR was 
used to quantify changes in relative mRNA levels, both in-vitro using neuronal 
cultures and in-vivo using transgenic mice with null mutations in genes encoding 
neurotrophic factors and their receptors.
TrkA null mutant mice suffer a dramatic loss of sensory neurons, an attenuated 
response to pain and die shortly after birth (Smeyne et al., 1994). NT-3 null mutant 
mice display severe movement defects of the limbs due to the loss of proprioceptive 
sensory and sympathetic neurons and also die shortly after birth (Emfors et al.,
1994). To overcome this loss of neurons, mice heterozygous for a null mutation of 
the pro-apoptotic protein Bax were crossed with TrkA and NT-3 heterozygous mice 
to create TrkA’^ /Bax'7' and N T ^ '/B ax’7' double knockout mice, respectively. Bax is 
a pro-apoptotic member of the bcl- 2  family and is required for apoptotic cell death in 
many tissues. In these double knockouts, the large decrease in cell death normally 
seen in the single knockouts is prevented. In TrkA'7TBax'7' mice, the cells that survive
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show a phenotype similar to those that are normally lost in the single knockout. In 
the DRG they have been shown to express TrkA and also the neuropeptides CGRP 
and SP suggesting that, in-vivo, a deficiency of Bax permits the survival of TrkA 
peptidergic neurons in the absence of NGF/TrkA signalling (Patel et al., 2000). 
Similarly, in N T ^ '/B ax '7' mice, NT-3 dependent sensory neurons survive and 
express the proprioceptive neuronal marker, paravalbumin (Patel et al., 2003).
The NGF and NT-3 mediated regulation of all the mRNAs studied in Chapter 2 were 
included in this study (a- and P- CGRP, SP, Navi.8 , Navi.9) alongside some 
additional primary sensory neuron expressed genes: Galanin, Pituitary Adenylate 
Cyclase-Activating Peptide (PACAP) and Vanilloid Receptor 1 (VR1). These genes 
are not exclusively expressed in primary sensory neurons, but are expressed 
significantly within these subpopulations. These additional genes will be discussed 
further here with regards to physiological relevance, expression patterns and 
regulation by neurotrophic factors.
3.1.1. Pituitary adenylate cyclase-activating peptide (PACAP)
PACAP is a neuropeptide belonging to the glucagon/secretin/vasoactive intestinal 
peptide (VIP) family, and shares 70% homology with VIP. Originally isolated from 
ovine hypothalamic tissues (Miyata et al., 1989), its name reflects its ability to 
stimulate production of adenylate cyclase (AC) in cultured rat anterior pituitary cells 
(Miyata A et al., 1998). A single gene product is alternatively spliced to give rise to 
two isoforms of the peptide. The predominant form is a 38 amino acid peptide, 
PACAPi.38, but it also exists as PACAP1-27, which consists of the 27 NH2 terminal 
residues of PACAP1.38 (Miyata et al., 1999).
Receptors
Ligand binging studies revealed two proposed binding sites for PACAP, one with a 
much higher affinity binding for PACAP than the other, which could bind both
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PACAP and VIP equally (Shivers et al., 1991). This led to the subsequent discovery 
o f two receptor types, PACi and VP AC (reviewed in Harmar et al., 1995). PACi was 
discovered by 6 different laboratories (Hashimoto et al., 1993; Hoysoya et al., 1993; 
Morrow et al., 1993; Pisegna and Wank, 1993; Spengler et al., 1993; Svoboda et al.,
1993) and was found to have a high affinity for PACAP and a very low affinity for 
VEP. It is located predominantly in the CNS, most abundantly in the olfactory bulb, 
thalamus, hypothalamus, the dentate gyrus o f the hippocampus; granule cells o f the 
cerebellum and in the adrenal medulla (Spengler et al., 1993; Hashimoto et al.,
1996). PACi expression has not been found in adult DRG neurons, but it is expressed 
by dorsal horn second order sensory neurons (Jongsma et al., 2000; Vaudry et al., 
2000). Six splice variants o f the PACi receptor have been isolated in the rodent.
They differ with binding affinities and potency o f second messenger stimulation. 
They can all act via Gs to activate AC and subsequently stimulate the production of 
cAMP (Spengler et al., 1993). Phospholipase C (PLC) accumulation is also triggered 
to varying degrees via Gq, although this is dependent on the splice variant receptor 
activated and the ligand form o f PACAP (38 or 27) (Spengler et al., 1993; for review 
see Sherwood et al., 2005). In addition to activating AC and PLC, PACAP also 
appears to modulate Ca2+ signalling pathways by signalling through PACi (Spengler 
et al., 1993; Chatteijee et a., 1996).
VP AC has equal binding affinity for both PACAP and VIP (Ishihara et al., 1992; 
Lutz et al., 1993; Couvineau et al., 1994; Rawlings and Hezareh, 1996; Cai et al.,
1997) and exists in two isoforms: VPACi and VPAC2 (reviewed in Harmar et al.,
1998). VPACi was isolated from a rat lung cDNA library (Ishihara et al., 1992) and 
VPAC2 was cloned from the rat olfactory bulb (Lutz et al., 1993) and later published 
independently by Usdin et al. (Usdin et al., 1994). VPACi and VPAC2 have very 
different distribution patterns. VPACi mRNA is widely distributed in the CNS, most 
abundantly in cerebral cortex and hippocampus (Ishihara et al., 1992; Usdin et al.,
1994) and in peripheral tissues including liver, lung and intestine (Ishihara et al., 
1992; Usdin et al., 1994). VPAC2 mRNA is abundant in the thalamus and 
superchiasmatic nucleus (SCN) and at lower levels in the hippocampus, brain stem, 
spinal cord and DRG (Usdin et al., 1994; Sheward et al., 1995). This receptor
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subtype is also found in many peripheral tissues including pancreas, skeletal muscle, 
heart, kidney, adipose tissue, testis and stomach (Adamou et al., 1995; Krempels et 
al., 1995; Usdin et al., 1994).
VPACi couples with Gs to stimulate an increase in cAMP via AC. Originally VPACi 
activation was not thought to stimulate the inositol phosphate/phospholipase C 
(IP/PLC) system (Ishihara et al., 1992; Couvineau et al., 1994), however following 
transfection into hamster Chinese hamster ovarian (CHO) cells, VPACi-receptor 
couples with Gj/0 to stimulate inositol phosphate (IP) production. IP production can 
then regulate intracellular calcium, affecting a number of pathways and signalling 
proteins. The VPAC2 receptor also stimulates the production of cAMP via activation 
of AC (Lutz et al., 1993; Usdin et al., 1994). Effects of VPAC2 activation on calcium 
regulation are suggested by the PACAP-induced increase in inositol trisphosphate 
(IP3) production in rat strial cells (Cai et al., 1997). Furthermore, effects on calcium- 
activated chloride currents mediated by the VPAC2 receptor have been observed in 
Xenopus oocytes (Inagaki et al., 1994).
PACAP expression
In the CNS, PACAP and PACAP mRNA are most abundantly expressed in the 
hypothalamus, with lower levels in other brain tissues (Ghatei et al., 1993). They are 
also present in peripheral tissues including: gastro-intestinal (GI) tract, adrenal gland 
and testis (Ghatei et al., 1993; reviewed in Arimura and Shioda, 1995). The 
expression patterns of PACAP suggest involvement in various bodily functions. 
PACAP expression within adult sensory neurons is primarily localised to small and 
medium sized neurons. The distribution pattern of PACAP is similar to that of CGRP 
and SP, but less widespread, PACAP being expressed by 10% of neurons and CGRP 
by 46% of neurons within adult DRG (Moller et al., 1993; Mulder et al., 1994). 
Developmentally, PACAP expression is detectable within sensory neurons at early 
embryonic stages. Both the peptide and PACI receptor mRNAs can be detected in 
El 1.5 mice in abundance in both DRG and trigeminal using in-situ hybridisation 
(Sheward WJ et al., 1998). Levels of PACAP mRNA and protein decrease with age, 
with less PACAP immunoreactive neurons being present in the adult mouse and fish
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(Shuto et al., 1996; Waschek et al., 1998; Jiang et al., 2003), indicative of an 
important role for PACAP in sensory neuron development.
Physiological functions of PACAP
PACAP has been shown to have a wide array of effects within the body. Roles in cell 
cycle and development, the cardiovascular system, the immune system, bone 
metabolism and as a mediator of endocrine, paracrine and exocrine secretions have 
all been suggested. I will briefly discuss some of these effects here.
Evolutionary conservation of PACAP combined with high level of expression in the 
embryo (Sheward et al., 1998) suggests a strong role for PACAP in embryonic 
development. Reglodi et al., found that injection of PACAP into young rat pups 
accelerated development with regards to facial features and sensory and motor 
neurological signs (Reglodi et al., 2003). Anti-PACAP treatment had the opposite 
effect, retarding ear folding, eye opening and hindlimb placing.
Sixty-percent of mice, with a null mutation in the VPACi gene, die within the first 
four weeks of birth (Jamen et al., 2000). Surviving VPACi'7' mice have an impaired 
insulintropic response to glucose, showing reduction in glucose-stimulated insulin 
secretion both in-vitro and in-vivo. This suggests that PACAP, acting via VPACi, has 
an important role in the normal insulin secretory response to glucose. Such a role has 
been suggested previously by findings that PACAP can potentiate glucose stimulated 
insulin secretion both in-vitro, in isolated perfused rat pancreas (Kawai et al., 1992; 
Bertrand et al., 1996) and in rat and mouse islets (Yada et al., 1994; Filipsson et al.,
1999), and in-vivo in the mouse (Filipsson et al., 1998). Both isoforms of PACAP 
(PACAP38 and PACAP27) can stimulate insulin secretion with similar efficacies in 
mouse and rat islets (Yada et al., 1994; Filipsson et al., 1998).
As well as insulin secretion, PACAP has also been shown to have effects on 
catecholamine secretion, potentiating the release of noradrenaline and adrenaline 
from chromaffin cells of the rat adrenal medulla (Chowdhury et al., 1994; Guo et al.,
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1994; Watanabe et al., 1994). Both PACAP27 and PACAP3g also have a mitogenic 
effect on such cells, stimulating the proliferation of cultured adult chromaffin cells 
via a PKA mediated signalling pathway (Tischler et al., 1995). Conversely mitogenic 
concentrations of PACAP inhibit mitogenic effects of NGF or FGF (unpublished 
observation in Frodin et al., 1994) indicating both mitogenic and anti-mitogenic roles 
for PACAP in adult rat chromaffin cell cultures (Tischler et al., 1995).
Within the cardiac system, intravenous or intra-arterial injection of PACAP into rats 
has been shown to cause a decrease in blood pressure (Nandha et al., 1991; Minkes et 
al., 1992). Such effects are mediated by the vasorelaxant activity of PACAP on 
arterial segments (Warren et al., 1991; Huang et al., 1993; Cardell et al., 1997), 
mediated via AC/cAMP signalling (Absood et al., 1992; Warren et al., 1991).
A role for PACAP as a daytime regulator of the biological clock has also been 
suggested. The suprachiasmatic nucleus (SCN), located in the hypothalamus acts as 
an endogenous pacemaker generating circadian rhythms. It regulates the production 
of melatonin from the pineal gland, in response to environmental cues such as 
light/dark cycles. PACAP immunoreactivity has been found in axons from the retinal 
ganglion cells, which transmit information on light/dark cues to the SCN (Hannibal 
et al., 1997). Levels of PACAP are low during the day, and high at night, suggestive 
of circadian rhythm signalling. Within the SCN, PACAP has been shown to regulate 
phosphorylation of CREB, which mediates melatonin synthesis (Kopp et al., 1997). 
This increase in melatonin is then thought to negatively feedback and inhibits the 
PACAP induced phosphorylation of CREB (Kopp et al., 1997). Evidence suggests 
that these effects of PACAP are mediated via the VPACi receptor subtype. Agonists 
of this receptor potently stimulate melatonin production and likewise, antagonists 
prevent the action of PACAP (Simonneaux et al., 1998).
A role for PACAP in the immune system has been suggested by its widespread 
location in central and peripheral lymphoid tissues (Gaytan et al., 1994; Abad et al.,
2 0 0 2 ). PACAP38 and PACAP27 can protect CD4+ CD8+ thymus lymphocytes from 
glucocorticoid-induced apoptosis in the rat (Delgado et al., 1996). Suggesting a role
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for PACAP in T-cell maturation. Furthermore, an indirect role for PACAP in 
lymphocyte maturation is suggested through the stimulation of interleukin-6 (IL-6) 
release from folliculostellate cells in the pituitary gland (Tatsuno et al., 1991), via a 
PACAP mediated increase in intracellular Ca2+ levels (Yada et al., 1993). The 
subsequent release of IL-6 stimulates the growth and maturation of B cells (Tatsuno 
et al., 1991; Yada et al., 1993).
Within the CNS and PNS, PACAP has been shown to promote the in vitro survival 
of several populations of neurons. It can prevent NMDA-induced cell death in rat 
cortical cultures (Frenchilla et al., 2001) and it can also promote survival and neurite 
outgrowth in rat cerebellar neuroblasts (Cavallaro et al., 1996; Gonzalez et al., 1997; 
Kienlen Campard et al., 1997; Vaudry et al., 1998), PC 12 cells (Hernandez et al., 
1995; Tanaka et al., 1997; Lazarovici et al., 1999) and rat basal forebrain cholinergic 
neurons (Takei et al., 2000) by signalling through the cAMP/PKA pathway. The 
same survival and neurite outgrowth promoting effects were observed in cultured 
embryonic and neonatal DRG neurons, alongside an increased immunoreactivity for 
the neuropeptide CGRP (Lioudyno et al., 1998). Such effects of PACAP on neurite 
outgrowth and gene expression suggest a role for PACAP in modulating sensory 
neuron differentiation as well as survival. Nielsen et al., (Nielsen et al., 2004) 
provided further evidence for this. They found that exogenous PACAP could 
enhance neuronal differentiation of cultured embryonic chick DRG. Furthermore, the 
addition of PACI receptor antagonists’ reduced neuronal differentiation in cultured 
DRG, suggesting that endogenously produced PACAP or a similar peptide acts via 
VPACI to produce neuronal differentiation. Of further interest was the discovery 
that both NT-3 and CNTF can block this effect. It has also been suggested that the 
survival promoting effects of PACAP are mediated through cross-talk with Trk 
neurotrophin receptors (Lee et al., 2002; Rajagopal et al., 2004). Such regulatory 
effects of neurotrophic factors on PACAP will be discussed later.
Further to its neurotrophic effects on sensory neuron survival, a role for PACAP in 
nerve regeneration has been suggested following facial nerve injury. PACAP 
treatment was shown to restore the latency of compound muscle action potentials
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after facial nerve transection in guinea pigs (Kimura et al., 2003; Kimura et al.,
2004). Numerous pieces of experimental data suggest that PACAP plays a role in 
nociception. For example, inflammation, that is associated with thermal and tactile 
hyperalgesia, causes an NGF-mediated increase in PACAP mRNA expression in 
TrkA expressing nociceptive neurons that can be blocked by administration of an 
anti-NGF antibody (Zhang et al., 1998; Jongsma-Wallin et al., 2003). Following both 
sciatic nerve transection and sciatic nerve compression (procedures that also lead to 
tactile and thermal hyperalgesia), a large up-regulation of PACAP mRNA and 
peptide is observed in DRG neurons. In the case of nerve transection this up- 
regulation predominantly occurs in medium and large neurons, which normally 
display negligible PACAP expression, and it is partially antagonised by exogenous 
NT-3 (Jongsma-Wallin et al., 2001). Nerve compression leads to an increase in 
PACAP expression in both large and small DRG neurons (Pettersson et al., 2004). 
This data may suggest a role for PACAP in the generation of inflammatory and 
neuropathic pain.
PACAP’s role in nociception is somewhat conflicting, with PACAP both inhibiting 
(Zhang et al., 1993; Zhang et al., 1996; Yamamoto and Tatsuno, 1995), and 
potentiating pain (Narita et al., 1996; Xu and Wiesenfeld-Hallin, 1996; Jongsma et 
al., 2001, Mabuchi et al., 2004). For example, PACAP administered intrathecally 
could produce anti-nociceptive effects following formalin-induced pain in adult rats 
(Yamamoto and Tatsuno, 1995). Conversely, VPACI7' mice have a 75% decrease in 
nociceptive response; and Mabuchi et al., showed that PACAP7' mice do not exhibit 
inflammatory pain induced by carrageenan injection, or neuropathic pain following 
nerve transection.
Neurotrophic factor regulation of PACAP and PACAP receptor/Trk cross-talk
In adult rat DRG, different neurotrophic factors have been shown to have differing 
effects on PACAP expression in inflammation and also following nerve injury, in 
both injured and intact neurons. Expression of PACAP mRNA is up-regulated in 
small-medium neurons in response to inflammation (Zhang et al., 1998; Jongsma-
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Wallin et al., 2003. The inflammation associated increase in NGF has been 
implicated in producing the observed alterations in neuropeptide levels (Reviewed in 
McMahon et al., 1996). Systemic administration of anti-NGF antibodies prevented 
the inflammation associated increase in PACAP mRNA (Jongsma-Wallin et al.,
2003).
Neurotrophic factor regulation of PACAP expression has also been observed in 
models of nerve damage and axotomy. In intact sensory neurons of the DRG, 
PACAP protein and mRNA is predominantly expressed by small/medium-sized 
neurons that also express TrkA. Following sciatic nerve transection, however, there 
is a large increase in the expression of PACAP mRNA in medium to large, 
predominantly TrkC expressing neurons (Zhang et al., 1995; Zhang et al., 1996; 
Jongsma Wallin et al., 2001). Infusion of NT-3 resulted in a decrease in the injury- 
induced increase in PACAP protein and mRNA expression in TrkC-positive neurons. 
In non-lesioned animals, NT-3 also decreased PACAP expression selectively in 
TrkA-expressing nociceptive neurons (Jongsma Wallin et al., 2001), an effect 
possibly mediated by NT-3 induced down-regulation of high affinity NGF receptors 
(Gratto and Verge, 1997). Whilst NGF increased the expression of PACAP in small, 
TrkA-expressing, nociceptive neurons in both lesioned and intact animals, it also 
selectively reduced the expression of PACAP in large proprioceptive neurons after 
nerve transection, but not in intact animals (Jongsma Wallin et al., 2001). How 
endogenously produced neurotrophic factors affect expression of this neuropeptide, 
is of interest with regards to the ability of PACAP peptide to provide its own trophic 
effects, possibly indirectly via effects on Trk receptors.
PACAP has been shown to have effects on differentiation in late embryonic and 
neonatal rat DRG neurons, alongside survival effects similar to that of NGF 
(Lioudyno et al., 1998). Recent work suggests that such effects could be mediated 
through GPCR cross-talk with the neurotrophin Trk receptors (Lee et al., 2002; 
Rajagopal et al., 2004). PACAP treatment has been shown to cause an increase in 
TrkA tyrosine kinase activity in PC 12 cells and TrkB activity in rat hippocampal 
cells (Lazarovici et al., 1999; Lee et al., 2002; Rajagopal et al., 2004). Furthermore, 
this VPACi mediated Trk activation led to an up-regulation of phosphorylated Akt
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and subsequent cell survival. Blockade of Trk receptors with K252a prevented 
PACAP-induced phosphorylation of Akt and neuronal survival confirming a Trk 
mediated pathway of cell survival (Lee et al., 2002; Rajagopal et al., 2004). More 
recently, however, Nielsen et al. (2004) found no such effect of Trk receptor 
blockade on PACAP induced neuronal differentiation in chick DRG, rather they 
demonstrated that differentiation was effected via a VPACI/MAPK pathway. It 
therefore seems that the many actions of PACAP are mediated through different 
pathways, which may interact with those of the neurotrophins.
The ability of PACAP to regulate the expression of neurotrophins is of further 
interest. In rat cortical cultures, presence of PACAP prevented cell death induced by 
NMD A and also attenuated serum-induced apoptosis (Frenchilla et al., 2001). BDNF 
protein expression was reduced by NMDA in both cellular injury conditions, but 
presence of PACAP prevented this decrease in BDNF and prevented cell death. 
Furthermore pre-incubation with anti-BDNF prevented the neuroprotective effects of 
PACAP38, suggesting PACAP-induced survival is mediated by preventing the 
suppressed expression of a neurotrophin essential for cortical neurotrophin survival. 
The ability of PACAP to regulate expression of neurotrophic factors, alongside the 
receptor cross-talk that occurs between its GPCRs and the Trk receptors adds 
complexity to the regulation of PACAP expression by neurotrophic factors 
investigated in this chapter.
3.1.2. Vanilloid receptor 1 (VR1)
Capsaicin, a component of chilli peppers, has been widely studied for its effects upon 
primary afferent neurons. It depolarises subsets of primary sensory neurons (Oh et 
al., 1996) to evoke pain. The associated release of the neuropeptides SP and CGRP 
contribute to inflammation and subsequent hyperalgesia (Malmberg and Yash, 1992; 
Hingtgen et al., 1995; Traub et al., 1996; Kilo et al., 1997). Conversely, capsaicin has 
been shown to act as an anti-inflammatory and anti-nociceptive agent for the 
treatment of painful disorders (e.g. bladder hyperreflexia), through nociceptor 
desensitisation (Maggi et al., 1987; reviewed in Szallasi and Blumberg, 1996).
Studies found that capsaicin, alongside other molecules such as resiniferatoxin
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(RTX), produce their effects by activating a sensory neuron specific calcium channel 
(Wood et al., 1988).
The cloned VR1 receptor, also known as TRPV1, encodes an 838 amino acid protein 
with a molecular weight of 92,000 Da that is a non-selective cation channel with high 
calcium permeability (Caterina et al., 1997; Szallasi and Blumberg, 1999). In 
addition to capsaicin, numerous other molecules can activate VR1. These include the 
vanilloids, zingerone and piperine, and non-vanilloids like the endocannabinoid, 
anandamide (Hwang et al., 2000; Reviewed in Sterner et al., 1999). Thermal stimuli 
in the noxious range, can also directly open the channel, further suggestive of a role 
for VR1 as a transducer of painful stimuli (Caterina et al., 1997; Helliwell et al.,
1998). Protons have been shown to act as modulators of VR1 gating, with low 
concentrations (moderate acidification) facilitating channel opening and lowering 
heat thresholds (Tominaga et al., 1998) and high concentrations blocking VR1 
activation (Baumann et al., 2000). VR1 appears also to be a sensor of noxious 
hypertonicity and can be directly gated by divalent and monovalent cations (Ahem et 
al., 2005).
Following the discovery of VR1, three more homologous receptors (VRL-1 (TRPV2) 
VRL-2 (TRPV4) and VRL-3 (TRPV3)) have been isolated and, together with VR1, 
these compose the transient receptor potential vanilloid (TRPV) family, a subgroup 
of the transient receptor potential (TRP) family of ion channels. See figure 3.1. for 
details of phylogenetic relationship among mammalian TRP channels and details of 
TRPV channel nomenclature.
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Vanilloid TRPV Alternative nom enclature Full cONA available Predicted Human
receptor family nom enclature (for vertebrates) protein size chrom osom al
nom enclature (human) localization
VR1 TRPV1 OTRPC1 Human, m ouse, r a t  chicken 95 kDa 17p13
VRL-1 TRPV2 GRC, OTRPC2 Human, m ouse, rat 86 kDa 17p11
VRL-2 TRPV4 OTRPC4, VR-OAC, TRP12 Human, m ouse, rat, chicken 98 kOa 12q24.1
VRL-3 TRPV3? - - - 17p13
ECAC1 TRPV5 CaT2, ECaC, OTRPC3 Human, rat, rabbit 83 kDa 7q35
ECAC2 TRPV6 CaT, CaT1, CaT-like Human, m ouse, rat 83 kDa 7q35
Figure 3.1. Phylogenetic relationship among the mammalian TRP channels with further detail on 
the nomenclature o f the TRPV channels. Taken from Tominga and Caterina, 2004 and Gunthorpe 
et al., 2002.
VRL-1 was identified through a search of genomic databases for TRPV1 
homologues (Caterina et al., 1999; Reviewed in Gunthorpe et al., 2002, Benham et 
al., 2003 and Tominaga and Caterina, 2004). VRL-1 is not activated by ligands of 
TRPV1, but is activated by noxious heat (>53°C). It has been suggested that VRL-1 
mediates responses to extreme noxious temperatures, whilst VR-1 responds to 
medium -  high noxious temperatures (Xu et al., 2002). VRL-1 is predominantly 
expressed in a subpopulation of medium sized thinly myelinated sensory neurons 
(A5 neurons), but it is also present at low levels in the CNS and non-neuronal tissues, 
suggestive of another role and other possible ligands.
VRL-2 (also named TRPV4, VR-OAC, OTRPC4 and TRP 12) was discovered using 
in-silico analysis of expressed sequence tag (EST) databases and conventional 
molecular cloning (Delany et al., 2001). It appears to be an osmotically regulated 
cation channel, opening in response to hypotonic swelling of the cell (Liedtke et al., 
2000; Strotmann et al., 2000; Delany et al., 2001). Like VR1 and VRL-1, VRL-2 is 
expressed in sensory neurons and their peripheral fibres (Leidtke et al., 2000; Guler 
et al., 2002; Alessandri-Haber et al., 2003). VRL-2 is also expressed in sympathetic 
and parasympathetic nerves, on airway and kidney epithelia, sweat glands, intestine 
and blood vessels (Delany et al., 2001). Additionally, VRL2 expression has been 
observed in keratinocytes where it appears to mediate warmth evoked currents in 
conjunction with VRL-3 (Chung et al., 2004; Tominaga and Caterina, 2004).
The virtual completion of the human genome project allowed identification of VRL- 
3 (TRPV3) through a search of genomic sequences (Smith et al., 2002; Xu et al.,
2002 , reviewed in Benham et al., 2003). In humans it is expressed mainly in CNS 
and sensory neurons (Smith et al., 2002; Xu et al., 2002), but also in skin and 
keratinocytes (Peier et al., 2002). Like VR1 and VRL-1, VRL-3 is sensitive to heat, 
although the reported temperature of activation varies from 23°C to 39°C (Smith et 
al., 2002; Xu et al., 2002; Peier et al., 2002). This discrepancy between the activation 
temperatures determined by different groups is thought due to the fact that the
203
channel becomes sensitised to heat, opening at lower temperatures, once it has been 
heat-gated for the first time. The result of this is that the recorded temperature of 
activation in any one experimental manipulation is dependent on the “heat history “ 
of the VL-3 expressing cells under investigation (Benham et al., 2003). The recent 
production of TRPV37' mice has confirmed a role for this receptor in heat sensation. 
Mice with a mutation in this receptor have strong deficits in responses to innocuous 
and noxious heat, but not in other sensory modalities (Moqrich et al., 2005). Recently 
non-thermal stimuli have also been determined for this receptor. 2- 
Aminoethoxydiphenyl (2-APB) was shown to activate the receptor in HEK cells 
(Chung et al., 2004). The natural compound camphor, known for its heat sensation- 
producing effects in humans, was also shown to produce effects in cultured mouse 
primary keratinocytes, an effect that was abolished in TRPV3'/' mice (Moqrich et al., 
2005). Other more distant cousins of VR1 include two epithelial Ca2+ channels, 
TRPV5 (ECAC1) and TRPV6 (ECAC2). I will not discuss these further here, but for 
a review see Gunthorpe et al., 2002.
Expression profile of VR1
VR1 is located predominantly in primary sensory neurons, but is also found in 
various brain nuclei and spinal cord (Mezey et al., 2000). Non-neuronal cells have 
also been shown to express VR1 (TRPV1) including: pancreatic B cells (Akiba et al., 
2004), liver epithelial cells (Reilly et al., 2003), astrocytes from the rat spinal cord 
(Doly et al., 2004), endothelial cells (Yamaji et al., 2003), polymorphonuclear 
granulocytes (Heiner et al., 2003), macrophages (Chen et al., 2003), oral epithelial 
cells (Kido et al., 2003) and thymocytes (Amantini et al., 2004).
In DRG, VR1 is expressed by small-medium sized neurons (Caterina et al., 1997) 
that have either non-myelinated (C-fibre) or thinly myelinated (A8-fibre) axonal 
processes (Michael and Priestly, 1999; Guo et al., 1999; Tominaga et al., 1998). In 
rat DRG, VR1 is expressed by both TrkA- positive, peptidergic nociceptive neurons, 
and GDNF responsive Griffonia simplicifolia isolectin B4 (IB4) positive c-fibre 
nociceptors (Michael and Priestly 1999; Guo et al., 199). In contrast, in mouse DRG,
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only a small (2-3%) population of neurons are both IB4 and VR1 positive (Zwick et 
al., 2002), the majority of functional VR1 receptors being expressed by the 
peptidergic TrkA expressing neurons. It is also worth noting that approximately 10% 
of VR1 positive rat lumbar DRG neurons are SP and IB4 negative (Tominga et al., 
1998). A heterogeneous population of cells therefore express VR1 within the DRG.
In nodose ganglia, expression of VR1 mRNA is co-localised with that of TrkB rather 
than TrkA (Michael and Priestly, 1999).
Roles of VR1
The apparent pro-nociceptive and anti-nociceptive effects of capsaicin mentioned 
above are thought to be mediated via VR1. Further evidence for such apparent 
contradictory roles of VR1 was provided by the production of a VR1 null mutant 
mouse (Caterina et al., 2000; Bolcskei et al., 2005). Mice lacking the capsaicin 
receptor exhibited impaired detection of painful heat and, unlike wild type mice, 
failed to develop thermal hyperalgesia after mustard oil, CFA or acid application to 
the hindpaw or a mild bum injury, showing that VR1 is necessary for normal thermal 
nociception and plays a role in the generation of thermal hyperalgesia in response to 
noxious chemical and heat insults. (Caterina et al., 2000; Bolcskei et al., 2005). In 
contrast, VR1 knockout mice were identical to wild type mice developed mechanical 
hyperalgesia in response to formalin and carrageenan treatment and partial sciatic 
nerve lesion in an identical manner to wild type mice. VR1 is therefore not 
apparently necessary for normal mechanical nociception or the development of 
mechanical hyperalgesia. The data from VR1 knockout mice have been confirmed by 
experiments that specifically blocked the peripheral activation of VR1 in sensory 
fibres of the sciatic nerve by intra-plantar injection of the potent VR1 antagonist 
iodoresiniferatoxin (IRTX). Low dose IRTX blocked the increase in excitatory 
electrical responses evoked by noxious heat in wide dynamic range (WDR) c-fibre 
nociceptive neurons that typically occurs after carrageenan application and spinal 
nerve ligation (SNL). In contrast, IRTX failed to inhibit the increased response of 
WDR neurons to mechanical stimuli that occur following carrageenan treatment and 
SNL. In addition, higher doses of IRTX reduced the heat response but not the
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mechanical response of naive WDR neurons that were not subjected to inflammatory 
insult or SNL (Jhaveri et al., 2005). Interestingly, anti-nociceptive effects of VR1 on 
mechanical thresholds have been suggested by examination of VR1 null mice 
subjected to agents that induce polyneuropathy. Chronic mechanical hyperalgesia 
evoked by streptozotocin-induced diabetes and cisplatin-evoked toxic 
polyneuropathy occurred earlier and was of greater magnitude in VR1 knockout mice 
compared to wild-type mice (Bolcskei et al., 2005).
Post-translational modification of VR1 in response to inflammation and chemical 
insult has been postulated to regulate onset of hyperalgesia and enhance VR1 
activity. In the absence of any other agonist, PKC activation has been shown to 
phosphorylate VR1, inducing its activity and enhancing the response of the receptor 
to capsaicin (Crandall et al., 2002; Premkumar et al., 2000). cAMP can similarly 
phosphorylate VR1, leading to an enhanced response to capsaicin through reduced 
desensitisation of the receptor (Bhave et al., 2002). This has also been illustrated in a 
mouse model of diabetic neuropathy (Hong and Wiley, 2005). Hong and Wiley 
(Hong and Wiley, 2005) show that painful diabetic neuropathy is associated with not 
only alterations in VR1 levels, but also by PKC-mediated phosphorylation, which 
blunts VR1 desensitisation, allowing enhanced flow of receptor currents. NGF 
rapidly potentiates TRPV1 channel activity in cultured DRG neurons treated with 
capsaicin (Shu and Mendell, 1999; Bonnington and McNaughton, 2003). Studies 
using pharmacological inhibitors in these neurons suggest that the PI3K pathway is 
crucial step in mediating NGF sensitization, with both calcium/calmodulin- 
dependent kinase II (CaMK II) and PKC involved downstream of PI3K (Bonnington 
and McNaughton, 2003; Zhuang et al., 2004). PKCe sensitizes TRPV1 by directly 
phosphorylating this channel, leading to increased channel activity (Cesare et al., 
1999; Premkumar and Ahem, 2000; Numazaki et al., 2002) and translocation of the 
channel to the cell surface (Morenilla-Palao et al., 2004). Consistent with these 
findings, NGF-induced hyperalgesia is inhibited by a PKCe-selective peptide 
inhibitor (Khasar et al., 1999).
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Aside from an obvious role in peripheral nociception, VR1 also appears to play a role 
in visceral nociception. A role for VR1 in the gastrointestinal (GI) tract is suggested 
by the demonstration of VRl-like immunoreactivity on sensory fibres that enter 
myenteric ganglia and surround enteric neurons and fibres that run in the 
interganglionic fibre tracts throughout the GI tract. These sensory fibres are largely 
CGRP positive and originate from thoracic and lumbar DRG, although a small 
number appear to originate from the nodose ganglion (Ward et al., 2003). 
Interestingly, the expression of VR1 is up-regulated in colonic nerve fibres of 
patients with active inflammatory bowel disease (IBD) compared to control subjects, 
suggesting a role for VR1 in the aetiology of this condition (Yiangou et al., 2001; 
Facer et al., 2001). More recently, it has been demonstrated that activating VR1 in 
nerve fibres innervating the mucosa, blood vessels and smooth muscles of the 
stomach by the intragastric administration of specific VR1 agonists in rats reduces 
the severity of gastric lesions due to the intragastric administration of 0.6 N HC1 in a 
dose dependent manner. Moreover, the protective effect of VR1 activation is blocked 
by specific VR1 antagonists, again in a dose dependent manner (Horie et al., 2004).
Recently, evidence has emerged suggesting that VR1 also plays a role in regulating 
urine production. Activation of VR1 in rat sensory afferents innervating the kidney 
by perfusion of capsaicin into the pelvis leads to increases in urine flow rate and 
urinary sodium excretion (Zhu et al., 2005). VR1 is expressed in bladder 
neuroepithelial cells and sensory fibres innervating the bladder. Up-regulation of 
VR1 in both these cell types is associated with neurogenic detrusor overactivity 
(NDO) and treatment with low doses of the VR1 agonist resiniferatoxin ameliorates 
the symptoms of this condition, possibly by causing a sustained slow depolarization 
of VR1 positive afferents (in the absence of action potentials) that prevents action 
potential generation by other physical and chemical VR1 agonists (Apostolidis et al., 
2005; Raisinghani et al., 2005). Recently it has been demonstrated TRPV1 is 
functionally expressed in rat islet p cells where it may play a role in insulin secretion 
as a calcium channel. This finding may account for the effect of capsaicin on food 
intake and energy consumption as well as on the pathophysiological regulation of 
pancreatic endocrine functions (Akiba et al., 2004)
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VR1 also appears to plays a role in regulating blood pressure and blood flow in the 
cardiovascular system. Anandamide has been shown to act via the VR1 receptor to 
produce vasodilation, most likely through the accompanied release of the vasodilator, 
CGRP (Zygmunt et al., 1999; Vaishnava et al., 2003). Additionally capsaicin, and 
also to a lesser extent anandamide, can produce a dose dependent decrease in heart- 
rate and blood pressure, an effect that can be reversed by the addition of the VR1- 
specific antagonist, capsazepine (Malinowska et al., 2001).
Regulation of VR1 expression by neurotrophic factors following nerve damage, 
axotomv and inflammation
Local inflammation, produced by application of the local irritant, Freuds Complete 
Adjuvant (CFA) causes a p38 MAP kinase dependent increase in VR1 protein 
expression in adult rat DRG neurons (Amaya et al., 2003; Ji et al., 2002). This 
increase in VR1 expression appears to play a role in the generation of thermal 
hyperalgesia, as mice lacking VR1 no longer show hypersensitivity to heat following 
inflammation (Caterina et al, 2000). Studies using anti-sera against NGF and GDNF 
in the adult rat have shown that both neurotrophic factors have a role in the onset of 
such thermal hyperalgesia following inflammation through up-regulation of VR1 
(TRPV1) expression. CFA induces an up-regulation of NGF and GDNF protein in 
adult rat DRG, and anti-serum to both trophic factors prevents the up-regulation of 
VR1 in TrkA expressing and IB4 positive nociceptors, respectively, and also 
ameliorates the thermal hyperalgesia that develops in response to CFA (Amaya et al., 
2004; Ji et al., 2002; Woolf et al., 1994). Up-regulation of VR1 by NGF and GDNF 
is not likely to be the only way these trophic factors contribute to the generation of 
thermal hyperalgesia in adult rodents. For example, NGF has been shown to regulate 
the expression of a number of other genes in DRG neurons, to increase the release of 
neuropeptides (possibly via increased VR1 activation) and lead to the release of a 
number of inflammatory mediators from mast-cells (reviewed in Hefti et al., 2006).
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VR1 mRNA and protein are down-regulated in injured adult rat DRG neurons 
following sciatic nerve or spinal nerve transection (Michael and Priestley, 1999; 
Michael and Priestley, 2002; Fukuoka T et al., 2002; Wendland et al., 2003). This 
effect is proposed to be due to the limited availability of endogenous neurotrophic 
factor support in such conditions. Much evidence supports this hypothesis. 
Administration of NGF and GDNF can prevent the axotomy-induced down- 
regulation of VR1 mRNA observed in cultured adult rat DRG (Winston et al., 2001; 
Ogun-Muyiwa et al., 1999 Wendland et al., 2003). Furthermore, in-vivo 
sequestration of NGF using neutralising anti-sera also reduces sensitivity of neurons 
to capsaicin through a loss of VR1 (McMahon et al., 1995). Following total or partial 
sciatic nerve transection (Hudson et al., 2001) or spinal nerve ligation (Hudson et al., 
2001; Fukuoka et al., 2002) in rats, expression of VR1 in intact DRG neurons 
increased (Hudson et al., 2001; Fukuoka et al., 2002). This increase in undamaged 
nerves may be due to increased availability of growth factors from target tissues 
because of an overall reduction in the amounts of growth factors taken up from the 
tissue by retrograde transport.
Nodose ganglia
Previous studies on the expression of VR1 in nodose ganglia have revealed 
expression and regulation patterns that differ from those observed in the DRG. In 
nodose ganglia, the majority of VR1 positive cells also express TrkB, with very few 
being TrkA immuno-reactive (Michael and Priestly, 1999). This co-expression of 
VR1 and TrkB agrees with the finding that BDNF, but not NGF, can regulate the 
capsaicin sensitivity of cultured adult rat nodose neurons (Winter, 1998). It is worth 
noting however that the use of BDNF in these experiments was very high at lpg/ml, 
suggesting that at physiological levels such effects may not be observed. This 
difference in the regulation of VR1 expression between nodose ganglia and DRG 
demonstrates that a particular determinant of nociceptive thresholds is not regulated 
in the same manner in all types of rat sensory neurons. A study of the regulation of 
VR1 expression in the trigeminal ganglion would therefore be of interest to
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determine whether VR1 is regulated by NGF or BDNF in these cranial sensory 
neurons.
Summary
VR1 (TRPV1) functions in many systems within the body, including the 
cardiovascular system, GI tract and nervous system, although most work has focused 
on the role of VR1 in pain. Several neurotrophic factors have been implicated in the 
regulation of VR1 expression and the gating properties of this ion channel. From a 
therapeutic perspective, it is important to understand fully the regulation of VR1 
expression as this is an established drug target in painful conditions.
To date there is little experimental data concerning the regulation of VR1 expression 
in neonatal sensory neurons. One of the objectives of the studies reported in this 
chapter was to explore how neurotrophic factors regulate the expression of VR1 in 
post-natal sensory neurons
3.1.3. Galanin
Background
The neuropeptide galanin was isolated from porcine intestine in 1983 by Tatemoto et 
al. (Tatemoto et al., 1983). It is a 29 amino acid peptide that is widely expressed in 
the nervous system and present in a small population of peptidergic, small-diameter 
adult DRG neurons (Chang et al., 1985; Skofitsch and Jacobowitz 1985). Galanin 
mRNA is expressed in the majority of embryonic sensory neurons, peaking at E 15- 
El 7 in DRG and trigeminal ganglia, but decreasing after birth so that only 2% of 
adult DRG neurons are galanin mRNA-positive (Xu et al., 1996; Ma et al., 1999). 
Such high levels of expression in embryonic sensory neurons suggest an important 
role for galanin in sensory neuron development (discussed below). Although galanin 
expression is predominantly in small/medium sized peptidergic neurons in the adult, 
some expression in large diameter neurons has been observed (Xu et al., 2000; Ma et
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al., 1999). Whilst galanin expression levels are low in adult sensory ganglia, 
expression is dramatically increased in large diameter neurons following nerve injury 
or axotomy. This contrasts with many neuropeptides, for example, SP and CGRP, 
whose expression decreases following axotomy. Up-regulation of galanin following 
injury raises the possibility that this neuropeptide may play a role in promoting 
neuron survival and/or regeneration following nerve trauma and may also play a role 
in the modulation of nociceptive thresholds, since these can change following nerve 
trauma. These aspects of galanin function are discussed below.
Receptors
Galanin mediates its effects via three G protein coupled receptors; GAL-R1 (Habert- 
Ortoli et al., 1994), GAL-R2 (Smith et al., 1997) and GAL-R3 (Wang et al., 1997; 
Smith et al., 1998). There is a region of 83 amino acids conserved in all three rat 
galanin receptor subtypes, whilst outside this conserved region, homology is only 
approximately 23% (Branchek et al., 2000). GAL-R1 mRNA is found in 
approximately 50% of rat DRG neurons, predominantly in those that are of medium 
and large size (O’Donnell et al., 1999; Xu et al., 1996). In contrast, GAL-R2 mRNA 
is expressed in approximately 80% of rat and mouse DRG neurons, with 60% of 
these being small CGRP-positive neurons (O’Donnell et al., 1999; Shi et al., 1997; 
Liu and Hokfelt, 2002). Only low levels of GAL-R3 can be detected in DRG neurons 
(Waters and Kraus 2000; reviewed in Branchek et al., 2000).
The expression patterns and the downstream signal transduction pathways recruited 
following receptor activation differ for the three galanin receptors (reviewed in 
Bartfai et al., 1993 and Branchek et al., 2000). GAL-R1 and GAL-R3 mediate their 
effects through Gj/0 type proteins, leading to an inhibition of adenylate cyclase 
(Habert-Orli et al., 1994; Smith et al., 1998; Wang et al., 1997). Conversely GAL-R2 
acts via Gq to activate phospholipase C that in turn causes a mobilisation of calcium 
and activation of protein kinase C (PKC) (Fathi et al., 1998; Howard et al., 1997; 
Waters et al., 2000). Signalling via GAL-R2 can also activate MAP kinase pathways 
(Wang et al., 1998).
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Physiological function
Because of its widespread distribution and interactions with multiple signalling 
pathways, a role for galanin in a wide variety of physiological processes is to be 
expected. The effects of galanin are commonly mediated through modulation of 
hormone and neurotransmitter secretion. For example, galanin inhibits the release of 
noradrenaline, serotonin, acetylcholine and glutamate (Seutin et al., 1989; Pieribone 
et al., 1995; reviewed in Bartfai et al., 1993). These molecules have a variety of 
actions within the body, hence the multiple effects of galanin throughout the nervous 
system. A role for galanin in a number of important bodily functions has been 
implicated. Effects on; cognition (Chan-Palay, 1988; Mastropaolo et al., 1988; Ogren 
et al., 1996; Robinson and Crawley, 1993; Malin et al., 1992; Reviewed in Wrenn 
and Crawley, 2001; Wrenn et al., 2004; Rustay et al., 2005), stress and anxiety 
(Ceresini et al., 1998; Reviewed in Branchek et al., 2000; Khoshbouei et al., 2002; 
Holmes et al., 2003), endocrine modulation (Bartfai et al., 1993; Carey et al., 1993 
Pieribone et al., 1995), nociception (Reviewed in Xu et al., 2000; Reviewed in Liu 
and Hokfelt, 2002, Hygge-Blakeman et al., 2004; Wiesenfeld-Hallin et al., 2005), 
feeding (Crawley et al., 1990; Dube et al., 1994; Crawley, 1999) and in nerve 
regeneration following injury (Wynick et al., 2001; Holmes et al., 2005) have all 
been reported.
Co-localisation of galanin with acetylcholine (ACh) and choline acetyltransferase 
(ChAT) in medial septal neurons projecting to the rodent hippocampus, suggest a 
role for galanin in the modulation of cholinergic transmission and thus cognition 
(Melander et al., 1995, 1996). Indeed, negative effects of galanin over-expression on 
learning and memory were demonstrated by several studies in the rat in which central 
injection of galanin produced performance deficits in working memory, fear 
conditioning and spatial tasks (Mastropaolo et al., 1988; Malin et al., 1992; Robinson 
and Crawley, 1993; Ogren et al., 1996). These findings, combined with the discovery 
that galanin is over-expressed in the basal forebrain during the onset of Alzheimer’s
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disease (AD) (Chan-Palay, 1988; Beal et al., 1990), has led to the conclusion that 
galanin may be the cause of the cognitive dysfunction characteristic of AD (Chan- 
Palay, 1988; Hokfelt et al., 1997; Wrenn and Crawley, 2001). The production of 
mice that over-express galanin has further supported this hypothesis. Although 
galanin over-expressing mice, display normal general health, they are impaired in 
cognitive tasks including the Morris water-maze probe trial and trace fear 
conditioning (Steiner et al., 2000; Kinney et al., 2002). They also displayed 
neurochemical deficits characteristic of AD, with reduced levels of ChAT-containing 
cells in the horizontal diagonal band (HDB) (Steiner et al., 2000). The signalling 
pathways galanin utilises to produce these detrimental effects are unclear. Of note, 
however, is that mice with a null-mutation in the GAL-R1 gene were found to 
behave normally on most memory tasks, implicating other receptor subtypes in such 
spatial learning and memory (Wrenn et al., 2004; Rustay et al., 2005).
Although GAL-R1 null mice show no deficits in memory-related tasks, they do 
display increased anxiety-like behaviour, suggesting a role for GAL-R1 and hence 
galanin in stress and anxiety (Holmes et al., 2003). This hypothesis is reinforced by 
the expression of galanin in neural systems that utilise noradrenaline and serotonin as 
neurotransmitters. Further studies have noted increased levels of prepro-galanin 
mRNA in the locus coeruleus (LC) in situations of high stress that produce high 
levels of noradrenaline release, e.g. repeated exercise (O’Neal et al., 2001) and 
chronic social stress (Holmes et al., 1995). However, low stress tasks such as 
swimming (Austin et al., 1990) or wheel running (Soares et al., 1999) show no such 
increase in prepro-galanin mRNA. These results suggest galanin gene expression is 
modulated in response to repeated stress, but not to low stress tasks. Its up-regulation 
in the LC in situations of high stress, and the increase in anxiety in GAL-R1 
knockout mice suggest galanin may attenuate noradrenergic neuron firing here to 
produce anxiolytic effects. Indeed an inhibitory effect of galanin on the firing rate of 
LC neurons has previously been observed (Seutin et al., 1989; Pieribone et al., 1995). 
Such a role for galanin in modulating stress responses is further supported by studies 
in the galanin over-expressing (OE) mouse. Such mice were normal with regards to 
general health, however showed no anxiety-like phenotype to three separate anxiety
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tests in comparison to wild-type mice (Holmes et al., 2002). Furthermore, stimulation 
of noradrenergic cells with the alpha 2 adrenoreceptor antagonist, yohimbine 
produced pro-anxiety effects in wild-type mice in the light-dark exploration test, but 
no such effects were observed in galanin over expressing mice (Holmes et al., 2002). 
Taken together, these data suggest that galanin and its receptors, particularly GAL- 
R l, are potential therapeutic targets for the development of novel anxiolytic 
treatments.
Epilepsy is a diverse neurological disorder caused by a misbalance between 
excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission leading to 
hyperexcitability in neuronal circuits. A potential role for galanin as an 
anticonvulsant is suggested following the discovery that galanin antagonises 
glutamatergic neurotransmission in the hippocampus (Zini et al., 1993, 1993b; 
reviewed in Mazarati et al., 2001). Such effects of galanin on glutamate are mediated 
by K+ channels, as effects were abolished by the K+ blocker, glibenclamide (Zini et 
al., 1993). The production of transgenic mice has further supported these hypotheses. 
Mice that over-express galanin have been shown to exhibit a marked suppression of 
seizure development in an animal model of human complex partial seizures (Kokai et 
al., 2001). Furthermore, mice with a null mutation in the GAL-R1 gene show an 
enhanced susceptibility to seizures in limbic status epilepticus (SE), suggesting that 
the ability of galanin to reduce seizures is mediated through GAL-R1 (Mazarati et 
al., 2004). A role for GAL-R2 has also been implicated in mediating the 
anticonvulsant effects of galanin (Mazarati et al., 2004a, Lu et al., 2005). Taken 
together, these results suggest that agonists for both GAL-R1 and GAL-R2 would be 
of therapeutic use in the treatment of seizures. However, since GAL-R2, but not 
GAL-R1, protein and mRNA levels are decreased following pilocarpine induced SE 
(Lu et al., 2005), GAL-R1 would seem to be the better therapeutic target.
The distribution of galanin in brain areas that regulate ingestive behaviours led to a 
number of studies on the role of galanin in feeding (reviewed in Crawley, 1999). It 
was shown that centrally administered galanin in the rat induced a dramatic increase 
in food consumption (Crawley et al., 1990; Dube et al., 1994), an effect that could
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be attenuated by injection of the galanin antagonist, M40 (Bartfai et al.,1993), into 
the hypothalamus or amygdala prior to injection of galanin (Bartfai et al., 1993; 
Corwin et al.,1993). No effect of M40 alone on food intake was observed (Bartfai et 
al., 1993; Corwin et al., 1993; reviewed in Crawley, 1999).
A role for galanin in nociception is well established. Following peripheral nerve 
damage or axotomy in adult rodents, a dramatic up-regulation in galanin mRNA and 
protein expression is observed in sensory neurons (Hokfelt et al., 1987; Villar et al., 
1989; Wiesenfeld-Hallin., 1992; Zhang et al., 1998; Holmes et al., 2005). This up- 
regulation of galanin expression is accompanied by a down-regulation in GAL-R1 
and GAL-R2 expression (Xu et al., 1996; Shi et al., 1997; Reviewed in Wiesenfeld- 
Hallin, 2001). Following nerve injury, intrathecal application of exogenous galanin 
produces an enhanced inhibitory effect on nociceptive behaviours (Hao et al., 1999; 
Yu et al., 1999; Liu and Hokfelt, 2000), whilst application of the high affinity 
galanin receptor antagonist, M3 5, increases pain-like behaviour (Wiesenfeld-Hallin 
et al., 1992, Liu and Hokfelt., 2000).
Transgenic mice have provided further evidence for an inhibitory role for galanin in 
nociception. Mice over-expressing galanin show significant elevation of nociceptive 
threshold to thermal stimulation in both the tail-flick and Hargreaves test (Blakeman 
et al., 2001) and a decrease in the development of pain-like behaviours following 
partial sciatic nerve injury (Hygge-Blakeman et al., 2004; reviewed in Wiesenfeld- 
Hallin et al., 2005). Interestingly, GAL-R1 knockout mice show no differences 
compared to wild type mice in either the tail flick test, or in paw withdrawal latency 
to radiant heat stimulation. There was a slight, but significant reduction in the latency 
to jumping/hind-paw licking in the hotplate test in GAL-R1 knockout mice versus 
wild type mice and also an increase in response scores to cold stimulation (Hygge- 
Blakeman et al., 2003; Reviewed in Wiesenfeld-Hallin et al., 2005). Such GAL-R1'7' 
mice therefore only have a subtle nociceptive phenotype, suggesting a possible role 
for other galanin receptor subtypes in mediating the inhibitory effects of galanin on 
nociception. As mentioned above, GAL-R2 is expressed predominantly on small
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nociceptive neurons, unlike GAL-R1, and hence may have a more prominent role 
than GAL-R1 in mediating galanin’s effects on nociceptive thresholds..
Alongside these physiological roles, galanin has also been shown to act as a survival 
factor for a population of developing sensory neurons. Adult galanin null mutant 
mice contain 13% less DRG neurons than wild type mice due to increased cell death 
neonatally. Analysis of neuronal properties determined that the neurons lost were 
those specifically <200microns in diameter (Holmes et al., 2000). This would 
suggest that galanin expression is important for the development of a specific 
subpopulation of small primary sensory neurons within the DRG. A further trophic 
role for galanin is suggested in the adult, since mice with a null mutation in the 
galanin gene showed a reduced rate of regeneration following nerve injury (Holmes 
et al., 2000). Additionally, a 30% reduction in neurite outgrowth was observed in 
cultures of adult DRG from these mice. (Holmes et al., 2000; reviewed in Holmes et 
al., 2005 and Wynick et al., 2001). This apparent neurotrophic effect of galanin will 
need to be considered when interpreting the effects of other neurotrophic factors on 
modulating galanin expression
Regulation of galanin mRNA expression by neurotrophic factors
Although some studies of the regulation of galanin mRNA expression by 
neurotrophic factors has been undertaken in the adult, little is known about the roles 
of neurotrophic factors in regulating galanin expression in developing sensory 
neurons. The role of NGF in strongly up-regulating galanin mRNA is suggested by 
several observations. NGF up-regulates galanin mRNA in cultured DRG (Kerekes et 
al., 1997; Ozturk and Tonge, 2001). Injection of anti-NGF antibody into mice 
produced an increase in galanin mRNA that mimicked the effects seen in axotomy 
(Shadiack et al., 2001). Infusion of NGF following nerve damage produced a 
decrease in galanin immunoreactivity (Verge et al., 1995). Interestingly, no effect of 
exogenous NGF on galanin mRNA or protein levels is observed in intact neurons 
(Verge et al., 1995), suggesting an inhibitory role for NGF on galanin expression in- 
vivo only following nerve damage.
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Aside from NGF, other neurotrophic factors have also been shown to regulate 
galanin expression. BDNF treatment decreases galanin mRNA levels in cultured 
adult DRG (Kerekes et al., 1997). Additionally, following nerve injury, GDNF given 
intrathecally was found to inhibit several of the nerve injury-related alterations in 
gene expression, including the up-regulation of galanin in large diameter neurons 
(Wang et al., 2003).
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3.2. Material and Methods
3.2.1. Transgenic mice
3.2.1.1. Bax double knockout mice
To produce the data in this chapter, several different transgenic mouse strains were 
used to study the effects of growth factors and their receptors on gene expression in- 
vivo.
Since neurons that are dependent on NGF for embryonic survival undergo extensive 
cell death in TrkA'7' and NGF'7‘ fetuses (Crowley et al 1994, Smeyne et al, 1994), it 
was necessary to produce double-transgenic mice that were homozygous for a null 
mutation in the gene encoding the pro-apoptotic protein BAX in order to study the 
in-vivo regulation of gene expression by NGF/TrkA signalling.. Both NGF'7TBax'7' 
and TrkA'7TBax'7' have been generated previously (Patel et al., 2000). In both double 
mutants the large decrease in cell death seen in TrkA or NGF knockout mice does 
not occur. In fact in DRG of TrkA+/+/Bax'7' mice at P0, neuron counts are actually 
higher than those in DRG of TrkA+7+/Bax+7+, most likely attributable to the 
elimination of naturally occurring cell death (Patel et al., 2000). Furthermore similar 
increases in neuronal number are found in DRG of TrkA'7TBax'7'mice at P0 in 
comparison to DRG of TrkA+7+/Bax+7+ indicating that the absence of Bax allows the 
rescue/survival of all neurons requiring NGF/TrkA signalling during embryonic life 
(Patel et al., 2000). The sensory neurons that survive in these double knockout mice 
are small and atrophic (Patel et al., 2000), however such “rescued” neurons have 
been shown to express peripherin and the neuropeptides CGRP and SP. DRG 
neurons of NGF'77Bax*7' mice have also have been shown to express TrkA. These 
findings suggest that an in-vivo deficiency of Bax permits the survival of peptidergic 
neurons in the absence of NGF/TrkA signalling (Patel et al., 2000).
218
In this chapter TrkA'7'/Bax'7' mice were used to explore the regulation of gene 
expression by NGF/TrkA signalling. It would have also been informative to use 
NGF‘7'/Bax'7' mice, however time constraints hindered this investigation.
TrkA'7/Bax'7' mice were generated by breeding TrkA+/7Bax+/\  The pups produced 
were therefore one of nine possible genotypes:
TrkA'7TBax'7\
TrkA'7TBax+7',
TrkA'7TBax+7+,
TrkA+/7Bax’7',
TrkA+/7Bax+/',
TrkA+/7Bax+/+,
TrkA+/+/Bax+7',
TrkA+7+/Bax'7‘,
TrkA+7+/Bax+7+
On the day of birth, the whole litter of mice were killed by decapitation just above 
the neck. Tail tips were kept for genotyping and each pup was individually dissected 
to remove trigeminal ganglia, nodose ganglia and DRG. Ganglia were stored at -  
80°C until genotyping was complete.
Following genotyping ganglia from mice that contained null mutations in both genes 
(TrkA'77Bax‘7') were kept alongside ganglia from wild-type litter mates 
(TrkA+7+/Bax+7+) for further investigation. In addition, as a control, to ensure that the 
deletion of functional Bax did not have profound effects on sensory neuron gene 
expression, sensory ganglia were also collected from Bax single knockout mice 
(TrkA+/+/Bax'7'). All other ganglia were discarded.
NT-3 null mutant mice also have a severe phenotype, displaying pronounced limb 
movement defects, due to loss of sensory and sympathetic neurons, and perinatal 
mortality (Emfors et al., 1994). In order to study the effects of NT-3 in regulating
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gene expression in sensory neurons in vivo, NT-3 7Bax'A mice were therefore 
generated. In these double null mutant mice, NT-3 dependent neurons can now 
survive, and express the proprioceptive marker paravalbumin, suggesting these 
“rescued” neurons display characteristics of proprioceptive neurons from normal 
wild-type mice (Patel et al., 2003).
NT-S^VBax7' mice were generated by breeding NT-3+/7Bax+/' with NT-3+/7Bax+/'. 
Each pup from these parents will therefore be one of nine possible genotypes: 
NT-3~/7Bax‘/',
NT-3'/7Bax+/',
NT-3'/7Bax+/+,
NT-3+/7Bax"\
NT-3+/7Bax+/',
NT-3+/7Bax+/+,
NT-3+/+/Bax+/',
NT-3+/+/Bax'/_,
NT-3+/+/Bax+/+
On the day of birth, the whole litter of mice were killed by decapitation just above 
the neck. Tail tips were kept for genotyping and each pup was individually dissected 
to remove trigeminal ganglia, nodose ganglia and DRG. Ganglia were stored at -  
80°C until genotyping was complete.
Following genotyping, ganglia from mice that contained null mutations in both genes 
(N T ^'/B ax7') were kept alongside ganglia from their wild-type litter mates (NT- 
3+/+/Bax+/+). In addition, as a control, to ensure that the deletion of functional Bax did 
not have profound effects on sensory neuron gene expression, sensory ganglia were 
also collected from Bax single knockout mice (NT-3+/+/Bax7*).
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3.2.1.2. Dissections
Trigeminal ganglia
At PO, this dissection is very similar to that of the late embryonic mouse (see 2.2.1). 
Serrated scissors are used to cut off the top of the skull in a plane just above the eyes 
and whisker pads. The brain was gently removed to reveal the two trigeminal ganglia 
lying at the base of the skull, sitting in two niches either side of the mid-bone (as 
seen previously in figure 2.2). The ganglia were removed with forceps and adherent 
connective tissue removed with tungsten needles.
Nodose ganglia
The two murine nodose ganglia, also known as the inferior vagal ganglia, are situated 
just below the base of the skull, close to the jugular foramen. The top of the skull and 
underlying brain were removed and the head bisected along the sagittal plane. The 
hindbrain was removed from each half of the head, and the slit-like jugular foramen 
was now visible. By opening up the mouth of the foramen, the nodose ganglion was 
revealed lying just above the superior cervical ganglia (SCG). The SCG is composed 
of sympathetic neurons and is distinct from the nodose ganglion by its oval, 
elongated structure and its attachment to the thin sympathetic chain. The nodose 
ganglion is a clearly defined spherical structure, which has the prominent vagus 
nerve projecting from its distal aspect. The nodose ganglion was removed from each 
side of the head using forceps to gently tease it from surrounding tissue, and once 
again ‘cleaned’ of any adherent connective tissue using tungsten needles (figure 3.2)
DRG
For the DRG, the dissection was very similar to that described in section 2.2.1. First, 
skin was cut away from the back of the mouse, and a portion of the lumbar spinal 
column was removed using serrated scissors. As with the embryo, small scissors 
were used to cut the length of this section of spinal column along the ventral aspect
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Figure 3.2: Dissection o f  the nodose ganglia
The medial aspect o f half o f the head of an E14 muse embryo. A: An incision is made from the jugular 
foramen (J) to the midline (dotted line) and the occipital bone is reflected in the direction of the arrow. B: 
The jugular foramen is now open to reveal the nodose (N) and superior cervical ganglion (s) just beneath. 
(T - tongue, ACF - anterior cranial fossa, IE - inner ear, R - root of the trigeminal nerv).
Taken from Davies, 1995.
3.2.2. Genotyping
Genotyping was performed in a similar manner to that outlined in section 2.2. DNA 
was extracted and the presence or absence of the knockout allele identified by PCR.
DNA Extraction
Genomic DNA was extracted from tails of all mice using the Nucleospin DNA 
extraction kit following the manufacturers protocol as detailed in section 2.2.
PCR
PCR reactions were carried out to determine the genotype of each mouse dissected. 
Details of primer sequences and PCR reactions are outlined below
A master mix solution containing all reagents was made up for each reaction, 19pl 
(or 15 pi for Bax) of which was added to lpl (or 5 pi for Bax) of genomic DNA. 
Mastermix recipes are shown below:
TRKA NT-3 BAX
lOx hot taq buffer 2pl 2pl 2pl
5mM dNTPs lpl lpl lpl
WT primers (lOpmol/pl) 0.2pl 0.4pl 0.45pl
KO Primers (lOpmol/pl) 0.2pl 0.4pl 0.3pl
Common Primer (lOpmol/pl) 0.23pl 0.4pl 0.525pl
Hot Start Taq (GeneSys Ltd.) 0.2pl 0.15pl 0.2pl
25mM MgCl2 lpl 0.4pl 2pl
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Mr solution - 3.8 pi 3.8pl
dH20 14.17pl 10.45 pi 4.725pl
DNA lpl lpl 5 pi
Table 3.1. Mastermix reagents for genotyping reactions
Primer sequences are outlined below:
TrkA:
P095-4 : 5’-CGG ACC TCA GTG TTG GAG AGC TGG-3’
P096-0: 5’-GAC CCT GCA CTG TCG AGT TTG C-3’
P097-0: 5’-GCT CCC GAT TCG CAG CGC ATC G-3’
Bax:
IN5R 5 ’-TTG ACC AGA GTG GCG TAG-3 ’
EX5F 5’-GCT GAT CAG AAC CAT CAT G-3 ’
NeoR 5 ’-GCT TCC ATT GCT CAG CG-3 ’
NT-3:
N3 (wild-type) 5’-CCT GGC TTC TTT ACA TCT CG-3’
N4 (mutant) 5’-TGG AGG ATT ATG TGG GCA AC-3’
PI (common) 5’-GGG AAC TTC CTG ACT AGG GG-3’
Two drops of mineral oil were layered on top of each PCR mix to prevent 
evaporation of reagents during thermocycling.
Initially samples were heated to 95°C for 15 minutes to activate taq. This was 
followed by a series of heating and cooling steps to allow denaturation of secondary 
structure, annealing of primers and elongation of product. Finally samples were 
heated to 72°C for lOmins for final extension. The length and temperature of these 
steps are specific to each reaction and are repeated in a cycling fashion to build up 
the PCR product. The details of each reaction are outlined in table 3.2.
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TRKA NT-3 BAX
Denaturation 95°C 15mins 95°C 15mins 95°C 15mins
Denaturation 95°C 40s 95°C 40s 95°C 40s
Annealing 65°C lmin 10s 65°C lmin 10s 50°C lmin 20s
Elongation 72°C lmin 40s 72°C lmin 40s 72°C 2min 20s
No. of cycles 38 40 38
Final Extension 72°C lOmin 72°C lOmin 72°C lOmin
Hold 4°C 4°C 4°C
Table 3.2. Reaction conditions for genotyping PCRs
Products were run on agarose gel cast with 1 X TAE and containing ethidium 
bromide (lpg/ml) (Sigma). PCR product DNA bands were then visualised using a 
UV gel documentation system (Biogene). An example gel for Bax genotyping is 
shown in Figure 3.3.
TRKA NT-3 BAX
Wt band size 400 250 307
KO band size 800 350 507
Table 3.3. Band sizes for genotyping gels
Bax genotyping
^  mm mm m i 4Mi m  mm mm mm ^  MB
mm mm mm mm m i #** E l  mm mmm m P
/>
1 2 3 4 5 6 7 8 9 10 11 12
Figure 3.3: Genotyping gel showing the three possible Bax genotypes.
Lanes 1,2,5 and 6 show the knock-out DNA, lanes 3,4,9,10,11 and 12 show products from 
heterozygote DNA and lanes 7 and 8 show products from the wild-type DNA.
For the TrkA/Bax and NT-3/Bax mice, double-knockout pups needed to have both 
copies of both genes knocked out, only a 1 in 16 chance. Similarly, double
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homozygous wild-type mice only occurred with a frequency of 1 in 16. Therefore, 
many litters of mice had to be dissected in order to obtain enough ganglia of each 
genotype to allow sufficient replicates for RT-QPCR. Following genotyping, ganglia 
from double knockouts, wild type and single Bax knockouts, were identified and 
RNA was extracted, as described later in this chapter. At least 4 replicates were 
collected for each ganglia for each of the desired genotypes.
Time-course
To study the expression of all genes of interest over a period of time in wild-type 
mice, ganglia were also dissected from E l6, PO, P5 and P60 mice. Six replicates of 
each ganglia at each age were collected. RNA was extracted and used to produce a 
time-course of mRNA expression for all genes.
3.2.3. Neuronal cultures
To confirm that changes in mRNA expression observed in knockout neonates were 
due to the absence of neurotrophic factors or receptors and not cell death, neuronal 
cultures of nodose and trigeminal ganglia neurons were set up to study the effects of 
the neurotrophic factors, NT-3, NGF and artemin on gene expression in primary 
sensory neurons in-vitro. DRG cultures were not set up since trigeminal neurons are 
functionally and biochemically similar to DRG neurons at neonatal ages and in vivo 
results showed gene expression to be similarly regulated in these two ganglia. At 
these early postnatal stages, wild-type sensory neurons do not survive in culture 
without the addition of neurotrophic factors (NGF for trigeminal neurons and BDNF 
for nodose neurons). For this reason, caspase inhibitors were used to prevent the 
normal apoptosis that would occur in the absence of trophic support, thus allowing a 
true no neurotrophic factors control to be set up.
Overnight matings of CD-I mice were set up. Pups were collected on the day of birth 
(PO) and killed by decapitation. All dissections and subsequent preparations were
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carried out in a laminar flow hood using standard sterile techniques. Dissections of 
trigeminal and nodose ganglia were performed (as described earlier in this chapter,
3.2.1.1) under stereomicroscope with fibre-optic light source to illuminate specimens 
but prevent overheating of tissue. Dissections were carried out in sterile plastic 
60mm petri dishes (Greiner) in Liebowitz (L-15, Invitrogen) medium, pH 7.3, 
(supplemented with streptomycin (100mg/l) and penicillin (60mg/l)), that had been 
filtered and pre-heated to 37°C. All dissection tools were sterilised by flaming in 
70% ethanol prior to dissection.
Ganglia were dissected and collected in Calcium and Magnesium free Hank’s 
Balanced Salt Solution (CMF-HBSS) in 15ml falcon tubes. Approximately 30 
ganglia were used per experiment with approximately 10 ganglia per tube. Ganglia 
were incubated in 0.05% trypsin (Worthington), at 37°C for 30 minutes, to allow 
enzymatic break down of the ganglia. Ham’s F12 medium, supplemented with 10% 
heat inactivated horse serum (HIHS), was then used to wash cells twice and to arrest 
trypsin action. The ganglia were transferred into defined, serum free, FI4 medium 
(Imperial), supplemented with Albumax I and 2mM glutamine (both from 
Invitrogen). A flame-polished, sterile, siliconised glass Pasteur pipette was used to 
mechanically dissociate ganglia and to produce a single cell suspension.
High-density cultures were required in order to obtain the concentrated RNA 
required for RT-QPCR analysis of rare genes. Cells were plated at approximately 
3000 - 5000 neurons per 35mm diameter plastic tissue culture dish (Greiner). The 
dishes had been prepared in advance by coating with a substratum of poly-DL- 
omithine (0.5mg/ml in 0.15M borate buffer, pH 8.4) overnight at room temperature. 
The following day they were washed three times with sterile water and left to dry. 
Prior to culture, dishes were treated with laminin (20pg/ml in CMF-HBSS, Sigma), 
for 4 hours, at 37°C.
After 4 hours, laminin was washed from dishes using F I2 + HIHS, before adding 
lml of F14 medium supplemented with glutamine and Albumax I. It was important 
to ensure that dishes were not allowed to dry at any point during this washing step.
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lml of the dissociated cell suspension was added to each dish to give a final volume 
of 2ml. After plating the cells, the appropriate neurotrophic factors were added to 
each dish. Additionally at this point four tubes of this single cell suspension were 
collected as a ‘time 0’ sample. These four tubes of cells (lml per tube) were spun 
down, the supernatant was removed and the cell pellets were re-suspended in 350pl 
RLT lysis buffer, containing 1% p mercaptoethanol (Qiagen) to lyse the cells and 
release RNA.
Cells were grown with no factors, or in the presence of lOng/ml NGF or NT-3 (these 
concentrations had been determined previously in the Davies lab to be saturating 
concentrations for promoting survival and neurite outgrowth of PO neurons). 3 or 4 
replicates per condition were set up. Caspase Inhibitors (caspase inhibitor 1 
(Calbiochem) to a final concentration of 50pM.) were added to all dishes so that 
some cells could be grown in the absence of all neurotrophic support as a true 
control. Representative photomicrographs of cultured sensory neurons are shown in 
Figure 3.3a
Plated cells were grown in 5.5% CO2 in a humidified incubator, at 37°C, for 24 
hours (nodose and trigeminal ganglia) or 48 hours (just trigeminal ganglia), after 
which RNA was extracted from them by gently removing the culture media and 
replacing it with 350pl RLT lysis buffer supplemented with 1% p mercaptoethanol. 
Dishes were left at room temperature for 10-15 minutes, to allow cell lysis, and then 
the lysis buffer containing extracted RNA was transferred to RNase free 1.5ml tubes 
and stored at 4°C until all samples had been collected. It was only possible to extract 
RNA from nodose neurons at one time point, since the small nodose ganglia contain 
too few neurons to seed enough tissue culture dishes for two time points.
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BFigure 3.3a: Representative photomicrographs o f cultured sensory neurons.
A) Nodose neurons cultured for 4 hours. B) A single trigeminal neuron, following 72 hours growth in 
the presence of NGF. Note the considerable growth of neurites following time in culture.
Survival counts
To ensure that differential survival of neurons in the different culture conditions did 
not confound the interpretation of gene regulation data, neuronal survival was 
assessed over the culture period. Initial neuronal counts were done 3 hours after 
plating (to allow cell attachment to culture dishes), and survival after 24 hours and 48 
hours was expressed as a percentage of this 3 hour count.
N.B. Details of all tissue culture reagents, their preparation and storage are given in 
appendix II.
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3.2.4. RNA extraction
A new method of RNA extraction (RNeasy Kit, Qiagen) was chosen for QPCR as 
preliminary experiments showed that the previous RNA extraction method, used in 
chapter 2, resulted in RNA that contained inhibitors of the QPCR reaction. In 
addition, the RNeasy protocol proved to be more reliable, faster to carry out and 
avoided the use of hazardous chemicals like phenol. (Data not included).
RNA was extracted following the manufacturers protocol. In brief, cells/ganglia were 
immersed in 350pl RLT lysis buffer containing 1% P mercaptoethanol. In the case of 
whole ganglia, the ganglia in lysis buffer were passed up and down through a 25G 
needle to break them up and ensure all cells within the ganglion were exposed to the 
lysis buffer. The same volume of 70% ethanol (analytical reagent grade) was added 
and samples thoroughly mixed. Each sample was transferred to an RNeasy filter 
mini-column in a 2ml collecting tube and centrifuged, in a microfuge, at 10,000 rpm 
for 15s. The supernatant was discarded and 350pl RW wash solution was added to 
the spin columns. Following this, the columns/tubes were centrifuged again, for 15s 
at 10,000rpm, and the supernatant was discarded. Next, a DNase step was included to 
remove any contaminating genomic DNA. 80pl DNase solution (10pl DNase (273U) 
+ 70j l x 1 RDD buffer, Qiagen) was added directly to the filter membrane and tubes 
were left at room temperature for 30 minutes. Several more wash steps, using an 
ethanol based wash solution and centrifugation, were performed after DNase 
treatment to remove residual DNase and RDD buffer. After the final wash step, the 
RNA was eluted in nuclease free water. The volume in which RNA was eluted was 
determined according to the amount of starting tissue and the RNA concentration 
required for RT-QPCR. In general, RNA was eluted in lOOpl for whole ganglia and 
40pl in the case of neuronal RNA. Samples were stored at -80°C until required for 
RT-QPCR.
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3.2.5. Reverse-transcription real-time quantitative PCR
Real Time quantitative PCR (QPCR), after reverse transcription of mRNAs to 
cDNA, was used to quantify the mRNA levels of the genes of interest in total RNA 
from both neuronal cultures and from whole ganglia collected from transgenic mice. 
The MX3000P (Stratagene) was used as outlined in section 2.2.5. Stratascript reverse 
transcriptase was used for the reverse transcription reaction as previously. Details of 
reaction preparation and conditions for both RT and PCR are outlined in section 
2.2.5. For each gene, the primers were designed on ‘Beacon Designer’ computer 
software, to ensure the utmost efficiency and specificity. The annealing temperature 
for all primer pairs for genes studied in this chapter was 51°C, and 40 cycles of 
amplification was sufficient to allow accurate quantification of all reverse transcribed 
mRNAs . The optimal reaction conditions to amplify each cDNA of interest were 
determined empirically in a series of pilot experiments. This ensured the highest 
reaction efficiencies and the absence of mispriming and primer dimer artifacts. These 
optimal conditions are outlined in table 3.4.
In the experimental work that is documented in this chapter, I investigated the roles 
that the neurotrophic factors NGF and NT-3 play in regulating neonatal sensory 
neuron expression of all the mRNAs studied in chapter 2 (aCGRP, pCGRP, SP, 
Navi.8, Navi.9 and GAPDH). In addition, I investigated the regulation of three 
additional mRNAs that encode proteins/peptides that play important roles within the 
peripheral sensory nervous system, namely Pituitary Adenylate Cyclase Activating 
Peptide (PACAP), Galanin and Vanilloid Receptor 1 mRNAs. Primers and reaction 
conditions for amplifying the cDNAs of these additional mRNAs are outlined below:
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GENE PRIMER
SEQUENCES
m g c l 2
CONCENTRATION
(MM)
ANNEALING 
TEMP. (°C)
Pituitary Adenylate 
Cyclase-Activating 
Peptide (PACAP)
Forward:
5’-TGG TGT ATG 
GGA TAA TAA 
TGC-3’
Reverse:
5’-TTC CGT CCT 
GGT CGT AAG-3’
4 51
Galanin Forward:
5’-GTT ACA ACT 
GGA GGT GGA G- 
3’
Reverse:
5’-TAG GTC TTC 
TGA GGA GGT G-3’
3 51
Vanilloid Receptor 
1 (VR-1)
Forward:
5’-CAA TGT GGG 
TAT CAT CAA CG- 
3’
Reverse:
5’-GGT GCT ATG 
CCT ATC-3’
5 51
Table 3.4. Primer sequences for additional genes.
Due to the relatively low abundance of p-CGRP mRNA, some difficulty was 
encountered when assaying its cDNA by QPCR (recalcitrant primer artifacts and 
insufficient sensitivity when input total RNA concentrations were low as in the case 
of total RNA from nodose ganglia). To ameliorate these problems a Molecular 
Beacon probe was employed to assay p-CGRP mRNA expression in nodose ganglia
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from transgenic and wild type. The sequence of the beacon is shown below. It was 
labelled with the fluorophore Quasar670 at its 5’ end , which was visible on the Cy5 
channel of the MX3000 QPCR machine, and had blackhole quencher 2 at its 3’ end.
B-CGRP Beacon
5’ Quasar670 d(CGC GAT AAA TAT GAT GGT GTC TCC CAC TGG ATC 
GCG)BHQ-2 3’
Molecular Beacons probes, unlike Sybr green, emit a fluorescent signal only when 
they bind to a specific DNA sequence and do not detect primer artifacts. 
Consequently, melting curve analysis after cycling is not required to validate the 
identity of the correct PCR products. Molecular Beacon probes emit very little 
background fluorescence compared to TaqMan probes, and are not as vulnerable to 
exonuclease attack resulting in a progressive increase in background fluorescence as 
the QPCR reaction proceeds. SYBR green was not included in QPCR reactions 
containing the p-CGRP Molecular Beacon. Molecular Beacon probes were not 
routinely used for QPCR throughout the work contained in this thesis because, 
despite their advantages in terms of specificity and insensitivity to primer artefacts, 
they are very expensive and complicate the design of QPCR assays.
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3.3. Results
3.3.1. Time course of expression
Initially, the expression of a- and P-CGRP, SP, galanin, PACAP, Navi.8, Navi.9 and 
VR1 mRNAs in each of the sensory ganglia were studied over a developmental time 
course to determine how the expression of these genes changes throughout 
development and into adulthood in normal wild-type mice. Once again, as in chapter 
2 (See 2.3.1), data was statistically analysed by use of the t-test.
Trigeminal, nodose and dorsal root ganglia were dissected from E l6, PO, P5 and adult 
(approximately P60) CD-I mice and RNA was extracted using the Qiagen RNeasy kit 
(see 3.2.4.). Two ganglia were collected per replicate and six replicates were collected 
for each kind of ganglion at each time point. RNA was reverse transcribed and the 
expression of a-CGRP, P-CGRP, SP, Navi.8, Navi.9, PACAP, VR1 and galanin 
cDNAs were quantified by QPCR. The expression of GAPDH mRNA was also 
quantified in all samples and used to normalise all results to account for any 
differences in the amounts of starting RNA and differences in the efficiency of 
reverse transcription between samples.
Although they are the products of two separate genes, a-CGRP and p-CGRP mRNAs 
showed very similar patterns of developmental regulation between El 6 and P60 
(adult) in all ganglia. In trigeminal, nodose and dorsal root ganglia, both mRNAs 
showed a steady increase in expression, relative to GAPDH, from E l6 to a peak at 
P60. Both mRNAs were also most highly expressed in DRG and expressed at lowest 
levels in nodose ganglia (figure 3.4 and 3.5).
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Figure 3.4. Expression o f alpha CGRP mRNA in sensory neurons throughout development 
Trigeminal ganglia (A), nodose ganglia (B) and DRG (C) were collected from E l6, PO, P5 
and adult mice and expression of alpha CGRP mRNA was quantified via real-time QPCR. 
Error bars = +/- standard error, n = 6
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Figure 3.5. Expression o f beta CGRP mRNA in sensory neurons throughout development 
Trigeminal ganglia (A), nodose ganglia (B) and DRG (C) were collected from E l6, PO, P5 
and adult mice and expression of beta CGRP mRNA was quantified via real-time QPCR. 
Error bars = +/- standard error, n = 6
The expression level of SP mRNA was very low in all ganglia at all ages studied. 
Again, as was the case for a- and p-CGRP mRNAs, expression levels of SP mRNA 
were consistently lower in the nodose ganglion compared to the other sensory ganglia 
studied. In the trigeminal ganglion, there was little developmental change in the levels 
of SP mRNA between E l6 and adult. In contrast, there was a small, but significant, 
increase in SP mRNA levels between E l6 and P5 in DRG neurons and the level at P5 
was maintained until P60. Similarly, the amount of SP mRNA expressed by nodose 
neurons increased gradually from El 6 to P5, however, in the case of the nodose 
ganglion, the levels of SP mRNA expressed by neurons dropped between P5 and the 
adult (figure 3.6).
The sodium channels Navi.8 and Navi.9, showed similar, but not identical, 
developmental mRNA expression patterns. In trigeminal ganglia and DRG, Navi.8 
mRNA levels increased markedly between E l6 and PO, remain constant between PO 
and P5 and fall about 50% from P5 to adulthood. In the nodose ganglion, there was 
little change in the levels of expression of Navi. 8 mRNA between El 6 and P5 and, in 
marked contrast to the two other sensory ganglia studied, there was an almost 100% 
increase in the levels of Navi.8 mRNA from P5 to P60. In the case of Navi.9, 
mRNA levels in trigeminal ganglia and DRG increased from E l6 to peak at P5 and 
then, in a similar way to Navi.8 mRNA, fall around 50% between P5 and adulthood. 
The expression pattern of Navi .9 mRNA in the nodose ganglia was broadly the same 
as that in DRG and trigeminal ganglia, although the drop in expression between P5 
and adult, seen in both DRG and trigeminal ganglia, did not occur in nodose ganglia. 
The levels of Navi.9 mRNA were significantly lower in nodose neurons at all ages 
compared to the other two sensory ganglia (figure 3.7. and 3.8.).
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Figure 3.6. Expression o f SP mRNA in sensory neurons throughout development 
Trigeminal ganglia (A), nodose ganglia (B) and DRG (C) were collected from E l6, PO, 
P5 and adult mice and expression of SP mRNA was quantified via real-time Q-PCR. 
Error bars = +/- standard error, n = 6
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Figure 3.7. Expression o f Navi.8 mRNA in sensory neurons throughout development 
Trigeminal ganglia (A), nodose ganglia (B) and DRG (C) were collected from E l6, PO, P5 
and adult mice and expression of N avi.8 mRNA was quantified via real-time QPCR.
Error bars = +/- standard error, n = 6
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Figure 3.8. Expression o f Navi.9 mRNA in sensory neurons throughout development 
Trigeminal ganglia (A), nodose ganglia (B) and DRG (C) were collected from E l6, P0, P5 
and adult mice and expression of Navi.9 mRNA was quantified via real-time QPCR.
Error bars = +/- standard error, n = 6
The developmental expression pattern of galanin mRNA was different in all three 
sensory ganglia studied. In DRG a high level of galanin mRNA expression at El 6 
drops 3.7 fold between E l6 and P5, and there was a further 25% drop in expression 
between P5 and P60. In trigeminal ganglia there were lower levels of galanin mRNA 
expressed than in DRG neurons, but there was a similar, 2.9-fold drop in galanin 
mRNA levels between E l6 and P5. However, in contrast to DRG, galanin mRNA 
expression did show a 50% increase between P5 and adulthood in trigeminal ganglia. 
There is little developmental change in the expression of galanin mRNA in nodose 
ganglia (figure 3.9).
PACAP mRNA showed a similar expression pattern and similar mRNA levels in all 
three sensory ganglia. Expression increased from E l6 to P0, after which it dropped by 
around 50% to P5. Between P5 and P60 PACAP mRNA levels fell a further 25% in 
all ganglia (figure 3.10.).
The developmental expression pattern of VR1 mRNA in the nodose ganglia, contrasts 
markedly with that seen in the DRG and trigeminal ganglia. In nodose ganglia, 
expression levels were low at E l6, but increased 3-fold to P0 and a further 2-fold 
from P0 to P5. There was a marked 5-fold drop in the amount of VR1 mRNA 
expressed by nodose neurons between P5 and P60. The expression of VR1 mRNA in 
trigeminal and DRG neurons showed a similar developmental pattern, with highest 
levels being observed at E l6, a gradual decrease in VR1 mRNA levels between E l6 
and P5 and a more pronounced drop, especially in DRG neurons, between P5 and 
adult. It seems that adult trigeminal neurons express significantly lower average levels 
of VR1 mRNA than either nodose or DRG neurons (figure 3.11).
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Figure 3.9. Expression o f galanin mRNA in sensory neurons throughout development 
Trigeminal ganglia (A), nodose ganglia (B) and DRG (C) were collected from E l6, PO, P5 
and adult mice and expression of galanin mRNA was quantified via real-time QPCR.
Error bars = +/- standard error, n -  6
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Figure 3.10. Expression o f PACAP mRNA in sensory neurons throughout development 
Trigeminal ganglia (A), nodose ganglia (B) and DRG (C) were collected from E l6, PO, P5 and 
adult mice and expression of PACAP mRNA was quantified via real-time QPCR.
Error bars = +/- standard error, n = 6
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Figure 3.11. Expression o f VR1 mRNA in sensory neurons throughout development 
Trigeminal ganglia (A), nodose ganglia (B) and DRG (C) were collected from E l6, PO, 
P5 and adult mice and expression of VR1 mRNA was quantified via real-time QPCR. 
Error bars = +/- standard error, n = 6
All mRNA levels were normalised against GAPDH mRNA to account for any 
differences in the starting concentration of total RNA (due to the varying size of the 
different ganglia and inconsistencies in the efficiency of RNA extraction and 
purification) and variations in the efficiency of reverse transcription between different 
samples. The expression level of GAPDH mRNA/ganglion in each type of ganglion 
at each of the ages studied is shown in figure 3.12.
All three types of ganglion showed a similar developmental pattern of GAPDH 
mRNA expression, with a 50-75% drop in GAPDH levels between E l6 and PO, a 7- 
to 8-fold increase between PO and P5 and a 3- to 4-fold drop in GAPDH mRNA 
expression between P5 and the adult. The relative levels of GAPDH mRNA expressed 
by the three ganglion types at each age reflects the difference in the size of the ganglia 
in terms of neuronal numbers, with the largest ganglion being the trigeminal ganglion 
and the smallest being the nodose ganglion.
In summary, the expression patterns of mRNA from all these predominantly sensory 
neuron specific genes, varied considerably. Some showed highest levels of expression 
in the adult, whilst others peaked at younger ages. The expression pattern of each 
mRNA is probably indicative of the discrete roles of each of these genes in sensory 
neuron development and function. Moreover, differences in the expression of 
individual mRNAs between the individual ganglia types may reflect differences in the 
number of sensory neurons subserving each sensory modality in different ganglia. 
These points are discussed more fully in the conclusion to this chapter.
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Figure 3.12. Expression o f GAPDH mRNA pePganglion in sensory neurons throughout 
development
Trigeminal ganglia (A), nodose ganglia (B) and DRG (C) were collected from E l6, P0, P5 and 
adult mice and expression of GAPDH mRNA was quantified via real-time QPCR and 
expression per ganglion calculated.
Error bars = +/- standard error, n = 6
3.3.2. Sensory neurons from Bax''* mice are phenotypically 
similar, but not identical, to those from Bax+/+ mice
Mice with double null mutations in either the TrkA or NT-3 locus, together with the 
Bax locus, were used in this chapter to obtain data reflecting the roles of NGF and 
NT-3 in regulating a number of sensory neuron mRNAs. As described above, by 
knocking out the gene encoding the proapototic protein Bax, the apoptotic cell death 
that normally occurs in the single TrkA or NT-3 null mutants is prevented and sensory 
neurons that are normally lost in the single null mutants survive. To ensure these 
surviving neurons are phenotypically similar to neurons from wild-type animals, and 
the relative ratios between phenotypically distinct sub-population of neurons are 
maintained, the expression levels of each of the mRNAs investigated in this chapter 
were assayed in ganglia from Bax"7' and wild-type mice
Trigeminal ganglia, nodose ganglia and DRG were dissected from PO Bax'7' mice and 
their wild-type littermates. RNA was extracted, reverse transcribed and the expression 
levels of each of the mRNAs to be examined in the double null mutants was 
quantified using QPCR. Figure 3.13 shows the expression of a-CGRP mRNAs in 
trigeminal, nodose and dorsal root ganglia from Bax'7' and wild-type mice. a-CGRP 
mRNA was detected at a similar level in trigeminal ganglia, however in nodose and 
dorsal root ganglia expression was significantly reduced in Bax'7' mice. Expression of 
the Sodium channels Navi.8 and Navl.9 mRNAs are shown in figure 3.14. Navi.8 
mRNA was expressed at similar levels in Bax'7' and Bax+/+ in all ganglia, however 
Navl.9 mRNA expression was significantly reduced in the DRG of Bax'7* mice, 
whilst levels were unaffected in the trigeminal and nodose ganglia.
Figure 3.15 shows the expression of galanin (A) and PACAP (B) mRNAs in Bax'7' 
and wild-type ganglia. For each mRNA, expression levels were, on the whole, 
comparable between Bax+/+ and Bax'7' mice in each of the ganglia. However, in DRG 
of Bax'7' mice, galanin mRNA expression was reduced by approximately 30%.
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Figure 3.13. Expression o f alpha CGRP mRNA in sensory neurons o f Bax single knockout 
mice at PO
Trigeminal ganglia, nodose ganglia and DRG were dissected from PO Bax*7' mice-and wild- 
type litter mates and expression of alpha CGRP mRNA was quantified using real-time 
QPCR. Expression was similar in trigeminal ganglia of both wild-type and Bax*7* mice, 
however in the nodose and dorsal root ganglia mRNA was significantly lower in the double 
knockout.
Error bars = +/- standard error, n = 6. * = p = <0.05, ** = p = <0.01 as determined by two 
tailed unpaired t-test.
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Figure 3.14. Expression o f Navi.8 and Navl.9 mRNAs in sensory neurons o f Bax 
single knockout mice at PO
Trigeminal ganglia, nodose ganglia and DRG were dissected from PO B ax'' mice-and 
wild-type litter mates and expression o f N avi.8 (A) and Navl.9 (B) mRNAs were 
quantified using real-time QPCR. For the majority, expression was similar in both 
wild-type and Bax'7' mice, however in the DRG, expression of Navl.9 mRNA was 
significantly lower in Bax_/‘ mice.
Error bars = +/- standard error, n = 6. * = p = <0.05, ** = p = <0.01 as determined by 
two tailed unpaired t-test.
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Figure 3.15. Expression o f galanin and PACAP mRNAs in sensory neurons o f Bax single knockout 
mice at PO
Trigeminal ganglia, nodose ganglia and DRG were dissected from PO Bax'^mice and wild-type litter 
mates and expression of galanin (A) and PACAP (B) mRNAs were quantified using real-time 
QPCR.
Expression is similar in both wild-type and Bax /' in most cases, although in the DRG of Bax' " mice 
expression of galanin mRNA was significantly lower.
Error bars = +/- standard error, n = 6. * = p = <0.05, ** = p = <0.01 as determined by two tailed 
unpaired t-test.
VR1 mRNA was unaffected in trigeminal and dorsal root ganglia of Bax7', however 
in the placode derived nodose ganglia, expression is reduced to approximately 50% of 
that observed in Bax+/+ (figure 3.16).
Finally the expression of GAPDH mRNA was quantified in Bax7' and wild-type 
ganglia, as shown in figure 3.17. Levels of GAPDH mRNA were similar in Bax7' 
mice and Bax+/+ mice in all ganglia, suggesting that little or no cell death occurred in 
the knockout mouse. Because of the reduction of cell death in Bax7* mice, an increase 
in GAPDH mRNA in these mice might be expected. The lack of an apparent increase 
will be discussed below in the concluding section of this chapter
Although, on the whole, levels of mRNA expression were similar for the genes 
studied in Bax7"and wild-type ganglia, significant differences in mRNA expression 
levels between the two genotypes do occur in some ganglia for some genes.
For this reason, ganglia from Bax7' mice and not true wild-type mice were used as a 
control when investigating the effects of neurotrophins on gene regulation using 
double-null mutant mice.
No data was collected for SP and p-CGRP. There was difficulty in detecting these 
two genes in these initial experiments, due to the low levels of expression in these 
ganglia, however due to costand time limitations it was decided that sufficient data 
had been obtained to conclude that further experiments should go ahead using Bax 
single knockout litter-mates mice as a control comparison rather than wild-type mice.
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Figure 3.16. Expression ofVRl mRNA in sensory neurons o f Bax single knockout mice at PO
Trigeminal ganglia, nodose ganglia and DRG were dissected from PO B ax7'mice and wild-type litter 
mates and expression of VRlmRNA was quantified using real-time QPCR.
Expression is similar in both wild-type and Bax'7' in trigeminal and dorsal root ganglia, although in 
the nodose of Bax'7' mice expression of VR1 mRNA is significantly lower in comparison to Bax+/+.
Error bars = +/- standard error, n = 6. * = p = <0.05, ** = p = <0.01 as determined by two tailed 
unpaired t-test.
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Figure 3.17. Expression o f gapdh mRNA in Trigeminal, DRG and nodose o f Bax single knockout 
mice at PO
Trigeminal ganglia, nodose ganglia and DRG were dissected from PO Bax ' and wild-type litter 
mates and expression of gapdh mRNA was quantified using real-time QPCR. No significant 
difference between wild-type and Bax_/ mice is obvious.
Error bars = +/- standard error, n = 6. * = p = <0.05, ** = p = <0.01 as determined by two tailed 
unpaired t-test.
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3.3.3. The use of TrkA' /^Bax"7' null mutant mice to study the 
role of TrkA signalling in gene expression in early postnatal 
sensory neurons.
Real time-QPCR was used to quantify the expression levels of a- and p-CGRP, SP, 
Galanin, PACAP, Navi.8, Navl.9 and VR1 mRNAs in trigeminal, nodose and dorsal 
root ganglia that had been dissected from PO TrkA'7TBax'7' and Bax'7' mice using RT- 
QPCR. The expression of both isoforms of CGRP was determined in PO TrkA'7TBax'7 
and Bax'7' mice (figure 3.18). By PO, the data clearly shows that the normal levels of 
expression of both a- and p-CGRP mRNA are reliant upon TrkA signalling (and 
presumably NGF induced TrkA signalling), as a significant reduction in the 
expression of both mRNAs was observed in trigeminal ganglia and DRG of TrkA'7' 
/Bax*7' neonates compared to Bax*7' neonates (figure 3.18). Nodose ganglia also 
showed a significant reduction in a-CGRP mRNA expression in the double null 
mutant compared to the single Bax knockout. p-CGRP mRNA levels were also 
reduced in nodose ganglia of TrkA'7TBax'7' mice compared to the single Bax null 
mutant, although this drop was not quite statistically significant. The reduction of p- 
CGRP mRNA levels, as a result of the loss of TrkA signalling, is less dramatic than 
the reduction in aCGRP mRNA levels in all three sensory ganglia.
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Figure 3.18. Expression o f  alpha CGRP and beta CGRP mRNAs in sensory neurons o f PO TrkA^ 
/Bax'/~mice
Trigeminal ganglia, nodose ganglia and DRG were dissected from PO Bax^/TrkA^ and also Bax'- 
mice, and expression o f alpha CGRP (A) and beta CGRP(B) mRNAs were quantified by real-time 
QPCR.
Expression o f both alpha and beta CGRP mRNA were significantly reduced in sensory ganglia of the 
TrkA-/*/Bax'/‘ mice.
N.B. where wt actually represents data from Bax single knockout mice.
Error bars +/- standard error, n = 6 -  8 .*  = p = <0.05, ** = p = <0.0 las determined by two-tailed 
unpaired t-test.
Figure 3.19 shows the expression of Navi. 8 and Navl.9 mRNAs in PO sensory 
ganglia from both genotypes. In accordance with the embryonic data presented in 
chapter 2, the normal levels of expression of both mRNAs was dependent upon TrkA 
signalling as illustrated by the significant reduction in mRNA levels observed in both 
trigeminal ganglia and DRG of TrkA77Bax7' neonates compared to Bax7' neonates 
(figure 3.19.). Interestingly, although nodose ganglia contain a sub-population of NGF 
responsive neurons, no difference in the levels of sodium channel mRNAs was 
apparent between nodose ganglia from the two genotypes. This would suggest that 
either the expression of both these mRNAs is not confined to the subset of TrkA 
expressing, NGF responsive, nodose neurons, or, if it is, the expression of TTX 
resistant sodium channels is regulated in a different manner in these neurons 
compared to TrkA expressing neurons within the trigeminal and dorsal root ganglia.
Like a-CGRP mRNA, the expression of SP mRNA appears to be dependent upon 
TrkA signalling in trigeminal, nodose and dorsal root ganglia during the neonatal 
period (figure 3.20A). This is not unexpected, since both mRNAs are co-expressed 
predominantly in the same sub-population of NGF responsive sensory neurons during 
postnatal development and both have previously been shown to be regulated in a 
similar manner in the adult(Lundberg et al., 1985; Lee et al., 1985; Skofitsch et al., 
1985)
The data presented in figure 3.20 B suggests that TrkA signalling does not regulate 
the expression of PACAP mRNA in neonatal trigeminal, nodose, or dorsal root 
ganglia, with levels of PACAP mRNA being comparable in TrkA7TBax7' neonates 
and Bax7' neonates. This is in marked contrast to the positive effect that NGF has on 
PACAP mRNA expression in adult rat nociceptive neurons (Jongsma Wallin et al., 
2001,2003).
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Figure 3.19. Expression o f Navi.8 and Navl.9 mRNAs in sensory neurons ofPO TrkA'1'/Bax1' 
mice
Trigeminal ganglia, nodose ganglia and DRG were dissected from PO Bax^/TrkA7' and also Bax' 
A mice, and expression of N avi.8 (A) and Navl.9 (B) mRNAs quantified by real-time QPCR. 
Expression of both N avi.8 and Navl.9 mRNA was dramatically down-regulated in trigeminal 
ganglia and DRG of the TrkA'7/Bax~7‘ mice. No alteration o f expression was observed in the 
nodose ganglia.
N.B. where wt actually represents data from Bax single knockout mice.
Error bars +/- standard error, n = 6 - 8 .  * = p  = <0.05, ** = p = <0.01as determined by two-tailed 
unpaired t-test
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Figure 3.20 Expression ofSP and PACAP mRNA in sensory neurons o f TrkA'/VBax'/'mice
Trigeminal ganglia, nodose ganglia and DRG were dissected from P0 TrkA^YBax- ' and Bax~/_ 
mice, and expression of SP (A) and PACAP (B) mRNAs were quantified by real time QPCR.
N.B. Where wt actually represents data from Bax single knockout mice.
Error bars +/- standard error, n = 6 - 8 .  * = p = <0.05, ** = p = <0.01 as determined by two- 
tailed unpaired t-test.
The expression levels of galanin and VR1 mRNAs in PO sensory ganglia from the two 
genotypes was also explored (figure 3.21). Galanin mRNA expression levels were the 
same in the trigeminal and nodose ganglia of double null neonatal mice as they were 
in Bax'7' neonates (figure 3.21 A). However, a small but significant decrease in galanin 
mRNA expression levels was observed in the DRG of double mutant neonates 
compared to the DRG of single Bax mutant neonates.
No significant differences in VR1 mRNA expression levels were apparent between 
TrkA'7'/Bax'7' and Bax'7' neonates in both trigeminal ganglia and DRG (figure 3.2IB). 
Conversely, the expression of VR1 mRNA was markedly higher in nodose ganglia 
from TrkA'7TBax'7'PO pups compared to nodose ganglia from Bax'7' pups (figure 
3.21B).
To compensate for cell death that may occur in the absence of functional TrkA 
signalling and to allow for variations in RNA extraction and reverse transcription 
efficiency between samples, mRNA levels were normalised against expression of 
GAPDH mRNA (shown in figure 3.22). No significant difference was observed 
between the different genotypes in the levels of GAPDH mRNA expressed in PO 
trigeminal and nodose ganglia. In contrast, the expression of GAPDH mRNA in DRG 
was significantly lower in double-knockout neonates compared to Bax'7' neonates.
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Figure 3.21. Expression o f galanin and VR1 mRNA in sensory neurons ofTrkA/VBax'/'mice
Trigeminal ganglia, nodose ganglia and DRG were dissected from PO TrkA^ /Bax 7' and B ax/_ mice, 
and expression of galanin (A) and VR1 (B) mRNAs were quantified by real time QPCR.
Expression of galanin mRNA was significantly decreased in DRG of TrkA'^/Bax7' mice, it is however 
still expressed at a relatively high level in the null mutant. No difference was observed in expression 
in trigeminal or nodose ganglia. Expression of VR1 mRNA was upregulated in nodose ganglia of 
TrkA'^/Bax*7' mice, no difference in mRNA expression was observed in trigeminal ganglia or DRG.
N.B. Where wt actually represents data from Bax single knockout.
Error bars +/- standard error, n = 6 - 8. * = p = <0.05, ** = p = <0.01 as determined by two-tailed 
unpaired t-test.
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Figure 3.22. Expression o f gapdh mRNA in sensory neurons o f TrkA'^/Bax^'mice
Trigeminal ganglia, nodose ganglia and DRG were dissected from TrkA_/'/B ax/_ and Bax A mice and 
expression of Gapdh mRNA was quantified by real time QPCR.
Expression of gapdh was significantly less in DRG of TrkA'^/Bax7' than single Bax 7' mice, but no 
difference is observed in trigeminal or nodose ganglia. The decreased level o f gapdh mRNA, suggests 
cell death in the DRG of double knockout mice.
N.B. Where wt actually represents data from Bax single knockout mice.
Error bars +/- standard error, n = 6 - 8 .  * = p = <0.05 ** = p = <0.01 as determined by two-tailed 
unpaired t-test.
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3.3.4. The use of NT^'/Bax'7' null mutant mice to study the 
role of NT-3 in gene expression in early postnatal sensory 
neurons
The expression levels of GAPDH mRNA in the three sensory ganglia from NT-3'7' 
/Bax’7’ mice and Bax'7' mice are shown in figure 3.23. There was markedly less 
GAPDH mRNA expressed by trigeminal ganglia and DRG dissected from double 
knockout neonates compared to those from Bax'7' neonates, although this difference 
only reaches statistical significance in the case of trigeminal ganglia. No difference 
was seen in the amount of GAPDH mRNA expressed by nodose ganglia from the two 
different genotypes
The levels of a-CGRP, P-CGRP (figure 3.24), Navi.8, Navl.9 (figure 3.25) and SP 
(figure 3.26A) mRNAs were similar in trigeminal, nodose and dorsal root ganglia of 
NT-3'7'/Bax'7' and Bax'7' neonates, suggesting that the expression of these mRNAs is 
not regulated by NT-3 at PO.
Although PACAP mRNA (figure 3.26B) levels were similar in nodose ganglia from 
single and double transgenic PO pups, there was a marked increase in the expression 
of PACAP mRNA in trigeminal and dorsal root ganglia in the absence of NT-3. In the 
case of DRG, this increase did not quite reach statistical significance (p = 0.061). 
Similarly, the expression levels of VR1 mRNA were also greater in both DRG and 
trigeminal ganglia dissected from the double knockout neonatal mice compared to 
those from Bax'7' neonates (figure 3.27A). There was no difference in the expression 
of VR1 mRNA between the nodose ganglia of the two genotypes.
In the case of galanin mRNA, significantly higher levels of expression were found in 
trigeminal ganglia from NT-3'7'/Bax*7' neonatal mice than trigeminal ganglia from 
Bax'7' neonates (figure 3.27B). In contrast, there was no significant difference 
between the two mouse strains in the expression of galanin mRNA in DRG and 
nodose ganglia (figure 3.27B).
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Figure 3.23. Expression o f GAPDH mRNA in sensory neurons o f NT-3'1'/Baxr'mice
Trigeminal ganglia, nodose ganglia and DRG were dissected from PO N T ^'/B ax"" and Bax'7" 
mice and expression of gapdh mRNA quantified by real time PCR.
N.B. Where wt actually represents data from bax single knockout mice.
Error bars = +/- standard error, n = 5 - 8 .  * = p < 0.05, ** = p < 0.01
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Figure 3.24. Expression o f alpha CGRP and beta CGRP mRNAs in sensory neurons o f 
NT-3'/'/Bax'/ mice
Trigeminal ganglia, nodose ganglia and DRG were dissected from PO NT-3'/'/Bax"/' 
and Bax'7 mice and expression of alpha CGRP (A) and beta CGRP (B) mRNAs were 
quantified by real time QPCR.
N.B. Where wt actually represents data from bax single knockout mice.
Error bars +/- standard error, n = 5 - 8. * = p = <0.05, ** = p = <0.01 as determined by 
two-tailed unpaired t-test.
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Figure 3.25. Expression o f Navi. 8 and Navl.9 in sensory neurons o f NT-3'1'/Bax1'mice
Trigeminal ganglia, nodose ganglia and DRG were dissected from P0 NT-3' VBax ' 
and Bax'/_ mice and expression of alpha N avi.8 (A) and Navl.9 (B) mRNAs quantified 
by real time QPCR.
N.B. Where wt actually represents data from bax single knockout mice.
Error bars +/- standard error, n = 5 - 8 .*  = p = <0.05, ** = p= < 0.01 as determined by
two-tailed unpaired t-test.
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Figure 3.26. Expression ofSP and PACAP mRNAs in sensory neurons o f NT-3~/~/Bax~/’mice
Trigeminal ganglia, nodose ganglia and DRG were dissected from P0 NT-3'/"/Bax-/- and 
Bax'y' mice and expression of SP (A) and PACAP (B) mRNAs were quantified by real time 
QPCR.
N.B. Where wt actually represents data from bax single knockout mice.
Error bars +/- standard error, n = 5-8. * = p = <0.05, ** = p = < 0.01 as determined by two- 
tailed unpaired t-test.
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Figure 3.27. Expression ofVRl and galanin mRNAs in sensory neurons o f NT-3'^/Bax^'mice
Trigeminal ganglia, nodose ganglia and DRG were dissected from PO NT-3'/*/Bax'/‘ and Bax /_ 
mice and expression o f VR1 (A) and galanin (B) mRNAs were quantified by real time QPCR.
N.B. Where wt actually represents data from bax single knockout mice.
Error bars +/- standard error, n = 5 - 8 . *  = p = <0.05, ** = p = < 0.01 as determined by two-
tailed unpaired t-test.
3.3.5. The use of primary neuronal cultures to explore the role 
of NGF and NT-3 in gene expression in early postnatal 
sensory neurons
Neuronal cultures were used to study the in-vitro expression of the mRNAs that were 
previously investigated in transgenic neonates to ascertain if NGF and NT-3 regulate 
the expression of these mRNAs when the neurons are cultured independently of their 
normal cellular environment. The previous analysis of transgenic neonates, detailed 
above, revealed that the mRNA levels of any given gene were modulated in a similar 
fashion by either NT-3 or TrkA dependent neurotrophic factor signalling in both 
trigeminal and dorsal root ganglion neurons. In contrast, transcriptional regulation of 
the panel of genes was often markedly different in nodose neurons compared to 
neurons from the other two sensory ganglia. For this reason, I decided to compare the 
transcriptional regulation of the selected panel of genes by neurotrophic factors only 
in cultured trigeminal and nodose ganglia neurons (trigeminal ganglia neurons were 
chosen rather than DRG neurons because PO trigeminal ganglia contain significantly 
more neurons than PO DRG).
CD-I litters were collected at birth and cultures were set up as outlined in 3.2.3. 
Neurons were plated onto poly-omithine/ laminin pre-treated dishes and placed into 
an incubator (5% CO2,37°C). In the case of trigeminal ganglion neuronal cultures, 
cells were cultured for 0, 24 and 48 hours, in either the presence or absence of 
lOng/ml NT-3 or NGF. Because PO nodose ganglia contain significantly less neurons 
than PO trigeminal ganglia, only two time points, 0 and 24 hours, were examined for 
nodose neuron cultures. Following incubation at 37°C for the appropriate time period, 
the neuronal cultures were lysed by the addition of a chaotropic RNA extraction 
buffer, RNA was purified with the RNeasy kit and mRNA expression was quantified 
using RT- QPCR.
3.3.5.1. Survival of cultured PO trigeminal and nodose neurons
Caspase Inhibitors were included in all culture dishes to prevent cell death in the 
absence of neurotrophic support confounding the interpretation of mRNA expression
269
data. To ensure that neuronal survival was similar in all the culture conditions, the 
number of healthy neurons in each culture was counted at 24 hours and/or 48 hours 
(depending on the neuron type) and neuronal survival was expressed as a percentage 
of the number of neurons in each culture at 3 hours (3 hours was chosen as the time 
point for the initial neuronal count as this period allowed time for neurons to adhere to 
the culture dishes and therefore be easily identified by their round phase bright 
appearance).
The survival of both trigeminal and nodose ganglia neurons, in the presence and 
absence of NGF, is shown in figure 3.28. Approximately all trigeminal neurons 
survive for 48 hours when cultured in the presence of caspase inhibitors and NGF, as 
would be anticipated. However, the number of surviving neurons falls to 80% of the 
initial starting number by 24 hours and 60% by 48 hours in the presence of caspase 
inhibitors alone. A similar decrease in the number of surviving neurons at 24 hrs (to 
60% of initial numbers) was seen for all conditions in the case of nodose ganglia 
neurons, which are largely dependent upon BDNF for survival at this age. Although 
there was significant death of nodose and trigeminal neurons in culture in the 
presence of caspase inhibitors alone (due to a lack of appropriate neurotrophic factor 
support), survival is much improved from the cell death that was seen in the absence 
of caspase inhibitor support. In the case of trigeminal neurons, approximately 30% 
trigeminal neurons survived after 24 hours with no factors, and by 48 hours this was 
down to 5%. In the case of nodose neurons, approximately only 25% of neurons 
survived in the absence of neurotrophic factors and caspase inhibitors following 24 
hours in culture.
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Figure 3.28. Survival o f P0 nodose ganglia (A) and trigeminal ganglia (B) neurons cultured in the 
presence or absence o f NGF and caspase inhibitors
Trigeminal and nodose were dissected from P0 CD-I mice and cultured in-vitro for 24 (nodose) or 48 
(trigeminal) hours in the presence or absence of NGF (lOng/ml). Caspase inhibitors (50pM) were added 
to the growing medium to allow survival of the neurons at this young age in the absence of trophic 
support.
60- 80% of cells survive after 24hours in culture and 60% survival is observed after 48hours in the 
absence of factors. Presence of NGF does not have an effect on survival of nodose neurons (A), however 
an increased survival is observed with trigeminal neurons (B) which are largely dependent upon NGF for 
survival.
Any gene expression analysed will be normalised against GAPDH mRNA to account for the small loss in 
cell number observed here.
N.B. Survival is calculated as a percentage of starting cell number in a 1cm grid at time 0 (counted 4 hours 
after plating)
Trigeminal ganglia:
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The survival of trigeminal and nodose neurons in cultures supplemented with caspase 
inhibitors either in the presence or absence of NT-3 is shown in figure 3.29. Once 
again, some loss of neurons was observed in the presence of caspase inhibitors alone, 
with approximately 80% survival of both nodose and trigeminal neurons at 24 hours. 
By 48 hours, trigeminal ganglia neurons survival was reduced to 60% in the presence 
of caspase inhibitors. NT-3 was not able to promote the survival of either neuron type 
above that seen with caspase inhibitors alone.
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Figure 3.29. Survival o f PO nodose ganglia (A) and trigeminal ganglia neurons (B) cultured in the 
presence or absence o f NT-3 and caspase inhibitors
Trigeminal and nodose were dissected from P0 CD-I mice and cultured in-vitro for 24 (nodose) or 48 
(trigeminal) hours in the presence or absence o f NT-3 (lOng/ml). Caspase inhibitors, 50pM were added 
to the growing medium to allow survival o f the neurons at this young age in the absence of trophic 
support.
Approximately 80% of cells survive after culture for 24 hours for both nodose and trigeminal ganglia. 
Approximately 60% survival of trigeminal ganglia neurons are observed after 48hours. No difference is 
observed with or without factors.
Any gene expression analysed will be normalised against GAPDH mRNA to account for the small loss 
in cell number observed here.
N.B. Survival is calculated as a percentage of starting cell number in a 1cm grid at time 0 (counted 4 
hours after plating)
Error bars = +/- standard error, n = 4
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3.3.5.2. The regulation of mRNA expression in cultured PO 
sensory neurons by NT-3 and NGF
Some mRNAs were difficult to accurately quantify using real-time-QPCR analysis of 
RNA extracted from sensory neuron cultures, since these cultures yielded little RNA 
in comparison to the whole ganglia that were used for previous RT-QPCR analysis of 
mRNA expression. For this reason no data for galanin mRNA expression could be 
obtained for cultured PO nodose and trigeminal ganglia neurons. pCGRP and VR1 
mRNAs could also not be quantified in RNA extracted from nodose neuron cultures, 
which contained fewer cells than trigeminal neuron cultures.
3.3.5.3. Trigeminal neuron cultures
Figures 3.30 and 3.31 show the expression levels of a-CGRP, P-CGRP and SP 
mRNAs in trigeminal ganglia neurons cultured in the presence or absence of NGF. 
The expression of a-CGRP mRNA (figure 3.30A) and SP mRNA (figure 3.31) both 
decreased around 5-fold over 48 hrs in culture, an effect that is also seen in 
axotomised adult neurons (Nielsch et al., 1987; Noguchi et al., 1990; Zhang et al., 
1995; Mulder et al., 1997; Sterne et al., 1998; Shi et al., 2001; Shadiack et al., 2001). 
Culturing trigeminal neurons with lOng/ml NGF effectively prevents this decrease. A 
similar positive regulation by NGF was observed for P-CGRP mRNA (figure 3.30B) 
at 24 hours, but not at 48hours, and in addition the decrease in expression over time 
in culture, which was observed for a-CGRP mRNA did not occur for p-CGRP 
mRNA. This suggests that the two isoforms respond to the same environment in 
different ways at this developmental stage. This provides another example of the 
distinct regulation of the two transcripts, despite their high sequence homology.
Figure 3.32 shows the expression levels of Navi.8 and Navi.9 mRNAs in trigeminal 
ganglia neurons cultured in the presence or absence of NGF. Both Navi. 8 and 
Navi.9, mRNAs all showed a greater than 10-fold decrease in expression over 48hrs 
in culture, again an effect which has been observed in adult DRG following axotomy 
(Okuse et al., 1997; Cummins et al., 1997; Tate et al., 1998; Dib-hajj et al., 1998;
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Novakovic et al., 1998 Sleeper et al., 2000; Decosterd et al., 2002). The presence of 
10 ng/ml NGF totally prevented the time dependent decrease in Navi .8 mRNA 
expression, but only partially prevented the decrease in Navi .9 mRNA levels.
In a similar fashion to the TTX sodium channels, expression of VR1 was reduced 
approximately 10 fold over time in culture to levels that cannot be detected accurately 
by PCR (figure 3.33A). Such a decrease has been observed in axotomised sensory 
neurons previously (Michael and Priestly, 1999; Michael and Priestly 2002; Fukuoka 
T et al., 2002). The presence of NGF inhibited this decrease, with levels returned 
close to those at time 0 by 48 hours (figure 3.33A).
In contrast to the mRNAs for CGRP, SP and TTX-resistant sodium channels, PACAP 
mRNA expression levels increased 5-fold during the first 24 hours in culture (figure 
3.33B). Over the next 24 hrs, the markedly elevated levels of PACAP mRNA 
decreased some 2.5-fold to remain at twice the initial level at 48 hrs. An increase in 
PACAP mRNA expression has also been observed in axotomised DRG neurons 
(Jongsma Wallin et al., 2001). No regulation of PACAP mRNA expression by NGF 
was observed in culture.
The expression of GAPDH mRNA in cultured trigeminal neurons is shown in figure 
3.34. As would be expected, the levels of GAPDH mRNA were higher in cultures 
containing NGF compared to those with caspase inhibitors alone (approximately a 
60% reduction compared to time 0 in cultures supplemented with only caspase 
inhibitors). This was due to a combination of decreased survival in cultures containing 
caspase inhibitors alone (40% reduction- see figure 3.28), along with the fact that 
cells cultured in caspase inhibitors alone are atrophic and are probably less healthy 
than those supplemented with NGF. This result re-affirms the need to normalise 
results against GAPDH mRNA to provide a true representation of mRNA expression 
that is not just a reflection of decreased cell vigour and cell death.
Data representing the effects of exogenous NT-3 on the expression of a-CGRP, p- 
CGRP and SP mRNAs in cultured trigeminal neurons is shown in figures 3.35 and 
3.36. As in previous trigeminal ganglion neuronal cultures, a decrease in the 
expression of a-CGRP (figure 3.35A) and SP (figure 3.36) mRNAs was observed
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over time in culture, but p-CGRP mRNA expression was slightly increased after 24 
hrs in culture and returned to initial levels at 48 hrs (figure 3.35B). The expression of 
a- and p-CGRP and SP mRNAs were not regulated by NT-3.
The expression levels of Navi. 8 and Navi. 9 in trigeminal neurons from control 
cultures, containing caspase inhibitors alone, and cultures supplemented with lOng/ml 
NT-3 are illustrated in figure 3.37. Both Navi.8 and Navi.9 mRNAs respond to the 
culture environment in a similar way to the previous NGF cultures (figure 3.32.), with 
marked decreases in the expression of both over time in culture. In contrast to NGF, 
culturing trigeminal neurons in the presence of lOng/ml NT-3 did not appear to 
ameliorate the decrease in Navi.8 and Navi.9 mRNA levels. Expression of VR1 
mRNA also showed similar effects to that seen in NGF trigeminal cultures (figure 
3.33A), with a substantial decrease observed over time in culture. Presence of NT-3 
did not affect this culture-induced reduction. In contrast to other genes, an increase in 
the expression of PACAP mRNA over the same time period was observed (figure 
3.33B). Additionally NT-3 did appear to increase the levels of PACAP mRNA 
expressed by trigeminal neurons after 24 and 48 hours in culture, although this 
increase only reached significance at 48 hours.
The expression of GAPDH mRNA in trigeminal neurons cultured in caspase 
inhibitors alone or with caspase inhibitors supplemented with lOng/ml NT-3 is shown 
in figure 3.39. In cultures containing caspase inhibitors alone, there was 
approximately a 60% reduction in the expression of GAPDH mRNA by 48 hrs, 
probably reflecting cell death in the cultures (40% see figure 3.28) and the 
compromised health of remaining neurons (discussed below). This is in agreement 
with the control trigeminal neuron cultures set up for the NGF experiments described 
above. However, in contrast to the effects of NGF, NT-3 was not able to prevent the 
decrease in GAPDH mRNA expression that occurs over time in culture, reflecting the 
inability of NT-3 to prevent the death of trigeminal neurons in culture or improve the 
vitality of those that avoid apoptosis.
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Figure 3.30. Expression o f alpha- and beta-CGRP mRNAs in P0 trigeminal ganglia neurons cultured in 
the presence or absence o f NGF (lOng/ml) and caspase inhibitors.
Trigeminal ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
of NGF (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression of alpha CGRP (A) and beta CGRP (B) 
were quantified by real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by two-
tailed unpaired t test.
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Figure 3.31. Expression ofSP mRNA in PO trigeminal ganglia neurons cultured in the presence or 
absence o f NGF (lOng/ml) and caspase inhibitors.
Trigeminal ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
of NGF (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression of SP mRNA was quantified by real-time 
QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by two- 
tailed unpaired t test.
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Figure 3.32. Expression o f Navi.8 and Navi.9 mRNAs in trigeminal ganglia neurons cultured in the 
presence or absence o f NGF (lOng/ml) and caspase inhibitors.
Trigeminal ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
of NGF (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression o f N avi.8 (A) and N avi.9 (B) were 
quantified by real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by two-
tailed unpaired t test.
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Figure 3.33. Expression ofVRl and PACAP mRNAs in trigeminal ganglia neurons cultured in the 
presence or absence o f NGF (lOng/ml) and caspase inhibitors.
Trigeminal ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
of NGF (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression o f VR1 (A) and PACAP (B) mRNAs were 
quantified by real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by two-
tailed unpaired t test.
M_M
T im eO  2 4 h r control 2 4 h r + N G F  4 8 h r con tro l 4 8 h r  + NG F
(10ng /m l) (10ng/m l)
180
160
_  140 (/)
I  120 
$ 100
I
03 80
60S.03o) 4 0  
20
♦
** I I
1t =HL f c ■ H H
Tim e 0 2 4 h r control 24 h r +NGF 
(10ng/m l)
4 8 h r control 4 8 h r + N G F 
(10ng /m l)
Figure 3.34. Expression o f GAPDH mRNA in trigeminal ganglia neurons cultured in the presence or 
absence o f NGF (lOng/ml) and caspase inhibitors.
Trigeminal ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
of NGF (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression o f GAPDH mRNA was quantified by real­
time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by two- 
tailed unpaired t test.
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Figure 3.35. Expression o f alpha- and beta-CGRP mRNAs in P0 trigeminal ganglia neurons cultured in 
the presence or absence ofNT-3 (lOng/ml) and caspase inhibitors.
Trigeminal ganglia were dissected from P0 CD-I mice and cultured in-vitro in the presence or absence 
ofNT-3 (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression of alpha-CGRP (A) and beta-CGRP (B) 
mRNAs were quantified by real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by two- 
tailed unpaired t test.
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Figure 3.36. Expression ofSP mRNA in PO trigeminal ganglia neurons cultured in the 
presence or absence ofNT-3 (lOng/ml) and caspase inhibitors.
Trigeminal ganglia were dissected from PO CD-I mice and cultured in-vitro in the 
presence or absence ofNT-3 (lOng/ml). Caspase inhibitors (50pM) were included in all 
dishes to allow survival in the absence of correct neurotrophic factor support. 
Expression of SP mRNA was quantified by real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as 
determined by two-tailed unpaired t test.
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Figure 3.37. Expression o f Navi.8 and Navi.9 mRNAs in PO trigeminal ganglia neurons cultured in the 
presence or absence ofNT-3 (lOng/ml) and caspase inhibitors.
Trigeminal ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
ofNT-3 (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression of Navi .8 (A) and Navi .9 (B) mRNAs were 
quantified by real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by two-
tailed unpaired t test.
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Figure 3.38. Expression ofVRl and PACAP mRNAs in PO trigeminal ganglia neurons cultured in the 
presence or absence ofNT-3 (lOng/ml) and caspase inhibitors.
Trigeminal ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
ofNT-3 (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression of VR1 (A) and PACAP (B) mRNAs were 
quantified by real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by two- 
tailed unpaired t test.
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Figure 3.39. Expression o f mRNA o f GAPDH trigeminal ganglia neurons cultured in the presence or 
absence ofNT-3 (lOng/ml) and caspase inhibitors.
Trigeminal ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
ofNT-3 (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression of GAPDH mRNA was quantified by real­
time QPCR an used to normalise data for other genes.
Error bars = +/- standard error, n = 4. Where * = p = < 0.05 and ** = p = < 0.01 as determined by two- 
tailed unpaired t test.
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3.3.5.4 Nodose neuron cultures
p-CGRP and VR1 mRNAs could not be accurately quantified in total RNA extracted 
from nodose neurons. This was due to a combination of low neuronal number in these 
cultures (due to the small size of nodose ganglia) combined with the low levels of 
expression of these genes in nodose ganglia.
Figure 3.40 shows the effect that lOng/ml NGF has on the expression of a-CGRP and 
SP mRNAs in cultured nodose neurons. The expression levels of both mRNAs were 
considerably lower than those found in cultured trigeminal neurons. As was observed 
for trigeminal neurons, both mRNAs showed decreased expression levels over time 
when cultured in the absence of neurotrophic factor support. NGF was able to 
partially prevent the decrease in expression of both of these neuropeptide mRNAs. 
Over the 24 hour culture period, Navi .8 and Navi .9 mRNAs displayed a dramatic, 
greater than 10-fold, decrease in their levels of expression in nodose neurons cultured 
without neurotrophic factor support (figure 3.41). NGF was able to increase the levels 
of both mRNAs by around 2-fold compared to neurons cultured in caspase inhibitors 
alone, a rise that was statistically significant. As in the case of trigeminal neurons, the 
expression of PACAP mRNA in nodose neurons increased some 5-fold over a 24 
hour period in culture (figure 3.42). The addition of lOng/ml to the culture medium 
was able to reduce the up-regulation of PACAP mRNA expression slightly, although 
the effect did not reach statistical significance (p = 0.0625) (figure 3.42).
GAPDH mRNA expression levels decreased by around 40% in nodose neurons, 
cultured in caspase inhibitors for 24 hours (figure 3.43). NGF was able to partially 
reduce the decrease in GAPDH mRNA expression levels, although the rescue of 
GAPDH mRNA expression was not statistically significant.
Unlike NGF, NT-3 cannot prevent any of the decrease in the expression of a-CGRP 
and SP mRNAs that occurs when nodose neurons are cultured for 24 hours without 
neurotrophic support (figure 3.44). Similarly, NT-3 was not able to enhance the 
expression of Navi. 8 and Navi.9 mRNAs and thereby prevent the marked drop in 
expression of these two mRNAs that occurs in nodose neurons cultured for 24 hours 
in caspase inhibitors (figure 3.45).
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The expression of PACAP mRNA in cultured nodose neurons is shown in figure 3.46. 
In accordance with the NGF series of experiments, the amount of PACAP mRNA 
expressed by nodose neurons increased markedly (over 5-fold) over a 24 hour culture 
period when the neurons were cultured with caspase inhibitors alone. NT-3, like NGF, 
appeared to be able to partially prevent the increase in PACAP mRNA expression, 
although, as in the case of NGF, this did not reach statistical significance (p = 0.123), 
possibly due to error bars. This data is in contrast to the positive regulatory effect that 
NT-3 appears to have on PACAP mRNA expression in cultured trigeminal neurons 
(figure 3.46), but is in agreement with the data for nodose ganglia from Bax v7  NT-3* 
/_transgenic neonates (figure 3.26).
As for NGF cultures (figure 3.43), expression of GAPDH was reduced in nodose 
neurons following 24 hours in culture in the absence of neurotrophic factor support 
and presence of caspase inhibitors (figure 3.47). NT-3 could not prevent this decrease, 
illustrating the inability of this factor to support survival of such sensory neuronal 
populations.
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Figure 3.40. Expression o f alpha CGRP and SP in PO nodose neurons ganglia cultured in the 
presence or absence o f NGF (lOng/ml) and caspase inhibitors.
Nodose ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or 
absence of NGF (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow 
survival in the absence of correct neurotrophic factor support. Expression o f alpha CGRP (A) 
and SP (B) mRNAs were quantified by real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by 
two-tailed unpaired t test.
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Figure 3.41. Expression o f mRNAs o f Navi.8 and Navi.9 in PO nodose ganglia neurons cultured in 
the presence or absence o f NGF (lOng/ml) and caspase inhibitors.
Nodose ganglia were dissected from PO, CD-I mice and cultured in-vitro in the presence or absence 
of NGF (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression of N avi.8 (A) and N avi.9 (B) mRNAs 
were quantified by real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by
two-tailed unpaired t test.
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Figure 3.42. Expression o f PACAP mRNA in PO nodose ganglia neurons cultured in the presence or 
absence o f NGF (lOng/ml) and caspase inhibitors.
Nodose ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
of NGF (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression o f PACAP mRNA was quantified by 
real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by 
two-tailed unpaired t test.
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Figure 3.43. Expression o f GAPDH mRNA in PO nodose ganglia neurons cultured in the presence 
or absence o f NGF (lOng/ml) and caspase inhibitors.
Nodose ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
of NGF (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression of GAPDH mRNA was quantified by 
real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by 
two-tailed unpaired t test.
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Figure 3.44. Expression o f alpha CGRP and SP mRNAs in PO nodose ganglia neurons cultured in the 
presence or absence o f NT-3 (lOng/ml) and caspase inhibitors.
Nodose ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence of NT- 
3 (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the absence of 
correct neurotrophic factor support. Expression of alpha CGRP (A) and SP (B) mRNAs were quantified 
by real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by two-
tailed unpaired t test.
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Figure 3.45. Expression o f Navi.8 and Navi.9 mRNAs in PO nodose ganglia neurons cultured in 
the presence or absence o f NT-3 (lOng/ml) and caspase inhibitors.
Nodose ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
of NT-3 (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression of N avi.8 (A) and N avi.9 (B) mRNAs 
were quantified by real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by 
two-tailed unpaired t test.
Time 0 24hr cont 24hr + NT3 (10ng/ml)
Figure 3.46. Expression o f PACAP mRNA in PO nodose ganglia neurons cultured in the presence 
or absence o f NT-3 (lOng/ml) and caspase inhibitors.
Nodose ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
of NT-3 (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression o f PACAP mRNA was quantified by 
real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by 
two-tailed unpaired t test.
Time 0 24hr cont 24hr + NT3 (10ng/ml)
Figure 3.47. Expression o f GAPDH mRNA in PO nodose ganglia neurons cultured in the presence 
or absence o f NT-3 (lOng/ml) and caspase inhibitors.
Nodose ganglia were dissected from PO CD-I mice and cultured in-vitro in the presence or absence 
of NT-3 (lOng/ml). Caspase inhibitors (50pM) were included in all dishes to allow survival in the 
absence of correct neurotrophic factor support. Expression of GAPDH mRNA was quantified by 
real-time QPCR.
Error bars = +/- standard error, n = 4. Where * = p = <0.05 and ** = p = < 0.01 as determined by 
two-tailed unpaired t test.
3.4. Discussion
In this chapter, I used RT-QPCR to determine the roles that NT-3 and NGF (via TrkA 
dependent signalling) play in regulating the mRNA expression of several functionally 
important sensory neuron genes in neonatal trigeminal, nodose and dorsal root 
ganglion neurons. The roles of these neurotrophic factors in regulating neonatal 
sensory neuron mRNA expression was studied in vivo in transgenic mice and in vitro 
in primary neuronal cultures.
One important caveat should be bom in mind when interpreting the data presented in 
this chapter. Previously published data suggest that all the genes investigated in this 
chapter are predominantly or exclusively expressed by neurons within peripheral 
sensory ganglia of “normal” adult rodents, in-vivo. Whilst this is probably the case in 
both neonatal and transgenic animals as well as in neuronal cultures, the possibility 
exists that under these circumstances that non-neuronal cells within sensory ganglia 
also begin to express the mRNAs being investigated. The only way to rule out this, 
albeit remote, possibility is to carry out a comprehensive in-situ hybridisation, 
immuno-histochemistry and immnuo-cytochemistry study for each of the genes under 
investigation. Unfortunately, limited time precluded such a study. Therefore, the 
formal possibility exists that some of the data presented in this chapter reflects 
unexpected mRNA expression by glial cells within whole sensory ganglia and non­
neuronal cells in dissociated cultures.
I will discuss the in-vitro and in-vivo regulation of each mRNA, in the various 
ganglia, in turn.
3.4.1. GAPDH
Non-neuronal cells within sensory ganglia contain extremely small relative levels 
(approximately 1000-fold to 5000 fold-less depending on neuron size) of GAPDH 
mRNA compared to the much larger neurons (S Wyatt unpublished observation), and 
as such only make up a small-percentage of the total amount of GAPDH mRNA 
expressed by neonatal sensory ganglia. The potential effects that TrkA and NT-3
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deletion have on non-neuronal cells and how this relates to alterations in the 
expression of GAPDH mRNA by non-neuronal cells can, therefore, be discounted.
In general the amount of GAPDH expressed by cells directly reflects the size of the 
cells (S Wyatt unpublished data). The smaller a cell is, the less energy it requires for 
maintenance and function. A reduced energy requirement would be expected to be 
reflected by a lowered rate of glycolysis and hence a reduced requirement for 
GAPDH (although obviously this is over simplistic and cell energy requirements are 
also dictated by cell function). The loss of TrkA did not significantly alter the levels 
of GAPDH mRNA expressed by neonatal trigeminal and nodose ganglia (figure 
3.22). In some respects the data for trigeminal ganglia is surprising, since the lack of 
NGF/TrkA signalling would be expected to make NGF-responsive neurons atrophic 
and would also be expected to limit their ability to innervate peripheral targets and 
decrease their degree of terminal arborisation (e.g. Patel et al., 1990; Lentz et al.,
1999; Gene et al., 2004). Moreover, cultured PO trigeminal neurons display a 
significant reduction in neurite outgrowth, cell soma size and expression of GAPDH 
mRNA in the absence of NGF (data not shown and figure 3.30), making the in-vivo 
data even more curious. In nodose ganglia, it is not surprising that the loss of TrkA 
had no discemable effects on GAPDH mRNA levels, since nodose ganglia contain 
such a small number of NGF-responsive neurons (Forgie et al., 1999). In contrast to 
the other two sensory ganglia studied, neonatal DRG from TrkA/Bax double-null 
mutants do show significantly lower levels of GAPDH mRNA compared to Bax 
single-null mutants, probably reflecting the atrophic nature of NGF-responsive 
neurons in the absence of NGF/TrkA signalling (figure 3.22).
Both neural crest-derived sensory ganglia showed a loss of GAPDH mRNA 
expression in NT-3/Bax double-null mutant neonates compared to Bax'7' neonates 
(figure 3.23). Although the TrkC-positive sub-population of proprioceptive neurons is 
only a small percentage of all DRG sensory neurons (predominantly being found in 
DRG innervating the limbs), proprioceptive neurons are large and as a consequence 
probably express a relatively large proportion of total DRG GAPDH mRNA (see 
above). NT-3 and Bax deficient DRG are likely to display a significant reduction in 
proprioceptive neuron cell size and a reduction in the complexity of terminal 
arborisation of these neurons, with a concomitant reduction in their expression of
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GAPDH mRNA. This phenomenon may account for some of the reduction in 
GAPDH mRNA levels seen in the DRG of NT-3/Bax double-null mutant neonates. In 
addition, it has recently been shown that NT-3/Bax double-null mutant neonatal DRG 
contain fewer TrkC-positive neurons and more TrkA-positive neurons than WT 
animals (Gene et al., 2004). In DRG, TrkA-positive cells are predominantly small 
nociceptive neurons, expressing relatively low amounts of GAPDH mRNA. In 
contrast, TrkC positive DRG neurons are predominantly large proprioceptors 
expressing large amounts of GAPDH mRNA. Therefore, the change in the ratio of 
TrkA-positive to TrkC-positive neurons is also likely to reduce GAPDH mRNA 
levels in the absence of NT-3.
The trigeminal ganglion does not have a proprioceptive neuron component (these 
reside in the trigeminal mesencephalic nucleus) and neonatal trigeminal ganglia 
contain few TrkC positive neurons (Emfors et al., 1992). Therefore, the reduction in 
the levels of GAPDH mRNA expressed by trigeminal ganglia in the absence of NT-3 
signalling is less likely to be as a consequence of a reduction in neuron size and/or 
extent of terminal arborisation of TrkC-positive neurons. It is also unlikely to be the 
consequence of a change in the ratio of TrkA-positive to TrkC-positive neurons. The 
reduction in GAPDH mRNA expression in the absence of NT-3, is also unlikely to be 
as a result of the loss of NT-3/TrkA signalling, since as observed in figure 3.22, TrkA 
deletion does not reduce GAPDH mRNA levels in trigeminal ganglia. It is of course 
possible that NT-3 normally signals through its other non-preferred receptor TrkB or 
through the common neurotrophin receptor, p75, to exert its trophic effects on 
trigeminal ganglion neurons. Since these receptors (especially p75) are widely 
expressed in the neonatal trigeminal ganglion, it is possible that a loss of NT-3 will 
cause a reduction in size and a reduction in target field innervation/terminal 
arborisation of a large number of neurons, hence leading to a reduction in GAPDH 
mRNA levels. Analysis of NT-3 null mutant mice has come up with a number of 
hypotheses to account for the loss of neurons in neural crest-derived sensory ganglia. 
These range from direct apoptosis of post-mitotic neurons (Wilkinson et al., 1996), to 
apoptosis of proliferating neuronal precursors (ElShamy and Emfors 1996 a and b) 
and finally to premature differentiation of neuronal precursors resulting in a reduction 
in the precursor pool during the peak period of neurogenesis (Farinas et al., 1996). At
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present, it is not clear which of these three scenarios is the correct one. The deletion of 
Bax will prevent the first two events taking place in the absence of NT-3 signalling, 
allowing the maintenance of neuronal numbers. However, the premature 
differentiation of neuronal precursors into neurons will not be prevented by Bax 
deletion. It is therefore possible that NT-3/Bax double-null mutant neonates contain 
fewer trigeminal neurons than Bax'7' neonates, and this could account for the drop in 
GADPH mRNA levels in trigeminal ganglia of NT-3'77Bax'7' neonates. Of course, this 
hypothesis could also explain some or all of the reduction in GAPDH mRNA levels 
found in double-null mutant DRG. Careful histology-based analysis of neuron 
numbers in sensory ganglia from NT-3'77Bax'7' mice and Bax'7' mice would determine 
whether this hypothesis is true.
The deletion of NT-3 did not significantly alter the levels of GAPDH mRNA 
expressed by neonatal nodose neurons in-vivo (figure 3.23), suggesting that NT-3 
does not exert trophic effects on significant number of neonatal nodose neurons. This 
data is in agreement with a visual inspection of neonatal nodose cultures in the 
presence or absence of NT-3. NT-3 did not markedly increase neuron cell body size 
or increase neurite outgrowth compared to nodose neurons grown without trophic 
factor support (data not shown).
GAPDH mRNA levels were significantly less, at both 24 and 48 hr time points, in PO 
trigeminal neurons cultured in the absence of NGF compared to those cultured in 10 
ng/ml NGF (figure 3.34). This reduction in GAPDH mRNA levels was not due to a 
reduction in neuronal survival, since neurons were grown in the presence of caspase 
inhibitors that block apoptosis. However, neurons grown in the absence of NGF were 
clearly small and atrophic and displayed very little neurite outgrowth compared to 
those cultured with NGF. Since cell size generally correlates directly with GAPDH 
mRNA expression levels (see above), this data is not surprising. NT-3, in contrast to 
NGF, did not markedly increase the size of neuronal soma in PO trigeminal cultures, 
nor did it enhance neurite outgrowth signficantly (data not shown). In accordance 
with this observation, NT-3 did not prevent the decrease in GAPDH mRNA 
expression that occurs when trigeminal neurons are placed in culture (figure 3.39).
282
NGF was only able to marginally prevent the drop in GAPDH mRNA expression that 
occurred when PO nodose neurons were cultured without neurotrophic factors for 24 
hrs (figure 3.43). This is not surprising in light of the small percentage of NGF- 
responsive nodose neurons at PO (Forgie et al., 1999). NT-3 did not alter GAPDH 
mRNA levels in neonatal nodose neuron cultures (figure 3.47)
The GAPDH mRNA data presented in this chapter clearly demonstrates that the levels 
of GAPDH mRNA expressed by sensory neurons, both in-vivo and in-vitro, can be 
modulated by exposure to the neurotrophins NGF and NT-3. This observation is 
important for interpreting expression data for other transcripts normalised to GADPH 
mRNA.
3.4.2. a- and p- CGRP
To date, few studies have addressed the regulation of the expression of a- and (3- 
CGRP separately, either at the mRNA or peptide level. Most mRNA expression 
studies have either used methods that are unable to distinguish between the two 
CGRP transcripts (e.g. Patel et al., 2000), or have just studied the expression of the a- 
CGRP transcript because this has been reported to be the more highly expressed 
transcript in the adult. Throughout development, however, p-CGRP is the 
predominant transcript expressed in many tissue types and, despite high sequence 
homology, a- and p- CGRP are transcribed from separate genes. This would, 
therefore, suggest functionally distinct roles for the peptide products of each transcript 
in development.
In chapter 2, the differential regulation of a- and p- CGRP mRNAs was demonstrated 
in sensory neurons of the embryonic mouse. This research has been extended in this 
chapter to explore a- and p- CGRP mRNA expression patterns and the regulation of 
their expression at postnatal ages. An initial investigation into the expression of both 
mRNAs in sensory neurons from wild-type late embryonic, neonatal and adult mice 
showed very similar expression patterns for both transcripts. Both mRNAs showed an 
increase in expression from embryonic ages into the adult in all three sensory ganglia 
studied. Such relatively high levels of P-CGRP mRNA in the adult were unexpected,
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since previous publications have suggested that p-CGRP is poorly expressed in adult 
tissues (Amara et al., 1985, Gibson et al., 1988). It should be bom in mind that the 
RT-QPCR data, although normalised to GAPDH mRNA expression, does not reflect 
the absolute levels of mRNA transcripts relative to the amount of GAPDH mRNA. To 
achieve a measure of this, a standard curve would need to be constructed, prior to 
reverse transcription of RNA, from known amounts of the cRNAs of GAPDH and the 
other assayed genes. In fact, the CT (threshold-crossing values) of RT-QPCR 
amplified p-CGRP transcripts from late embryonic, neonatal and adult sensory 
ganglia, were higher than those of a-CGRP. Since the efficiency of both QPCR 
reactions was very similar (data not shown), this demonstrates that a-CGRP is 
expressed at higher levels than P-CGRP. Nevertheless, it was surprising to find P- 
CGRP transcripts expressed at higher levels in RNA extracted from adult sensory 
ganglia compared to RNA from neonatal sensory ganglia given the previously 
published data (this can be stated with certainty, since the mRNA levels of p-CGRP 
from the different ganglia at different ages were all assayed in the same QPCR plates 
using the same standard curve).
During the embryonic period, the presence of NGF was not essential for the initial 
induction of either a- or p- CGRP mRNAs in trigeminal ganglia or p-CGRP in DRG 
neurons (see chapter 2). However, NGF/TrkA signalling seems to be important for the 
expression of both isoforms by birth, since TrkA7'/Bax7' neonates showed a 
significant loss of a- and p~ CGRP mRNAs in both trigeminal ganglia and DRG 
compared to Bax7' neonates (figure 3.18). NGF/TrkA signalling also appeared to be 
required for full expression of both a- and P-CGRP mRNAs by nodose neurons 
(figure 3.18). Interestingly, it would appear that the reduction in p-CGRP mRNA 
expression in all three ganglia in the absence of NGF/TrkA signalling was less 
pronounced than the reduction in a-CGRP mRNA expression. This suggests that 
either other factors co-operate with NGF in regulating the expression of p-CGRP 
mRNA in NGF responsive neurons, or that p-CGRP mRNA expression is not entirely 
restricted to the TrkA positive, NGF responsive, sub-population of sensory neurons in 
each ganglion at PO. Immuno-histochemistry and/or in-situ hybridisation, using 
probes and antibodies against TrkA and P-CGRP, would help to resolve these 
possibilities.
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Much of the data presented in this chapter came from TrkA/Bax and NT-3/Bax 
double-null mutant neonatal mice and from single-null mutant Bax'7' neonates.
Because these animals are not temporally controlled, conditional null mutants, they 
lack functional NGF/TrkA and NT-3-dependent signalling and are devoid of Bax 
from the moment of conception. This has two potentially important consequences on 
sensory neuron development that must be kept in mind when interpreting results. The 
differentiation of sensory neurons can effectively be divided into “primary” and 
“secondary” processes. In the primary differentiation event, proliferating, committed 
sensory neuron precursors stop dividing and become post-mitotic sensory neurons. In 
mice, this occurs between E9 and E l4, and results in broad sub-classes of 
presumptive proprioceptive, mechanoreceptive and nociceptive (TrkA-positive) 
neurons. A second period of differentiation occurs around birth and extends to around 
P7 in the mouse. During this second period of differentiation, sensory neurons of each 
broad sub-class become “specialized” into distinct sub-populations that have specific, 
refined, functional characteristics and sensory modalities (e.g. Molliver et al., 1997). 
The data comparing gene expression between wild type mice and Bax'7' mice tends to 
suggest that the differentiation program of sensory neurons is largely unaffected by 
the lack of Bax expression (figures 3.13 to 3.17). However, it is not clear to what 
extent the lack of NGF/TrkA- or NT-3-dependent signalling during the embryonic 
and neonatal period effects either the primary or secondary differentiation of sensory 
neurons.
This chapter explores the expression of mRNAs that are predominantly restricted to 
TrkA-positive, peptidergic nociceptive neurons within adult sensory ganglia. Any 
changes in primary or secondary differentiation, as a result of the loss of NT-3- or 
TrkA-dependant signalling, may alter the number of TrkA-positive presumptive 
nociceptive neurons initially generated between E10 and E14 or the number of TrkA- 
positive peptidergic, nociceptors present within neonatal sensory ganglia at PO. This 
phenomenon may alter the levels of the mRNAs under investigation in the absence of 
genuine transcriptional regulation by NT-3 or NGF/TrkA-dependant signalling. The 
loss of NT-3 has been shown to effect the timing of the “primary” differentiation of 
DRG neurons (Farinas et al., 1996), and is associated with an increase in the ratio of 
TrkA-positive neurons to TrkC-positive neurons in developing sensory ganglia of NT-
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3'/7Bax'/‘ double-null mutants compared to wild-type mice (Gene et al., 2004.)
Sensory ganglia have not been examined in the TrkA'^/Bax'7' double-null mutant to 
determine whether there is a change in the number of TrkA-positive neurons initially 
generated in the absence of NGF/TrkA signalling (this would necessitate using a 
reporter gene driven by the TrkA promoter, since TrkA is deleted). Neither double­
null mutant strain has been examined to determine whether there is an alteration in the 
secondary differentiation process that may lead to a change in the number of TrkA- 
positive, peptidergic nociceptors that reside within postnatal sensory ganglia.
The second thing that must be taken into account when interpreting data from the 
transgenic neonatal ganglia is the possibility that the loss of neurotrophic support 
during the period of target field innervation, that occurs when TrkA or NT-3 is 
deleted from conception, may alter the pattern and density of normal target field 
innervation. Moreover, at older ages the loss of trophic support from NGF or NT-3 
may alter the degree of terminal arborisation, particularly in peripheral targets (e.g. 
Patel et al., 2000; Lentz et al., 1999; Gene et al., 2004). The alteration in target field 
innervation/arborisation may effectively reduce the accessibility of sensory neurons to 
other target field-derived trophic factors, and this may in turn affect neuronal gene 
expression. Thus the deletion of TrkA or NT-3 from conception could again lead to 
changes in gene expression within neonatal sensory neurons that are not the result of 
direct transcriptional regulation by NGF or NT-3.
This scenario, described in the above two paragraphs, could theoretically account for 
some or all of the reduction in the expression of both CGRP mRNAs in sensory 
ganglia from TrkA/Bax double-null mutant neonates, rather than a direct regulation of 
CGRP mRNA expression by NGF per se. However, this would seem unlikely given 
that the in-vitro data (see below) and previous publications on adult rodents (Lindsay 
et al., 1989; Verge et al., 1995; Jiang and Smith, 1995; Price et al., 2005; Ma et al., 
1995; Schuligoi and Amann, 1998; Schicho et al., 1999; Tandrup et al., 1999; Price et 
al., 2005) clearly demonstrate that NGF can directly influence the expression of 
CGRP. Further experiments using in-situ hybridisation and immuno-histochemistry 
(with probes against well characterized phenotypic markers of different neuronal sub­
populations) and/or experiments with temporally controllable TrkA or NGF 
conditional knockout mouse lines would categorically address this question.
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In-vitro cell culture data revealed that NGF is necessary to maintain the expression of 
a-CGRP mRNA over time in culture in both trigeminal and nodose neurons (figure 
3.30. and 3.40 respectively). Dissecting out neurons and culturing them in-vitro 
effectively removes them from target field-derived neurotrophic factor support, and it 
is this lack of neurotrophic factor support that is largely responsible for the decrease 
in a-CGRP mRNA expression over time in culture. Sciatic nerve transection in adult 
mice and rats also removes target field-derived neurotrophic factor support from DRG 
neurons and leads to a reduction in the expression of a-CGRP mRNA and peptide 
(Noguchi et al., 1990; Mulder et al., 1997; Sterne et al., 1998; Shi et al., 2001; 
Shadiack et al., 2001). The fact that NGF can totally restore a-CGRP mRNA levels in 
cultured trigeminal neurons to levels comparable (in fact slightly greater) to those 
found at the time of plating, and hence in-vivo, suggests that a-CGRP mRNA is 
predominantly expressed in TrkA expressing NGF-responsive trigeminal neurons at 
P0. Developing nodose ganglia contain a small sub-population of NGF responsive 
neurons (Forgie et al., 1999). Since NGF can totally prevent the culture induced 
down-regulation of a-CGRP mRNA expression in nodose neurons, it is tempting to 
speculate that it is target field-derived NGF withdrawal that is responsible for the drop 
in a-CGRP mRNA expression and that a-CGRP is predominantly expressed by the 
NGF responsive sub-population of nodose neurons at P0.
Interestingly, P-CGRP mRNA expression was sustained in culture at in vivo (time 0) 
levels in trigeminal neurons in the absence of neurotrophic factor support for at least 
48 hrs (figure 3.30.). This could suggest that NGF, or indeed other target field-derived 
neurotrophic factors, is/are not entirely responsible for setting the steady state in vivo 
expression levels of this mRNA at P0. In support of this is the fact that, although p- 
CGRP mRNA expression is clearly reduced in trigeminal ganglia of transgenic mice 
lacking functional TrkA/NGF signalling, the reduction is only two-fold and is 
significantly less than the reduction of a-CGRP expression in the same ganglia. An 
alternative explanation for the lack of a fall in pCGRP mRNA expression in 
trigeminal neurons deprived of neurotrophic factor support (and in particular NGF), 
may be that pCGRP mRNA is a stable mRNA with a long “turn-over” time and so it 
takes longer for mRNA levels to fall after withdrawal of support from target field
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derived NGF. It is curious that whilst lOng/ml NGF can enhance 24-hour p-CGRP 
mRNA expression levels to levels significantly above those found in-vivo, it cannot 
maintain this enhanced expression at 48 hours (figure 3.30). All the other mRNAs that 
showed enhanced in-vitro expression levels when trigeminal neurons were cultured 
for 24 hours with NGF, remained at elevated expression levels at 48 hours (e.g. a- 
CGRP and see below).
The data presented in this chapter suggests an essential role for NGF/TrkA signalling 
in regulating the expression of a- and p-CGRP mRNAs in neonatal trigeminal, 
nodose and DRG neurons. This data compliments the previous study by Patel et al., 
(Patel et al., 2000) who explored CGRP expression in PO mouse DRG by immuno- 
histochemistry. The data is also in accordance with numerous studies in the adult 
rodent highlighting the positive effects of NGF signalling on the expression of CGRP 
by DRG neurons, as discussed in 2.1.1. (Verge et al., 1995; Jiang et al., 1995; Price et 
al., 2005; Lindsay et al., 1989; Shadiack et al., 2001; Christensen et al., 1997; 
McMahon et al., 1995; Schicho et al., 1999; Schuligoi and Amann, 1998; Ma et al., 
1995).
In stark contrast to the NGF/TrkA dependent regulation of a- and p-CGRP mRNA 
expression, NT-3 does not appear to regulate the expression of CGRP mRNAs in any 
ganglia either in-vitro or in-vivo (figures 3.24, 3.35 and 3.44). To date, no other data 
has arisen from other publications to suggest that NT-3 can regulate either of these 
mRNAs in sensory neurons under other experimental paradigms. This finding is not 
entirely unexpected given that the cognate NT-3 receptor, TrkC, is not expressed by 
peptidergic nociceptive neurons. However, NT-3 can, in certain circumstances signal 
through TrkA and also activates the common neurotrophin receptor p75 (Davies et al., 
1995, Huang et al., 1999) which raised the possibility that NT-3 could possibly play a 
role in regulating gene expression in TrkA expressing, nociceptive sensory neurons (a 
sub-population that also express p75). Moreover, it has been suggested that NT-3 
plays a role in regulating the timing and extent of sensory neuron differentiation from 
proliferating neuronal precursors in mid-gestation mouse embryos, and may thus in 
some way regulate the functional phenotype of sensory neurons (Farinas et al., 1996). 
This published data further suggests that a perturbation in normal NT-3 dependent
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signalling during development may effect the expression of certain phenotypic 
markers that characterise functionally distinct sensory neuron sub-populations. These 
reasons were the rationale behind measuring the expression of nociceptive sensory 
neuron specific markers in NT-3'7'/ Bax'7' mice and determining whether NT-3 could 
regulate their expression in-vitro.
3.4.3. Substance P
On the whole, Substance P (SP) mRNA showed a very similar pattern of regulation to 
that of a- and p-CGRP mRNAs with which it is co-expressed in the same sub­
population of small diameter peptidergic, TrkA positive, adult sensory neurons 
(Lundberg et al., 1985; Lee et al., 1985; Hokfelt et al., 1975; Cuello et al., 1978; 
Skofitsch and Jacobowitz, 1985). The expression levels of SP mRNA, however, show 
little change between E l6 and adult in all three sensory ganglia studied, a situation 
that is markedly different to the significant developmental increase in expression 
levels observed for CGRP mRNAs (figure 3.6.). SP mRNA levels are, on the whole, 
markedly lower than those of CGRP mRNAs (especially at postnatal ages), as 
evidenced by the higher QPCR CT values for SP mRNA compared to CGRP mRNAs 
and a similar QPCR reaction efficiency (data not shown). The data in chapter 2 
revealed that SP mRNA required NGF/TrkA signalling for embryonic induction. In 
accordance with this, the transgenic studies carried out in this chapter revealed a 
dramatic loss of SP mRNA in all three sensory ganglia of PO TrkA'7'/Bax'7' mice 
compared to PO Bax '7' mice (figure 3.20A), suggesting that NGF/TrkA signalling is 
required to establish and maintain the correct in-vivo expression levels of SP mRNA 
in nociceptive sensory neurons of all three ganglia in the neonatal period. It seems 
that the loss of SP mRNA in the absence of NGF/TrkA signalling is not as dramatic as 
the loss of CGRP, suggesting that an additional factor may also positively regulate the 
expression of SP at the transcriptional level. These data differ slightly from those of 
Patel et al (1990). These authors were unable to detect either SP peptide or mRNA in 
DRG from TrkA'7' /Bax'7' neonates. This difference may be due to the different mouse 
strains used in my study (CD1 background) and the Patel study (C57 background) or, 
more likely, due to the greater sensitivity of RT-QPCR compared to in-situ 
hybridisation.
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It is possible that, as in the case of a- and P-CGRP, the lack of functional NGF/TrkA 
signalling from the earliest stages of development changes the programme of neuronal 
differentiation in sensory ganglia and significantly alters the pattern of target field 
innervation (see above). Such a scenario could theoretically account for some/all of 
the reduction in SP mRNA expression in sensory ganglia, rather than reflecting a 
direct regulation of SP mRNA expression by NGF per se. However, this would seem 
unlikely given that the in-vitro data (see below) and previous publications on adult 
rodents (Lindsay et al., 1989; Zhang et al., 1995; Schuligoi and Amann, 1998;
Tandrup et al., 1999) clearly demonstrate that NGF can directly influence the 
expression of SP. Again, as in the case of CGRP, further experiments with temporally 
controllable TrkA or NGF conditional knockout mouse lines, as well as detailed in- 
situ hybridisation and/or immuno-histochemical analysis of ganglia from knockout 
neonates, would definitively address this question.
NGF was able to prevent the rapid decrease in the levels of SP mRNA expressed by 
cultured neonatal sensory neurons as a result of their removal from a source of target 
field-derived neurotrophic factors (figures 3.31. and 3.40B.). This result reflects the 
drop in SP mRNA and peptide levels that are observed in small, peptidergic, L4-L6 
DRG neurons of adult rodents following sciatic nerve injury due to a reduction in the 
availability of foot-pad derived neurotrophic factors (Nielsch et al., 1987; Zhang et 
al., 1995; Sterne et al., 1998). The results in this chapter show that in the case of 
trigeminal neurons, lOng/ml NGF can totally prevent the decrease in SP mRNA 
expression that occurs over time in culture, suggesting that SP mRNA is 
predominantly expressed in NGF responsive, PO trigeminal neurons in a similar 
manner to adult DRG sensory neurons. In contrast, lOng/ml NGF can only partially 
prevent the time-dependent decrease in SP mRNA levels that occurs in cultured 
nodose neurons, perhaps suggesting that SP mRNA is expressed by both the small 
NGF-responsive sub-population of nodose neurons and also by another sub­
population of non NGF-responsive nodose neurons. In-situ hybridisation and/or 
immuno-histochemistry of neonatal nodose ganglia could determine whether this is 
the case. Alternatively, NGF may act in conjunction with other trophic factors, in a 
partially redundant way, to regulate SP mRNA expression in TrkA-positive nodose 
neurons. Data from culture experiments and RT-QPCR analysis of RNA extracted
290
from sensory ganglia of NT-3'7TBax'7' and Bax'7’ mice did not reveal a role for NT-3 in 
regulating the neonatal expression of SP mRNA, either in-vitro or in-vivo (figures 
3.26A, 3.36, 3.44B.
3.4.4. Nav1.8 and Nav1.9
Messenger RNAs for the two TTX-resistant sodium channels, Navi.8 and Navi.9, 
were expressed at all developmental ages assayed (figures 3.7 and 3.8). The mRNAs 
for both of these TTX-resistant sodium channels showed a similar, but not identical 
developmental pattern of expression between the ages of El 6 and adult. For both 
mRNAs, the lowest levels of expression were found at El 6 in all three sensory 
ganglia, and both showed a drop in expression between neonatal ages and adulthood 
in all ganglia. An exception to this was Navi.8 mRNA, which showed peak levels of 
expression in adult nodose ganglia, not neonatal nodose ganglia. These data raise the 
possibility that Navi.8 and Navi.9 mRNAs are regulated in-vivo by a similar 
mechanism, as might be expected given the co-localization of both sodium channels 
in many nociceptive adult DRG sensory neurons (Roy and Narahashi 1992; Black et 
al., 1996; Rush et al., 1998; Amaya et al., 2000). Navi.8 is expressed in most C- and 
A-8- (and a few A-p) fibre rodent DRG nociceptive neurons (Sangameswaren et al., 
1996; Amaya et al., 2000; Fang et al., 2005). Navi.9 seems to be more restricted in its 
expression pattern, being most highly expressed in small diameter, non-peptidergic, 
IB4-positive, C-fibre nociceptors (Black et al., 1996; Amaya et al., 2000; Benn et al., 
2001; Fang et al., 2002).
In chapter 2 ,1 provided data to show that NGF/TrkA signalling is required for the 
induction and correct regulation of both Navi.8 and Navi.9 mRNA expression in 
mouse sensory neurons during the embryonic period. The results presented in this 
chapter suggest that the expression of both of these mRNAs is also regulated by 
NGF/TrkA signalling in P0 trigeminal ganglia and DRG. A significant reduction in 
the expression levels of both mRNAs was observed in trigeminal and dorsal root 
ganglia of P0 TrkA'7TBax'7’ mice compared to Bax'7* mice (figure 3.19). This decrease 
in TTX-resistant sodium channel expression was not seen in TrkA'7TBax'7' nodose 
ganglia neurons. The number of NGF responsive, TrkA-positive neurons within the
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PO nodose ganglion is small (Forgie et al., 1999), whilst the number of nociceptive 
neurons that would be expected to express these TTX-resistant sodium channels is 
likely to be large. Therefore, it is not surprising that NGF does not play a significant 
role in regulating the expression of Navi.8 and Navi.9 mRNAs in the nodose 
ganglion. The fact that there is absolutely no decrease in the expression of either 
sodium channel mRNA in the absence of NGF/TrkA signalling (in fact a slight 
increase was apparent) may be because the NGF responsive sub-population of nodose 
neurons are not nociceptive, and hence do not normally express nociceptor specific 
TTX-resistant sodium channel mRNAs. However, this seems unlikely since the 
CGRP and SP mRNA expression data presented above suggests that NGF responsive 
nodose neurons are peptidergic and as has been previously discussed peptidergic 
TrkA-positive neurons are nociceptive in neural crest-derived sensory ganglia. In-situ 
hybridisation could be used to address this question.
Perhaps a more likely scenario to explain the nodose ganglion data from TrkA/Bax 
double-null mutant neonates is that other growth factors act (possibly in a partially 
redundant way) to regulate the expression of TTX-resistant sodium channels in the 
NGF-responsive sub-population of nodose neurons (see discussion of in-vitro data 
below). BDNF, NT-4 and GDNF have all been demonstrated to have trophic effects 
on nodose ganglion neurons and are candidates for growth factors that may regulate 
TTX-resistant sodium channel expression in this ganglion (Davies et al., 1986; 
Lindsay et al., 1985; Davies et al., 1993; Buj-bello et al., 1994; Cummins et al., 2000; 
Wiklund et al., 2000; Blum et al., 2002).
Data from P0 neuronal cultures demonstrate that NGF positively regulates the 
expression of Navi. 8 and Navi.9 mRNA in trigeminal neurons. Exogenous NGF 
prevented, to some extent, the rapid drop in TTX-resistant sodium channel mRNA 
levels that is a consequence of removing trigeminal neurons from their target field- 
derived source of neurotrophic factor support (figure 3.32). The drop in Navi.8 and 
Navi.9 levels in culture mirrors that seen in L4-L6 DRG neurons following peripheral 
axotomy or sciatic nerve section (Okuse et al., 1997; Cummins et al., 1997; Tate et 
al., 1998; Dib-hajj et al., 1998; Novakovic et al., 1998 Sleeper et al., 2000; Decosterd 
et al., 2002). It is worth noting that although levels of Navi.8 mRNA are retained at 
levels close to those at time 0 in the presence of exogenous NGF, Navi.9 mRNA
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expression is only partially rescued by NGF. This could be due to a difference in the 
expression patterns of these two sodium channels. In the adult, Navi. 8 is expressed by 
the majority of C- and A-fibre nociceptive rodent DRG neurons, whilst Navi.9 is 
more highly expressed by, and more restricted to, the IB4-positive, TrkA-negative 
population of small-diameter DRG neurons. It has not been determined whether this is 
the case in neonatal sensory neurons where the majority of presumptive nociceptive 
neurons are still TrkA-positive. In the adult rodent, the IB4-reactive population of 
neurons are predominantly responsive to GDNF family members, and in particular 
GDNF itself, rather than the neurotrophins. It is therefore possible that the presence of 
both NGF and GDNF in PO trigeminal neuron cultures might restore expression of 
Navi.9 mRNA to that seen at time 0 in-vivo. Although a number of TrkA-negative, 
NGF non-responsive, neurons expressing Navi.8 mRNA almost certainly exist in the 
neonatal trigeminal ganglion, NGF appears to be able to almost completely maintain 
the levels of Navi. 8 mRNA in cultured trigeminal neurons. It is possible that the 
addition of exogenous NGF at a concentration of lOng/ml can increase Navi.8 
mRNA expression to levels higher than those found in-vivo in TrkA-positive cultured 
trigeminal neurons, hence giving the illusion that NGF is regulating Navi.8 mRNA 
expression in cultured TrkA-negative nociceptors.
Interestingly, NGF appears to be able to prevent part of the decrease in Navi .8 and 
Navi.9 mRNA expression levels in nodose neurons that occur as a consequence of in- 
vitro culture. Although the efficacy of NGF in maintaining TTX-resistant sodium 
channel expression in nodose neurons is small, it is statistically significant (figure 
3.41). As it is such a small effect it is likely that this represents the ability of NGF to 
maintain levels of these sodium channel mRNAs in the small sub-population of TrkA- 
positive nodose neurons, rather than acting through p75 to promote Navi.8 and 
Navi.9 mRNA expression across the nociceptive nodose neuron population as a 
whole. A question that arises from the in-vitro data is why nodose ganglia from PO 
TrkA’7'/ Bax7' mice do not show a reduction in TTX-resistant sodium channel mRNA 
expression compared to nodose ganglia of PO Bax7' mice when NGF appears to be 
able to positively regulate the expression of both sodium channel mRNAs in culture? 
In fact, nodose ganglia from double-null mutant neonates appear to express higher 
levels of these mRNAs, although this is not statistically significant (figure 3.19). As 
alluded to above, it is possible that there is a redundancy inherent in the regulation of
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TTX-resistant sodium channel expression in NGF-responsive nodose neurons that 
could account for this discrepancy. If NGF and another growth factor can both 
promote Navi .8 and Navi .9 mRNA expression in NGF-responsive nodose neurons, 
the loss of TrkA by these neurons may not reduce the expression of either sodium 
channel mRNA, as the second growth factor would be sufficient to maintain 
expression. Alternatively, the lack of NGF/TrkA signalling from conception raises the 
possibility that neuronal differentiation is altered in the TrkA/Bax double-null mutant 
mouse line with the consequence that the NGF responsive nodose neuron sub­
population do not arise but are replaced by neurons of a different phenotype. If this is 
correct and the “replacement” neurons express higher levels of Navi.8 and Navi.9 
mRNAs than the “normal” TrkA expressing sub-population, this would account for 
the data obtained in the in-vivo study. Careful analysis of nodose ganglia from TrkA'7' 
/Bax'1' and Bax'7' neonates using a combination of in-situ hybridisation and immuno- 
histochemistry and/or further experiments with a temporally controllable, TrkA 
conditional knockout mouse line would address this possibility. As in the case of 
CGRP and SP mRNAs, RT-QPCR data from transgenic animals and in-vitro cultures 
suggests that NT-3 plays no role in regulating the expression of Navi. 8 and Navi.9 
mRNAs in sensory ganglia of neonatal mice (figures 3.25, 3.37 and 3.45).
3.4.5. Galanin
The expression of galanin mRNA was investigated in TrkA/Bax double-null mutant 
and NT-3/Bax double-null mutant transgenic neonatal mice. However, since galanin 
mRNA could not be reliably quantified in sensory neuron cultures, no culture data is 
presented in this chapter. This is most likely due to low-level expression of galanin in 
the neuronal cultures combined with the small amount of total RNA that can be 
extracted and purified from cultured neurons. In addition, the galanin QPCR reaction 
was not as efficient, or sensitive as many of the other QPCR reactions.
The developmental expression pattern of galanin mRNA was similar in both 
trigeminal and dorsal root ganglia, with highest expression levels at E l6 and levels 
gradually decreasing as development proceeds (figure 3.9). Once again, as with 
Navi.8 and Navi.9 mRNAs, the developmental expression pattern was different in
294
nodose ganglia compared to the other two sensory ganglia. In the case of nodose 
ganglia, there was no significant difference in the levels of galanin mRNA expressed 
from El 6 to adult, suggesting that a similar number of nodose ganglion neurons 
express the message for this neuropeptide at all developmental stages (figure 3.9). The 
data from trigeminal and dorsal root ganglia is broadly in agreement with previous 
studies, and is indicative of an important role for galanin in developing sensory 
neurons (Xu et al., 1996; Ma et al., 1999). It is, perhaps, a little strange that the drop 
in galanin mRNA expression levels that occurs between neonatal ages and adult in 
both trigeminal and dorsal root ganglia was not greater than that observed, as previous 
research has shown that whilst the majority of developing sensory neurons from these 
ganglia express galanin, only 5% of adult neurons continue to express mRNA for this 
neuropeptide (Xu et al., 1996; Ma et al., 1999). It can only be assumed that this small 
population of neurons that retain expression of galanin mRNA significantly up- 
regulate the expression of this mRNA between birth and adulthood.
There was a significant decrease in galanin mRNA expression in the DRG of TrkA'7' 
/Bax'7' neonates compared to Bax'7' neonates (figure 3.21 A). A small decrease in the 
expression of this neuropeptide mRNA was also observed in the trigeminal ganglia of 
TrkA'77Bax'7' neonates compared to Bax'7' neonates, although this decrease was not 
statistically significant. These data suggest a role for NGF as a positive regulator of 
galanin mRNA expression within neonatal, neural crest-derived sensory neurons. 
However, since the reduction in galanin mRNA in trigeminal and dorsal root ganglia 
of TrkA'7'/Bax'7' neonates was small, it would appear that NGF/TrkA signalling is 
not absolutely essential for maintaining galanin mRNA expression at this age, and 
other factors have a role in the regulation of this neuropeptide in these ganglia. This 
is not surprising in light of the fact that galanin mRNA is expressed in the majority of 
neonatal trigeminal and DRG neurons, whereas TrkA expression is becoming more 
restricted by this stage to presumptive peptidergic, nociceptive neurons. Indeed,
GDNF and BDNF (Wang et al., 2003; Kerekes et al., 1995 respectively) have both 
been shown to regulate galanin mRNA expression in adult rat DRG (albeit in a 
negative manner). Receptors for these neurotrophic factors (especially TrkB) are 
expressed on neonatal DRG and trigeminal neurons, therefore a role for these 
neurotrophic factors in regulating galanin expression in neonatal neural crest-derived 
sensory neurons is also possible. The levels of galanin mRNA expressed by nodose
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neurons from TrkA^TBax'7' neonates were similar to those found in nodose neurons 
from Bax’7' neonates. This would suggest that either galanin is not expressed in the 
small TrkA-positive sub-population of nodose neurons, or that, if it is, NGF plays no 
role in regulating its expression at neonatal ages.
The apparent positive regulatory effects of NGF on galanin mRNA expression 
conflicts with previous work on adult, rodent sensory neurons that suggested a 
negative role for NGF in regulating galanin mRNA and peptide expression (Verge et 
al., 1995 Kerekes et al., 1997; Ozturk and Tonge; Shadiack et al., 2001). There may 
be several reasons why the results from transgenic animals presented in this chapter 
suggest a positive rather than a negative regulatory role for NGF in modulating 
neonatal galanin expression. The simplest explanation is that neonatal rodent neurons 
respond differently to NGF compared to adult neurons. The widespread expression of 
galanin in developing sensory ganglia and its subsequent restriction to a very small 
subset of neurons in the adult (Xu et al., 1996; Ma et al., 1999), suggests that galanin 
plays an important role in the survival and/or development of sensory neurons, a role 
that becomes redundant in the adult. Differential regulation of this neuropeptide 
mRNA in developing and adult neurons may therefore be anticipated. The data from 
transgenic animals presented in this chapter was obtained from intact, non-lesioned 
neurons. The negative effects of NGF on modulating galanin expression that were 
observed in previously published research appears to have been restricted to damaged 
neurons. For example, exogenous NGF is unable to decrease the expression of galanin 
in non-injured lumbar DRG neurons following partial sciatic nerve lesion in adult 
rodents, but it can prevent the up-regulation of galanin expression in neighbouring 
injured neurons (Verge et al., 1995). Postnatal culture data from PO sensory neurons, a 
situation that effectively mimics injured/axotomised neurons, would have proved 
informative in determining whether the ability of NGF to inhibit galanin mRNA 
expression is restricted to damaged sensory neurons in the neonatal rodent in the same 
way as it appears to be in the adult. Unfortunately, this data could not be obtained due 
to a lack of sensitivity of the PCR reaction and the small amount of total RNA that 
can be extracted and purified from cultured sensory neurons.
Once again, it is also possible that the lack of functional NGF/TrkA signalling from 
conception in the TrkA/Bax double null mutants effects the differentiation of sensory
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neurons into different functional sub-populations. This raises the possibility that the 
reduction of galanin expression in the absence of TrkA reflects an alteration in the 
composition of sensory ganglia, with regards to the numbers of neurons with different 
functional modalities, rather than a direct effect of NGF/TrkA signalling on galanin 
mRNA regulation. Further experiments with temporally controllable TrkA or NGF 
conditional knockout mouse lines would address this possibility, as would a detailed 
m-situ hybridisation and immuno-histochemistry analysis of sensory ganglia from 
TikA/Bax double-null mutants using antibodies and probes against galanin and other 
markers that characterise functionally distinct neuronal-sub-populations.
It is also possible that the lack of functional NGF/TrkA signalling throughout 
development reduces the target field innervation density of sensory neurons and/or 
leads to inappropriate target field innervation patterns. This may affect the 
accessibility of sensory neurons to additional target field-derived trophic factors that 
normally positively regulate galanin mRNA expression during embryonic 
development and in the neonatal period.
Galanin has been shown to have survival promoting effects on developing, mainly 
- nociceptive, sensory neurons. Analysis of the adult galanin null mutant mouse 
revealed a 13% reduction in, predominantly, small DRG neurons. This loss of neurons 
equated to a 24% decrease in TrkA-positive neurons that express SP, i.e. peptidergic 
nociceptive neurons (Holmes et al., 2000). Since NGF/TrkA signalling appears to 
promote the expression of galanin mRNA in developing sensory neurons, it is 
intriguing to propose that some of the sensory neuron cell loss observed in NGF and 
TrkA single knockout embryos/neonates occurs as a result of a galanin deficiency that 
is as consequence to the lack of functional NGF/TrkA signalling.
The data obtained from RT-QPCR analysis of RNA extracted from sensory ganglia of 
NT-3'7'/Bax'7' and Bax *7' neonatal mice suggests that NT-3 may play a role in 
regulating galanin mRNA expression in neonatal trigeminal neurons, but not nodose 
or DRG neurons (figure 3.27B). Trigeminal ganglia from NT-3'7'/Bax'7' neonates 
contained significantly higher levels of galanin mRNA than trigeminal ganglia from 
Bax'7' mice, suggesting that NT-3 normally acts to suppress galanin mRNA 
expression. Since the deletion of TrkA resulted in a decrease in galanin mRNA
expression in trigeminal ganglia, it is unlikely that NT-3 signals through TrkA to 
suppress galanin mRNA expression. Unlike DRG, trigeminal ganglia do not contain a 
sub-population of proprioceptive neurons expressing full-length functional TrkC in 
the neonatal period (these reside in the trigeminal mesencephalic nucleus) and 
, therefore probably contains very few neurons expressing functional TrkC (Emfors et 
al., 1992). This raises the possibility that NT-3 suppresses galanin mRNA expression 
by signalling through the common p75 neurotrophin receptor. NT-3 can, under certain 
|  ihcumstances signal via TrkB (Davies et al., 1995; Huang et al., 1999), so it is also 
possible that NT-3 signals through TrkB to inhibit galanin mRNA expression in the 
trigeminal ganglion. As mentioned previously, study of null mutant mice has shown 
. that a lack of NT-3 expression from conception can also alter the timing and dynamics 
of sensory neuron differentiation (Farinas et al., 1996). It is therefore possible that the 
increased expression of galanin mRNA within trigeminal ganglia in the absence of 
NT-3 observed here, reflects a change in the number of trigeminal neurons that 
differentiate into galanin-positive neurons rather than an indication of direct 
regulation of galanin mRNA expression by NT-3. Alternatively, the marked drop in 
GAPDH mRNA expression observed in trigeminal ganglia of NT-3*/'/Bax'/' neonates 
(3.23A) (see explanation above) may give the impression that galanin mRNA 
' expression is higher in trigeminal ganglia from these animals compared to ganglia 
from Bax7' mice after normalisation, when in reality the galanin mRNA levels per 
galanin-positive neuron may be very similar in ganglia from both genotypes. Once 
again, a detailed immuno-histochemistry and in-situ hybridisation analysis of sensory 
ganglia from NT-3/Bax double-null mutant neonates would prove useful in addressing 
these questions. In addition, further experiments using p75 and TrkB null mutants, or 
* a temporally controllable, conditional NT-3 null mutant would help to determine 
which of the above mechanisms operate to alter the levels of galanin mRNA 
expression within the neonatal trigeminal ganglion in the absence of NT-3. Culture 
data from experiments where trigeminal neurons were grown in the presence or 
absence of NT-3 would also shed light on this question, however, the limited 
? sensitivity and efficiency of the galanin mRNA RT-QPCR reaction preclude this 
approach at present.
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3.4.6. PACAP
The developmental time-course of PACAP mRNA expression is identical in all three 
sensory ganglia studied. In all three ganglia, there is a 2- to 3-fold increase in the 
expression of this neuropeptide mRNA between El 6 and PO, followed by a drop back 
to E l6 levels by P5. PACAP mRNA levels are maintained at P5 levels until adulthood 
in all ganglia (figure 3.10). This conflicts, somewhat, with previous data that shows a 
significantly more widespread expression of PACAP mRNA and peptide in 
embryonic sensory ganglia compared to adult (Shuto et al., 1996; Waschek et al.,
1998; Jiang et al., 2003). This result might therefore suggest that as the expression of 
PACAP mRNA becomes more restricted, the levels of mRNA expression increase in 
those cells that retain expression.
No difference in the expression of PACAP mRNA was observed between sensory 
ganglia isolated from either TrkA^'/Bax7' or Bax*7* neonates, suggesting that 
NGF/TrkA signalling plays no role in regulating PACAP mRNA expression 
perinatally (figure 3.20). This conclusion would seem to be confirmed by the results 
obtained from PO trigeminal and nodose neuron cultures. PACAP mRNA expression 
levels increased significantly over the first 24 hrs in culture for both trigeminal and 
nodose neurons cultured in the absence of neurotrophic factor support (figures 3.33B 
and 3.42). This increase mirrors that seen following axotomy of adult DRG neurons 
and probably reflects the removal of target field derived neurotrophic support from 
neurons (Jongsma Wallin et al., 2001). Whilst PACAP mRNA levels fell after 24 hrs 
in trigeminal neuron cultures, they still remained above in-vivo, levels at 48 hrs. The 
addition of lOng/ml NGF to cultures had no statistically significant effect on the 
levels of PACAP mRNA expressed by either nodose or trigeminal ganglia neurons 
(figure 3.33B and 3.42). The in-vitro and in-vivo data presented in this chapter 
conflicts with data from previous research using adult rodents which demonstrated 
that PACAP mRNA expression is positively regulated by NGF in both intact and 
injured DRG neurons, and following inflammation (Jongsma-Wallin et al., 2001, 
2003).
The simplest explanation of the discrepancy between the in-vivo data presented here 
and the data published previously, is that the regulation of PACAP mRNA expression
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is fundamentally different in neonatal sensory neurons compared to adult sensory 
neurons. PACAP mRNA and peptide are reported as widely expressed in embryonic 
and neonatal sensory ganglia, whereas in adult sensory ganglia, expression is 
predominantly restricted to a small sub-population of peptidergic nociceptors 
(Sheward WJ et al., 1998; Shuto et al., 1996; Waschek et al., 1998; Jiang et al., 2003; 
Moller et al., 1993; Mulder et al., 1994). The identity of the neuronal sub-populations 
expressing PACAP mRNA in neonatal sensory ganglia has not been established. 
However, it is possible that the majority of PACAP mRNA positive neonatal sensory 
neurons do not express TrkA, therefore the deletion of TrkA would not be expected to 
significantly alter the levels of PACAP mRNA in neonatal sensory neurons. 
Alternatively, it is possible that NGF regulates the expression of PACAP mRNA in 
neonates and adults by signalling through the common neurotrophin receptor, p75, 
and not TrkA, a scenario that is consistent with both the in-vivo data presented here 
and previously published in-vivo data from adult rats. Indeed, NGF has been reported 
to reduce the expression of PACAP mRNA in adult proprioceptive, TrkA negative, rat 
DRG neurons following nerve transection (Jongsma Wallin et al., 2001). Whilst this 
may reflect a paracrine effect of NGF on proprioceptive neurons, via actions on TrkA 
positive peptidergic nociceptors, it may also indicate that NGF can regulate PACAP 
mRNA expression via p7 5-dependent signalling (data suggesting that lesioned 
proprioceptive neurons start expressing TrkA has not emerged). Additional analysis 
of PACAP expression in neonatal and adult NGF/Bax and p75/Bax double-null 
mutants would determine whether NGF regulates PACAP mRNA expression in 
sensory neurons in-vivo via TrkA or p75 dependent signalling.
Another possible explanation for the unexpected data from TrkA/Bax double-null 
mutants stems from the observation that NT-3 appears to decrease PACAP mRNA 
and peptide expression selectively in TrkA-expressing nociceptive neurons in intact, 
non-lesioned adult rats (Jongsma-Wallin et al., 2001). If the actions of NT-3 are 
mediated by TrkA (and not p75), PACAP mRNA expression in peptidergic 
nociceptors would appear to be regulated in an antagonistic manner by NGF and NT- 
3 both signalling via TrkA. If the regulatory influences of both neurotrophins were of 
similar magnitude, the loss of TrkA expression in TrkA/Bax double-null mutants 
would not be expected to significantly alter the expression levels of PACAP mRNA.
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Based on the results of previous in-vivo experiments, one would perhaps predict that 
NGF would up-regulate the expression of PACAP mRNA in cultured neural crest- 
derived neonatal sensory neurons. Figure 3.33B clearly shows that this is not the case. 
This unexpected data can be explained in a number of alternative ways, none of which 
are mutually exclusive. First, it has been widely reported that axotomy, a situation that 
is largely mimicked by placing neurons in culture, leads to an increase in PACAP 
mRNA expression in large, non-nociceptive TrkC/TrkB expressing neurons that do 
not express TrkA (Zhang et al., 1995; Zhang et al., 1996; Jongsma-Wallin et al.,
2001). The up-regulation of PACAP mRNA in cultured sensory neurons is clearly 
evident from the data presented in figures 3.33B, 3.38B, 3.42 and 3.46. Since the 
majority of sensory neurons expressing PACAP mRNA in culture do not express 
TrkA (particularly in the case of the nodose ganglion), it is perhaps not surprising that 
NGF does not appear to regulate the expression of this peptide in culture. In-vivo data 
showing that NGF up-regulates the expression of PACAP mRNA and peptide in adult 
DRG neurons has been based on in-situ hybridisation and immuno-histochemistry, 
techniques that allow analysis of gene expression at the level of the individual neuron. 
The RT-QPCR assay used in this thesis reveals the changes in gene expression across 
the whole population of neurons within sensory ganglia. If the number of neurons 
expressing TrkA is small in the neuronal population from which total RNA for RT- 
QPCR analysis was extracted, and at the same time the number of neurons expressing 
PACAP message is large, NGF induced changes in PACAP mRNA levels in the small 
NGF-responsive sub-population will be unlikely to be detected. This explanation, 
however, cannot be the whole answer, as data presented in chapter 4 clearly show that 
NGF down-regulates PACAP mRNA expression in cultured adult DRG neurons 
where the majority of neurons are likely to be TrkA-negative.
Second, it is possible that the in-vitro regulation of PACAP mRNA expression does 
not reflect the in-vivo regulation of expression. All the data on the regulation of 
PACAP mRNA published to date has come from in-vivo experiments, predominantly 
sciatic nerve lesion. It appears that for most genes investigated in this thesis, placing 
neurons in culture mimics the effects of sciatic nerve lesion with regard to changes in 
mRNA expression. It also appears that for most genes investigated the regulation of 
mRNA expression by trophic factors in-vitro mirrors that seen after sciatic nerve 
lesion following infusion of trophic factors. It may be that PACAP is just an
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exception to this apparently general rule. Placing neurons in culture alters the 
expression of a large number of mRNAs and proteins. Perhaps key elements of the 
signalling pathways regulating PACAP mRNA expression show aberrant 
expression/phosphorylation in-vitro and this perturbs the normal regulation of mRNA 
expression. Alternatively, it may be that NGF normally regulates PACAP mRNA 
expression in-vivo in a co-operative manner with additional trophic factors.
Exogenous NGF therefore may not have the expected effects on PACAP mRNA 
expression in the absence of these additional trophic factors in the culture medium.
The third possible explanation to account for the discrepancy between my culture data 
and the previously published results of in-vivo experiments concerns the fact that all 
the latter data has come from the analysis of DRG neurons. It may simply be that 
neurotrophic factors regulate PACAP mRNA expression in trigeminal neurons in a 
different manner to DRG neurons. However, since NGF is shown to repress the 
expression of PACAP mRNA by cultured adult DRG neurons, in a dose-dependent 
manner, in chapter four of this thesis, this hypothesis seems unlikely. The fourth 
possible explanation for the inability of NGF to positively regulate PACAP mRNA 
expression in cultured neonatal, PO, trigeminal neurons concerns the fact that all 
previous in-vivo experiments have been performed on the rat, whereas my data is 
from mouse sensory neurons. It is possible that the regulation of PACAP mRNA 
expression differs between rat and mouse sensory neurons. There is a precedent for 
this in data from previous work. For example, it has been observed that the regulation 
of expression of the mRNAs encoding the NT-3 receptor, TrkC, and the MSP 
receptor, RON, are fundamentally different in cultured rat sensory neurons compared 
to cultured mouse sensory neurons (S. Wyatt unpublished data). This explanation is 
also consistent with the data on PACAP mRNA expression presented in chapter 4.
One interesting observation from the culture data is that PACAP mRNA levels 
increase significantly more in cultured nodose neurons (approximately nine-fold) 
compared to cultured trigeminal neurons (approximately four-fold) over the first 24 
hours after plating (figures 3.33B, 3.38B, 3.42 and 3.46). This raises the possibility 
that PACAP plays a particularly important role in regeneration following lesion of the 
vagal nerve or other trauma to nodose neurons. Unfortunately, the lesion-induced 
dynamics of gene expression changes in nodose neurons in-vivo have not been
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investigated, so it is not known whether the dramatic up-regulation of PACAP mRNA 
expression occurs in nodose neurons following trauma.
Trigeminal ganglia from PO NT-3"7TBax'7' neonates displayed a small but statistically 
significant increase in the expression levels of PACAP mRNA compared to ganglia 
from Bax single-null mutant neonates (figure 3.26B). An increase in the levels of 
PACAP mRNA was also observed in DRG obtained from double-null mutants 
compared to those from Bax'7* neonates, although in this case the increase was not 
quite statistically significant. These data would suggest a role for NT-3 as a negative 
regulator of PACAP mRNA expression in neonatal sensory neurons. A similar role 
for NT-3 has been shown in adult sensory neurons. In the adult rat, NT-3 infusion 
down-regulates the expression of PACAP mRNA in non-lesioned peptidergic 
nociceptors residing within lumbar DRG, and prevents the increased expression of 
PACAP mRNA by large, predominantly proprioceptive, DRG neurons following 
sciatic nerve lesion (Jongsma-Wallin et al., 2001). In contrast to trigeminal and DRG 
neurons, the data in figure 3.26 shows that NT-3 does not regulate PACAP mRNA 
expression in neonatal nodose neurons in-vivo. NT-3 also does not regulate PACAP 
mRNA expression in cultured neonatal nodose neurons (figure 3.46). These data 
provide another example of gene expression being regulated in a different manner in 
placode-derived sensory neurons compared to neural crest-derived sensory neurons.
Previously published data from experiments with adult rodents, and the data I 
obtained from NT-3/Bax double-null mutant neonates, indicate that NT-3 normally 
acts to suppress the expression of PACAP mRNA in neural crest-derived sensory 
neurons. However the results from my culture experiments with PO trigeminal 
neurons suggest the opposite. As shown in figure 3.38B, NT-3 significantly increases 
the amount of PACAP mRNA expressed by neonatal trigeminal neurons after 48 
hours in culture. This somewhat surprising result is difficult to explain. Neurons 
placed in culture can often show aberrant gene expression. An unpublished 
observation that has been made previously in our lab, is that early embryonic mouse 
trigeminal sensory neurons rapidly down-regulate expression of the full-length 
functional form of the cognate NT-3 receptor, TrkC, when placed in culture. Although 
it is not clear whether the same phenomenon occurs in the case of neonatal trigeminal 
neurons, this may explain why NT-3 cannot prevent the increase in PACAP mRNA
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expression that occurs in predominantly larger, non-nociceptive (TrkC/TrkB 
expressing), sensory neurons when target field derived neurotrophic factor influences 
are removed. This does not, however, explain why NT-3 appears to enhance PACAP 
mRNA expression in trigeminal neuron cultures. Some or all of the explanations in 
the previous paragraph regarding the unexpected effect of NGF in regulating the in- 
vitro expression of PACAP mRNA may apply to the unexpected effects of NT-3. As 
mentioned previously, adult trigeminal ganglia do not contain a sub-population of 
TrkC positive proprioceptive neurons and neonatal trigeminal ganglia contain few 
full-length TrkC-positive neurons (Emfors et al., 1992). This would suggest that the 
effects of NT-3 in increasing PACAP mRNA expression in cultured trigeminal 
neurons are mediated via TrkA, TrkB or p75.
3.4.7. VR1 (TRPV1)
The developmental pattern of VR1 mRNA expression is similar for both trigeminal 
and dorsal root ganglia, although expression levels are significantly higher at all ages 
in DRG compared to trigeminal ganglia (figure 3.11 A and C). In both ganglia, the 
highest expression levels of VR1 mRNA are found at E l6 and there is a gradual, but 
highly significant, drop in the expression of this ion channel from El 6 to adulthood. 
This is in agreement with the observation that virtually all newly “bom” mouse TrkA- 
positive, presumptive nociceptive sensory neurons express VR1 mRNA and protein 
(Patrik Emfors, Karolinska Institute, personal communication). During the late 
embryonic period and first post-natal week many of these VR1 positive sensory 
neurons lose expression of this ion channel, especially the sub-population that become 
IB4-positive c-fibre nociceptors (P Emfors, personal communication). The expression 
data presented in figure 3.11A and C is also in agreement with previously published 
data. In the adult mouse, VR1 expression is predominantly restricted to TrkA- 
positive, peptidergic nociceptive neurons (Zwick et al., 2002). During the first post­
natal week around half of the population of nociceptive neurons down-regulate 
expression of TrkA and begin to express receptors for the GDNF family of trophic 
factors (Molliver et al, 1997).
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Once again, the data presented in figure 3.11 B (and figure 3.19B) reveals that the 
regulation of nociceptive neuron markers differs in the predominantly placode- 
derived nodose ganglia, compared to the neural-crest derived sensory ganglia. E l6 
nodose ganglia express significantly lower levels of VR1 mRNA than trigeminal and 
dorsal root ganglia. Expression of this ion channel mRNA increases significantly in 
the nodose ganglion between E l6 and PO, and then between PO and P5, so that by P5 
the levels of VR1 mRNA are markedly higher in the nodose ganglia that they are at 
E l6 in trigeminal and dorsal root ganglia. This would suggest that VR1 mRNA is not 
restricted to the small TrkA-positive, apparently peptidergic, sub-population of 
nodose neurons during development, as discussed below. Between P5 and adulthood, 
there is a dramatic drop in the levels of VR1 mRNA expressed by nodose neurons, 
although the adult levels of this ion channel mRNA are still higher than those in adult 
trigeminal and dorsal root ganglia. This raises the possibility that VR1 mRNA 
expression become largely restricted to TrkA-positive peptidergic neurons in the adult 
mouse nodose ganglion in the same way as it is in adult neural-crest derived sensory 
ganglia (although it is not certain whether a TrkA positive, peptidergic sub-population 
of neurons exists in the adult mouse nodose ganglion). This would not appear to be 
the case according to a previous publication from the rat (Michael and Priestley,
1999). In-situ hybridisation and/or immuno-histochemistry would determine whether 
VR1 expression patterns are the same in adult mouse and rat placode-derived sensory 
ganglia.
The data from neonatal trigeminal ganglia cultures, clearly demonstrates that NGF 
can significantly prevent the drop in VR1 mRNA expression that occurs when 
trigeminal neurons are removed from their source of target-field derived neurotrophic 
factor support (figure 3.33A). This drop in VR1 mRNA expression mirrors the 
changes in the expression of VR1 mRNA within adult rodent DRG neurons following 
sciatic nerve lesion (Michael and Priestley, 1999; Michael and Priestley 2002; 
Fukuoka T et al., 2002; Wendland et al, 2003). Interestingly, this drop in VR1 mRNA 
expression over time in culture is dependent on culture conditions and/or neuron 
density. Trigeminal neurons from neonatal rats and mice do not show a reduction in 
VR1 mRNA or protein expression when they are cultured at a high density, in serum 
containing media, in the absence of added growth factors (Simonetti et al., 2006). 
Presumably under these conditions the culture media contains sufficient levels of
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NGF (and/or other growth factors), either as a result of autocrine/paracrine production 
by neurons or non-neuronal cells, or from the serum itself, to prevent a decrease in 
VR1 mRNA expression. My data clearly shows that in the absence of exogenous 
NGF, VR1 mRNA is virtually undetectable in RNA extracted from trigeminal 
neurons that have been cultured for 48 hours, at low density, in defined medium 
(figures 3.33A and 3.38A). lOng/ml NGF can restore VR1 mRNA levels to those 
found in-vivo (figure 3.33A). This would suggest that VR1 mRNA, a known marker 
of nociceptive neurons, is predominantly expressed in TrkA-positive, nociceptive, 
neonatal mouse trigeminal neurons (at this age the majority of presumptive 
nociceptive neurons express TrkA, although the IB4-positive, TrkA-negative 
nociceptive population are beginning to appear (Molliver et al, 1997)). Indeed, in the 
adult mouse, VR1 is predominantly a marker of TrkA-positive, peptidergic 
nociceptors in the same way as substance P and CGRP (Zwick et al., 2002).
The in-vitro NGF data presented in this chapter are in agreement with previous in- 
vitro and in-vivo data from adult rodent DRG neurons showing that NGF can promote 
VR1 mRNA expression following both sciatic nerve lesion and in culture, and also 
data showing that sequestration of NGF with an antibody reduces the capsaicin 
sensitivity of naive DRG neurons (McMahon et al., 1995; Michael and Priestly, 1999; 
Shu and Mendell, 1999). Moreover, an increase in VR1 expression, driven by an 
inflammation associated increase in NGF expression, has been observed in TrkA- 
positive nociceptive neurons within rat lumbar DRG following CFA injection to the 
rat hindpaw. This increase in VR1 expression can be prevented by the concomitant 
administration of an NGF blocking antibody (Amaya et al., 2004).
No difference in VR1 mRNA expression was observed in neural crest-derived sensory 
ganglia dissected from TrkA^'/Bax'7' mice, compared to those from Bax’7' mice (figure 
3.2IB). This data is somewhat surprising in light of the in-vitro data obtained from PO 
trigeminal neuron cultures (figure 3.33A) and the substantial evidence indicating that 
NGF can up-regulate the in-vitro and in-vivo expression of VR1 mRNA in adult DRG 
neurons (including the data presented in chapter 4 of this thesis). Results presented in 
this chapter from NT-3*/'/Bax'/' mice, however, may provide an explanation for this 
observation (figure 3.27 A). An increase in VR1 mRNA levels was observed in 
trigeminal ganglia and DRG of N T ^ '/B ax7' neonates, suggesting that NT-3 may
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normally act in the neonatal period to repress VR1 mRNA expression in-vivo 
(although see alternative explanations below). Since VR1 is predominantly expressed 
by TrkA positive, peptidergic neurons in the adult mouse, and not those expressing 
TrkC (or the other possible NT-3 receptor, TrkB), it is quite possible that the negative 
effects of NT-3 on neonatal VR1 mRNA expression are predominantly mediated 
through its non-preferred receptor TrkA. If one hypothesised that NGF and NT-3 are 
both signalling via TrkA to regulate VR1 expression in opposite directions during the 
neonatal period, deleting TrkA may therefore not be expected to significantly alter 
VR1 expression in neonatal ganglia. However, although a feasible explanation, it 
should be borne in mind that the time course data suggested that VR1 mRNA is likely 
to be more widely expressed in neonatal trigeminal and DRG neurons and not entirely 
restricted to TrkA-positive cells (see above), and it is also possible that NGF and/or 
NT-3 can regulate VR1 expression via p75 dependent signalling. Analysis of VR1 
mRNA expression in neural crest-derived sensory ganglia from TrkC/Bax double-null 
mutant, NGF/Bax double-null mutant and p75/Bax double- null mutant mice would 
help to determine whether this hypothesis is correct. Such analysis is, however, 
beyond the scope of this thesis.
It is possible that peripheral target fields contain trophic factors, apart from NT-3, that 
normally act to suppress VR1 mRNA expression. Target field innervation is seriously 
compromised in TrkA/Bax double-null mutant animals (Patel et al, 2000) thus 
preventing sensory neurons from being exposed to putative target field-derived 
negative regulators of VR1 mRNA expression. If this hypothesis were correct, 
neonatal TrkA^TBax7" sensory neurons would be deprived of exposure to positive and 
negative regulators of VR1 mRNA expression and the net result may be no change in 
VR1 mRNA expression levels.
An alternative hypothesis to explain the TrkA/Bax double-null mutant data for 
trigeminal and dorsal root ganglia is that VR1 mRNA expression is positively 
regulated by a number of different trophic factors in a partially redundant way in 
neonatal mice. The data from chapter 4 of this thesis support this idea. NGF, MSP and 
artemin can all positively regulate VR1 mRNA expression in cultured adult mouse 
DRG neurons (figures 4.9C, 4.15B, 4.23B). If all these trophic factors play a role in 
positively regulating VR1 mRNA expression in neonatal neural crest-derived sensory
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neurons, the loss of NGF/TrkA signalling may not lead to a decrease in VR1 
expression if MSP and/or artemin (or possibly additional, as yet unidentified, factors) 
can compensate for its loss. Determining the validity of this hypothesis would require 
a careful analysis of VR1 mRNA expression in sensory ganglia of double- and triple­
null mutants for TrkA, GFR-a 3 and RON, preferably as temporally controllable 
conditional null mutants. This is clearly beyond the scope of this thesis.
Once again, it is possible that the lack of functional NGF/TrkA signalling from 
conception perturbs the programme of “primary” and/or “secondary” differentiation 
in neural crest-derived sensory ganglia in such as way as to result in the loss, or 
reduction, of the sub-population of neurons that ordinarily become neonatal TrkA- 
positive peptidergic nociceptors. This functional sub-group may, under these 
circumstances, be partly or wholly replaced by other sub-populations of VR1 mRNA- 
positive neurons that are not responsive to NGF. Careful immuno-histochemical 
analysis of sensory ganglia from TrkA/Bax double-null mutants and Bax null mutant 
neonates and/or analysis of VR1 mRNA in temporally-controlled TrkA conditional 
null mutants would determine whether this hypothesis is valid.
Interestingly, VR1 mRNA levels are significantly increased in nodose ganglia of 
TrkA'77Bax'7' neonates compared to nodose ganglia of Bax'7' mice (figure 3.21 B). The 
simplest explanation for this is that NGF/TrkA signalling negatively regulates the 
expression of VR1 mRNA in the small NGF-responsive sub-population of neonatal 
nodose neurons. This explanation makes the assumption that VR1 mRNA expression 
is predominantly restricted to TrkA-positive, peptidergic, placode-derived neonatal 
mouse sensory neurons in the same way as it is in adult mouse neural crest-derived 
sensory neurons. The high levels of VR1 mRNA expressed by neonatal nodose 
ganglia, in comparison to the levels of VR1 mRNA in adult trigeminal and dorsal root 
ganglia (figure 3.11), and the observation that VR1 is co-expressed with TrkB in adult 
rat nodose ganglia (Michael and Priestley, 1999) would tend to argue against this 
possibility, however, as mentioned for other genes, expression patterns differ between 
rat and mouse in adult neural crest-derived sensory ganglia as could be the case for 
VR1. In-situ hybridisation and/or immuno-histochemical analysis of neonatal nodose 
ganglia would address this point.
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Alternatively, if VR1 mRNA is indeed expressed by a large proportion of neonatal 
nodose neurons, most of which are TrkA-negative, it is possible that NGF/TrkA 
signalling normally represses VR1 mRNA expression in these neurons by an indirect, 
paracrine mechanism. For example, NGF activation of TrkA expressed on a small 
sub-population of nodose neurons may result in the release of a second trophic 
molecule that can then down regulate VR1 mRNA expression in TrkA-negative 
nodose neurons. Determining whether NGF can down-regulate VR1 mRNA 
expression, in low-density cultures of neonatal nodose neurons, would be useful to 
show whether NGF has the ability to decrease VR1 mRNA expression under 
conditions where paracrine mechanisms are likely to be inefficient. Unfortunately, 
reliable quantitative data on VR1 mRNA expression in cultured nodose neurons could 
not be obtained due to a combination of the small amount of total RNA that can be 
extracted from nodose neuron cultures and the relative inefficiency or the VR1 QPCR 
reaction. Once again, a perturbation in primary and secondary neuronal differentiation 
may account for the data from TrkA/Bax double-null mutant animals, especially if 
this results in the expansion of a sub-population of TrkA-negative neurons that 
express high levels of VR1 mRNA.
Although the data from NT-3/Bax double-null mutant neonates suggest that NT-3 acts 
during the perinatal period to suppress VR1 mRNA expression in neural crest-derived 
sensory ganglia, but not nodose sensory ganglia, the in-vitro data does not 
conclusively support this hypothesis (figure 3.38A). The VR1 mRNA levels 
expressed by PO trigeminal neurons show a significant reduction after 24 hours in 
culture in the absence of neurotrophic factor support. It appears that lOng/ml NT-3 
may accentuate this reduction, however, the effect of NT-3 does not reach statistical 
significance. By 48 hrs in culture, VR1 mRNA can no longer be detected in 
trigeminal neurons, therefore any further reduction in VR1 mRNA expression as a 
result of exogenous NT-3 are impossible to detect. More detailed time-course 
experiments (with readings at 6, 12,18 and 24 hrs) may help to determine whether 
NT-3 can down-regulate VR1 mRNA expression in cultured PO trigeminal neurons.
The in-vivo data presented in figure 3.27A is in agreement with a recent publication 
documenting the role of NT-3 in regulating VR1 mRNA expression following chronic
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constriction injury (CCI) of the adult rat sciatic nerve. Although there is a large 
decrease in VR1 mRNA expression in injured nociceptive neurons following CCI, 
non-injured nociceptive neurons and a few large mechanoreceptive neurons display 
greatly increased expression of VR1 mRNA that can be prevented by NT-3 infusion. 
NT-3 infusion also concomitantly decreased injury associated hyperalgesia (Wilson- 
Gerswing et al., 2005). It has been proposed by the authors that the effects of NT-3 
are mediated through TrkA rather than TrkC.
3.4.8. Summary
This chapter has focussed on the regulation of gene expression in neonatal trigeminal, 
nodose and dorsal root ganglia. The regulation of gene expression by the neurotrophic 
factors NGF and NT-3 was explored both in-vivo, using transgenic mice, and in-vitro, 
using cultured neurons.
The data for a-CGRP, SP, Navi.8 and Navi.9 mRNAs in neural crest derived- 
sensory ganglia was broadly in line with previously published in-vitro and in-vivo 
data from adult rodents, and demonstrated that NGF/TrkA, but not NT-3, signalling 
plays an important role in regulating the expression of these mRNAs in the neonatal 
period. In fact, the data for a-CGRP, SP and Navi.8 mRNAs, in particular, would 
suggest that NGF alone is the primary positive-regulator of transcriptional activity for 
these genes in neonatal neural crest-derived sensory neurons. Whilst p-CGRP and 
Navi.9 mRNAs are clearly regulated by NGF/TrkA signalling in neonatal, neural 
crest-derived sensory ganglia, the data suggest that other factors co-operate with NGF 
in regulating the expression of these mRNAs.
Much of the data presented on the regulation of CGRP, substance P and TTX-resistant 
sodium channel mRNAs in the neonatal period is novel, since most previous 
investigations have concentrated on their regulation in the adult, predominantly in 
models of nerve-lesion and inflammation. This neonatal data has important 
implications, since all of these mRNAs encode proteins and peptides that play 
important roles in setting sensory thresholds. Changes in their expression are also
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associated with neuropathic pain syndromes as detailed in section 1. The data 
suggests that the regulation of these genes following nerve-trauma (a situation that 
often leads to neuropathic pain) will be similar in neonatal and juvenile mice 
compared to adult mice. Extrapolation of this data to the human may be useful in 
future studies on chronic pain conditions in babies and children.
Analysis of the regulation of galanin, PACAP and VR1 mRNA expression in neural 
crest-derived sensory neurons produced some results that are in accordance with the 
regulation of these mRNAs in adult rodent neural-crest derived sensory neurons. 
However, some of the data highlights important differences in the regulation of these 
mRNAs in the neonatal period compared to the adult. One thing these three mRNAs 
have in common is that they are much more widely expressed amongst different 
sensory neuron sub-populations in the developing mouse nervous system than they 
are in the adult (in the adult mouse, these mRNAs are predominantly expressed in a 
sub-population of TrkA-positive, peptidergic, nociceptive neurons). This fact alone 
may account for much of the unexpected data that arose during my investigation of 
their neonatal expression.
The existing published literature has established that galanin mRNA expression is not 
affected by exogenous NGF in intact adult sensory neurons. In contrast, NGF appears 
to suppress the expression of galanin in damaged neural crest-derived sensory neurons 
(Hokfelt et al., 1987; Villar et al., 1989; Wiesenfeld-Hallin., 1992; Zhang et al., 1998; 
Holmes et al., 2005). Surprisingly, my data suggests that NGF positively regulates the 
expression of galanin mRNA in neonatal trigeminal and DRG neurons, probably in 
conjunction with other neurotrophic factors. In contrast, NT-3 appears to be able to 
suppress the expression galanin mRNA in neonatal trigeminal neurons. A number of 
caveats have to be bom in mind when interpreting the in-vivo data presented in this 
chapter, and alternative explanations of the data, other than direct transcriptional 
regulation of the various mRNAs by NGF and NT-3, are possible (see above). 
However, if galanin transcription is directly regulated by NGF and NT-3 in 
undamaged neonatal, neural crest-derived neurons, this data may have important 
implications for the study of pathological pain states in babies and children given the 
anti-nociceptive effects of galanin in the adult rodent (Hao et al., 1999; Yu et al.,
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1999; Liu and Hokfelt 2000; Blakeman et al., 2001; Hygge-Blakeman et al., 2004; 
reviewed in Wiesenfeld-Hallin et al., 2005).
The existing literature, based predominantly on in-vivo studies of the adult rat, 
indicates that NGF positively regulates the expression of PACAP mRNA in neural 
crest-derived sensory neurons (Jongsma-Wallin et al., 2001, 2003). My data, however, 
suggests that NGF does not regulate the expression of PACAP mRNA in neonatal 
sensory neurons. Whilst a number of hypotheses could account for this discrepancy 
(described in detail above), the data may reflect a genuine difference in the regulation 
of PACAP mRNA expression between neonatal and adult sensory neurons. The data 
presented in this chapter indicates that NT-3 negatively regulates PACAP mRNA 
expression in neonatal neural crest-derived mouse sensory neurons in a similar 
manner to its action on PACAP mRNA expression in the adult rat (Jongsma-Wallin et 
al., 2001).
The in-vitro data presented in this chapter shows that NGF can regulate the expression 
of VR1 mRNA in cultured neonatal, neural crest-derived sensory neurons. This data is 
in agreement with data from adult rodents and the observations made in chapter 4 of 
this thesis (McMahon et al., 1995; Michael and Priestly, 1999; Shu and Mendell,
1999). In contrast to the in-vitro data, no loss of VR1 mRNA expression was observed 
in either the trigeminal or dorsal root ganglia of TrkA/Bax double-null mutant 
neonates. This may reflect a combination of the widespread expression of VR1 
mRNA in neonatal sensory ganglia together with a redundancy in the regulation of 
VR1 mRNA by a combination of growth factors. The data presented in chapter 4 of 
this thesis supports the validity of the latter hypothesis. It is not known to what extent 
other growth factors positively regulate the expression of VR1 mRNA in adult rodent 
sensory ganglia in-vivo. An analysis of VR1 mRNA expression in either TrkA/Bax or 
NGF/Bax double-null mutant adult mice (preferably temporally controlled conditional 
knockouts) may reveal a similar redundancy in the regulation of VR1 mRNA 
expression in adult sensory neurons. Given the importance of VR1 in setting sensory 
thresholds and its implication in the aetiology of neuropathic pain, determining 
whether several factors can regulate the expression of VR1 mRNA in a redundant 
way, in both neonates and adults, is an important question. In agreement with data 
from adult rodents, NT-3 appears to have a negative regulatory influence on VR1
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mRNA expression in neonatal, neural crest-derived, mouse sensory neurons. The 
negative regulatory effects of NT-3 on galanin, PACAP and VR1 mRNA expression 
within neonatal and adult sensory neurons (data presented here and Wilson-Gerswing 
et al., 2005; Jongsma-Wallin et al., 2001) may warrant a thorough investigation into 
the efficacy of NT-3 in treating neuropathic pain.
To date very little has been known about the regulation of expression of nociceptive 
neurons markers in the neurogenic placode derived nodose ganglion, either under 
normal conditions or following nerve lesion/trauma. The data presented in this chapter 
demonstrates that developmental expression patterns and transcriptional regulation 
differs between placode-derived, neonatal sensory neurons and neural-crest derived, 
neonatal sensory neurons for many of the mRNAs investigated. Whilst this may partly 
reflect the small population of TrkA-positive nociceptors that reside within nodose 
ganglia, it seems likely that there are some genuine differences in the growth factor 
control of nociceptive neuron marker mRNA expression. The data presented in this 
chapter suggests that a-CGRP is almost exclusively restricted to the NGF-responsive 
population of nodose neurons whereas substance P and P-CGRP mRNAs are 
expressed in this neuronal subset and another, probably small, subset of nodose 
neurons. Navi.8 and 1.9 mRNAs would appear to be expressed widely in the nodose 
ganglion. NGF can positively regulate the expression of all these mRNAs, with the 
largest regulatory effect apparent for a-CGRP mRNA in accordance with the 
apparently exclusive expression of this mRNA within NGF-responsive nodose 
neurons. Of particular note, is the observation that NT-3 appears to be able to 
negatively regulate galanin, PACAP and VR1 mRNA expression in neural crest- 
derived sensory neurons, but not in nodose ganglion neurons. This may reflect a lack 
of functional NT-3 receptors on neonatal nodose neurons, or a genuine difference in 
the regulation of these mRNA between placode-derived and neural-crest derived 
sensory neurons. Further work will be needed to determine which of these two 
possibilities are correct and whether the same situation exists in the adult. Given the 
importance of all three of these molecules in nociception, and their potential 
involvement in the generation of neuropathic pain, these are important questions to 
answer. The most striking difference between neonatal nodose- and neural crest- 
derived sensory neurons is in the regulation of VR1 mRNA expression by NGF. NGF
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positively regulates the expression of VR1 mRNA in both cultured neonatal and adult 
neural-crest derived sensory neurons in-vivo. In marked contrast, NGF appears to 
repress the expression of VR1 mRNA in neonatal nodose neurons in-vivo, possibly 
via a paracrine mechanism. A number of possible alternative explanations exist for 
the data suggesting this, especially in the absence of in-vitro culture data showing a 
direct down-regulation of VR1 mRNA by NGF. However, if NGF really is a negative 
regulator of VR1 mRNA expression in placode-derived sensory neurons this has 
important implications for researchers working on the role of VR1 in the aetiology of 
neuropathic pain and visceral pain states, especially if VR1 mRNA expression is 
regulated in a similar way by NGF in adult nodose neurons. Further experimental 
work is needed to clarify whether NGF is a true negative regulator of VR1 mRNA 
expression in neonatal and adult mice.
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3.5. Results in Brief
Chapter 3 focussed upon the expression of particular mRNAs of interest, and their 
neurotrophic regulation in the postnatal mouse. Both transgenic mice and neuronal 
cultures were used and expression of mRNAs of interest were quantified using real­
time Q-PCR. The key findings can be outlined as below:
a-CGRP (and also p-CGRP and SP):
• NGF/TrkA signalling is required for expression of a- and p-CGRP, and SP 
mRNAs in trigeminal, nodose and dorsal root ganglia.
• NT-3 produces no effect on the expression of these mRNAs.
Nav1.8 (and Nav1.9):
• NGF/TrkA signalling is required for expression of both Navi .8 and Navi .9 
mRNAs in trigeminal ganglia and DRG, but results suggest this is not the case 
for cells of the nodose ganglia.
• NT-3 produces no effect on the expression of these mRNAs.
PACAP:
• Results show no apparent effects of NGF on PACAP mRNA expression 
despite previous research showing a positive role for NGF/TrkA signalling on 
PACAP mRNA and protein expression in DRG.
• NT-3 appears to show an inhibitory effect on PACAP mRNA expression in 
vivo, and this effect could explain why no alteration in expression, either 
positive or negative is observed in TrkA^TBax7' mice. If both the inhibitory
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effects of NT-3 and the positive effects of NGF are produced via TrkA, then 
the antagonistic effects of both factors will be lost in the transgenic knockout.
• In contrast to the above finding, NT-3 seems to show a positive effect on 
PACAP mRNA in vitro.
G alanin:
• A significant down-regulation in galanin mRNA in trigeminal ganglia of 
TrkA'7TBax'7' mice in comparison to Bax'7' mice, and a notable, but not 
significant, down-regulation in DRG of TrkA"77Bax'7* was observed in 
comparison to Bax'7' mice. These results suggest a role for NGF as a positive 
regulator of galanin mRNA within neural crest derived sensory neurons, 
however, as effects were only small it suggests that NGF is not exclusively 
responsible for the regulation of galanin mRNA expression in these ganglia at 
this age.
• No effect on galanin mRNA expression was observed in neurons of the nodose 
ganglia, suggestive that either galanin is not expressed in small TrkA positive 
subpopulation of nodose neurons, or that, if it is, NGF plays no role in 
regulating its expression at neonatal ages.
• NT-3 may act to suppress galanin mRNA expression in the trigeminal, but not 
in the nodose or dorsal root ganglia, however results from the TrkA'7TBax'7' 
mouse suggest that this effect is not mediated via TrkA. Since trigeminal 
ganglia do not contain a subpopulation of neurons that expression functional 
TrkC receptors, this raises the possibility that NT-3 suppresses galanin mRNA 
expression by signalling through the common p75 neurotrophin receptor.
VR1:
• NGF was found to positively regulate the expression of VR1 mRNA in 
cultured trigeminal ganglia neurons.
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• BUT no difference in VR1 mRNA in trigeminal or dorsal root ganglia was 
observed in TrkA7TBax7' mice vs Bax7' mice.
• NT-3 could suppress expression of VR1 mRNA in trigeminal and dorsal root 
ganglia, as revealed by study of NT-37TBax7' mice. This may explain why no 
positive effects of NGF/TrkA signalling were observed in TrkA7'/Bax7' mice. 
If both the negative effects of NT-3 and the positive effects of NGF are 
mediated via TrkA, then no alterations in VR1 mRNA expression would be 
anticipated in mice lacking functional TrkA receptors.
• Other explanations for results observed in TrkA7TBax7' mice include:
o Compensation by other neurotrophic factors 
o Lack of TrkA from conception could alter the differentiation of 
a subset of neurons, such that those that express TrkA no longer 
express VR1
• Study of results for nodose neurons suggests NGF/TrkA signalling negatively 
regulates the expression of VR1 mRNA in nodose neurons. However nodose 
neurons tend to express TrkB rather than TrkA, so results might suggest 
NGF/TrkA signalling can repress VR1 mRNA expression via a paracrine 
mechanism.
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Chapter 4
Neurotrophic Factor Regulation of Gene Expression in Adult
Sensory Neurons
4.1 Introduction
In chapters 2 and 3 of this thesis, I investigated the developmental transcriptional 
regulation of a number of proteins and peptides that are markers of peptidergic, 
nociceptive sensory neurons in the adult rodent. The developmental mRNA 
expression profile for each of these markers was determined in neural crest- and 
placode-derived sensory neurons. In addition, the role that the neurotrophic factors 
NGF and NT-3 play in initiating and regulating the transcriptional expression of each 
mRNA was investigated using in-vivo and in-vitro approaches. In this chapter, I 
investigate the transcriptional regulation of the same mRNAs in cultured adult DRG 
neurons. In addition to the genes examined in previous chapters, I also examine the 
transcriptional regulation of a number of other genes that may play important roles 
both in determining normal nociceptive thresholds, and in the generation of 
inflammatory and neuropathic pain conditions. These additional genes are the non- 
peptidergic nociceptive neuron marker, P2X3; the TTX-sensitive sodium channels, 
Navi.6 and Navi.7; and two proteins whose expression is associated with neuronal 
damage, DINE and ATF3. The previous two chapters have concentrated on 
examining the transcriptional regulation of nociceptive neuron markers by NGF and 
NT-3.1 extend the study in this chapter to include an investigation of the effects that 
the neurotrophic factors artemin, MSP and LIF have on the regulation of gene 
expression at the transcriptional level.
Under normal circumstances, the mRNA levels of all the genes examined in this 
chapter are likely to be fairly static within each adult sensory neuron sub-population 
(in the case of DINE and ATF3 expression is effectively absent, as described below). 
Since all these genes have important roles in determining nociceptive thresholds, it is
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important to establish the neurotrophic growth factor, or combination of growth 
factors, that set these steady state expression levels. This of particular importance, 
since changes in the expression of these genes that occur during inflammation and 
following nerve trauma, and which may be causally related to pathological pain 
conditions, are likely to be driven, at least in part, by a change in the availability of 
neurotrophic factors that normally regulate their steady state levels in the “normal” 
adult. For example, inflammation is associated with an increase in the levels of NGF 
and GDNF in tissues surrounding nerves, Schwann cells and within DRG themselves. 
These increases in neurotrophic factor expression drive changes in neuronal gene 
expression, either directly or indirectly, that can lead to mechanical and thermal 
hyperaglesia (e.g. Amaya et al., 2004; Ji et al., 2002; Hefti et al., 2006). Conversely, 
neuronal damage reduces the accessibility of neurons to target field-derived 
neurotrophic factors and leads to changes in gene expression in damaged neurons that 
may contribute to the development of neuropathic pain. The reduced ability of 
damaged neurons to sequester and retrogradely transport target field-derived 
neurotrophic factors effectively increases the availability of these factors to 
undamaged sensory neurons innervating the same target field. This in turn leads to 
changes in the expression of functionally important genes in these “spared” neurons, 
which in itself may drive the generation of pathological pain (e.g. Hudson et al., 2001; 
Fukuoka et al., 2002; Winston et al., 2001; Ogun-Muyiwa et al., 1999 Wendland et al,
2003). Quite clearly, therefore, it is vital to fully understand the neurotrophic 
factor/factors that regulate the expression of functionally important genes within adult 
sensory neurons, as this will lead to an increased understanding of how inflammatory 
and neuropathic pain develops. Such an increased understanding of gene regulation 
may lead future research down fruitful therapeutic avenues.
The most direct way of determining which neurotrophic factors regulate the 
expression of sensory neurons genes in the adult would be to use transgenic animals 
that have null deletions of either the neurotrophic factors, or their receptors. This 
approach was used, successfully, in chapter 2 to determine whether NGF/TrkA 
signalling was important for the induction of a number of genes that are nociceptive 
neuron markers. In chapter 3, double-null-mutant mice, that contained a deletion of 
either TrkA or NT-3 in addition to a deletion of the pro-apoptotic protein, Bax, were 
used to examine the regulation of sensory neuron gene expression in neonatal sensory
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ganglia. The double-null mutant approach was necessary to ensure that results were 
not confounded by widespread loss of specific neuronal sub-sets in the absence of 
neurotophic factor signalling during the period of naturally occurring neuronal death. 
Despite the deletion of Bax and the concomitant prevention of neuronal cell death, 
there are a number of caveats to the interpretation of data from chapter 3 regarding the 
effects of trophic factor/receptor deletion on neuronal differentiation and target field 
innervation (discussed in detail in chapter 3). For this reason, it was necessary to 
validate data from the transgenic mice with cell culture data. Such cautionary 
interpretation of data is likely to be more important in the case of adult transgenic 
mice, so, although null mutants of artemin, NGF, MSP and LIF receptors are 
available, it was decided to carry out the entire study on gene regulation in adult 
sensory neurons using an in-vitro, cell culture approach.
Ideally, a temporally and spatially controlled knockout of neurotrophic factor receptor 
genes, using a cre-ERT2/loxP-site system, would have been used to generate in-vivo 
gene regulation data, thus avoiding the pitfalls of aberrant differentiation and/or target 
field innervation affecting the results. However, whilst suitable nociceptive neuron- 
specific cre-recombinase (Agarwal et al., 2004) and floxed LIF and MSP receptor 
(Betz et al., 1998; Waltz et al., 2001) mouse lines exist, mouse strains containing loxP 
flanked TrkA and GFR-a 3 have not been generated to date. Using gene targeting 
approaches to generate floxed TrkA and GFR-a 3 alleles is both time-consuming and 
costly and far beyond the scope of this thesis. Another alternative approach that could 
be used to, determine the effects that neurotrophic factors have on regulating gene 
expression in the adult, is intraplantar injection of exogenous neurotrophic factors, 
function blocking antibodies or receptor-Fc constructs into one hindpaw footpad of 
mice over a number of days. Hindpaw footpads receive their sensory innervation from 
L4, 5 and 6 lumbar DRG. An analysis of mRNA expression from ipsilateral L4-L6 
DRG and contralateral L4-L6 DRG (as controls) would allow analysis of the effects 
that increasing (neurotrophic factors) or decreasing (blocking antibodies and receptor- 
Fc) target field neurotrophic factor levels has on the transcriptional regulation of the 
genes in question. This approach, however, has two major drawbacks. The first is the 
cost of the large amounts of neurotrophic factors and blocking reagents required to 
successfully alter gene expression in L4-L6 DRG of a number of animals. The second
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drawback is the possibility that any effects that exogenous neurotrophic factors and 
blocking reagents have on changing DRG mRNA expression may be via a paracrine 
effect, on other tissues expressing receptors for the neurotrophic factors, and hence 
not reflect the direct effects of neurotrophic factor signalling on DRG neurons. For 
these two reasons, I decided not to pursue this approach.
Since adult rodent DRG neurons can survive in culture independently of neurotrophic 
factors (Lindsay, 1988), they allow a direct comparison of the effects of specific 
neurotrophic factors on regulating gene expression as a true ‘no neurotrophic factors 
control’ can be set up without the need for caspase inhibitors to prevent apoptosis.
In many respects, culturing neurons can be regarded as a model of axotomy and/or 
peripheral nerve injury. In culture, and following peripheral nerve injury, neurons 
have their processes damaged and are deprived of their usual source of target field- 
derived neurotrophic factors. In both cases, neurotrophic factor deprivation leads to 
significant changes in the expression of a number of functionally important proteins 
and peptides including CGRP, SP, Navi.8, Navi.9, PACAP and VR1 (Lindsay et al., 
1989; Verge et al., 1995; Jiang and Smith, 1995; Price et al, 2005; Lindsay et al., 
1989; Zhang et al., 1995; Aguayo and White, 1992; Black et al., 1997; Fjell et al., 
1999; Jongsma Wallin et al., 2001; McMahon et al., 1995; Winston et al., 2001; 
Ogun-Muyiwa et al., 1999 Wendland et al., 2003). Indeed, adult DRG cultures have 
been extensively used in the fields of inflammatory and neuropathic pain research to 
examine the regulation of a number of genes that have previously been implicated in 
the aetiology of neuropathic pain following in-vivo nerve lesion/axotomy/crush 
models (Nielsch et al., 1987; Zhang et al., 1995; Sterne et al., 1998; Zhang et al., 
1996; Jongsma-Wallin et al., 2001; Armstrong et al., 2003 Hokfelt et al., 1987; Villar 
et al., 1989; Noguchi et al., 1993; Nahin et al., 1994; Ma et al., 1997; Shi et al., 1999; 
Michael and Priestly, 1999; Michael and Priestly 2002; Fukuoka T et al., 2002; 
Waxman et al., 1994; Cummins and Waxman, 1997, Sleeper et al., 2000; Kim et al., 
2001; Abe et al., 2002; Chung et al., 2004 Okuse et al., 1997; Cummins et al., 1997; 
Tate et al., 1998; Dib-hajj et al., 1998; Novakovic et al., 1998; Sleeper et al., 2000; 
Decosterd et al., 2002). For this reason, the data generated in this chapter will largely 
be interpreted in the context of its relevance to studies on inflammatory and 
neuropathic pain.
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The main introduction in chapter one includes a detailed account of the biology of the 
neurotrophic factors; NGF, artemin, MSP, and their respective receptors LIF was 
mentioned briefly and is described in more depth further in this chapter. The 
introductions to chapters 2 and 3 discuss the function, significance and regulation of: 
the neuropeptides SP, galanin, PACAP, and a- and p-CGRP; the TTX-resistant 
sodium channels Nav 1.8 and Nav 1.9; and the TRP ion channel, VRl.The remainder 
of this introduction will give some background to the new genes studies in this 
chapter, namely; P2X3, Nav 1.6, Nav 1.7, DINE and ATF3.
4.1.1. Damage-induced neuronal endopeptidase (DINE)
Damage-induce neuronal endopeptidase (DINE) is a membrane-bound enzyme 
belonging to the family of Zn-metalloproteases, which includes: neural endopeptidase 
(NEP); Kell blood group antigen (KELL); the endothelin-converting enzymes, ECE-1 
and ECE-2 and PEX (See Turner et al., 1997 for a review; Valdenaire et al., 2000). 
Two independent groups, using different techniques, initially discovered DINE. 
Valdenaire et al., (Valdenaire et al., 1999) screened human caudate nucleus and spinal 
cord cDNA libraries, whilst Kiryu-Seo et al., (Kiryu-Seo et al., 2000) used differential 
display PCR on reverse transcribed RNA that had been extracted from either lesioned 
or non-lesioned hypoglossal nuclei.
In the developing rat, DINE mRNA expression is first apparent in the neural tube at 
El 2-El 3. DINE mRNA expression is restricted to differentiated neurons and is absent 
from neural precursors, glial precursors and glial cells (Nagata et al., 2006). At early 
developmental stages (El 2-El 4), most differentiated neurons of the neural tube 
express DINE mRNA. However, as these cells migrate during development, DINE 
mRNA expression becomes increasingly restricted to several specific brain nuclei that 
characteristically contain cholinergic and/or peptidergic neurons. DINE mRNA 
expression is significantly more widespread in the embryonic and neonatal CNS 
compared to the adult CNS. In the developing PNS, DINE mRNA is only expressed 
transiently in sensory ganglia shortly before birth. In contrast, DINE expression is 
maintained in sympathetic ganglia in the adult (Nagata et al., 2006). DINE mRNA
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expression is highest in the hypothalamus; large cholinergic cells within the striatum 
and some cranial motor nerve nuclei within the adult rodent CNS (Valdenaire et al., 
1999; Kiryu-Seo et al., 2000; Nagata et al., 2006).
Whilst DINE protein and mRNA are only detectable at very low levels in the adult 
nervous system under normal circumstances, they are dramatically up-regulated in 
response to nerve injury (Kiryu-Seo et al., 2000; Kato et al., 2002; Ohba et al., 2004). 
For example, sciatic nerve lesion induces DINE mRNA expression in predominantly 
IB4-negative, TrkA-positive neurons, in a similar pattern to that of the neuropeptide 
galanin (Kato et al., 2002). The dramatic increase in DINE expression is only 
observed in neurons, with no detectable expression in injured glial cells (Kiryu- Seo et 
al., 2000; Kato et al., 2002; Ohba et al., 2004; Nagata et al., 2006).
To date, no specific substrate for the enzymatic activities of DINE has been identified. 
However, since the expression of many neuropeptides, growth factors and 
transcription factors are increased following nerve injury, it is possible that DINE 
processes some of these molecules to activate them (Nagata et al, 2006). This may be 
particularly true in the case of neuropeptides, since DINE is largely restricted to the 
endoplasmic reticulum, which is the major site of neuropeptide processing (Benoit et 
al, 2004). Within motor neurons, at least, DINE is the only known protease that is 
significantly up-regulated in response to nerve injury, suggesting it may modulate the 
cellular response to injury and act in a neuroprotective manner (Kiryu-Seo et al.,
2000). In support of this hypothesis, DINE can partially inhibit C2-ceramide-induced 
apoptosis in COS cells, possibly by enzymatically activating enzymes such as Mn- 
superoxide dismutase and Cu/Zn-superoxide dismutase (Kiryu-Seo et al., 2000).
A CNS neuroprotective role for DINE is also suggested following ischemic injury. A 
late-onset, prolonged expression of DINE mRNA is detected in the peri-infarct cortex 
and specific nuclei of the thalamus following middle cerebral artery occlusion in adult 
rats (Ohba et al., 2004). It has been suggested that this up-regulation could stimulate 
antioxidant activity that in turn promotes neuroprotective effects. This hypothesis is in 
accordance with the observation that middle cerebral artery occlusion leads to 
increased neuronal cell death, as a result of increased oxidative stress, in mice
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deficient in Mn-superoxide dismutase or Cu/Zn-superoxide dismutase (Kondo et al.,
1997).
A DINE knockout mouse has been generated to further investigate the biological roles 
of this enzyme. Homozygous null-mutant mice die shortly after birth from respiratory 
failure, due to a lack of lung ventilation (Schweizer et al., 1999; Valdenaire and 
Schweizer, 2000). Histological analysis of homozygous null-mutant neonates revealed 
that all other tissues and organs developed normally (Schweizer et al., 1999; 
Valdenaire and Schweizer, 2000). The restricted expression of DINE in the nervous 
system and the lethal phenotype of the knockout mouse would, therefore, suggest a 
vital role for DINE in the nervous system control of respiration.
In addition to its proposed neuroprotective role, and a role in regulating respiration, 
recent experimental evidence has suggested a possible role for DINE in the regulation 
of the sleep cycle. The expression of DINE mRNA is significantly suppressed in a 
subgroup of anterior pituitary cells in animal models of extreme fatigue. Furthermore, 
DINE mRNA expression continues to decrease in these cells if the period of sleep 
disturbance is extended (Ogawa et al., 2005). No alterations in DINE mRNA were 
observed in other brain areas. This effect is reversible, although the recovery is slow, 
taking approximately 72 hours for DINE mRNA levels to return control levels 
(Ogawa et al., 2005).
The nerve trauma induced up-regulation of DINE mRNA expression by adult rat 
DRG neurons has previously been studied using both in-vitro and in-vivo approaches 
(Kato et al., 2002). It appears as if DINE mRNA induction within adult DRG neurons 
is the consequence of a combination of target field-derived NGF withdrawal and 
increased exposure to LIF that is generated by Schwann cells at the site of lesion.
4.1.2. Activating Transcription Factor 3 (ATF3)
Activating transcription factor 3 (ATF3), also known as LRF-1, LRG-21or CRG-5, is 
a member of the ATF/CREB family of transcription factors. The name ATF was 
assigned in 1987 to refer to proteins that could bind to the adenovirus early promoters
324
E2, E3 and E4 at a specific core sequence ‘CGTCA’ (Lee et al., 1987). The specific 
consensus sequence for binding was later defined as TGACGT(C/A)(G/A) (Lin and 
Green, 1988). The cAMP responsive element binding protein (CREB) was named in a 
similar manner to define a category of proteins that could bind to the cAMP 
responsive element (CRE), TGACGTCA, on the somatostatin promoter (Montminy 
and Bilezsikjian, 1987). The unexpected discovery of an identical consensus 
sequence for both subfamilies led to the amalgamation of both families to create the 
ATF/CREB family.
ATF3 regulates transcription by binding, through a leucine zipper region, to its 
consensus DNA binding sites. ATF3 is an unusual member of the ATF family, as it 
has the ability to both activate and suppress transcription. As a homo-dimer, ATF3 
represses transcription (Chen et al., 1994), but upon forming a heterodimeric complex 
with Jun proteins it becomes an activator of transcription (Hai and Curran, 1991; Hsu 
et al., 1991). Multiple splice variants of ATF3 mRNA have been identified that 
encode different variants of the protein (e.g. Hashimoto et al., 2002; Hua et al., 2006).
The rapid, marked induction of ATF3 expression has become a well-established 
marker of stress and injury in a number of cells and tissues. Examples of injuries that 
induce ATF3 expression include: mechanical and toxin-induced injury to the rodent 
liver; ischemia in the rat heart and kidney; the action of pro-inflammatory cytokines 
on p cells; excito-toxic brain seizure; diabetes-induced peripheral neuropathies; 
exposure to high concentrations of nitric oxide (NO) (Chen et al., 1996; Yin et al., 
1997; Hai et al., 1999; Allen-Jennings et al., 2002; Hartman et al., 2004; Wright et al.,
2004). ATF3 is also dramatically up-regulated in DRG neurons following axotomy, 
with 82% of L4 DRG neurons becoming immuno-reactive for ATF3 following sciatic 
nerve transection; whilst in control rats no immuno-reactivity for ATF3 is observed 
(Wang et al, 2003; Averill et al., 2004). In partial nerve injury paradigms, ATF3 
mRNA and protein are only induced in damaged neurons, in a pattern that 
corresponds to the expression of phosporylated c-Jun, and remains absent from 
neighbouring “spared neurons” (Tsujino et al., 2000; Tsuzuki et al., 2001; Obata et 
al., 2003; Wang et al., 2003). An up-regulation of ATF-3 mRNA expression has also 
been demonstrated in cultured trigeminal ganglion neurons, a further indication that
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culturing neurons can be regarded as a model of injury/axotomy (Dussor et al., 2003). 
Interestingly, ATF3 and its dimerisation partner, c-Jun, are also dramatically up- 
regulated in Schwann cells ensheathing peripheral nerves following nerve lesion. The 
timing of Schwann cell ATF3/c-Jun induction appears to coincide with the onset of 
Wallerian degeneration (Hunt et al., 2004).
Although the functional significance of ATF3 induction in response to injury in non­
neuronal cells is still unclear, its up-regulation following insult and injury suggests 
that it may play a role in protecting cells from stress. Indeed, a role in cell survival has 
been implicated by data from Kawauchi et al. (Kawauchi et al., 2002). They found 
that the adenoviral mediated over-expression of ATF3 in human umbilical vein 
endothelial cells could protect these cells from TNF-a induced apoptosis by 
suppressing the expression of the pro-apoptotic protein p53. Interestingly, p53 itself 
may induce the expression of ATF3 in human cell lines following cell trauma (Zhang 
et al., 2002). Conversely, however, several laboratories have suggested that the 
induction of ATF3 in liver cells, following stress from ischemia (Haber et al., 1993), 
partial hepatectomy (Hsu et al., 1991) or overexposure to toxins such as alcohol or 
acetaminophen (Chen et al., 1996), may actually exacerbate cell damage and promote 
apoptosis. Data from transgenic mice supports this latter interpretation of the role of 
ATF3 in non-neuronal cells following traumatic stimuli. Mice over-expressing ATF3 
display many symptoms of liver dysfunction, including; enhanced levels of; serum 
bilirubin, bile acids, alkaline phosphatase, alkaline transaminase and aspartate 
transaminase. Furthermore, the over-expression of ATF3 leads to a repression of a 
key enzyme in the gluconeogenic pathway, phosphoenolpyruvate carboxy-kinase, 
(PEPCK) leading to alterations in glucogenesis and subsequent detrimental effects on 
glucose homeostasis (Allen-Jennings et al., 2002). In addition to this, mice over­
expressing ATF-3 in the heart display contractile dysfunction and conduction 
abnormalities (Okamoto et al., 2001).
Micro-array analysis of MDA-1986 cells treated with the tumour repressor curcumin 
has suggested that ATF3 plays a part in mediating the beneficial effects of this drug 
(Yan et al., 2005). Curcumin treatment causes an increase in ATF3 mRNA expression 
that appears to be casually linked to the pro-apoptotic, anti-tumour effects of
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curcumin (Yan et al., 2005). It has been suggested that induced ATF3 may act by 
blocking the ubiquitination and subsequent degradation of the tumour suppressor, p53 
(Yan et al., 2005). In contrast to the data from MDA-1986 cells, ATF3 has been 
causally implicated in the malignant growth of Hodgkin/Reed-Stemerg (HRS) cells, 
which underlie classical Hodgkin lymphoma (cHL). Micro-array analysis of Hodgkin 
and non-Hodgkin cell lines initially demonstrated that ATF3 mRNA was much more 
highly expressed in the former cell lines (Janz et al., 2005). Subsequent RNA 
interference experiments, in which ATF3 expression was selectively “knocked 
down”, significantly reduced the viability of Hodgkin cells, suggesting that over­
expression of ATF3 contributes to the malignant growth of Hodgkin cells.
In-vitro and in-vivo experiments investigating the role of ATF3 in the nervous system 
suggest that ATF3 may be both neuroprotective and enhance nerve regeneration 
following nerve injury. For example, co-expression of ATF3 with its potential 
dimerisation partner, c-Jun enhances neurite outgrowth in both PC 12 and Neuro2a 
cell cultures (Pearson et al., 2003). Moreover, inhibition of c-Jun phosphorylation, by 
inhibition of JNK (c-Jun N-terminal Kinase) dramatically reduces axonal outgrowth, 
and ATF-3 induction, in nodose, dorsal root, and superior cervical ganglia explant 
cultures. The same effect is observed in dissociated cultures of nodose and DRG 
neurons (Lindwall et al., 2004; 2005). In accordance with these observations, JNK 
activation, c-Jun phosphorylation and ATF3 induction are associated with 
regenerating sensory neurons in-vivo following sciatic or vagal nerve transection 
(Lindwall et al., 2004). DNA micro-array analysis has revealed that JNK activation 
(and hence c-Jun phosphorylation) in combination with the over-expression of ATF3 
induces the expression of the heat shock protein Hsp27 in PC 12 cells (Nakagomi et 
al., 2003). Over-expression of Hsp27 itself can block JNK-mediated apoptosis of 
cultured SCG neurons and PC 12 cells, apparently by phosphorylating and activating 
Akt. It is the activation of Akt that enhances neurite outgrowth from neuronal cells 
(Nakagomi et al., 2003). Taken together, this data suggests that the JNK mediated 
phosphorylation of c-jun promotes the induction of ATF-3 expression in neurons. 
ATF-3/c-Jun heterodimers, in turn, induce Hsp27 expression, which in turn 
phosphorylates and activates Akt to both prevent JNK-mediated apoptosis and to 
promote neurite outgrowth. The hypothesis that ATF3 plays a neuroprotective role 
following neuronal trauma finds support in the observation that adenovirus mediated
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over-expression of ATF3 in adult rat hippocampal neurons prevents excitotoxic cell 
death following intra-hippocamapal injection of kainic acid (Francis et al., 2004).
Regulation of ATF-3 expression by neurotronhic factors
The dramatic increase in ATF-3 protein expression that occurs within adult rat DRG 
neurons following sciatic nerve transection can be partly ameliorated by infusion of 
NGF or GDNF. NGF appears to suppress ATF3 expression in predominantly small 
neurons, whereas GDNF exerts its effects on both small and large neurons (Wang et 
al., 2003; Averill et al., 2004). It is not clear whether the effects of the two trophic 
factors in ameliorating the induction of ATF3 are partially or totally additive. 
Exogenous GDNF can also partially block the increase in ATF3 expression that 
occurs in adult mouse facial motor neurons following facial nerve transection 
(Parsadanian et al., 2006). The experimental paradigms used in these studies cannot 
rule out the possibility that the effects of GDNF and/or NGF in suppressing ATF3 
expression occur as a result of a paracrine action of the neurotrophic factors on other 
cell types rather than a direct action on neurons. This may explain why a previous 
study failed to demonstrate that NGF regulates the expression of ATF3 mRNA in 
cultured adult rat trigeminal neurons (Dussor et al., 2003). Alternatively, the 
regulation of ATF3 mRNA and protein expression may differ in trigeminal neurons 
compared to motor neurons and DRG neurons. To date, there are no other reports in 
the literature describing the regulation of ATF3 mRNA or protein expression by other 
neurotrophic factors.
4.1.3. P2X3
ATP has many roles within both the PNS and CNS, functioning as an energy source, a 
neurotransmitter, a neuromodulator and a transmitter of pain (Bean, 1992; Gallighan 
and Bertrand, 1994). In the latter case, the source of ATP that activates sensory 
neurons to signal pain is usually ATP that is released from damaged cells following 
inflammation or physical trauma (reviewed in North, 2002 and 2003). ATP mediates 
its effects by binding to purinoceptors of two families, the P2X and the P2Y family 
(for reviews see Bumstock, 2000 or North, 2002). Upon binding ATP is rapidly
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degraded by cell surface phosphatases to adenosine diphosphate (ADP), adenosine 
monophosphate (AMP) and adenosine.
The P2X3 receptor protein is one of seven cloned P2X receptor subunits (P2X1 -  
P2X7) that are between 384 and 595 a.a. in length and act as cell surface, ATP-gated 
ion channels. Each P2X protein has two membrane spanning hydrophobic regions 
separated by a large extra-cellular region. Carboxyl and amino terminal domains are 
located within the cytoplasm (North, 2002 and 3003). Whilst it is certain that 
functional channels comprise many subunits interacting with each other, in either a 
homo- or hetero-multimeric way, the precise topology of native functional P2X ATP- 
gated ion channels has remained elusive.
Two separate laboratories originally cloned P2X3 from a sensory neuron cDNA 
library in 1995 (Chen et al., 1995; Lewis et al., 1995). P2X3 expression appears to be 
almost entirely restricted to primary afferent sensory neurons in adult rodents. In 
particular, P2X3 mRNA and protein expression is mainly localised to a sub­
population of C-fibre nociceptive neurons that are predominantly non-peptidergic and 
IB4-positive, and, in the case of DRG neurons, whose central projections terminate in 
the inner region of lamina II of the dorsal horn (Vulchanova et al., 1997 and 1998; 
Bradbury et al., 1998; Ramer et al., 2001). Interestingly, the more rostral DRG at 
cervical levels contain a greater number of P2X3-positive neurons than those at lower 
levels. In particular, cervical DRG contain a sub-population of IB4-negative, A-5 
fibre (myelinated) peptidergic nociceptive neurons that express P2X3 (Ramer et al.,
2001). This is in accordance with a study reporting that 40% of RT-97-positive, 
myelinated, trigeminal ganglion neurons (the most rostral neural crest-derived sensory 
ganglia) express protein for this ion channel in addition to virtually all IB-4 positive 
C-fibre neurons (Eriksson et al., 1998). P2X3 protein expression is found in the 
central and peripheral terminal arbors of nociceptive neurons as well as their cell 
bodies (North et al., 2003). In addition, P2X3 expression often coincides with the 
expression of the TRP ion channel, VR1, in the rat (Petruska et al., 2000 a and b and
2002).
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In contrast to the adult, P2X3 protein is expressed in a number of sites outside of 
sensory ganglia in the embryonic mouse (Kidd et al., 1998; Boldogkoi et al., 2002). 
For example, P2X3 immuno-reactivity is evident between E9.5 and E14 in: the 
hindbrain, midbrain, marginal layer of the diencephalon and motor neuron precursors 
within the CNS; paravertabral sympathetic chain; testis; aorta. However, P2X3 
protein is no longer detectable in the rodent CNS by P14 (Kidd et al., 1998).
Similarly, P2X3 immuno-staining (and ATP gated channels with characteristics 
resembling P2X3) is widespread in perinatal rat SCG neurons, but largely disappears 
by PI7 (Dunn et al., 2005). P2X3 immuno-reactivity is found in DRG and trigeminal 
ganglion neurons as early as E9.5. In contrast to the adult expression pattern, P2X3 
protein is found within the majority of sensory neurons between E9.5-E14.5, rather 
than being predominantly restricted to small IB4-positive sensory neurons (Boldogkoi 
et al., 2002; Ruan et al., 2004). P2X3 expression progressively disappears from the 
majority of large myelinated neurons and CGRP-positive nociceptors during the first 
two post-natal weeks, so that by P14 the expression pattern of P2X3 in sensory 
ganglia resembles that of the adult (Ruan et al., 2004). The restriction of P2X3 
expression to IB4-positive nociceptive sensory neurons in the adult suggests an 
important role for ATP and P2X3 in pain processing. This is discussed in more detail 
below.
Immuno-histochemistry has detected both P2X2 and P2X3 proteins in the same adult 
rat sensory neuron terminal arbors, suggesting that P2X3 subunits are able to form 
both homo-multimeric ion channels and hetero-multimeric ion channels, in 
combination with P2X2 subunits, in these neurons (Vulchanova et al., 1997). 
Heterologous expression of P2X subunits in cell lines has demonstrated that P2X3 
homo-multimers have a high binding affinity for agonists and display rapid activation 
and rapid desensitisation kinetics following repeat agonist exposure (North et al., 
1997; for a review see Ralevic and Bumstock, 1998). P2X2 homo-multimers, 
however, have a low agonist affinity combined with slow activation rates and slow, 
only partial, desensitisation following repeated agonist exposure (Evans et al., 1992; 
Collo et al., 1996). P2X3 subunit containing channels are also unique in that they 
respond to the synthetic agonist aPmeATP. Hetero-multimeric P2X2/P2X3 channels 
have activation kinetics that combine properties of both subunits in that they display 
sensitivity to aPmeATP, have high affinity, rapid agonist binding and slow,
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incomplete, desensitisation (Ralevic and Bumstock, 1998). Experimental evidence 
suggests that heterologously expressed P2X2/P2X3 hetero-multimeric receptors 
contain one P2X2 subunit and two P2X3 subunits (Jiang et al., 2003). 
Electrophysiological recordings of sensory neurons appear to confirm the existence of 
P2X3 homo- and P2X2/P2X3 hetero-multimeric channels, but not P2X2 homo­
multimeric channels, in adult rat trigeminal and dorsal root ganglion neurons (Lewis 
et al., 1995; Roberson et al., 1996; Cook et al., 1997). However, homo-multimeric 
P2X2 channels appear to be present in adult nodose neurons (Zhong et al., 2001)
P2X3 and Pain
As mentioned above, ATP has been shown to elicit pain. For example, application of 
ATP, via ionophoresis, to the forearms of human volunteers produces a modest 
burning pain (Hamilton et al., 2000). Similarly, the injection of ATP into the trapezius 
of human volunteers produces a moderate sensation of pain (Mork et al., 2003). The 
injection of ATP into the footpad of rats produces nocifensive behaviour that includes 
paw licking and lifting. Such nocifensive behaviour is an indication of the animals 
suffering pain (Bland Ward et al., 1997; Hamilton et al., 1999). Furthermore, ATP 
injection into the footpads of rats suffering carrageenan induced inflammation, 
produces an enhanced pain response in comparison to injection into naive rats, 
suggesting enhanced sensitisation of P2X receptors by inflammation (Hamilton et al.,
2001). Further studies have revealed that the enhanced sensitivity may be due to the 
release of the inflammatory mediators, SP and bradykinin. Downstream signalling 
following the binding of SP and bradykinin to their receptors is thought to potentiate 
the activation of P2X3 and P2X2/3 ion channels by phosphorylating them (Paukert et 
al., 2001). The observation that CFA-induced inflammation produces an increase in 
P2X3 protein expression in small-medium neurons of the DRG, further suggests that 
P2X3 plays a role in the generation of inflammatory hyperalgesia (Xu and Huang,
2002). Moreover, the intrathecal administration of antisense oligo-deoxynucleotides 
against P2X3 or subcutaneous injection of a specific P2X3 antagonist can reduce CFA 
(but not carrageenan) induced thermal and mechanical hyperalgesia in the rat (Honore 
et al., 2002; Barclay et al., 2002; Jarvis et al., 2002; Wu et al., 2004).
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The role of P2X3 in the generation of inflammatory hyperalgesia suggests that this 
ion channel may also play a role in the aetiology of neuropathic pain following nerve 
trauma, a hypothesis that is supported by data showing that P2X3 is up-regulated in 
some experimental nerve injury paradigms. For example, the expression of P2X3 
protein has been shown to be up-regulated in small-medium sized neurons of the 
DRG following chronic constriction injury of the rat sciatic nerve (Novakovic et al., 
1999). An increase in the number of neurons showing P2X3 immunoreactivity was 
also observed in the trigeminal ganglion following either ligation/section or chronic 
constriction of the mandibular inferior alveolar nerve in adult rats (Eriksson et al.,
1998). Both these injury models are partial injury models in that the ganglion from 
which the damaged nerve generates will contain ATF3-positive damaged neurons and 
ATF3-negative “spared” neurons (see above). A more detailed examination of P2X3 
mRNA expression following two partial nerve injury models in the rat demonstrates 
that P2X3 mRNA expression only increases in undamaged or “spared” trigeminal and 
dorsal root ganglion neurons, whilst it actually decreases in damaged, ATF3-positive, 
neurons (Tsuzuki et al., 2001). In accordance with this observation, P2X3 protein 
expression is significantly reduced in L4 and L5 DRG when the rat sciatic nerve 
(arising from L4, 5 and 6 DRG) is completely transected (Bradbury et al., 1998). A 
similar decrease in P2X3 protein expression was observed in L5 and L6 DRG using a 
model of tight spinal nerve ligation of both L5 and L6 nerves, a model that effectively 
leaves no “spared” neurons in the corresponding DRG (Kage et al., 2002). Further 
analysis of activation kinetics suggested that the channels down-regulated were homo­
multimeric P2X3 channels without a P2X2 component. Interestingly, no alteration in 
P2X3 immunoreactivity was observed in the small subpopulation of A-p fibre large 
DRG neurons that express this ion channel. One can postulate that this decrease in 
P2X3 expression in damaged neurons is partly the consequence of the reduced ability 
of damaged neurons to retrogradely transport neurotrophic factor/neurotrophic factor 
receptor complexes from their central and/or peripheral terminals back to the cell 
body. Spared neurons may well have greater accessibility to target field-derived 
neurotrophic factors and this may be partly responsible for the increase in P2X3 
expression observed. In contradiction to the other published data described above, an 
injury model that involves ligation of the rat L5 spinal nerve, failed to promote an
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increase in P2X3 protein expression in “spared” L4 DRG neurons (Fukuoka et al.,
2002). The reasons behind this unexpected observation are unclear.
The up-regulation of P2X3 mRNA and protein in spared neurons following nerve 
injury supports the notion that this ion channel could play a role in the generation of 
mechanical and thermal hyperalgesia that can occur following nerve injury. In support 
of this hypothesis, antisense oligo-deoxynucleotides or siRNA knockdown of P2X3 
expression in DRG neurons (following intrathecal administration) reduces the degree 
of hyperalgesia that results from partial sciatic nerve and spinal nerve ligation in rats 
(Honore et al., 2002; Barclay et al., 2002; Dorn et al., 2004). Similarly, subcutaneous 
injection of a specific and selective P2X3 antagonist, blocks the generation of thermal 
hyperalgesia and mechanical allodynia following sciatic nerve chronic constriction 
injury in the rat (Jarvis et al., 2002). Moreover, sciatic nerve injury appears to enhance 
the cell surface expression of P2X3 containing channels by inducing an alteration in 
receptor trafficking, and this has been proposed to contribute to the generation of 
hyperalgesia and allodynia (Chen et al., 2005). After peripheral nerve injury there is 
extensive sprouting of post-ganglionic sympathetic nerves into the site of injury 
(neuroma) and DRG (McLachlan et al., 1993; Ramer et al., 1997). Since sympathetic 
neurons can release ATP as a neurotransmitter, P2X3 and P2X2/P2X3 channels may 
mediate part of the sympathetic maintenance/enhancement of neuropathic pain that 
results in complex regional pain syndromes (reviewed in Janig and Habler, 2000). A 
significant up-regulation of P2X3 protein expression in the terminal arbors of CGRP 
immuno-reactive nociceptive neurons, but not non-peptidergic nociceptive neurons, in 
a mouse bone cancer model has recently led to the suggestion that P2X3 is involved 
in the aetiology of bone cancer pain (Gilchrist et al., 2005).
Two different laboratories have generated P2X3*7' mice (Cockayne et al., 2000; 
Souslova et al, 2000). In both strains of mice apmeATP fails to elicit currents in 
nodose or dorsal root ganglia neurons, demonstrating a lack of functional P2X3 
homo-multimeric or P2X2/P2X3 hetero-multimeric receptors. P2X3 7' mice also 
display a dramatically reduced pain and electrophysiological response to intraplantar 
injection of ATP, highlighting the importance of P2X3 and P2X2/P2X3 multimeric 
channels in mediating the response to ATP. Both strains of mice also display a
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modest reduction in hindpaw licking and lifting after interplantar injection of 
formalin, confirming that P2X3 plays a role in the generation of inflammatory 
hyperalgesia. In contrast, P2X3 "A mice show normal responses to acute noxious 
thermal and mechanical stimuli. The effect that P2X3 deletion has on the generation 
of hyperalgesia and allodynia following sciatic nerve lesion has not been tested to 
date. Interestingly, the reduced inflammatory pain response to formalin is also 
observed in P2X2"7' and P2X2'7' /P2X3‘A double knock-out mice (Cockayne et al.,
2005), suggesting a role for the P2X2/P2X3 heterodimeric receptors in inflammatory 
pain sensation. Unexpectedly, the development of thermal hyperalgesia in response to 
chronic inflammation induced by CFA, but not short term inflammation induced by 
carrageenan or capsaicin, is markedly potentiated in P2X3‘/_ mice compared to wild 
type mice (Souslova et al., 2000). In addition, P2X3 mice appear to have a deficit in 
response to non-noxious thermal stimuli in the absence of an inflammatory lesion. A 
more thorough investigation of the response of P2X3’7' animals to noxious and 
innocuous heat stimuli reveals a blunted response of dorsal horn second order sensory 
neurons to innocuous heat and a paradoxical increased avoidance of noxious heat and 
cold by P2X3"7’ animals placed in a thermal gradient. In addition P2X3‘/_ animals 
show significantly shorter latencies of withdrawal to noxious temperatures in the tail- 
flick test (Shimizu et al., 2005). Systemic application of specific P2X3 antagonists in 
wild type mice failed to reproduce the behavioural phenotype of P2X3'7' mice, 
suggesting that the phenotype of the null-mutant mice is partially due to 
compensatory changes in the expression of other P2X / P2Y receptor subunits, and/or 
other ion channels, in the absence of P2X3.
Another striking phenotype of P2X3‘7‘ mice is bladder hypo-reflexia. Null mutant 
mice show an increased bladder capacity and decreased voiding frequency (Cockayne 
et al., 2000). Bladder distension has subsequently been shown to induce the release of 
ATP from bladder endothelial cells of mice, and application of ATP to the bladder 
endothelium, or bladder distension, rapidly induces activity of pelvic nerve afferents. 
These latter effects are absent in P2X3'7' mice (Vlaskovska et al., 2001) and P2X27' 
and P2X3 '77P2X2 ''' mice (Cockayne et al., 2005). These observations strongly 
suggest a role for P2X3 homo-multimeric and P2X2/P2X3 hetero-multimeric 
channels in regulating mechanosensory signal transduction in the rodent bladder. 
Evidence to suggest that these purine channels may also play an important role in
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regulating sensory perception in the human bladder comes from the observations that 
an increase in the expression of P2X3 and P2X2 proteins is observed in the bladder 
urothelium of patients suffering from interstitial cystitis (Tempest et al., 2004). In 
addition, human bladder endothelial cells release ATP and increase expression of 
P2X3 when mechanically stretched (Sun and Chai, 2004). Antagonists of the P2X3 
and P2X2 receptor could thus be of therapeutic potential in the treatment of 
overactive bladder and in relieving the pain of chronic interstitial cystitis.
Neurotrophic factor regulation of P2X3 expression
Since P2X3 expression is predominantly localised to the IB4-reactive subpopulation 
of small-diameter sensory neurons, it would seem likely that its expression will be 
regulated by members of the GDNF family of neurotrophic factors rather than the 
neurotrophins. Indeed, intrathecal administration of GDNF or artemin to rats 
following sciatic nerve lesion significantly reduces the injury induced decrease in 
P2X3 observed in damaged DRG neurons (Bradbury et al., 1998; Wang et al., 2003; 
Gardell et al., 2003). Intrathecal administration of GDNF to non-lesioned adult rats 
also increases the expression of P2X3 in cervical and lumbar DRG neurons that 
project to the inner region of lamina II in the dorsal horn of the spinal cord (Ramer et 
al., 2001). In contrast, whilst null deletion of the neurturin receptor GFR-a2 reduces 
the size and degree of terminal arborization of IB4-positive c-fibre nociceptors, it 
does not decrease the number of DRG neurons expressing P2X3, suggesting that this 
GDNF family member does not regulate P2X3 expression in intact neurons (Lindfors 
et al., 2006). Perhaps surprisingly, intrathecal administration of NGF to non-lesioned 
rats appears to produce a small, but significant, increase in the number of DRG 
neurons expressing P2X3 protein (Ramer et al., 2001). The additional DRG neurons 
that express P2X3 are CGRP-positive and project to more superficial laminae of the 
dorsal horn than those of control animals, as well as to the ventro-medial afferent 
bundle that lies close to the central canal of the spinal cord. It is not clear whether 
NGF causes de-novo expression of P2X3 in some peptidergic nociceptors or merely 
increases expression of this ion channel to make it more readily detectable by 
immuno-histochemistry. In either case, the fact that NGF appears to increase the 
expression of P2X3 in peptidergic nociceptive neurons may partly explain why pre­
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existing inflammatory conditions (that will increase NGF expression in the vicinity of 
the inflammation (Hefti et al., 2006)) sensitise the response of sensory neurons to 
ATP (Hamilton et al., 2001; Paukert et al., 2001; Xu and Huang, 2002).
4.1.4. Nav1.6 and 1.7
In chapter 2 ,1 outlined the structure and function of the voltage-gated sodium 
channels with particular reference to the TTX-resistant sodium channel alpha 
subunits, Navi.8, and Navi.9. In this chapter, I investigate the transcriptional 
regulation of two TTX-sensitive (TTX-S) sodium channel alpha subunits, Navi.6 and 
Navi.7.
As discussed in chapter 2, sodium channels are responsible for the current flow 
required within sensory neurons to propagate an action potential. Electrophysiological 
recordings indicate that there are two general sodium currents in DRG neurons, one 
sensitive to TTX (TTX-S), and one unaffected by TTX (TTX-R) (Kostyuk et al.,
1981; Cafffey et al., 1992; Roy and Narahashi, 1992). The TTX-S current is the 
predominant current in large proprioceptive and mechanoreceptive sensory neurons, 
whereas small nociceptive neurons contain both the TTX-S and TTX-R currents (Roy 
and Narahashi 1992; Rush et al., 1998; Cummins et al., 1998; Herzog et al., 2003).
In general, TTX-S channels tend to have a low threshold for activation (-55 to - 
40mV) and are rapidly activating and inactivating (reviewed in Lai et al., 2004). The 
application of TTX to distal axons, blocks nerve impulse conduction completely, 
providing evidence that TTX-S channels are required to mediate action potential 
generation in both myelinated and unmyelinated axons (Brock et al., 1998; Gold et 
al., 2003).
Navi.6
Navi.6 is encoded by the gene Scn8a and was initially isolated from the rat CNS and 
PNS (Schaller et al., 1995). Navi.6 is broadly expressed throughout the nervous 
system, in both neurons and glia of the CNS, PNS and enteric nervous system
336
(Schaller et al., 1995; Black and Waxman, 1996; Felts et al., 1997; Black et al., 2002; 
Bartoo et al., 2005). Navi.6 produces a strong, persistent sodium current with high 
firing rates (Smith et al., 1998) and has been shown to cluster at the nodes of Ranvier 
of mature myelinated sensory, motor and other CNS neuron axons. In addition,
Navi.6 is also localized to some neuronal dendrites and synapses within the CNS 
(Caldwell et al., 2000; Tzoumaka et al., 2000). Navi.6 channels within myelinated 
sensory neurons display rapid repriming kinetics and the rapid development of closed- 
state inactivation. These two properties are significantly different to other TTX- 
sensitive sodium channels and account for the high repetitive firing rates, and the lack 
of response to slow depolarising stimuli, that are characteristic of myelinated sensory 
neurons (Cummins et al., 1998 and 2001; Herzog et al., 2003a). The lack of response 
to slow depolarising stimuli is important, since it ensures that transient nodal after 
currents, which can occur after action potential propagation through the nodes, do not 
trigger additional, spontaneous action potentials.
Two important studies have used the optic nerve as a model to address the 
mechanism that leads to the clustering of Navi.6 at the nodes of Ranvier in mature 
myelinated neurons (Boiko et al., 2001; Kaplan et al., 2001; reviewed in Salzer,
2002). The optic nerve is populated by axons from retinal ganglion cells (RGCs). 
RGC axons display clearly demarcated myelinated regions, outside of the eye in the 
optic nerve, and unmyelinated regions, within the retina, making them an ideal system 
in which to study the role of myelination in regulating sodium channels clustering and 
expression. RGCs express two TTX-S sodium channels, Navi.2 and Navi.6. The 
expression of these two TTX-S sodium channels, and their axonal location, appear to 
be developmentally regulated in the mouse in accordance with the timing of 
myelination (Boiko et al., 2001; Kaplan et al., 2001). Navi.2 is expressed prior to 
Navi.6 during embryonic development, and it is initially localised at developing 
nodes of Ranvier. As myelination continues, Navi.2 is gradually down-regulated at 
the maturing nodes and replaced by Navi .6, so that by adulthood Navi .2 is only 
present within the retina whilst Navi .6 is localised at the nodes of Ranvier in 
myelinated axons (Boiko et al., 2001). The study of shiverer mice, a strain that 
displays severe hypomyelination within the CNS as a result of oligodendrocyte 
dysfunction, has confirmed that the myelination process regulates the expression and 
localization of Navi.6 in RGC axons. In shiverer mice, the expression of Navi.2 is
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abundant in all regions of damaged, poorly myelinated RGC axons, whereas Navi. 6 
is only detectable in the few nodes that retain functional integrity (Boiko et al., 2001). 
It appears that oligodendrocytes release a soluble factor that is responsible for 
regulating the initial clustering of Navi.2 at immature RGC axonal nodes. However, a 
physical interaction between Navi.6 and myelinating oligodendrocytes would appear 
to be required for clustering of this channel to mature RGC nodes of Ranvier (Kaplan 
et al., 2001).
Several proteins are known to interact with TTX-sensitive sodium channel alpha units 
and are thought to help direct their trafficking to nodes, as well as regulating their 
functional characteristics. These include sodium channel beta-subunits pi and p3, 
neurofascin-186 and calmodulin (Ratcliffe et al., 2001; Herzog et al., 2003b). Navi.6, 
in particular, has been shown to interact with ankyrin-G, pIV spectrin, neurofascin, 
NrCAM, calmodulin and FHF2 (Jenkins and Bennet, 2001; Herzog et al., 2003b; 
Wittmack et al., 2004). A further study has suggested that contactin-associated- 
protein regulates the formation of transverse bands in axonal paranodal regions, and 
these are important in regulating nodal formation. Indeed, the lack of contactin- 
associated-protein, and the subsequent loss of transverse bands, leads to aberrant 
Navi.6 and Navi.2 expression in myelinated CNS neurons (Rios et al., 2003).
To date, the mechanism that regulates the nodal clustering of Navi.6 in myelinated 
peripheral sensory neurons has not been fully determined. However, of note is the 
observation that contactin-associated-protein deletion does not lead to aberrant 
expression of Navi .6 or Navi .2 in myelinated peripheral neurons in the same way as 
it does in myelinated CNS neurons (Rios et al., 2003). Furthermore, a recent 
publication has also suggested that, unlike the situation in the CNS, immature PNS 
nodes do not undergo a period of transient Navi .2 expression prior to Navi .6 
channels populating the nodes, rather Navi.6 is the major sodium channel expressed 
at immature nodes (Shafer et al., 2006). These two observations suggest that 
myelinating glial cells within the PNS use a different instructive mechanism, 
compared to those within the CNS, to regulate nodal Navi.6 expression. This 
hypothesis is further supported by the observation that Navi.6 is associated with 
fibroblast growth factor homologous factor 2 (FHF2) at sensory neuron nodes of 
Ranvier, but not motor neuron or optic nerve nodes (Wittmack et al., 2004). Ectopic
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expression of the closely related factor, FHF2B, in the neuronal cell line ND7/23 
increases the amplitude of the sodium current that is generated by Navi .6, 
demonstrating that the association of FHF2 family members with Navi.6 has 
functionally important consequences (Wittmack et al., 2004).
Whilst the current view is that Navi.6 expression is largely restricted to myelinated 
neurons, and is indeed the main effecter of saltatory action potential conduction 
within these neurons, evidence has also been presented to suggest that Navi .6 plays a 
functional role in generating sodium currents in unmyelinated C-fibre nociciceptive 
sensory neurons of rat and mouse (Black et al., 2002). Navi.6 protein appears to be 
expressed throughout the entire length of peripherin-positive C-fibres innervating the 
epidermis (DRG derived) and the cornea (trigeminal ganglion derived). Expression is 
generally low and in a continuous pattern, not being restricted to nodal or other 
specific regions. A number of naturally occurring mouse Navi.6 null-mutant strains 
have been identified. These mouse strains lack functional expression of Navi.6 due 
either to the insertion of transposable elements into the Scn8a gene or spontaneous 
mutations in the gene. Animals in these med (Motor isnd-Plate Disease) mouse lines 
develop various motor disorders within the first two weeks of birth and die by three 
weeks (Duchen and Stefani, 1971; Burgess et al., 1995; Kohrman et al., 1996a and b; 
Garcia et al., 1998; Hamann et al., 2003). C-fibre nociceptors (and nodes of 
myelinated axons) do not stain for Nav 1.6 protein in postnatal med mice. The lack of 
functional Navi.6 in med mice C-fibres does not lead to conduction block in these 
neurons, but it does lead to a signficant reduction in compound action potential 
amplitude and conduction velocity, thus highlighting the functional significance of 
Navi.6 sodium channels in these neurons (Black et al., 2002). The absence of 
conduction block in c-fibres from med mice reflects the fact that C-fibre nociceptors 
also express the TTX-sensitive sodium channel, Navi.7 (see below). The observation 
that Navi.6 is expressed in unmyelinated C-fibres of the sensory nervous system is 
not the only report of Nav 1.6 being expressed in unmyelinated fibres. Navi .6 
channels also appear to be present in unmyelinated parallel fibres derived from 
granule cells in the molecular layer of the cerebellar cortex (Krzemien et al., 2000; 
Tzoumaka et al., 2000; Levin et al., 2006).
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Navi.6 appears to be responsible for the phenomenon of resurgent sodium currents in 
cerebellar Purkinje cells and large DRG neurons. In this phenomenon sodium 
channels open transiently during recovery from activation, thereby generating a 
“resurgent” sodium current that flows immediately after action potential propagation 
and displays very slow decay kinetics. Resurgent sodium currents are thought to be 
critical in determining the rapid firing pattern of Purkinje cells and are virtually 
eliminated in med mice and conditional knockout mice containing a Purkinje cell 
specific deletion of Navi.6 (Raman and Bean, 1997; Raman et al., 1997; Levin et al.,
2006). The role that resurgent currents play in regulating the excitability of 
myelinated sensory neurons is not clear, but such currents certainly exist in large 
myelinated DRG neurons and are dependent on Navi.6 expression (Cummins et al.,
2005).
The role of Navi .6 in injury and inflammation
There is a scarcity of data investigating the role of Nav 1.6 in the aetiology of neuropathic 
and inflammatory pain syndromes. This is likely due to the widespread assumption that 
Navi.6 is only expressed in myelinated neurons (despite Black et al., 2002) and the even 
more widespread assumption that unmyelinated nociceptive C-fibre neurons are the only 
neurons involved in the aetiology of these pathological conditions. In a study examining a 
possible link between Navi.6 and pathological pain conditions, the expression of Navi.6 
mRNA has been shown to decrease in ipsilateral L4 DRG (containing “spared” neurons) 
and L5 DRG (containing damaged neurons) following L5 tight spinal nerve ligation (Kim 
et al., 2002). This has been interpreted as an indication that Nav 1.6 is not involved in the 
generation of the ectopic electrical discharges that are associated with the onset of 
hyperalgesia/allodynia following sciatic nerve lesion. However, this study measured 
Nav 1.6 mRNA levels by an RNase protection assay on total RNA extracted from L4 and 
L5 DRG. This approach can only measure a global change in Navi.6 mRNA expression 
within all neurons and cannot determine whether certain neuronal subpopulations show 
increased or decreased expression of Nav 1.6 mRNA. In addition, it is not clear whether 
Navi.6 protein levels alter following sciatic nerve lesion. In any case, a decrease in Navi.6 
mRNA/protein expression following sciatic nerve injury could be causative in the aetiology 
of neuropathic pain/hyperalgesia as its expression may be replaced by that of other TTX-S
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sodium channels like Navi.3 and Nax (e.g. Kim et al., 2001 and 2002). This in turn may 
alter the response of myelinated sensory neurons to slow, sub-threshold depolarisations and 
lead to ectopic firing (see above). Therefore, to date, it is not entirely clear whether altered 
Nav 1.6 sodium channel expression, or modulation of its functional properties, contributes 
to the generation of lesion induced spontaneous ectopic sodium currents, and hence 
neuropathic pain. Likewise, no data has emerged, to date, that directly addresses whether 
altered Nav 1.6 expression or function contributes to the generation of inflammatory 
hyperalgesia. However, it has recently been demonstrated that p38 MAP kinase can 
phosphorylate Nav 1.6, thereby leading to a reduced sodium current density. The reduced 
current density has been postulated to be the result of the phosphorylation event targeting 
Nav 1.6 channels for ubiquitination and degradation (Wittmack et al., 2005). P38 MAP 
kinase has been shown to be activated in lumbar DRG neurons following sciatic nerve 
lesion and NGF driven inflammation, and is causally related to the generation of 
hyperalgesia/allodynia (Jin et al., 2002; Ji et al., 2002; Obata et al., 2004). These 
observations further raise the possibility that_aberrant Nav 1.6 expression/modulation is 
involved in the generation of neuropathic and/or inflammatory pain. Clearly this hypothesis 
needs to be investigated further.
Despite no obvious function in the generation of pathological pain, following nerve 
injury or inflammation, aberrant Navi.6 expression and function has been implicated 
in the onset of other neurological disorders.
Navi.6 and Multiple Sclerosis
The regulation of Navi.6 expression, and its subsequent nodal localization, by 
myelination raises the possibility that this sodium channel may play a role in the 
aetiology of pathological disease symptoms in demyelinating disorders. Multiple 
Sclerosis (MS) is an inflammatory, demyelinating disease of the CNS. Originally it 
was thought that myelinating oligodendrocytes were the cell type most affected by the 
disease. However, more recently it has become evident that axonal and neuronal 
degeneration occurs in both MS and experimental autoimmune encephalomyelitis 
(EAE), a mouse model showing many features of MS (Reviewed in Bechtold et al.,
2005).
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Initial studies, on the optic nerve, established that voltage-gated sodium channels can 
participate in the production of calcium-mediated axonal degeneration, following 
anoxia, by providing a route for persistent sodium influx that drives reverse Na /Ca 
exchange through the Na+/Ca2+ exchanger, NCX (Stys et al., 1992). Later studies in 
spinal cord dorsal columns provided further evidence for the involvement of sodium 
channels and NCX in axonal degeneration following exposure to anoxia (Imaizumi et 
al., 1998) and high levels of nitric oxide, a characteristic of MS (Kapoor et al., 2003). 
In accordance with these observations, non-specific blocking of sodium channels by 
flecainide or phenytoin in mice with EAE prevents axonal degeneration in the spinal 
cord and attenuates the reduction in compound axonal potential that is characteristic 
of the disease (Lo et al., 2003; Bechtold et al., 2004). However, until recently the 
identity of the sodium channels involved in triggering calcium-mediated axonal 
degeneration has remained a mystery. It has now been established that mice with EAE 
show abnormal retinal ganglion cell (RGC) and optic nerve expression of Navi.2 and 
Nav 1.6 (Craner et al., 2003). In particular, mice with EAE show widespread 
expression of Navi.2 in RGCs and degenerating optic nerve nodes with significantly 
reduced expression of Nav 1.6, a situation that is characteristic of immature RGCs and 
optic nerve. Further in the progression of the disease, mice with EAE display random 
diffuse expression of both TTX-S sodium channels along the entire optic nerve. 
Furthermore, mice with EAE also display diffuse expression of Navi.2 and Navi.6 
protein in demyelinated spinal cord axons, and the expression of Navi.6, in particular, 
coincides with that of the beta amyloid precursor protein, a marker of axonal injury, 
and the Na+/Ca2+ exchanger (NCX) (Craner et al., 2004 a). This data strongly supports 
the notion that aberrant Navi.6 (and Navi.2) expression, as a result of defective 
myelination and/or demyelination, contributes to the axonal and neuronal 
degeneration that is characteristic of EAE. Nav 1.6 protein has also been shown to be 
expressed in a diffuse pattern, overlapping that of NCX, within demyelinated axons 
residing in areas of acute MS plaques in human optic nerve and spinal cord post­
mortem tissue, suggesting that the aetiology of EAE and MS are the same (Craner et 
al., 2004b). A recent publication has also implicated Navi.6 as having a causative role 
in the activation of microglia and macrophages that is concomitant with the onset of 
inflammation in the early stages of MS and EAE (Craner et al., 2004). Sodium 
channel blockade may, therefore, not only reduce neuronal degeneration in the latter
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stages of MS/EAE, but may also ameliorate the inflammatory insult that contributes 
to the onset of these pathological conditions.
Navi.6 and other neurological disorders
The analysis of med mice has suggested that aberrant Nav 1.6 expression and function 
may play a role in the aetiology of a number of neurological disorders. As mentioned 
above, the various strains of med mice develop a number of progressively worsening 
motor disorders within the first two weeks after birth (a time period coinciding with 
the replacement of Nav 1.2 with Nav 1.6 at developing nodes of Ranvier) and neonates 
of most strains die by three weeks. Neonatal med mice display certain symptoms of 
several human diseases including; dystonia, motor endplate disease and inherited 
cerebellar ataxia (Burgess et al., 1995; Garcia et al., 1998; Hamann et al., 2003;
Levine et al., 2006).
Motor end plate disease has been postulated to arise in med mice because changes in 
the conduction velocity and amplitude of motor neuron action potentials, together 
with aberrant sprouting of motor neuron terminal arbors, prevent current penetration 
through the neuromuscular junction (Duchen, 1970; Duchen and Stefani, 1971; 
Kearney et al., 2002). A recent publication has demonstrated robust Navi .6 
expression in the Schwann cells that wrap around motor neuron terminal arbors at the 
neuromuscular junction. These Schwann cells are absent in med mice, and it has been 
postulated that their absence (probably due to the lack of Navi.6 expression) 
contributes to the aberrant sprouting of motor neuron terminal arbors (Musarella et al.,
2006).
Other aspects of med mouse motor disorders are likely to arise from inappropriate 
signalling through brain regions that regulate coordination, such as the cerebellum and 
basal ganglia. For example, TTX-sensitive resurgent and steady-state sodium currents 
decrease disproportionately relative to transient currents in Purkinje cells of juvenile 
med mice, thereby changing the kinetics of total sodium currents in these cells. The 
result of changed sodium channel kinetics is that the action potential activation
343
threshold of Purkinje cells is shifted by +10mv and the rate of spontaneous, repetitive 
firing of action potentials within these cells is reduced (Harris et al., 1992; Raman and 
Bean, 1997; Raman et al., 1997; Smith et al., 1998). Because med mice die within 
three weeks of birth and lack Nav 1.6 expression in all cell types that normally express 
this sodium channel, it has not previously been possible to determine the extent to 
which the specific lack of Navi.6 expression in Purkinje cells, or other cells within 
the cerebellum, directly contributes to the behavioural phenotype of med mice.
Neither has it been possible to determine whether Navi .6 deletion in adult cells of the 
cerebellum leads to adult mice with a similar behavioural phenotype to that of 
juvenile med mice. A recent study, using conditional deletion of Navi.6 in Purkinje 
cells, granule cells or both, has attempted to address these questions (Levin et al.,
2006). Whilst adult mice with a granule cell specific deletion of Navi.6 only exhibit 
minor behavioural abnormalities, adult mice lacking Navi.6 specifically in Purkinje 
cells display ataxia, tremor and impaired coordination that correspond to a significant 
drop in both the ratio of resurgent-to-transient currents and spontaneous firing rates in 
Purkinje cells. This data clearly demonstrates that the lack of Navi.6 expression in 
Purkinje cells is responsible for many of the motor related behavioural abnormalities 
of med mice.
To date, no data has emerged regarding the transcriptional or translational regulation 
of Navi.6 expression by neurotrophic factors.
Navi.7
The existence of a sodium channel with the expression pattern and functional 
characteristics of Navi.7 was initially suggested by a study on PC12 cells that 
revealed a TTX-sensitive sodium current that was distinct from that generated by 
Navi .2, a sodium channel that was known to be expressed in this cell line, and that 
was rapidly up-regulated by NGF- induced PC 12 differentiation (D’Arcangelo et al., 
1993; Toledo-Aral, 1995). Northern blotting of PC 12 cell RNA, using a probe against 
a highly conserved region of all known sodium channels, revealed a novel 11 kb 
transcript that did not correspond in size to any known sodium channels and was also 
present in RNA extracted from rat DRGs, but not rat brain. This transcript was shown
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to be rapidly up-regulated by NGF-induced PC 12 cell differentiation, in accordance 
with the NGF induced increase in sodium currents (Toledo-Aral, 1995). The first 
cDNA corresponding to Nav 1.7 was initially isolated from the human medullary 
carcinoma cell line (hMTC) and termed human neuroendocrine sodium channel 
(hNE-Na), (Klugbauer et al., 1995). A rabbit homologue was cloned a in the same 
year from a rabbit Schwann cell library (Belcher et al., 1995) and the cloned cDNA 
was used to identify the location of the corresponding gene, Scn9a, within the mouse 
genome (Beckers et al., 1996).The rat homologue of Navi.7, also known as PN1, was 
isolated soon afterwards from PC 12 cell and rat DRG cDNA libraries (Toledo-Aral et 
al., 1997 Sangameswaran et al., 1997).
An initial screen of rat tissues, using Western Blotting, RNase protection assay and 
Northern Blotting, demonstrated that Navi .7 mRNA and protein are principally 
expressed in sensory and sympathetic ganglia of the PNS and are virtually 
undetectable in the brain, spinal cord and non-neuronal tissues (Toledo-Aral et al., 
1997). A more sensitive RT-PCR assay has revealed low-level expression of Nav 1.7 
mRNA in adult rat brain and heart, but not skeletal muscle (Sangameswaran et al., 
1997). Indeed, a recent publication has demonstrated expression of Navi.7 mRNA in 
the atrio-ventricular node of the mouse heart (Marionneau et al., 2005). Functional 
Nav 1.7 also appears to be expressed in mouse smooth muscle myocytes and mouse 
pancreatic B cells (Saleh et al., 2005; Vignali et al., 2006)
In situ hybridization and immunohistochemistry have localised Navi.7 mRNA and 
protein expression specifically to neurons within embryonic and adult rat DRG, with 
no apparent expression in either satellite cells or Schwann cells (Toledo-Aral et al., 
1997; Sangameswaran et al., 1997). Interestingly, Navi.7 protein expression is 
highest at the terminal arbors of cultured embryonic rat DRG neurons, with only low 
level, diffuse expression along neurites and within cell bodies (Toledo-Aral et al., 
1997). The majority of adult and embryonic rat DRG neurons appear to express 
Nav 1.7 mRNA, although with some variation in the levels of expression between 
neurons (Felts et al., 1997; Black et al., 1996; Toledo-Aral et al., 1997). In accordance 
with this observation, embryonic DRG also display widespread neuronal expression 
of Navi.7 protein (Toledo-Aral et al., 1997). In contrast, immunohistochemistry has 
revealed that Nav 1.7 protein is predominantly expressed in small, presumptive
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nociceptive, DRG neurons in the adult rat and guinea pig (Porreca et al., 1999, Gould 
et al., 2000; Djouhri et al., 2003). An electrophysiological analysis of adult guinea pig 
DRG neurons expressing high levels of Nav 1.7 protein has demonstrated that, whilst 
nociceptive neurons predominantly express this sodium channel, some low-threshold 
mechanoreceptors also express Navi.7 at high levels and Navi.7 is more closely 
correlated to action potential conduction velocity than cell size (Djouhri et al., 2003). 
A recent publication has investigated alternative splicing of Navi.7 mRNA in both 
human and rat DRG (Raymond et al., 2004). Four alternative splice variants of 
Nav 1.7 exist in human and rat DRG, encompassing changes in the splicing of exon 5 
and exon 11 of the Scn9a gene by the use of alternative splice donor sites. Whilst all 
splice variants are reduced in rat lumbar DRG following L5 spinal nerve ligation, two 
of the transcripts are significantly enriched in comparison to the others, suggesting 
that alternative splicing of Nav 1.7 may play a role in the generation of neuropathic 
pain associated with spinal nerve ligation (Raymond et al., 2004). The differences in 
the functional properties of the Nav 1.7 channels encoded by each splice variant have 
not yet been determined.
Over-expression of mouse Navi .7 in mouse DRG neurons has revealed that this 
sodium channel produces a fast activating and inactivating TTX-sensitive current that 
is characterised by having very slow rates of closed state inactivation and repriming 
(Herzog et al., 2003a). The properties of ectopically expressed Navi.7 are similar to 
the properties of native TTX-sensitive currents in nociceptive A-delta and C-fibre 
neurons, further suggesting that Nav 1.7 is largely responsible for generating the TTX- 
sensitive currents in nociceptive neurons (Herzog et al., 2003a). The ectopic 
expression of human Navi.7, in the non-neuronal cell lines CHO and HEK293, has 
revealed that the human homologue of rat Navi.7 has similar electrophysiological 
properties to its rodent counterpart (Cummins et al., 1998; Akiba et al., 2003).
Navi.7 and Pain
The observation that Nav 1.7 is generally expressed at higher levels in nociceptive 
sensory neurons of the DRG, compared to proprioceptive neurons and the majority of 
low-threshold mechanoreceptive neurons, suggests that this sodium channel may have
346
a role in the response of sensory neurons to noxious stimuli and may be involved in 
pain signalling. The expression of Nav 1.7 predominantly in nociceptive neurons also 
raises the possibility that it is involved in the aetiology of inflammatory and/or 
neuropathic pain.
Conditional transgenic mice, using cre-recombinase mediated deletion of loxP flanked 
Navi.7 exons that encode the voltage sensor of the channel, have been used to 
investigate the role of Nav 1.7 in normal nociception and in the generation of 
pathological pain states (Nassar et al., 2004). Globally deleting floxed Navi.7 exons 
during the embryonic period confers neonatal lethality, apparently because of a failure 
of neonates to feed, precluding an investigation of the role Nav 1.7 in normal 
nociception. To circumvent this problem, a Navi .8 promoter driven cre-recombinase 
was used, by the same authors, to delete Navi.7 specifically in nociceptive sensory 
neurons of the mouse PNS. Surprisingly, isolated Navi.7 deficient DRG neurons only 
show a small reduction in peak TTX-sensitive current, probably reflecting the 
continued expression, or perhaps increased expression, of Navi. 1 and Navi.6 in 
Navi.7 deficient nociceptive neurons. Similarly, deleting Navi.7 in afferent 
nociceptive neurons does not significantly alter the evoked electrophysiological 
response of spinal cord dorsal horn neurons following peripheral stimulation with 
innocuous or noxious thermal (hot or cold) stimuli. However, Navl.7 A mice show a 
small, but significant, reduction in their sensitivity to noxious heat in the Hargreaves 
test (Nassar et al., 2004). The evoked electrophysiological response of dorsal horn 
neurons to peripheral noxious mechanical stimulation, but not low threshold 
mechanical stimuli, is significantly reduced in the absence of nociceptor Navi.7. In 
accordance with this observation, mice with a nociceptive neuron specific deletion of 
Navi.7, show a pronounced analgesia to noxious, but not low-threshold, mechanical 
stimuli in behavioural tests.
The most dramatic phenotype of mice containing a nociceptive neuron specific 
deletion of Nav 1.7 is a striking deficit in the development of inflammatory 
hyperalgesia. Navi.7 deficient mice show significantly less nocifensive behaviour in 
the first and second phase responses to intraplantar injection of formalin (Nassar et 
al., 2004, 2005). In addition, the marked thermal and mechanical hyperalgesia that 
arises following intraplantar CFA injection is virtually absent in mice lacking Navi.7
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expression in nociceptive neurons. Thermal hyperalgesia is also significantly reduced 
in Navl.7'A mice following NGF and carrageenan induced inflammation (Nassar et 
al., 2004).
The role that Navi.7 plays in the generation of neuropathic pain has been investigated 
in mice containing a nociceptive neuron specific deletion of Navi.7, and also in mice 
with a nociceptor specific double-deletion of both Nav 1.7 and the TTX-resistant 
sodium channel, Navi.8 (Nassar et al., 2005). Both mutant mouse strains display a 
normal development of mechanical allodynia following L5 spinal nerve ligation, 
suggesting that neither sodium channel plays a role in the aetiology of allodynia 
following nerve damage. This is, perhaps, a surprising result in light of the role that 
Nav 1.7 plays in determining normal sensory thresholds to noxious mechanical stimuli 
and the significant change in the ratios of Navi.7 splice variants that is observed in 
the same lesion model (Nassar et al., 2004; Raymond et al., 2004). However, in 
accordance with the null mutant data, Navi .7 mRNA expression within DRG neurons 
appears to fall significantly following spinal nerve ligation (Kim et al., 2002). 
Furthermore, Navi.7 protein levels decrease significantly in DRG from human 
patients suffering from traumatic central or peripheral axotomy (Coward et al., 2001).
The data from both conditional Navi.7 null mice and conditional Navl.7/Navl.8 
double-null mice demonstrates that Navi .7 plays a role in determining the response to 
high-threshold painful thermal and, in particular, mechanical stimuli. The data also 
demonstrates that Navi .7 plays an important role in the generation of inflammatory 
thermal and mechanical hyperalgesia (Nassar et al., 2004, 2005). Other experimental 
evidence supports this latter conclusion. For example carrageenan-induced 
inflammation has been shown to increase Navi .7 protein expression within DRG 
neurons in parallel with an increase in TTX-sensitive sodium currents and the 
development of hyperalgesia (Black et al., 2004). Moreover, Herpes virus vector 
mediated antisense knockdown of Nav 1.7 has been shown to ameliorate CFA 
induced, inflammatory thermal hyperalgesia in mice (Yeomans et al., 2005). In 
addition, the anti-inflammatory cyclooxygenase (COX) inhibitors ibuprofen and NS- 
398 can prevent the CFA-induced up-regulation in Navi.7 protein levels observed in 
adult rat DRG when they are applied prior to CFA administration (Gould et al., 2004).
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Importantly, the COX inhibitor associated amelioration of CFA induced Navi.7 up- 
regulation corresponds with a reduction in inflammation-induced hyperalgesia.
The important role that Navi.7 plays in regulating normal nociceptive thresholds to 
noxious stimuli has been highlighted by the recent discovery that mutation of this 
sodium channel is associated with the painful condition, primary erythermalgia (also 
called erythromelalgia). This neuropathy is characterised by burning pain and redness 
of the skin of the extremities, in response to warm stimuli or moderate excercise, and 
can either arise spontaneously or be inherited (Layzer et al., 2001). The symptoms of 
this condition are probably due to a combination of peripheral sensory neuron hyper­
excitability and an alteration of sympathetic vasomotor activity (Rush et al., 2006). A 
number of research groups have now identified at least 10 point mutations in the 
Scn9a gene that are associated with either familial or spontaneous (sporadic) 
erythermalgia (Kanadia et al., 2003; Yang et al., 2004; Drenth et al., 2005; Michiels et 
al., 2005; Dib-Hajj et al., 2005; Han et al., 2006). The effects that two of these point 
mutations have on the functional properties of Navi. 7 have been investigated by 
ectopically expressing mutated Navi.7 in a kidney cell line (Cummins et al., 2004). 
Both mutations shift the activation threshold of Navi.7 by 15 mV in a hyperpolarizing 
direction, as well as significantly slowing the rate of channel closing. In addition, 
mutant channels show a much larger response to slow, small depolarising stimuli. The 
net result of these changes in-vivo is likely to be hyper-excitability of primary sensory 
neurons. The transfection of cDNAs encoding mutant channels into cultured DRG 
neurons has been used to investigate the electrophysiological properties of Navi.7 
channels carrying a different erythermalgia-associated point mutation to those 
investigated by Cummins et al., (Dib-Hajj et al., 2005). Once again, the mutation 
confers a gain of function phenotype on mutated channels that is characterised by a 
lowered activation threshold and delayed channel closure. Interestingly, one of the 
first mutations of Navi. 7 to be characterised as being involved in erythermalgia, 
L858H, (Yan et al., 2004) produces functional hyper-excitability when over-expressed 
in sensory neurons but hypo-excitability when over-expressed in sympathetic neurons, 
clearly demonstrating that the physiological functional effects of any one ion channel 
is partly dependant on the cellular context in which it is expressed (Rush et al., 2006). 
Despite the growing data implicating aberrant Navi.7 function in the aetiology of
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erythermalgia, one group has documented cases of the disease that are not associated 
with mutation of Navi.7 (Bums et al., 2005).
Regulation of Navi.7 expression bv neurotrophic factors
Initial studies on the regulation of Navi.7 mRNA expression were carried out using 
Northern Blotting analysis of RNA extracted from PC12 cells (D’Arcangelo et al., 
1993; Toledo-Aral et al., 1995). A brief 1 minute exposure of PC12 cells to NGF has 
been shown to rapidly up-regulate the expression of the 11Kb Navi .7 message.
Navi.7 mRNA expression peaks at 3 hours post-NGF exposure and returns to basal 
levels by 24 hours. Patch clamping experiments have revealed that the increase in 
Navi.7 mRNA expression is accompanied by a dramatic increase in sodium current 
that is first apparent at eight hours after NGF application and persists for at least 24 
hours (Toledo-Aral et al., 1995). Interestingly, the up-regulation of Navi.7 mRNA 
appears to be dependent on new protein synthesis, suggesting that NGF-induced 
immediate early genes mediate the increase in sodium channels expression. A brief 
exposure to interferon-y, epidermal growth factor or basic fibroblast growth factor 
also increases the expression of Navi.7 mRNA in PC12 cells (Toledo-Aral et al., 
1995).
In contrast to PC 12 cells of the sympatho-adrenal lineage, NGF dose not appear to 
regulate Navi.7 expression in sensory neurons. Transgenic mice that over-express 
NGF specifically in skin do not show increased expression of Navi.7 mRNA in DRG 
neurons (Fjell et al., 1999a). Moreover, Schwann cells or Schwann cell conditioned 
media, that are a source of NGF, do not increase neuronal expression of Navi.7 
mRNA when added to cultured adult DRG neurons, although they increase the 
neuronal expression of other sodium channels that have previously been shown to be 
regulated by NGF (Hinson et al., 1997). In agreement with this, TTX-sensitive 
currents do not decrease in TrkA expressing nociceptive neurons (in which Navi.7 is 
the main TTX-S sodium channel) in animals that have reduced levels of target field 
NGF, as a result of immunization-induced anti-NGF antibody production. TTX- 
resistant sodium currents, however, are reduced in these animals in accordance with
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the known ability of NGF to regulate both TTX-resistant sodium channel alpha- 
subunits, thus demonstrating the effectiveness of anti-NGF antibody production in 
NGF-immunized mice (Fjell et al., 1999b). It can be hypothesised that the reduction 
in the expression of Navi. 7 mRNA and protein within DRG neurons that has 
previously been observed following peripheral nerve lesion (Coward et al., 2001 ;Kim 
et al., 2002) occurs as a result of the loss of accessibility of DRG neurons to target 
field-derived factors. This would suggest that additional target-field derived factors, 
other than NGF, normally regulate the expression of Navi.7 in adult DRG neurons.
In this chapter I will determine whether the other target field-derived factor/s that 
regulate Navi.7 mRNA expression in sensory neurons could be artemin or MSP.
4.1.5. LIF
Leukaemia inhibitory factor (LIF) is a neuropoietic cytokine (also known as 
cholinergic differentiation factor, or CDF) that has pleiotropic activity in several adult 
and embryonic systems. In the haematopoietic system, LIF induces the proliferation 
of haematopoietic stem cells (Fletcher at al., 1990; Leary et al., 1990) as well as the 
differentiation of leukaemia cells (Tomida et al., 1984) and megakaryocytic 
progenitor cells (Metcalf et al., 1990). LIF affects bone resorption (Abe et al., 1986) 
and also inhibits adipogenesis by negative regulation of lipoprotein lipase (Mori et al.,
1989). Furthermore, LIF inhibits kidney epithelial cell and embryonic stem cell 
differentiation (Tomida et al., 1990; Smith et al., 1988; Williams et al., 1988). In the 
latter case, LIF acts to maintain the multipotent developmental potential of embryonic 
stem cells. Within the nervous system, LIF displays neurotrophic factor like activity 
with effects on both neuronal differentiation and survival within the CNS and PNS. 
LIF can also modulate astrocyte and oligodendrocyte differentiation (Yamamori et al., 
1989; Murphy et al., 1991; Murphy et al., 1993; Murphy et al., 1997; Horton et al., 
1998; Thier et al., 1999; Arce et al., 1999).
LIF belongs to the family of gpl30 cytokines, (also known as the interleukin-6 family 
of cytokines). Family members include interleukin-6 (IL-6), IL-11, ciliary derived
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neurotrophic factor (CNTF), Oncostatin M, cardiotrophin-1 (CT-1), and 
cardiotrophin-like cytokine (CLC) (reviewed in Taga, 1996; Murphy et al., 1997)
All the members of this cytokine family utilise a common p receptor signalling 
subunit, gpl30. gpl30 can form hetero- or homodimers with additional a  and/or p 
receptor subunits. IL-11 and IL-6 signal by inducing homodimerisation of gpl30, 
whereas CNTF, LIF and CT-1 induce heterodimerisation of gpl30 and the LIF p 
receptor subunit (LIFR). OSM induces heterodimerisation of gpl30 and the OSM (3- 
receptor subunit (Gearing et al., 1991, Taga et al., 1996; Tanaka et al., 1999). IL-6,
IL-11 and CNTF initially bind to ligand specific a  subunits (IL6Ra, IL-1 la ,
CNTFRa) before inducing p subunit dimerisation and signal transduction.
Neither gpl30 nor LIFR contain intrinsic tyrosine kinase activity, so in order for the 
receptor complex to become active, membrane bound j anus kinases (JAKs) must 
phosphorylate tyrosine residues in the cytoplasmic region of gpl30. Signal 
transducers and activators of transcription (STAT) family members can then bind via 
their SH2 domain to these phosphorylated residues. Phosphorylated STAT dimers are 
then translocated to the nucleus where they initiate transcription of target genes 
(reviewed in Heinrich et al., 1998).
LIF and its role in the peripheral sensory nervous system
LIF has neurotrophic properties on developing peripheral sensory neurons. For 
example, LIF promotes the differentiation of sensory neurons from proliferating 
progenitors in neural crest cells cultures. LIF also promotes the survival of late 
embryonic sensory neurons with an efficacy comparable to NGF (Murphy et al.,
1991; Murphy et al., 1993; Horton et al., 1998; Horton et al., 1996) LIF is 
retrogradely transported and accumulates in specific DRG neurons following intra- 
neural injection into the sciatic nerve of adult rats. The neurons that express functional 
LIF receptors and retrogradely transport this cytokine are predominantly small in 
diameter, with the majority (~81%) co-labelling for CGRP. Interestingly, 62% of LIF 
containing neurons are immuno-positive for TrkA and 34% are immuno-reactive for 
IB4 (Thompson et al., 1997), suggesting that LIF can exert neurotrophic effects on a
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sub-population of nociceptive adult sensory neurons that are partly peptidergic and 
partly IB4-reactive.
LIF appears to play an important role in the response to nerve injury and, in 
particular, may enhance axonal regeneration. LIF is not normally detectable in the 
adult nervous system (Yammamori, 1991), however, an increase in LIF mRNA and 
protein is observed following sciatic nerve ligation, transection or crush. This increase 
occurs at the site of injury within dedifferentiating Schwann cells (Banner and 
Paterson, 1994; Bolin et al., 1995; Sun and Zigmund, 1996; Hirota et al., 1996; Kurek 
et al., 1996; Ito et al., 1998; Thompson and Majithia, 1998). LIF expression is not 
enhanced within DRG following sciatic nerve lesion. In contrast, LIF is induced in 
both the lesioned nerve and in sympathetic ganglia following post-ganglionic 
sympathetic nerve lesion (Sun and Zigmond 1996 a and b). LIF can initiate enhanced 
neurite outgrowth in freshly plated, CGRP-positive, cultured DRG neurons, but only 
in the presence of added NGF (Cafferty et al., 2001). LIF also enhances the 
elongation of established neurites in more mature DRG cultures in the absence of 
NGF. A conditioning lesion, prior to a second lesion, has been shown to enhance the 
regenerative capacity of sciatic nerves lesioned for a second time (Sjoberg and Kanje,
1990). The conditioning lesion appears to change the intrinsic growth characteristics 
of injured nerves, from branched growth to more elongated growth, and the effect 
appears to require novel gene transcription (Smith and Skene, 1997). The regeneration 
enhancing effects of a conditioning lesion are lost in LIF'7' mice, suggesting that the 
primary lesion induces Schwann cells to produce LIF, and that Schwann cell-derived 
LIF is responsible for enhanced regeneration following a second lesion (Cafferty et 
al., 2001). Surprisingly, in-vivo peripheral nerve regeneration appears to be unaffected 
in LIF*7' mice in the absence of a conditioning lesion, despite the fact that an in-vitro 
assay demonstrates that damaged nerves from wild type mice, but not LIF'7' mice, can 
enhance neurite outgrowth from cultured DRG neurons (Ekstrom et al., 2000). 
However, this unexpected result may be as a result of the extended time points at 
which regeneration was assessed in this study if LIF, as has been suggested (Cafferty 
et al., 2001) only accelerates the rate of initial nerve regeneration.
Since LIF is up-regulated following nerve lesion, there is a possibility that it plays a 
role in the generation of inflammatory and neuropathic pain. Experimental evidence is
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now building to support this hypothesis. For example, intraplantar injection of LIF 
into juvenile rats induces mechanical allodynia, but not thermal hyperalgesia, that can 
be prevented by a LEF blocking antibody (Thompson et al., 1996). In addition, 
intrathecal administration of LIF, via a mini osmotic pump, can induce the sprouting 
of sympathetic nerves into adjacent DRG and their peripheral nerves (Thompson and 
Majithia, 1997). Furthermore, the sprouting of sympathetic neurons into DRG that 
occurs following spinal nerve ligation can be significantly reduced by a gp 130 
blocking antibody and increased by exogenous LIF. Sympathetic innervation of DRG 
and damaged nerves has been implicated in the aetiology of neuropathic pain, and in 
particular in sympathetically maintained complex regional pain syndromes (reviewed 
in Janig and Habler, 2000). LIF null-mutant mice show a deficit in the number of 
macrophages, neutrophils, mast cells and T lymphocytes that infiltrate the lesion site 
in the first few days following sciatic nerve injury, and this is concomitant with a 
reduced inflammatory response (Sugiura et al., 2000). This would suggest that LIF 
might mediate some aspects of inflammatory hyperalgesia, although nociceptive 
thresholds were not measured in this study. In contrast, LIF knockout mice display an 
increased inflammatory response to CFA injection, a treatment that appears to raise 
the endogenous levels of LIF within the skin of wild type mice (Banner et al,. 1998). 
Moreover, exogenous LIF ameliorates CFA induced thermal and mechanical 
hyperalgesia in rats but does not change nociceptive thresholds in non-CFA treated 
animals, suggesting that endogenous LIF normally acts in an anti-inflammatory 
manner. In agreement with this hypothesis, LIF mRNA levels within damaged nerves 
are negatively correlated with the number of macrophages infiltrating the nerve in 
post-mortem samples from human patients with varying peripheral neuropathies (Ito 
et al., 2001). However, LIF mRNA levels are dramatically increased in damaged 
human nerves, posing the question of whether LIF up-regulation is either protective or 
causative in human cases of peripheral painful neuropathy. The demonstration that 
exogenous LEF can reverse deficits in sensory neuron conduction velocity and tail 
flick latency in mice with cisplatin induced sensory neuropathy, mainly by beneficial 
effects on Schwann cells, suggests that the former scenario is true (Ozturk et al.,
2005).
A number of studies have examined the role of LIF in modulating the widespread 
changes in neuronal gene expression that occur within DRG following nerve trauma.
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For example, it is now well established that placing adult DRG neurons in culture 
leads to a time-dependent increase in the expression of galanin mRNA and protein 
that mimics the in-vivo changes in galanin expression following sciatic nerve lesion 
(Hokfelt et al., 1987; Villar et al., 1989; Wiesenfeld-Hallin., 1992; Kerekes et 
al.,1997, Zhang et al., 1998; Ozturk and Tonge, 2001; Holmes et al., 2005). The 
addition of LIF to adult and embryonic rodent DRG cultures significantly increases 
the number of galanin immuno-reactive neurons after 3 days, but only in the absence 
of exogenous NGF (Comess et al., 1998; Ozturk and Tonge., 2001). Furthermore, 
significantly fewer DRG neurons from LIF'7' mice express galanin message associated 
peptide (GMAP) and galanin mRNA after 72 hours in culture compared to cultured 
DRG neurons from wild-type mice, demonstrating the importance of Schwann cell 
derived LIF in regulating galanin expression following nerve injury (Kerekes et al., 
1999). The addition of exogenous LIF to DRG cultures from LIF -/- mice restores the 
number of galanin mRNA and GMAP-positive neurons to that seen in DRG cultures 
from wild type mice. In accordance with the above in-vitro data, DRG from LIF'7' 
mice contain dramatically fewer galanin and GMAP immuno-reactive neurons 
following sciatic nerve transection compared to DRG from wild type mice (Comess et 
al., 1996, Sun and Zigmond, 1996).
LIF also appears to play a role in modulating the up-regulation of DINE mRNA 
expression within small lumbar DRG neurons following sciatic nerve injury (Kato et 
al., 2002). Intra-sciatic nerve injection of a neutralizing anti-gpl30 antibody 
ameliorates the increase in DINE mRNA expression following sciatic nerve 
transection in adult rats. Interestingly, intra-sciatic nerve injection of LLF or an anti- 
NGF antibody can induce DINE mRNA expression in lumbar DRG neurons of non- 
lesioned rats, and the effects of LIF and anti-NGF are additive, suggesting that DINE 
expression is induced in sensory neurons by a combination of increased Schwann cell- 
derived LIF and a reduction in NGF availability following nerve lesion.
Reg-2 is a secreted protein that is not normally expressed in the adult nervous system. 
Reg-2 is rapidly induced in a subset of small DRG neurons following sciatic nerve 
crush or transection and appears to enhance axonal regeneration by acting as a 
Schwann cell mitogen (Livesey et al., 1997; Averill et al., 2002). By 7days post 
sciatic nerve lesion, Reg-2 is no longer expressed in a subset of small, damaged DRG
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neurons, rather its expression in prominent in a sub-population of medium- to large­
sized damaged DRG neurons. Reg-2 is normally expressed in embryonic sensory 
neurons, however, it is not expressed in embryonic sensory neurons from LIF receptor 
knockout mice, suggesting that LEF controls its developmental expression in sensory 
neurons (Livesey et al., 1997; Averill et al., 2002). This observation raises the 
possibility that Schwann cell-derived LEF induces Reg-2 expression in sensory 
neurons following sciatic nerve lesion. Since, galanin, DINE and Reg-2 have been 
postulated to have a neuroprotective role following nerve trauma (Holmes et al., 2000; 
Holmes et al., 2005; Kiryu-Seo et al., 2000; Livesey et al., 1997; Averill et al., 2002), 
the above data re-affirms the potentially important role that LEF plays in promoting 
neuronal regeneration following injury.
Whilst the available experimental data suggests that Schwann cell derived LEF may, at 
least partly, drive the changes in DINE, galanin and Reg-2 expression that occur 
within sensory neurons following nerve lesion, this does not appear to be the case for 
two neuropeptides, SP and CGRP, that also displays dramatic changes in expression 
following nerve trauma. The down-regulation of SP peptide following sciatic nerve 
transection is of the same magnitude in LEF7' mice as it is in wild type mice (Sun and 
Zigmond, 1996a). The application of LEF to the proximal transected sciatic nerve 
stump can reduce the axotomy-induced down-regulation of SP mRNA in lumber 
DRG neurons (Zhang et al., 1995). The apparent up-regulation of substance P mRNA 
in axotomized DRG neurons by LEF mirrors the effects of LEF in up-regulating the 
expression of SP mRNA and peptide in sympathetic ganglia following sympathetic 
nerve transection, and the ability of LEF to increase the expression of SP mRNA in 
cultured sympathetic neurons (Ludlam et al., 1995; Sun and Zigmond 1996b). 
Exogenous LEF increases the expression of CGRP peptide in explanted mouse lumbar 
DRGs compared to explants cultured in the absence of growth factors (Ozturk et al., 
2002). This data is a little difficult to interpret however, since explanted lumbar 
DRGs, unlike dissociated lumbar DRG neuron cultures, do not appear to be a good 
model of sciatic nerve lesion. In the absence of added growth factors the number of 
CGRP immuno-positive neurons within lumbar DRG explants hardly changes over 
time, and NGF does not appear to enhance CGRP expression (Ozturk et al., 2002). In 
contrast, lumbar DRG neurons display a dramatic reduction in CGRP staining both in-
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vivo, following sciatic nerve lesion, and in-vitro in dissociated cultures. In both these 
latter cases, exogenous NGF significantly prevents the fall in CGRP expression 
(Noguchi et al., 1990; Mulder et al., 1997; Sterne et al., 1998; Shi et al., 2001;
Shadiack et al., 2001Lindsay et al., 1989; Verge et al, 1995; Jiang and Smith, 1995; 
Price et al, 2005). There is no data documenting the effects of exogenous LIF on the 
expression of CGRP in dissociated sensory neuron cultures.
To date, there is no published data addressing the question of whether LIF plays a role 
in regulating the transcriptional expression of the sodium channels Navi.6, 1.7, 1.8 or 
1.9, either in culture of following nerve lesion. Similarly, it is not known whether LIF 
can regulate the expression of ATF3, P2X3, VR1 or PACAP in sensory neurons. In 
this chapter, I will report the results of experiments to investigate whether LIF can 
regulate the transcription of these mRNAs, as well as the transcription of galanin, SP 
and a- and P-CGRP mRNAs, in dissociated cultures of adult mouse DRG neurons.
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4.2 Materials and Methods
4.2.1 Neuronal Cultures
Neuronal cultures of adult DRG were set up to identify the effects of NGF, Artemin 
and additionally MSP on the expression of various mRNAs in sensory neurons. DRG 
was the most suitable of the sensory ganglia to culture at this age. Practically, it is the 
easiest to dissect and culture, and, as each mouse contains a large number of DRG, it 
facilitates setting up a large number of dense cultures from a small number of mice, 
thus allowing many different experimental conditions to be included in each 
experiment. In addition, the majority of other studies on gene regulation and nerve 
injury and regeneration in adult sensory neurons, as well as models of neuropathic 
pain and sensory neuropathy, have used rodent DRG.
Adult CD-I Mice (approximately P60) were killed with CO2 followed by cervical 
dislocation. All subsequent dissections and preparations were carried out in a laminar 
flow hood using standard sterile techniques. Dissections were performed under a 
stereomicroscope using a fibre optic light to effectively illuminate samples, but 
prevent overheating of the specimen. Ganglia were initially dissected using forceps 
and scissors that had previously been sterilised by flaming in alcohol. Tungsten 
needles were required to complete the dissection by removing any adherent 
connective tissue. Dissections were carried out in filter sterilised LI 5 medium, pH 
7.3, supplemented with penicillin and streptomycin as previously.
Dorsal Root Ganglia (DRG):
The DRG dissection in the adult is essentially the same as that for the postnatal mouse 
(see 3.2), but requiring tougher instruments to cut through bone. Several ganglia are 
present per mouse and run the length of the spinal cord. Dissection from the adult 
firstly involved the removal of the skin from the back. The whole spinal column was 
then removed and cut into 2 or 3 pieces to facilitate the next step of the dissection. As 
for the postnatal and embryonic mouse, cuts were then made by inserting one scissor
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blade inside the spinal column and cutting the full length of the column on both sides. 
The ventral section of the spinal column was now removed and the spinal cord taken 
out. The DRG were visible on either side of the dorsal half of the column, spread out 
uniformly along the length of the column. The membrane covering the surface of the 
spinal column was removed, followed by each DRG. At this age there is an 
abundance of nerves and connective tissue, and so time had to be spent using tungsten 
needles to remove as much adherent material as possible. Ganglia were transferred to 
15ml falcon tubes using a flame-sterilised, siliconised glass Pasteur pipette. 
Approximately 50 ganglia per culture were dissected, and the ganglia were divided 
into approximately 10 ganglia per tube to allow thorough enzymatic degradation of 
collagen and connective tissue within the ganglia, prior to dissociation of the ganglia 
into a single cell suspension.
Because of the increasing amounts of collagenous connective tissue in older ganglia, 
the use of collagenase was required initially to breakdown this tissue, prior to 
trypsinization. Once all ganglia were dissected 980pl Hanks Balanced Salt Solution 
(+ Calcium(0.097mg/ml) and Magnesium (0.0185mg/ml)) and 20pl collagenase 
(lOOmg/ml) (Sigma) was added to each tube. Ganglia were initially incubated on ice 
for 30mins followed by incubation at 37°C for 25mins. Ganglia were then washed 
twice in CMF-HBSS and further enzymatically treated by incubation with 0.05% 
trypsin, for 30 minutes, at 37°C. To arrest trypsin action, ganglia were washed in FI2 
+ HIHS. Ganglia could then be mechanically dissociated by gentle trituration using a 
fire-polished, narrowed, siliconized Pasteur pipette to produce a single cell 
suspension. This trituration was done in F I4 medium supplemented with albumax I 
and glutamine. The trituration was monitored at various stages by examining droplets 
of the dissociated cell suspension under an inverted phase-contrast microscope.
Once a single cell suspension was obtained, cells were made to up to the required 
volume in FI4 + Albumax and plated onto 35mm culture dishes (Greiner). As these 
cultures were to be used for RT-PCR they were plated at high density (approximately 
1000-2000 cells per dish). Dishes had been previously prepared by coating with 
substratum of poly-DL-omithine (0.5mg/ml in 0.15M borate buffer, pH 8.4, overnight 
at room temperature) and then laminin (20pg/ml, Sigma in F14 medium, 4 hours at
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37°C). Prior to plating, dishes were washed twice with F12+HIHS to remove laminin 
and then 1ml F14 supplememted with Albumax I and 2mM glutamine was added to 
each dish. Next, 1ml of cell suspension was added per dish and cells were grown with 
or without neurotrophic factors in a humidified 5.5% CO2 incubator, at 37°C for 48 or 
96hours.
In the adult, sensory neurons do not require neurotrophic support for survival so 
caspase inhibitors were not required. Cells were, therefore, either grown without 
factors or in the presence of NGF (lOng/ml), Artemin (lOng/ml) or MSP (50ng/ml). 
LIF was also used in some cultures at a concentration of 50ng/ml.
Following incubation cells were collected for RNA extraction in 350pl RLT buffer (+ 
1% P mercaptoethanol) (Qiagen) ready for RNA extraction.
To ensure any observed changes in mRNA expression were not due to differential 
survival of neurons in the presence of neurotrophic factors, survival counts were done 
at 3,48 and 96 hours after plating using a 1cm grid. Survival at 48 hrs and 96hrs was 
expressed as a percentage of the 3 hour count.
4.2.2. RNA extraction
RNA was extracted using the Qiagen RNeasy kit (described in 2.2.5), and Stratascript 
reverse transcriptase was used for reverse transcription (described previously in 
2.2.5).
4.2.3. Real-time PCR-Stratagene MX3000P
Real Time PCR was used to identify changes in gene expression in adult sensory 
neurons cultured for 96 hours in the presence or absence of NGF, Artemin or MSP.
Reverse Transcription of RNA samples was done as in chapter 2 (see 2.2.5.1) and 
PCRs set up as in 2.2.5.2. All genes mentioned in chapters 2 and 3 were investigated, 
and this study was also extended further to examine other potentially interesting
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genes. Newer genes included many that are up-regulated following axotomy or nerve 
damage, and also in in-vitro cultures. Experiments were performed ostensibly to see if 
NGF, ART and MSP could reverse axotomy-induced changes in gene expression.
Additional genes investigated included: the purine receptor, P2X3; the sodium 
channels Navi.3, Navi.6 and Navi.7; Damage Induced Neuronal Endopeptidase 
(DINE); Activating Transcription Factor 3 (ATF3). The latter two mRNAs are 
expressed at very low levels in vivo under normal circumstances but are massively up- 
regulated following axotomy or nerve damage (Tsujino et al., 2000, Kiryu-Seo et al., 
2000).
All genes outlined in 3.2.5 were investigated alongside several others. The primers 
used and reaction conditions for new genes are outlined below.
Primers:
GENE PRIMER SEQUENCE MGCL
CONCENTRATION
(MM)
ANNEALING
TEMPERATURE
(°C)
P2X3 Forward:
5-GTG CTT CCC GCT 
AAG ACC TG-3* 
Reverse:
5’_TTT g g a  a a t  g g a  
TGG ATG CTT GG-3’
3 52
Navi.6 Forward:
5’-GAC ACA CAG 
AGC AAG CAG ATG- 
3’
Reverse:
5’-GGA GAG AAT 
GAC CAC CAC AAA 
G-3’
3 52
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Navi.7 Forward:
5’-GCT ACA TCA TCA 
TAT CCT TCC TG-3’ 
Reverse:
5’-GAA CAT CTC AAA 
GTC GTC CTC-3’
3 49
Damage
Induced
Neuronal
Endopeptidase
(DINE)
Forward:
5’-GTA TTG GCA CCA 
TCA TTG-3’
Reverse:
5’-GTG AAG TTG TCA 
TAG AGG-3’
3 52
Activating 
Transcription 
Factor 3
Forward:
5’-GAG AGT GTG 
AAT GCT GAG-3’ 
Reverse:
5’-TCT GTT GGA TAA 
AGA GGT TC-3’
3 51
Table 4.1. Primer sequences, annealing temperatures and Mg concentration used fo r  detection o f  new 
genes.
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4.3. Results
4.3.1. Developmental expression patterns of the new mRNAs 
assayed in chapter 4
The expression of DINE, ATF3, P2X3, Navi.6 and Navi.7 mRNAs were quantified 
by real time QPCR using RNA that had been extracted from E l6, PO, P5 and adult 
trigeminal, nodose and dorsal root ganglia. Results are shown in figures 4.1 and 4.2.
In this chapter, results were statistically compared by the use of an ANOVA (analysis 
of variance) test. This test is useful as, although similar to the t-test, it can be used to 
compare several sets of data. This was thus useful in this chapter, when several 
variables were apparent.
As anticipated from the published literature (see above), the levels of DINE and ATF3 
mRNAs were extremely low in all ganglia studied, at all ages (figure 4.1 B and C).
The developmental expression pattern of P2X3 mRNA within sensory ganglia is 
shown in figure 4.1 A. All three sensory ganglia displayed similar patterns of P2X3 
mRNA expression and the amounts of P2X3 mRNA expressed were of the same order 
of magnitude within each of the three ganglia. In general, fairly constant levels of 
P2X3 mRNA were expressed between E l6 and P5 in all three ganglia and this is 
followed by a marked drop in expression between P5 and adulthood. The drop in 
P2X3 mRNA levels between P5 and the adult was most marked in the trigeminal 
ganglion.
This chapter also explores the expression of two TTX-sensitive sodium channel 
alpha-subunits, Navi.6 and Navi.7. The developmental expression pattern of Navi.6 
mRNA is very similar in both trigeminal and dorsal root ganglia and is markedly 
different to the expression patterns of the TTX-resistant sodium channels, Navi. 8 and 
Navi.9 (see chapter 3). In both neural crest-derived sensory ganglia, Navi .6 mRNA
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levels increased approximately 3-fold from E l6 to P5, followed by a modest drop in 
the levels of expression between P5 and adulthood (figure 4.2 A). In both ganglia the 
levels of Navi.6 mRNA expressed in the adult were higher than those expressed at 
E16. Navi.6 mRNA showed a slightly different developmental pattern of expression 
in nodose ganglia compared to trigeminal and dorsal root ganglia. In this placode- 
derived ganglion the increase in expression between E l6 and neonatal ages was 
modest and the peak of expression was at PO. However, once again, as in the case of 
the neural crest-derived sensory ganglia, there was a small drop in the level of Navi.6 
mRNA between P5 and adulthood, so that in the adult the levels of Navi.6 mRNA 
were slightly lower than those at E l6 (figure 4.2A).
The developmental expression pattern of Navi.7 mRNA more closely resembles that 
of the TTX-resistant channels, Navi.8 and Navi.9, than Navi.6 mRNA does. In all 
ganglia, significantly less Navi.7 mRNA was expressed in the adult compared to E l6 
(figure 4.2B). In the case of the nodose ganglion, Navi.7 mRNA expression levels 
peak at PO, whereas in trigeminal and dorsal root ganglia, peak expression of Navi.6 
mRNA occurs at E l6.
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Figure 4.1. Developmental expression o f P2X3, DINE and ATF3 mRNAs in sensory neurons
Trigeminal ganglia, nodose ganglia and DRG were collected from E l6, PO, P5 and adult mice 
and RNA extracted. Expression of P2X3, DINE and ATF3 mRNAs were quantified via real­
time QPCR.
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Figure 4.2. Developmental expression o f  N avi.6 and Navi. 7 mRNAs in sensory neurons
Trigeminal ganglia, nodose ganglia and DRG were collected from E l6, PO, P5 and adult mice 
and RNA extracted. Expression o f N avi.6 and N avi.7 mRNAs were quantified via real-time 
QPCR.
Error bars = +/- standard error, n = 6
4.3.2. Survival of adult DRG neurons in culture
It is well-established belief that adult sensory neurons can survive in culture in the 
absence of neurotrophic support (e.g. Lindsay et al., 1988), although this view has 
been occasionally challenged (e.g. Acheson et al., 1995). To confirm that DRG 
neuron survival was not compromised over time in culture, or indeed further 
enhanced in the presence o f additional neurotrophic factors, experiments were 
performed to assess the survival o f adult DRG neurons over 96 hours in culture, either 
without the addition o f exogenous neurotrophic factors or with the addition of 
lOng/ml artemin, lOng/ml NGF or 50ng/ml MSP (these concentrations were 
determined in a series o f pilot experiments and were used for all future experiments - 
see 4.3.3 below). Neuronal numbers were initially determined 3 hours after plating to 
allow sufficient time for the neurons to adhere to the laminin substratum. A second 
neuron count was made 96 hours after plating and the percentage o f healthy, phase 
bright cells was calculated relative to those at the 3-hour count. The survival data is 
presented in figure 4.3. In the absence o f neurotrophic support, approximately 75 % of 
neurons survived for 96 hours. The 25% reduction in neuronal number is unlikely to 
be due to the effects o f withdrawal from target field-derived neurotrophic support, 
rather it is likely to reflect lethal cell damage during the dissociation procedure. A 
similar number of neurons were lost after 96 hours o f culture in the presence o f 
50ng/ml MSP. lOng/ml NGF appears to increase neuronal survival by about 10 % 
over control cultures, however this increase does not reach statistical significance. 
Interestingly, the presence o f lOng/ml artemin seemed to completely prevent neuronal 
loss at 96 hours. This increase in survival was statistically significant compared to 
control cultures and MSP supplemented cultures. The apparent survival promoting 
effect of artemin, and to a lesser extent NGF, may have more to do with both factors 
having a hypertrophic effect on neuronal morphology, thus making small neurons 
more obvious and easier to count at 96 hrs, rather than direct effects on neuronal 
survival. This is discussed more fully below. Since neuronal survival was not 
significantly compromised by the lack o f neurotrophic factor support, all future
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culture experiments analysing the effects of NGF, MSP and artemin on adult sensory 
neuron gene expression were carried out in the absence of caspase inhibitors.
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Figure 4.3. Survival o f  cultured adult DRG neurons
Adult DRG neurons were cultured in the presence or absence of artemin (lOng/ml), NGF 
(10ng/ml) or MSP (50ng/ml) for 96 hours. The number o f phase bright healthy neurons 
were counted 3 hours after plating (Ohrs) and then a further 96 hours later. Survival was 
calculated as a percentage o f this ‘Ohr’ count. Error bars are +/- standard error, where n = 
4, * = p<0.05, ** = p<0.01
4.3.3. Pilot neurotrophic factor dose responses
Throughout this chapter several experiments were set up to explore the effects of 
artemin, MSP and NGF on gene expression within cultured DRG neurons. To 
determine the most suitable concentration of each factor to use for these experiments, 
initial pilot dose response experiments were set up.
Adult DRG cultures were set up as outlined in 4.2.1. and either MSP, artemin or NGF 
was added to dishes at concentrations of 2ng/ml, lOng/ml or 50ng/ml. Control dishes 
containing no neurotrophic factors were also included. As these initial experiments 
were designed to determine suitable concentrations of neurotrophic factors for use in 
future, more comprehensive, experiments, it was decided to only analyse the effects 
of neurotrophic factors on the expression of three mRNAs, SP, Navi. 8 and ATF3. 
These mRNAs were chosen simply because they produced robust real time-QPCR 
reactions. Following culture for 96 hours in various concentrations of neurotrophic 
factors, RNA was extracted from DRG neurons and the expression of SP, Navi.8 and 
ATF-3 mRNAs were quantified by real time-QPCR. Several samples of DRG neurons 
were lysed immediately following dissociation to provide RNA for a time 0 time- 
point that could used to evaluate the levels of mRNA expression within DRG neurons 
in-vivo. The data from the pilot dose response experiments is presented in figures 4.4 
to 4.6. Statistical analyses were performed using ANOVA tests to compare data 
groups (n = 4). Statistical comparisons between the different neurotrophic factor 
concentrations and controls are presented in the tables underneath each graph.
In chapters 2 and 3, t-tests were sufficient to analyse the statistical significance 
between data sets, so data was analysed and graphs were presented in an Excel 
spreadsheet format. However, in this chapter several data sets are being compared 
against each other, thus requiring a statistical package that could carry out more in- 
depth analyses. For this reason, results in this chapter were calculated in StatView and 
hence the graphs appear in a different format.
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The expression of SP mRNA in control cultures and cultures supplemented with 
different concentration of either artemin, MSP or NGF is shown in figure 4.4. The 
levels of SP mRNA expressed by adult DRG neurons grown in the absence of 
neurotrophic factor support decreased markedly over time in culture. This is in 
accordance with the neonatal sensory neuron culture data presented in chapter three of 
this thesis and previously published data from sciatic nerve lesion experiments 
(Nielsch et al., 1987; Zhang et al., 1995; Sterne et al., 1998). The decrease in SP 
mRNA was significantly attenuated by the addition of NGF at all concentrations and 
artemin at lOng/ml and 50ng/ml. The expression enhancing effects of NGF were not 
significantly different between 2ng/ml and 50ng/ml. Likewise, 50ng/ml artemin was 
not significantly more effective in enhancing SP mRNA expression than lOng/ml 
artemin. MSP could also partially prevent the time-dependent decrease in SP mRNA 
expression that occured in cultured DRG neurons, although not at a concentration of 
2ng/ml.
The amount of Navi. 8 mRNA expressed by cultured adult DRG neurons also 
decreased over time in culture in the absence of neurotrophic factor support (figure 
4.5). Once again, this is in agreement with the neonatal culture data presented in 
chapter 3 of this thesis and the published literature documenting the expression of this 
sodium channel following sciatic nerve lesion (Okuse et al., 1997; Cummins et al., 
1997; Tate et al., 1998; Dib-hajj et al., 1998; Novakovic et al., 1998 Sleeper et al., 
2000; Decosterd et al., 2002). The addition of 2, 10 or 50ng/ml of NGF or artemin 
significantly attenuated the decrease in Navi.8 mRNA expression. Once again, as in 
the case of SP mRNA, there was no statistically significant difference between the 
regulatory effects of 2ng/ml NGF and 50ng/ml NGF. In the case of Navi. 8 mRNA, 
50ng/ml artemin was significantly more effective in ameliorating the decrease in 
mRNA expression than 2ng/ml or lOng/ml artemin. Whilst all concentrations of MSP 
were capable of enhancing Navi.8 mRNA expression, only 50ng/ml had a statistically 
significant effect on Navi.8 mRNA expression.
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Figure 4.4. Effect o f increasing concentrations o f  artemin, MSP and NGF on the expression o f  SP 
mRNA in cultured adult mouse DRG neurons
Adult mouse DRG neurons were cultured for 96 hours in the presence and absence o f concentrations of 
Artemin MSP and NGF ranging from 2ng/ml to 50ng/ml. Expression of SP mRNA was quantified 
using real-time QPCR and all results were normalised against GAPDH mRNA levels. Results of 
ANOVA analyses are outlined in B-D.
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A2.25 -
1.75 -
051.25 -
£
- n 0, Ohr
- hi 0, 96hr
- □ 2ng/ml, 96hr
- □ lOng/ml, 96hr
-  □ 50ng/ml, 96hr
B
u
control artemin MSP NGF
c
artemin P value S ig n ifican ce MSP P v a lu e S ig n ifican ce
2ng/ml, 10ng/ml 0.5597 2ng/ml, 10ng/ml 0.2733
2ng/ml, 50ng/ml 0.0034 ** 2ng/ml, 50ng/ml 0.0219 *
2ng/ml, control 0.0069 ** 2ng/ml, control 0.5298
10ng/ml, 50ng/ml 0.0012 10ng/ml, 50ng/ml 0.1402
10ng/ml, control 0.0040 ** 10ng/ml, control 0.1115
50ng/ml, control 0.0001 ** 50ng/ml, control 0.0074 **
NGF P v a lu e S ig n if ic a n ce
2ng/ml, 10ng/ml 0.4138
2ng/ml, 50ng/ml 0.1696
2ng/ml, control 0.0011
10ng/ml, 50ng/ml 0.5202
10ng/ml, control 0 .0003 ★ ★
50ng/ml, control 0.0001 **
Figure 4.5. Effect o f  increasing concentrations o f  artemin, MSP and NGF on the expression o f  Navi. 8 
mRNA in cultured adult mouse DRG neurons
Adult mouse DRG neurons were cultured for 96 hours in the presence and absence o f concentrations of 
Artemin MSP and NGF ranging from 2ng/ml to 50ng/ml. Expression of Navi .8 mRNA was quantified 
using real-time QPCR and all results were normalised against GAPDH mRNA levels. Results of 
ANOVA analyses are outlined in B-D.
Error bars = +/- standard error, n = 3 -  4 *  = <0.05 , ** = <0.01
As anticipated from previously published data documenting the effects of nerve 
damage on the expression of ATF3 (e.g. Averill et al., 2004), the expression of this 
transcription factor increased in adult DRG neurons over time in culture (figure 4.6), 
Both artemin (lOng/ml) and NGF (2, 10 and 50 ng/ml) could significantly reduce the 
up-regulation of ATF3. Interestingly, artemin was not significantly effective in 
reducing ATF3 mRNA levels at concentrations of 2ng/ml or 50ng/ml, suggesting that 
the effects of artemin on regulating ATF3 mRNA expression follow a bell shape dose 
response curve. MSP did not seem to be capable of significantly reducing the 
expression of ATF3 mRNA. However, 50ng/ml MSP was able to decrease ATF3 
mRNA expression to a level that was close to statistical significance.
In light of the data presented above, I decided to use lOng/ml artemin and NGF and 
50ng/ml MSP in all subsequent experiments designed to investigate the modulation of 
DRG neuron gene expression by these neurotrophic factors.
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Figure 4.6. Effect o f  increasing concentrations o f  artemin, MSP and NGF on the expression o f  ATF3 
mRNA in cultured adult mouse DRG neurons
Adult mouse DRG neurons were cultured for 96 hours in the presence and absence o f concentrations of 
Artemin MSP and NGF ranging from 2ng/ml to 50ng/ml. Expression of ATF3 mRNA was quantified 
using real-time QPCR and all results were normalised against GAPDH mRNA levels. Results of 
ANOVA analyses are outlined in B-D.
Error bars = +/- standard error, n = 3 -  4 * = <0.05 , ** = <0.01
4.3.4. Pilot experiments to determine the best culture time 
point for mRNA expression analysis.
Pilot experiments were performed (using the neurotrophic factor concentrations that 
were empirically determined as being optimal in 4.3.3) to investigate whether 
extracting RNA from adult DRG cultures after 48 or 96 hours of culture would 
provide the best assay range for measuring the effects of artemin, MSP and NGF on 
regulating mRNA expression. Once again, the “test genes” chosen for these pilot 
experiments were SP, N avi.8 and ATF3. Adult DRG cultures, supplemented with 
either lOng/ml NGF, 50ng/ml MSP or lOng/ml artemin, were set up and incubated for 
either 48 or 96 hours prior to RNA extraction and purification. Control dishes 
containing no neurotrophic factors were also set up in parallel. Once again, samples of 
DRG neurons were lysed immediately following dissociation to provide RNA for a 
time 0 time-point for evaluating the levels of mRNA within DRG neurons in-vivo.
The results of these pilot experiments are shown in figures 4.7. Significant differences 
in mRNA expression levels, compared to control cultures, at 96 hours are indicated by 
* (p<0.05) or ** (p<0.01) directly above bars as determined by anova statistical 
analysis.
Once again, these cultures demonstrate a marked decrease in the expression of SP and 
Navi.8 mRNAs over time in culture, whilst the expression of ATF3 mRNA 
increased. SP mRNA expression levels dropped 8-fold by 48 hours and this drop was 
increased to 15-fold by 96 hrs. At 48 hours, lOng/ml artemin was able to increase the 
expression of SP mRNA by 3-fold in comparison to the levels in control cultures. By 
96 hours, artemin increased the levels of SP mRNA more than 10-fold compared to 
control cultures. Similarly, 1 Ong/ml NGF doubled SP mRNA expression compared to 
control cultures at 48 hours and this difference between NGF supplemented cultures 
and control cultures was increased to 5-fold by 96 hours. At 48 hours, 50ng/ml MSP 
increased the expression of SP mRNA, although this increase was not statistically 
significant. However, by 96 hours 50ng/ml MSP was as effective as 1 Ong/ml NGF in 
ameliorating the decline in SP mRNA expression (figure 4.7A).
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Navi.8 mRNA levels within control adult DRG cultures dropped by 6-fold compared 
to in-vivo levels over the first 48 hours of culture, and this decrease reached 10-fold 
by 96 hours (figure 4.7B). Artemin appeared to be ineffective in attenuating the 
decrease in Navi.8 mRNA expression at 48 hours, whereas 1 Ong/ml NGF and 
50ng/ml MSP were able to slightly, but significantly, increase the expression of this 
TTX-resistant sodium channel mRNA. At 96 hours, mainly due to the continued 
decreasing expression of Navi.8 mRNA in the absence of neurotrophic factor 
support, all three neurotrophic factors could significantly increase the levels of 
Navi.8 mRNA compared to those in control cultures. However, it is clear that these 
three neurotrophic factors were less able to rescue Navi.8 mRNA expression at 96 
hours than SP mRNA expression.
The mRNA levels of the injury induced factor, ATF3, increased more than 6-fold 
after 48 hours in control cultures compared to the presumptive in-vivo, or time 0, level 
(figure 4.7C). It should be noted that in the case of ATF3 and DINE mRNAs, but not 
the other mRNAs assayed in this chapter, the time 0 mRNA expression levels are 
significantly higher than those found in-vivo, since the dissection and dissociation 
procedures appear to stimulate immediate-early gene type expression of these mRNAs 
(S Wyatt personal communication - data not shown.). At 48 hours, all three 
neurotrophic factors tested appeared to be able to reduce the expression of ATF3 
mRNA by around 25% compared to control cultures, although the reduction was only 
statistically significant in the case of NGF and artemin. After 96 hours in culture,
ATF3 mRNA levels in DRG neurons cultured in the absence of neurotrophic factor 
support dropped 25% compared to 48 hour control culture levels. However, all three 
neurotrophic factors could reduce the expression of this transcription factor mRNA in 
a statistically significant manner at this time-point.
It is clear from the data presented above that determining mRNA expression levels in 
DRG neurons after 96 hours of culture, rather than 48 hours of culture, provides an 
assay with the best dynamic range for investigating the effects of neurotrophic factors 
on regulating gene expression. Therefore, all subsequent real time-QPCR analysis of 
gene expression was performed on RNA extracted from adult DRG neurons that had 
been in culture for 96 hours.
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Figure 4.7. Effect o f artemin, MSP and NGF on the expression ofSP, Navi.8 and ATF3 mRNAs in 
adult mouse DRG neurons cultured for 48 or 96 hours
Adult mouse DRG neurons were cultured in the presence or absence o f artemin (1 Ong/ml), MSP 
(50ng/ml) or NGF (1 Ong/ml) for 48 or 96 hours. SP (A) Navi .8 (B) and ATF3 (C) mRNA levels 
were quantified using real-time QPCR. * = p = <0.05, ** = p = <0.01 as determined by two-tailed 
t-test, in comparison to control samples at that time-point.
Error bars = +/- standard error, n = 4
4.3.5. 96 hour cultures -  artemin, MSP and NGF
The optimal parameters determined in the pilot experiments described above were 
applied in a series of DRG neuron cultures to determine whether the neurotrophic 
factors NGF, MSP and artemin can regulate the neuronal expression of the genes 
studied in chapter 3, together with the additional genes introduced in 4.1. Adult DRG 
neurons were cultured for 96 hours either without neurotrophic factor support or in 
the presence of eitherl Ong/ml artemin, 50ng/ml MSP or 1 Ong/ml NGF. After 96 
hours, RNA was extracted from the neuronal cultures and mRNA levels were 
determined by real time-QPCR. The results of these experiments are presented in 
figures 4.8 -  4.13.
As might be anticipated, due to their co-expression in a similar sub-population of 
small-diameter peptidergic neurons (Lundberg et al., 1985; Lee et al., 1985; Hokfelt et 
al., 1975; Cuello et al., 1978; Skofitsch and Jacobowitz, 1985), the regulation of a- 
CGRP and SP mRNAs by the neurotrophic factors NGF, artemin and MSP appeared 
to be almost identical (4.8A and C). In accordance with both the neonatal data 
presented in chapter 3 of this thesis, and (if one views in-vitro culture as model of 
nerve injury) previously published data from in-vitro and in-vivo experiments using 
adult rodents, both mRNAs were down-regulated over time in culture (Noguchi et al., 
1990; Mulder et al., 1997; Sterne et al., 1998; Shi et al., 2001; Shadiack et al., 2001; 
Nielsch et al., 1987; Zhang et al., 1995). In the case of a-CGRP mRNA, the reduction 
in expression after 96 hours in culture was around 3-fold, whereas for SP mRNA the 
reduction in expression after 96 hours in culture was almost 8-fold. Artemin, MSP 
and NGF all acted to significantly attenuate the decreases in a-CGRP and SP mRNA 
expression in cultured adult DRG neurons. All three neurotrophic factors appeared to 
have a similar efficacy in promoting the transcriptional expression of a-CGRP, 
effectively doubling the levels of a-CGRP mRNA expressed by adult DRG neurons 
after 96 hours in culture compared to control cultures. Artemin appeared to be the 
most effective neurotrophic factor at regulating SP mRNA expression. 1 Ong/ml 
artemin could increase the levels of SP mRNA expressed by DRG neurons that have
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been in culture for 96 hours by 6-fold compared to the levels of this neuropeptide 
mRNA in control cultures. 1 Ong/ml NGF and 50ng/ml MSP were only able to 
increase SP mRNA levels by 3-fold compared to control cultures.
The levels of p-CGRP mRNA expressed by adult DRG neurons also decreased over 
time in culture, although the decrease, only being 2-fold, is not as dramatic as that of 
a-CGRP mRNA (figure 4.8B). NGF, at 1 Ong/ml, entirely prevented the decrease in P- 
CGRP mRNA levels. Whilst MSP and artemin had a tendency to increase the levels 
of this neuropeptide mRNA compared to controls after 96 hours in culture, the 
increases in P-CGRP mRNA levels were not statistically significant. However, in a 
second series of experiments, carried out to produce the “additive” data that is 
presented below, both MSP and artemin were able to significantly enhance the levels 
of P-CGRP mRNA in DRG cultures compared to control cultures (figure 4.14 B).
The two TTX-R sodium channel mRNAs showed a dramatic 10-fold decrease in 
neuronal expression following 96 hours in culture in the absence of neurotrophic 
factor support (figure 4.9 A and B). This decrease in expression levels reflects the 
down-regulation previously observed within small-diameter neurons of the DRG 
following peripheral nerve damage (Okuse et al., 1997; Cummins et al., 1997; Tate et 
al., 1998; Dib-hajj et al., 1998; novakovic et al., 1998 Sleeper et al., 2000; Decosterd 
et al., 2002). The addition of artemin, MSP or NGF significantly increased the 
expression of both mRNAs compared to control cultures. However, these increases in 
the expression of both mRNAs, compared to control cultures, was only of the order of 
2-fold for all the neurotrophic factors. This would suggest that other neurotrophic 
factors are involved, in addition to artemin, MSP and NGF, in regulating the 
expression of these TTX-resistant sodium channels within adult sensory neurons. This 
is discussed more fully below.
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Figure 4.8 Expression o f alpha CGRP, beta-CGRP and SP mRNAs in adult DRG cultured in the presence o f  
artemin, MSP or NGF
Adult mouse DRG were cultured for 96 hours in the presence of artemin (1 Ong/ml), MSP (50ng/ml) or NGF 
(1 Ong/ml). Cultures with no factors were included as a control for comparison. Expression of alpha- 
CGRP(A), beta-CGRP (B) and SP (C) mRNAs were quantified using real-time QPCR. Error bars = +/- 
standard error, n = 15-20. Significant differences to control 96 hours are illustrated. * = p<0.05, ** = p<0.01 
as determined by two tailed t-test.
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Figure 4.9. Expression o f Navi.8, Navi.9 and VR1 mRNAs in adult DRG cultured in the presence o f  
artemin, MSP or NGF
Adult mouse DRG were cultured for 96 hours in the presence o f artemin (1 Ong/ml), MSP (50ng/ml) or NGF 
(lOng/ml). Cultures with no factors were included as a control for comparison. Expression of N avi.8 (A), 
Navi .9 (B) and VR1 (C) mRNAs were quantified using real-time QPCR. Error bars = +/- standard error, n = 
15-20. Significant differences to control 96 hours are illustrated. * = p<0.05, ** = p<0.01 as determined by 
two tailed t-test.
The levels of both VR1 mRNA and protein have been shown to be down-regulated in 
injured adult rat DRG neurons following both sciatic nerve and spinal nerve 
transection (Michael and Priestley, 1999; Michael and Priestley, 2002; Fukuoka T et 
al., 2002; Wendland et al., 2003). Since in-vitro culture of adult DRG neurons can, in 
many respects, be viewed as a model of axotomy, my results, which show a 4-fold 
down-regulation of VR1 mRNA levels over 96 hours in culture in absence of added 
neurotrophic factors, are in agreement with the published data (figure 4.9C). The 
addition of either 50ng/ml MSP or 1 Ong/ml artemin significantly ameliorated the 
reduction in VR1 mRNA levels. Whilst 1 Ong/ml NGF increased the expression of 
VR1 mRNA compared to control cultures at 96 hours, this increase did not quite 
reach statistical significance.
The in-vitro neuronal expression of the mRNAs for the neuropeptides galanin and 
PACAP are shown in figure 4.10. Both neuropeptide mRNAs showed a dramatic, 
greater than 15-fold, increase in expression over 96 hrs in culture. This reflected the 
increases in PACAP mRNA and peptide observed in rodent DRG neurons following 
sciatic nerve transection/compression (Jongsma-Wallin et al., 2001; Pettersson et al., 
2004) and the similar increases in galanin expression within rodent sensory neurons 
following peripheral nerve damage or axotomy (Hokfelt et al., 1987; Villar et al., 
1989; Wiesenfeld-Hallin., 1992; Zhang et al., 1998; Holmes et al., 2005). In my 
experiments, the up-regulation of galanin mRNA could be significantly inhibited by 
the addition of either 10 ng/ml artemin, 50 ng/ml MSP or 1 Ong/ml NGF. NGF and 
artemin were able to reduce the levels of galanin mRNA by as much as 60% 
compared to control cultures. MSP was slightly less efficacious, only being able to 
reduce the levels of galanin mRNA by 40% compared to control cultures. The culture- 
induced up-regulation of PACAP mRNA expression was significantly inhibited by the 
addition of 1 Ong/ml NGF to cultures. The addition of either 50 ng/ml MSP or 10 
ng/ml artemin to DRG cultures also ameliorated some of the increase in PACAP 
mRNA levels observed in control cultures, although the effect did not reach statistical 
significance.
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Figure 4.10. Expression o f galanin and PACAP mRNAs in adult DRG cultured in the presence o f artemin, 
MSP or NGF
Adult mouse DRG were cultured for 96 hours in the presence of artemin (lOng/ml), MSP (50ng/ml) or NGF 
(1 Ong/ml). Cultures with no factors were included as a control for comparison. Expression o f galanin (A) and 
PACAP (B) mRNAs were quantified using real-time QPCR. Error bars = +1- standard error, n = 15-20. 
Significant differences to control 96 hours are illustrated. * = p<0.05, ** = p<0.01 as determined by two 
tailed t-test.
ATF3 and DINE mRNAs were also significantly up-regulated, by 3- and 50-fold, 
respectively, in adult DRG cultures that do not contain neurotrophic factors over a 96 
hour time period (figure 4.11). The increase in the expression of both mRNAs is in 
agreement with previously published data demonstrating an increase in their 
expression within sensory neurons (and in the case of ATF3 glial cells) following 
nerve lesion (Kato et al, 2002; Wang et al., 2003; Averill et al., 2004). The addition of 
either artemin, MSP or NGF to adult mouse DRG cultures could significantly 
attenuate the increase in the expression of both these mRNAs, with artemin appearing 
to be the most effective neurotrophic factor of the three.
As discussed previously, culturing adult DRG neurons can, in many respects, be 
considered to be an in-vitro model of peripheral nerve lesion, since many of the 
changes in neuronal gene expression that occur following sciatic or spinal nerve 
constriction/ligation/transection appear to occur when DRG neurons are placed in 
culture. The two TTX-sensitive sodium channels investigated in this chapter, Navi.6 
and Navi.7, are no exception to this rule. Transcripts for both these sodium channels 
decreased markedly when adult mouse DRG neurons are cultured for 96 hours in the 
absence of neurotrophic factor support (figures 4.12 A and B), reflecting the decrease 
in both these mRNAs observed in rat lumbar DRG following spinal nerve ligation 
(Kim et al., 2002). The decrease in the levels of Navi.6 mRNA over 96 hours in 
culture was modest at around 3.5-fold, whereas the levels of Navi.7 mRNA decreased 
nearly 10-fold. It appears as if neither artemin, MSP or NGF could significantly 
attenuate the decreases in the expression of either TTX-sensitive sodium channel 
mRNA, although, as observed in the “additive” cultures below, NGF and MSP 
appeared to have a tendency to slightly increase the expression of both mRNAs.
Perhaps surprisingly, P2X3 mRNA expression did not appear to significantly change 
when adult DRG neurons are placed in culture for 96 hours (figure 4.12 C) This data 
contradicts the previously published observation that P2X3 mRNA levels decrease 
significantly in damaged, ATF 3-positive, sensory neurons following nerve 
transection (Tsuzuki et al., 2001). Neither MSP nor NGF significantly altered the 
expression levels of P2X3 mRNA over the 96 hour culture period. Whilst the addition
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of 1 Ong/ml artemin appeared to significantly decrease the expression of P2X3 mRNA 
in adult DRG neuron cultures, the decrease was small and inconsistent, not being 
apparent in later tissue culture experiments (see 4.3.6 and 4.3.7).
Figure 4.13 shows the expression of GAPDH mRNA within adult DRG cultures after 
96 hours. In accordance with the low amount of neuronal death observed in adult 
mouse DRG cultures (figure 4.3), GAPDH mRNA levels did not markedly change in 
control cultures compared to those at time 0. The addition of either 1 Ong/ml artemin,
1 Ong/ml NGF or 50ng/ml MSP to cultures did not significantly alter the expression of 
GAPDH mRNA compared to control cultures.
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Figure 4.11. Expression o f ATF3 and DINE mRNAs in adult DRG cultured in the presence o f artemin, MSP 
or NGF
Adult mouse DRG were cultured for 96 hours in the presence of artemin (1 Ong/ml), MSP (50ng/ml) or NGF 
(1 Ong/ml). Cultures with no factors were included as a control for comparison. Expression of ATF3 (A) and 
DINE (B) mRNAs were quantified using real-time QPCR. Error bars = +/- standard error, n = 15-20. 
Significant differences to control 96 hours are illustrated. * = p<0.05, ** = p<0.01 as determined by two 
tailed t-test.
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Figure 4.12 Expression o f Navi.6, Navi. 7 and P2X3 mRNAs in adult DRG cultured in the presence o f  
artemin, MSP or NGF
Adult mouse DRG were cultured for 96 hours in the presence o f artemin (1 Ong/ml), MSP (50ng/ml) or NGF 
(lOng/ml). Cultures with no factors were included as a control for comparison. Expression of N avi.6 (A), 
Navi.7 (B) and P2X3 (C) mRNAs were quantified using real-time QPCR. Error bars = +/- standard error, n 
= 15-20. Significant differences to control 96 hours are illustrated. * = p<0.05, ** = p<0.01 as determined by 
two tailed t-test.
Figure 4.13. Expression o f GAPDH,mRNA in adult DRG cultured in the presence o f artemin, MSP or NGF 
Adult mouse DRG were cultured for 96 hours in the presence of artemin (1 Ong/ml), MSP (50ng/ml) or NGF 
(1 Ong/ml). Cultures with no factors were included as a control for comparison. Expression of GAPDH 
mRNA was quantified using real-time QPCR, and results were used to normalise other data. Error bars = +/- 
standard error, n = 15-20. Significant differences to control 96 hours are illustrated. * = p<0.05, ** = p<0.01 
as determined by two tailed t-test.
4.3.6. Additive experiments
In section 4.3.5.1 have demonstrated that saturating levels of NGF, artemin and MSP 
can modulate the expression of a number of mRNAs in cultured adult mouse DRG 
neurons, effectively reversing, or partially reversing, culture-induced changes in gene 
expression. The receptors for NGF and artemin are expressed on specific, partially 
overlapping, sub-populations of predominantly small nociceptive sensory neurons in- 
vivo. In the case of the MSP receptor, RON, the identity of the sub-population of 
neurons expressing this receptor in the adult has not yet been determined. Although 
the sub-populations of neurons expressing these receptors may change in culture, it is 
still likely that each receptor is only expressed in a specific sub-population of neurons. 
In order to try and determine whether the receptors for NGF, artemin and MSP are 
expressed on distinct or overlapping sub-populations of adult mouse DRG neurons in 
culture, and how these neuronal sub-populations correlate to the sub-populations of 
neurons expressing each of the mRNAs investigated in this chapter, I carried out a 
series of “additive” tissue culture experiments where neurons were cultured either 
without neurotrophic factors, with a single neurotrophic factor or with combinations 
of two or three neurotrophic factors. The rationale behind this is that one may expect 
the effects of two neurotrophic factors on the expression of any one mRNA to be 
partially additive if the sub-populations of neurons expressing receptors for these 
neurotrophic factors, in addition to the mRNA in question, are not entirely 
overlapping. Conversely, if two neurotrophic factors do not produce an additive effect 
on regulating mRNA expression, it is likely that the majority of neurons responding to 
any one neurotrophic factor, and also expressing the mRNA of interest, contains 
receptors for the other neurotrophic factor i.e. the two sub-populations that express the 
mRNA of interest and respond to each neurotrophic factor are virtually entirely 
overlapping. This rationale is based on two assumptions. First, that each neurotrophic 
factor is being used at a saturating concentration for effects on modulating the 
transcriptional expression of the analysed genes. Second, that the intracellular signal 
transduction pathways that lead to an increase in transcriptional expression of the 
analysed genes are similar for each neurotrophic factor. Therefore, if signalling 
pathways are maximally activated with saturating concentrations of one neurotrophic
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factor within any one cell, the addition of a second trophic factor should not increase 
transcription of the gene in question within the same cell.
The results of the “additive” experiments are presented in figures 4.14 - 4.21. 
Determining the statistical significance of the data is quite complex due to the number 
of conditions under test, thus requiring ANOVA statistical analysis of data sets. 
Significant differences in the expression of each mRNA in comparison to ‘control 
cultures’ at 96hours are highlighted by * (p<0.05) or ** (p<0.01) above the relevant 
bar. To prevent graphs from becoming crowded and over-complicated, other relevant 
comparisons are shown in tables C and D of each figure.
The expression of a-CGRP and p-CGRP mRNAs for the series of cultures that 
provided data for the “additive” experiments is shown in figure 4.14A and B. The data 
for both CGRP mRNAs are very similar. A 3- to 4-fold down-regulation of CGRP 
mRNAs was observed over time in control cultures, which was significantly reversed 
by the addition of either artemin, MSP or NGF. The addition of both 1 Ong/ml artemin 
and 1 Ong/ml NGF to cultures produced significantly higher levels of a-CGRP and P- 
CGRP mRNAs than the addition of either artemin or NGF alone, restoring both 
mRNAs to levels found in-vivo. The partially additive effects of NGF and artemin on 
promoting a- and p-CGRP mRNA expression suggests that these two factors act on 
two partially overlapping sub-populations of peptidergic DRG neurons. This in turn 
suggests that a sub-population of DRG neurons exist, at least in culture, that are 
peptidergic but do not express TrkA, rather they express the artemin receptor, GFR- 
a3. The addition of 5Ong/ml MSP to cultures containing either 1 Ong/ml artemin or 
1 Ong/ml NGF did not significantly increase a-or p-CGRP mRNA levels above those 
found in cultures containing either NGF alone or artemin alone, suggesting that few 
sensory neurons express the MSP receptor RON in the absence of either TrkA or 
GFR-a3. Similarly, the addition of MSP to cultures containing both artemin and NGF 
did not increase a- or p-CGRP mRNA levels above those in cultures containing just 
NGF and artemin.
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Figure 4.14. Additive effects o f artemin, MSP and NGF on expression o f alpha CGRP and beta CGRP 
mRNAs in adult mouse cultured DRG
Adult mouse DRG were cultured in the presence or absence of artemin (1 Ong/ml), NGF (1 Ong/ml), 
MSP (50ng/ml) or a combination of factors, for 96 hours. Expression o f alpha CGRP (A) and beta 
CGRP (B) mRNAs were quantified using real-time Q-PCR. ANOVA statistical analyses were carried 
out. Significant differences to expression at ‘control 96 hours’ are inducated directly above bars, other 
relevant comparisons are outlined in C (alpha CGRP) and D (Beta CGRP). * = p<0.05 ** = p<0.01. 
Error bars = +/- standard error, n = 4
The “additive” experimental data for SP mRNA is shown in figure 4.15 A. Once 
again, in accordance with the data presented in section 4.3.5 above, the level of SP 
mRNA expressed by DRG neurons cultured for 96 hours in the absence of 
neurotrophic factor support was dramatically lower than in freshly dissociated 
neurons. Once again, the addition of either 1 Ong/ml artemin, 1 Ong/ml NGF or 
50ng/ml MSP to cultures significantly increased the expression of SP mRNA 
compared to control cultures, with artemin having the greatest efficacy. As in the case 
of CGRP mRNAs, the addition of NGF and artemin to cultures increased the 
expression of SP mRNA to levels above that found in cultures with either factor 
alone. Interestingly, in contrast to the data for CGRP mRNAs, the addition of MSP to 
cultures containing either artemin or NGF alone significantly increased the levels of 
SP mRNA expressed by cultured DRG neurons to levels above those found with 
either artemin or NGF alone. The addition of all three neurotrophic factors to DRG 
cultures did not increase the expression of SP mRNA compared to cultures containing 
any combination of two neurotrophic factors.
The data from the additive cultures for VR1 mRNA is markedly different to that for 
a- and p-CGRP and SP mRNAs (figure 4.15 B). In agreement with the data from 
section 4.3.5 above, VR1 mRNA levels within adult mouse DRG neurons decreased 
significantly over time in culture in the absence of added neurotrophic factors. NGF, 
artemin and MSP could all significantly enhance the expression of VR1 mRNA 
compared to VR1 mRNA levels in control cultures, with NGF being the least 
effective of the three neurotrophic factors. However, unlike SP and CGRP mRNAs, 
no combinations of neurotrophic factors significantly increased the expression of VR1 
mRNA compared to VR1 mRNA levels observed in cultures containing a single 
neurotrophic factor.
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P value Significance
Art, art + MSP 0.0020 **
Art, art + NGF 0.0057 **
Art, all factors 0.0638
MSP, art + MSP <0.0001 **
MSP, M SP + NGF 0.0526
MSP, all factors <0.0001 irk
NGF, art + NGF <0.0001 kk
NGF, MSP + NGF 0.0356
NGF, all factors <0.0001 kk
B . VR D .  VR
P value Significance
Art, art + MSP 0.0789
- Art, art + NGF 0.8559
Art, all factors 0.2192
■  Ohr MSP, art + MSP 0.1613
DD 96hr MSP, MSP + NGF 0.3122
MSP, all factors 0.1116
- NGF, art + NGF 0.1116
NGF, MSP + NGF 0.4170
NGF, all factors 0.8382
Figure 4.15. Additive effects o f artemin, MSP and NGF on expression o f SP and VR1 mRNAs in adult 
mouse cultured DRG
Adult mouse DRG were cultured in the presence or absence o f artemin (1 Ong/ml), NGF (1 Ong/ml), 
MSP (50ng/ml) or a combination of factors, for 96 hours. Expression of SP (A) and VR1 (B) mRNAs 
were quantified using real-time Q-PCR. ANOVA statistical analyses were carried out. Significant 
differences to expression at ‘control 96 hours’ are indicated directly above bars, other relevant 
comparisons are outlined in C (SP) and D (VR1). * = p<0.05 ** = p<0.01.
Error bars = +/- standard error, n = 4
■
The “additive” culture data for the two TTX-resistant sodium channels N avi.8 and 
Navi.9 are similar, but not identical (figure 4.16 A and B). A greater than 10-fold 
decrease in the expression of both mRNAs was apparent in DRG neurons that were 
cultured for 96 hours without neurotrophic factor support. The addition of either 
1 Ong/ml artemin, 1 Ong/ml NGF or 50ng/ml MSP to cultures significantly increased 
the expression of both mRNAs compared to control cultures, although increases are 
only of the order of 2- to 3- fold. The addition of both NGF and artemin to control 
cultures increased the expression of both mRNAs to higher levels than those found in 
cultures containing either neurotrophic factor alone in a partially additive way. In 
contrast, a combination of MSP and NGF did not increase the expression of either 
mRNA compared to cultures containing either factor alone. In the case of Navi.9 
mRNA, artemin and MSP appear to enhance expression in a partially additive way 
compared to cultures containing either neurotrophic factor. This is not the case for 
Navi. 8 mRNA. For both mRNAs, the addition of all three neurotrophic factors to 
cultures did not increase the levels of mRNA expressed compared to cultures 
containing combinations of any two of the neurotrophic factors, suggesting that very 
few neurons exist in adult mouse DRG cultures that express TTX-resistant sodium 
channel mRNAs and only one of the three neurotrophic factor receptors under 
investigation.
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P value Significance
Art, art + MSP 0.1322
Art, art + NGF 0.0014 **
Art, all factors 0.0015 **
MSP, art + MSP 0.0153 *
MSP, MSP + NGF 0.0683
MSP, all factors 0.0001 **
NGF, art + NGF 0.0032 **
NGF, MSP + NGF 0.6171
NGF, all factors 0.0035 **
D. Nav1.9:
P value Significance
Art, art + MSP 0.0225 *
Art, art + NGF 0.0001 **
Art, all factors 0.0863
MSP, art + MSP 0.0003 **
MSP, MSP + NGF 0.9572
MSP, all factors 0.0015 **
NGF, art + NGF <0.0001 **
NGF, MSP + NGF 0.0628
NGF, all factors <0.0001 **
Figure 4.16. Additive effects o f  artemin, MSP and NGF on expression o f Navi.8 and Navi.9 mRNAs in 
adult mouse cultured DRG
Adult mouse DRG were cultured in the presence or absence of artemin (1 Ong/ml), NGF (1 Ong/ml), 
MSP (50ng/ml) or a combination of these factors, for 96 hours. Expression o f N avi.8 (A) and N avi.9 
(B) mRNAs were quantified using real-time Q-PCR. ANOVA statistical analyses were carried out. 
Significant differences to expression at ‘control 96 hours’ are indicated directly above bars, other 
relevant comparisons are outlined in C (Sen 10a) and D (Scnl la). * = p<0.05 ** = p<0.01.
Error bars = +/- standard error, n = 4
The regulation of galanin and PACAP mRNA expression in cultured adult mouse 
DRG neurons is shown in figure 4.17. The 10-fold up-regulation of galanin mRNA 
that occured in control cultures was partially, but significantly, inhibited by all 
neurotrophic factors in agreement with the data presented in figure 4.10A. In 
accordance with the previously presented data, NGF and artemin were more effective 
than MSP at ameliorating the increase in galanin mRNA expression that occurred in 
cultured adult DRG neurons. A combination of MSP and artemin was significantly 
more effective in reducing the expression of galanin mRNA than either neurotrophic 
factor alone. In contrast, a combination of NGF and artemin was not significantly 
more effective at attenuating galanin mRNA expression than artemin alone. Similarly 
MSP in combination with NGF did not significantly reduce galanin mRNA levels 
compared to cultures only supplemented with NGF.
Neither NGF, MSP nor artemin could significantly affect the approximately 5-fold 
up-regulation in PACAP mRNA expression observed in adult DRG neurons cultured 
for 96 hours in the absence of neurotrophic factor support (figure 4.17B). 
Interestingly, a combination of either artemin and MSP or NGF together with MSP 
could slightly, but significantly, attenuate the increase in PACAP mRNA that occurs 
in adult mouse DRG neurons placed in culture.
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A. galanin: C. galanin:
D 96hr
B. PACAP:
P value S ig n ifican ce
Art, art + MSP 0.0199 *
Art, art + NGF 0.0910
Art, all factors 0.0105 *
MSP, art + MSP <0.0001 **
MSP, MSP + NGF <0.0001 **
MSP, all factors <0.0001 **
NGF, art + NGF 0.0166 *
NGF, MSP + NGF 0.2970
NGF, all factors 0.0015 **
Ohr
96hr
D. PACAP:
P value S ig n ifican ce
Art, art + MSP 0.0084 **
Art, art + NGF 0.1707
Art, all factors 0.0286 *
MSP, art + MSP 0.0037 **
MSP, MSP + NGF 0.0237 *
MSP, all factors 0.0134 *
NGF, art + NGF 0.3535
NGF, MSP + NGF 0.1317
NGF, all factors 0.0851
Figure 4.17. Additive effects o f  artemin, MSP and NGF on expression o f galanin and PACAP mRNAs 
in adult mouse cultured DRG
Adult mouse DRG were cultured in the presence or absence of artemin (lOng/ml), NGF (lOng/ml), 
MSP (50ng/ml) or a combination of these factors, for 96 hours. Expression o f galanin (A) and PACAP 
(B) mRNAs were quantified using real-time Q-PCR. ANOVA statistical analyses were carried out. 
Significant differences to expression at ‘control 96 hours’ are indicated directly above bars, other 
relevant comparisons are outlined in C (galanin) and D (PACAP). * = p<0.05 ** = p<0.01.
Error bars = +/- standard error, n = 4
In accordance with the data presented in figure 4.11, all three neurotrophic factors 
could partially ameliorate the 50-fold increase in DINE mRNA expression that 
occurred in adult mouse DRG neurons cultured for 96 hours in the absence of 
neurotrophic factor support (figure 4.18 B). However, only artemin, the most 
efficacious neurotrophic factor in figure 4.11, could reduce DINE mRNA expression 
in a statistically significant manner. The addition of either MSP or NGF to cultures in 
combination with artemin did not decrease DINE mRNA levels to a greater extent 
than adding artemin to cultures on its own. Once again, MSP and NGF did not effect 
gene expression in an additive way in the case of DINE mRNA.
The addition of either lOng/ml artemin, lOng/ml NGF or 50ng/ml MSP to adult 
mouse DRG cultures could significantly attenuate the up-regulation in ATF3 mRNA 
expression that occurred in control cultures (figure 4.18A). In agreement with the data 
presented in figure 4.11 A, artemin was the most effective neurotrophic factor in 
reducing ATF3 mRNA levels and MSP was the least effective. Additionally adding 
either NGF or MSP, or indeed NGF and MSP, to cultures containing artemin did not 
further reduce ATF3 mRNA expression compared to cultures containing artemin 
alone. Similarly, NGF and MSP together did not have an additive effect in reducing 
ATF3 mRNA expression compared to NGF alone.
P2X3 mRNA expression did not significantly change over time in culture in adult 
mouse DRG neurons cultured without neurotrophic factor support (figure 4.19A), an 
observation also made in figure 4.12C. As in figure 4.12C lOng/ml artemin appeared 
to reduce the levels of P2X3 mRNA compared to control cultures, although in this 
case the decrease did not quite reach statistical significance. In fact, no neurotrophic 
factor or combination of neurotrophic factors significantly altered the expression of 
P2X3 mRNA in cultured mouse adult DRG neurons
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- P value Significance
. Art, art + MSP 0.7592
Art, art + NGF 0.7173
■  Ohr Art, ail factors 0.5052
■  96 hr MSP, art + MSP 0.0181 *
MSP, MSP + NGF 0.6966
- MSP, all factors 0.0078 **
- NGF, art + NGF 0.0731 *
NGF, MSP + NGF 0.7486
NGF, all factors 0.0389 *
B. DINE: D. DINE:
P value Significance
Art, art + MSP 0.2872
Art, art + NGF 0.3808
Art, all factors 0.3589
MSP, art + MSP 0.0041 **
MSP, MSP + NGF 0.4417
MSP, all factors 0.0059 **
NGF, art + NGF 0.0070 **
NGF, MSP + NGF 0.4272
NGF, all factors 0 .0063 **
Figure 4 .18  Additive effects o f artemin, MSP and NGF on expression o f mRNA ofgenes o f 
interest in adult mouse cultured DRG
Adult mouse DRG were cultured in the presence or absence of artemin (1 Ong/ml), NGF 
(lOng/ml), MSP (50ng/ml) or a combination o f these factors, for 96 hours. Expression of 
ATF3 (A), DINE (B) mRNAs were quantified using real-time Q-PCR. ANOVA statistical 
analyses were carried out. Significant differences to expression at ‘control 96 hours’ are 
highlighted directly above bars, other relevant comparisons are outlined in C (ATF3) and D 
(DINE). * = p<0.05 ** = p<0.01.
Error bars = +/- standard error, n = 4
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P value Significance
Art, art + MSP 0.6238
Art, art + NGF 0.9704
Art, all factors 0.3480
MSP, art + MSP 0.4698
MSP, MSP + NGF 0.3423
MSP, all factors 0.7647
NGF, art + NGF 0.1921
NGF, MSP + NGF 0.3060
NGF, all factors 0.7490
Figure 4.19. Additive effects o f artemin, MSP and NGF on expression o f P2X3 and Navi.6 
mRNAs in adult mouse cultured DRG
Adult mouse DRG were cultured in the presence or absence of artemin (1 Ong/ml), NGF 
(lOng/ml), MSP (50ng/ml) or a combination o f these factors, for 96 hours. Expression o f P2X3 
(A), N avi.6 (B) mRNAs were quantified using real-time Q-PCR. ANOVA statistical analyses 
were carried out. Significant differences to expression at ‘control 96 hours’ are indicated 
directly above bars, other relevant comparisons are outlined in C (P2X3) and D (Navi.6).
* = p<0.05 ** = p<0.01.
Error bars = +/- standard error, n = 4
The expression of levels of Navi.6 and Navi.7 mRNAs (figures 4.19B and 4.20) both 
decreased over time in control cultures as was observed in figure 4.12A and B. 
However, in the cultures set up for the “additive” data presented in figures 4.19B and 
4.20, the drop in the expression of both mRNAs was attenuated compared to previous 
experiments. No single neurotrophic factor, or combination of neurotrophic factors, 
were able to significantly modulate the expression of either sodium channel mRNA in 
cultured adult DRG neurons, although MSP and NGF did appear to have a tendency 
to increase the expression of both mRNAs.
Figure 4.21 shows the expression of GAPDH mRNA within the neuronal cultures set 
up for the “additive” experiments. In accordance with the low amount of neuronal 
death observed in adult mouse DRG cultures (figure 4.3), GAPDH mRNA levels did 
not significantly change in control cultures compared to time 0. No single 
neurotrophic factor, or combination of neurotrophic factors, significantly altered the 
expression of GAPDH mRNA compared to control cultures.
403
A. Nav1.7:
T3
CL
CDcn
2.5
2
1.5
1
0
Ohr
96hr
B. Nav1.7:
P  v a lu e
Art, art + MSP 0.3099
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Art, all factors 0.3896
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MSP, all factors 0 .6197
NGF, art + NGF 0.5021
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Figure 4.20. Additive effects o f artemin, MSP and NGF on expression o f Navi. 7 mRNA in 
adult mouse cultured DRG
Adult mouse DRG were cultured in the presence or absence of artemin (lOng/ml), NGF 
(lOng/ml), MSP (50ng/ml) or a combination o f these factors, for 96 hours. Expression of 
N avi.7 (A) mRNA was quantified using real-time Q-PCR. ANOVA statistical analyses were 
carried out. Significant differences to expression at ‘control 96 hours’ are indicated directly 
above bars, other relevant comparisons are outlined in B (N avi.7). * = p<0.05 ** = p<0.01. 
Error bars = +/- standard error, n = 4
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Art, a rt + MSP 0.1099
Art, a rt + NGF 0.1557
Art, all factors 0.3448
MSP, art + MSP 0.0724
MSP, MSP + NGF 0.2053
MSP, all factors 0.2485
NGF, art + NGF 0.0232 *
NGF, MSP + NGF 0.0524
NGF, all factors 0.0665
Figure 4.21. Additive effects o f artemin, MSP and NGF on expression o f GAPDH 
mRNA in adult mouse cultured DRG
Adult mouse DRG were cultured in the presence or absence of artemin (lOng/ml), 
NGF (lOng/ml), MSP (50ng/ml) or a combination of these factors, for 96 hours. 
Expression o f GAPDH mRNA was quantified using real-time Q-PCR. Significant 
differences to expression at ‘control 96 hours’ are indicated directly above bars, other 
relevant comparisons are outlined in B (GAPDH). * = p<0.05 ** = p<0.01.
Error bars = +/- standard error, n = 4
4.3.7. The effects of LIF on sensory neuron gene expression
The data presented in this chapter has clearly displayed that adult DRG neurons 
cultured in the absence of neurotrophic support undergo many alterations in gene 
expression, most of which reflect changes in gene expression observed in damaged 
DRG neurons following nerve transection, constriction or ligation. Whilst many of 
these changes in gene expression are probably, at least partly, due to an alteration in 
the availability of target field-derived neurotrophic factors, alternative mechanisms 
may come into play to modulate gene expression following nerve damage or in-vitro 
culture. For example, another consequence of nerve injury is an up-regulation in LIF 
expression, and its release into the extracellular milieu, by de-differentiating Schwann 
cells (Banner and Paterson, 1994; Bolin et al., 1995; Sun and Zigmund, 1996; Hirota 
et a., 1996; Kurek et al., 1996; Ito et al., 1998; Thomson and Majithia, 1997). This up- 
regulation has been suggested to play a role in some axotomy related changes in gene 
expression, as discussed in the introduction to this chapter. The possibility arises that 
Schwann cells within dissociated DRG cultures release LIF into the culture medium 
and this may be partly responsible for orchestrating some of the changes in neuronal 
gene expression observed in adult DRG cultures. As a first step in determining the 
role of LIF in regulating the in-vitro expression of the mRNAs investigated in this 
chapter, neurons were cultured in the presence or absence of LIF, artemin, MSP or 
NGF and also with LIF in combination with artemin, MSP or NGF for 96 hours. To 
further determine whether the release of LIF from Schwann cells within DRG neuron 
cultures contributes to the changes in neuronal gene expression that occur in culture, I 
had planned to culture DRG neurons in the presence and absence of an antibody that 
functionally blocks LEF from binding to the LIF receptor component, gpl30. 
Unfortunately, time constraints precluded the completion of this work.
The results of culture experiments that included LIF are shown in figures 4.22 - 4.29. 
ANOVA statistical analyses were carried out to compare results. Any significant 
difference to ‘control’ samples at 96 hours is shown directly above the relevant bar by 
the use of* (p<0.05) or ** (p<0.01). Details of other comparisons are shown in the 
table to the right of the appropriate graph.
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Data showing the expression of CGRP mRNAs within adult DRG neurons in the “LIF 
culture” series of experiments is presented in figure 4.22. As previously demonstrated, 
a-CGRP mRNA showed a down-regulation over time in culture in the absence of 
neurotrophic factors, which was significantly attenuated by supplementing cultures 
with either NGF, MSP or artemin. The addition of lOng/ml LIF to DRG cultures did 
not alter the expression of a-CGRP mRNA compared to control cultures. Similarly, 
the addition of LIF to cultures containing either artemin, NGF or MSP did not change 
the expression of a-CGRP mRNA compared to cultures containing the three 
neurotrophic factors alone (figure 4.22A).
In contrast to its lack of effects on a-CGRP mRNA expression, the addition of 
lOng/ml LIF to adult DRG cultures significantly enhanced the down-regulation of p- 
CGRP mRNA that is observed when adult DRG neurons were placed in culture in the 
absence of neurotrophic factor support (figure 4.22 B). Furthermore, lOng/ml LIF 
significantly inhibited the positive regulatory effects that artemin, MSP and NGF have 
on p-CGRP mRNA expression. This not only suggests a role for endogenous LIF in 
regulating the injury induced changes in P-CGRP mRNA expression within DRG in- 
vivo, but also further demonstrates that the two CGRP mRNAs are expressed and 
regulated in different manners.
The effects of LIF on the expression of SP and VR1 mRNAs lie somewhere in 
between its contrasting effects on the regulation of a- and p-CGRP mRNAs. 
Supplementing adult DRG neuron cultures with lOng/ml LIF did not alter the 
expression of SP or VR1 mRNAs compared to control cultures. However, LIF did 
appear to attenuate the expression enhancing effects of artemin, NGF and MSP on 
these mRNAs (figures 4.23 A and B). In most cases the ability of LEF to attenuate 
neurotrophic factor enhanced expression of SP and VR1 mRNAs was significant, 
however LEF failed to significantly down-regulate the expression of VR1 mRNA in 
DRG cultures containing NGF and MSP.
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-
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S ig n ifican ce
- NGF, NGF + LIF 0.1369
H  Ohr Art, Artemin + LIF 0.3734
■  96hr LIF, MSP + LIF 0.0494 *
- LIF, NGF + LIF <0.0001 **
LIF, Artemin + LIF 0.0182 *
B. beta CGRP: D. beta CGRP:
_ MSP, MSP + LIF
P v a lu e
0.0002
S ig n ifican ce
**
NGF, NGF + LIF <0.0001 **
Art, Artemin + LIF <0.0001 **
■  Ohr LIF, MSP + LIF 0.4463
■  96hr
LIF, NGF + LIF 0.0167 *
LIF, Artemin + LIF 0.1316
Figure 4.22. Effect o f LIF in combination with various neurotrophic factors on the expression 
o f alpha and beta CGRP mRNAs in cultured adult mouse DRG neurons 
Adult mouse DRG neurons were cultured in the presence or absence o f NGF (lOng/ml), MSP 
(50ng/ml), artemin (lOng/ml), LIF (50ng/ml) or LIF in combination with one of the fore 
mentioned neurotrophic factors. Expression o f alpha CGRP (A) and beta CGRP (B) mRNAs 
were quantified using real-time QPCR. Significant differences in expression o that at ‘control 
96 hours’ are indicated directly above bars, other relevant comparisons are outlined in C (alpha 
CGRP) and D (beta CGRP). * = p<0.05 ** = p<0.01.
Error bars = +/- standard error, n = 4
A. S C. S
B. VR
P value Significance
MSP, MSP + LIF 0.0017 **
NGF, NGF + LIF 0.0075 **
Art, Artemin + LIF 0.0168 *
LIF, M SP + LIF 0.2081
LIF, NGF + LIF 0.0276 *
LIF, Artemin + LIF <0.0001 **
D. VR
P value Significance
- MSP, MSP + LIF 0.2032
NGF, NGF + LIF 0.1345
H  Ohr Art, Artemin + LIF 0.0043 **
| ]  96hr
~ LIF, MSP + LIF 0.0494 *
LIF, NGF + LIF <0.0001 **
LIF, Artemin + LIF 0.0182 *
Figure 4.23. Effect o f LIF in combination with various neurotrophic factors on the expression 
o f SP and VR1 mRNAs in cultured adult mouse DRG neurons
Adult mouse DRG neurons were cultured in the presence or absence o f NGF (lOng/ml), MSP 
(50ng/ml), artemin (1 Ong/ml), LIF (50ng/ml) or LIF in combination with one o f the fore 
mentioned neurotrophic factors. Expression of SP (A) and VR1 (B) mRNAs were quantified 
using real-time QPCR. Significant differences in expression to that at ‘control 96 hours’ are 
indicated directly above bars, other relevant comparisons are outlined in C (SP) and D (VR1). 
* = p<0.05 ** = p<0.01.
Error bars = +/- standard error, n = 4
The effects of LIF on the expression of the two TTX-resistant sodium channel 
mRNAs, Navi.8 and Navi.9 are not clear cut (figures 4.24 A and B). This is probably 
partly due to the fact that the expression of these two mRNAs, and the regulatory 
effects of artemin, NGF and MSP, are not exactly the same as that seen in previous 
culture experiments in this chapter. For example, the expression levels of Navi.8 
mRNA only falls some 3.5-fold after 96 hours in control cultures compared to the 10- 
fold plus drop seen in previous experiments. Moreover, in this set of experiments only 
MSP significantly increased the expression of Navi. 8 mRNA compared to control 
cultures. Although NGF and artemin both increased the expression of this mRNA 
compared to control cultures, this increase was not statistically significant. Similarly, 
MSP did not significantly increase the levels of Navi.9 mRNA compared to control 
cultures in this set of experiments, although both NGF and artemin did. The reasons 
behind these discrepancies are unclear, but it is possible that neuronal density in the 
cultures holds the key. It has been observed within our lab that the expression of 
certain mRNAs are very sensitive to cell density in adult DRG cultures, probably due 
to the release of neurotrophic factors that regulate mRNA expression from Schwann 
cells that contaminate cultures and that are in greater numbers in dense cell cultures (S 
Wyatt unpublished observations). It seems clear that the addition of lOng/ml LIF to 
adult mouse DRG cultures did not further decrease the expression of either Navi. 8 or 
Navi. 9 mRNAs compared to the levels of these mRNAs found in control cultures. 
Whilst it is generally true that LIF acts to attenuate the increases in the expression of 
both mRNAs observed when either artemin, NGF or MSP are added to cultures, this 
was only statistically significant in two cases; for Navi.8 mRNA in cultures 
containing MSP and Navi.9 mRNA in cultures containing NGF.
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Figure 4.24. Effect ofLIF in combination with various neurotrophic factors on the expression o f 
Navi.8 and Navi.9 mRNAs in cultured adult mouse DRG neurons
Adult mouse DRG neurons were cultured in the presence or absence of NGF (lOng/ml), MSP 
(50ng/ml), artemin (lOng/ml), LIF (50ng/ml) or LIF in combination with one o f the fore mentioned 
neurotrophic factors. Expression o f ScnlOa (N avi.8) (A) and Scnl la  (Navl.9) (B) mRNAs were 
quantified using real-time QPCR. Significant differences in expression to that at ‘control 96 hours’ 
are indicated directly above bars, other relevant comparisons are outlined in C (N avi.8) and D 
(Navl.9). * = p<0.05 ** = p<0.01.
Error bars = +/- standard error, n = 4
Figure 4.25 shows the expression of galanin and PACAP mRNAs and illustrates a 
greater than 10 fold up-regulation of both mRNAs over the 96 hour culture period.
The up-regulation of galanin mRNA was inhibited, by approximately 30%, by the 
presence of MSP, NGF or artemin (figure 4.25 A). The addition of lOng/ml LIF alone 
to cultures appeared to enhance the culture-induced up-regulation of galanin mRNA, 
further promoting the ‘injured phenotype’, and reflecting the findings of other groups 
that have illustrated positive effects of LIF on galanin expression (Comess et al.,
1996; Thompson et al., 1998; Kerekes et al., 1999; Ozturk and Tonge, 2001). The 
differential effects of LIF and the afore-mentioned neurotrophic factors on regulating 
galanin mRNA expression were highlighted when artemin, NGF and MSP were added 
to cultures in combination with LIF. The inhibitory effects of MSP, NGF or artemin 
on galanin mRNA expression were totally reversed by the addition of LIF to the 
cultures. Indeed, the levels of galanin mRNA expressed by cultures containing LIF 
and each of the other neurotrophic factors was significantly higher than that found in 
control cultures after 96 hours.
In the data presented so far in this section, LIF either does not effect mRNA 
expression or it apposes the regulatory effects of the other neurotrophic factors 
investigated in this chapter. The regulation of PACAP mRNA expression appears to 
contrast to the previously presented data. Once again, the large increase in PACAP 
mRNA expression that occurs in control cultures was slightly ameliorated by artemin, 
NGF and MSP. However, the reduction in PACAP mRNA expression was only 
statistically significant in the case of NGF (figure 4.25 B). The addition of LIF on its 
own to cultures also significantly attenuated the culture-induced increase in PACAP 
mRNA expression. Moreover, adding lOng/ml LIF to cultures that also contain either 
NGF, artemin or MSP further enhanced the effects of these neurotrophic factors in 
reducing PACAP mRNA expression. Whilst the effects of LIF in reducing PACAP 
mRNA expression in cultures also containing either artemin, NGF or MSP did not 
quite reach statistical significance compared to cultures containing these factors in the 
absence of LIF, the data is significant compared to non-supplemented control 
cultures.
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A. galanin: C. galanin:
Ohr 
96 hr
P va lue S ig n ifican ce
MSP, MSP + LIF 0.0005 **
NGF, NGF + LIF <0.0001 **
Art, Artemin + LIF <0.0001 **
LIF, MSP + LIF <0.0001 **
LIF, NGF + LIF 0.0001 ft*
LIF, Artemin + LIF 0.0002 **
B. PACAP: D. PACAP:
_ MSP, MSP + LIF
P v a lue  S ig n ifican ce
0.0512
- NGF, NGF + LIF 0.6098
- Art, Artemin + LIF 0.0688
■  Ohr 
1 9  96hr LIF, MSP + LIF 0.1953
- LIF, NGF + LIF 0.7429
- LIF, Artemin + LIF 0.3288
CO o
Figure 4.25. Effect o f LIF in combination with various neurotrophic factors on the expression o f  
galanin and PACAP mRNAs in cultured adult mouse DRG neurons
Adult mouse DRG neurons were cultured in the presence or absence o f NGF (lOng/ml), MSP 
(50ng/ml), artemin (lOng/ml), LIF (50ng/ml) or LIF in combination with one o f the fore mentioned 
neurotrophic factors. Expression of galanin (A) and PACAP (B) mRNAs were quantified using real­
time QPCR. Significant differences in expression to that at ‘control 96 hours’ are indicated directly 
above bars, other relevant comparisons are outlined in C (galanin) and D (PACAP).
* = p<0.05 ** = p<0.01.
Error bars = +/- standard error, n = 4
The effects of LIF on DINE mRNA expression were very similar to its effects on 
PACAP mRNA expression (figure 4.26B) As in previous adult DRG culture 
experiments, DINE mRNA displayed an approximately 50-fold increase in levels 
after 96 hours in culture in the absence of neurotrophic factors. Whilst supplementing 
cultures with NGF, artemin or MSP appeared to attenuate the increase in DINE 
mRNA expression, only NGF ameliorated the increase in a statistically significant 
manner. Supplementing adult mouse DRG cultures with lOng/ml LIF significantly 
decreased DINE mRNA levels compared to control cultures. Similarly, the addition of 
LIF to cultures containing either artemin, NGF or MSP significantly decreased DINE 
mRNA levels compared to cultures supplemented with any one of these neurotrophic 
factors alone.
The addition of LIF to adult DRG cultures, either alone or in combination with the 
other three neurotrophic factors, did not alter the expression of ATF-3 mRNA 
compared to either control DRG cultures or cultures containing either artemin, NGF 
or MSP alone. In accordance with data presented previously in this chapter, NGF,
MSP or artemin significantly attenuated the increase in ATF3 mRNA expression that 
occurred in adult DRG neurons cultured in the absence of neurotrophic factors (figure 
4.26A).
The expression of P2X3 mRNA in the series of cultures set up to investigate the 
effects of LIF on gene expression is shown in figure 4.27A. As for previous cultures 
(figures 4.12 C and 4.19 A), the expression levels of P2X3 mRNA within cultured 
DRG neurons were not significantly different to those in-vivo. Neither artemin, NGF, 
MSP or LIF could significantly change the expression of P2X3 mRNA compared to 
control cultures.
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D. DINE:
■  Ohr
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P value Significance
MSP, MSP + LIF 0.0020 **
NGF, NGF + LIF 0.0049 **
Art, Artemin + LIF 0.0018 **
LIF, MSP + LIF 0.0524
LIF, NGF + LIF 0.0885
LIF, Artemin + LIF 0.0258 *
Figure 4.26. Effect o f  LIF in combination with various neurotrophic factors on the 
expression o f  ATF3 and DINE mRNAs in cultured adult mouse DRG neurons
Adult mouse DRG neurons were cultured in the presence or absence o f NGF (lOng/ml), MSP 
(50ng/ml), artemin (lOng/ml), LIF (50ng/ml) or LIF in combination with one of the fore 
mentioned neurotrophic factors. Expression o f ATF3 (A) and DINE (B) mRNAs were 
quantified using real-time QPCR. Significant differences in expression to that at ‘control 96 
hours’ are indicated directly above bars, other relevant comparisons are outlined in C (ATF3) 
and D (DINE). * = p<0.05 ** = p<0.01.
Error bars = +/- standard error, n = 4
The expression of Navi.6 and Navi.7 mRNAs in the “LIF culture” series of 
experiments are shown in figure 4.27B and 4.28, respectively. In agreement with 
previously presented data (figures 4.12 A, 4.12 B, 4.19 B and 4.20), the amount of 
Navi.6 and Navi .7 mRNAs expressed within adult DRG neurons decreased greatly 
over 96 hours in culture in the absence of neurotrophic factor support. Also, in 
accordance with previously presented data, MSP and NGF had a tendency to slightly 
ameliorate the decrease in Navi.6 and Navi.7 mRNA expression. However, in 
contrast to previous data, the effects of NGF, but not MSP, were statistically 
significant for both mRNAs in this series of cultures. The addition of lOng/ml LIF on 
its own to adult DRG cultures did not significantly alter the expression of either TTX- 
sensitive sodium channel alpha-subunit mRNAs compared to control cultures. In 
contrast, supplementing cultures containing either one of the other neurotrophic 
factors, with LIF appeared to decrease the expression of both sodium channel mRNAs 
compared to cultures containing NGF, MSP or artemin alone. However, the 
inhibitory effects of LIF on TTX-sensitive sodium channel mRNA expression are 
only statistically significant in the case of Navi.6 mRNA with MSP and Navi.7 
mRNA with NGF.
The expression of GAPDH mRNA for the “LIF series” of cultures is shown in figure 
4.29. There was no significant difference in this series of cultures between the time 0 
levels of GAPDH mRNA and the levels of this mRNA in control cultures after 96 
hours. Similarly, there was no significant difference in the amount of GAPDH mRNA 
expressed by cultures containing NGF, MSP, artemin or LIF compared to control 
cultures. The addition of LIF to adult DRG cultures that also contained NGF, MSP or 
artemin appeared to slightly increase the expression of GAPDH mRNA compared to 
cultures containing only NGF, MSP or artemin.
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A. P2X C. P 2X
P value S ig n ificance
MSP, MSP + LIF 0.8357
NGF, NGF + LIF 0.5294
Art, Artemin + LIF 0.4153
LIF, MSP + LIF 0.7972
LIF, NGF + LIF 0.3025
LIF, Artemin + LIF 0.2243
B. Nav1 D. Nav1
U
Ohr
96hr
P va lue S ig n ifican ce
MSP, MSP + LIF 0.0040
NGF, NGF + LIF 0.1610
Art, Artemin + LIF 0.5191
LIF, MSP + LIF 0.5013
LIF, NGF + LIF 0.1108
LIF, Artemin + LIF 0.5191
Figure 4.27. Effect o f LIF in combination with various neurotrophic factors on the 
expression o f P2X3 and Navi. 6 mRNAs in cultured adult mouse DRG neurons
Adult mouse DRG neurons were cultured in the presence or absence o f NGF (lOng/ml), MSP 
(50ng/ml), artemin (lOng/ml), LIF (50ng/ml) or LIF in combination with one o f the fore 
mentioned neurotrophic factors. Expression o f P2X3 (A) and Navi.6 (B) mRNAs were 
quantified using real-time QPCR. Significant differences in expression to that at ‘control 96 
hours’ are indicated directly above bars, other relevant comparisons are outlined in C (P2X3) 
and D (Navi.6). * = p<0.05 ** = p<0.01.
Error bars = +/- standard error, n = 4
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B. Nav1.7:
P v a lue S ig n ifican ce
MSP, MSP + LIF 0.0543
NGF, NGF + LIF 0.0061 **
Art, Artemin + LIF 0.2992
LIF, MSP + LIF 0.6620
LIF, NGF + LIF 0.8712
LIF, Artemin + LIF 0.2500
Figure 4.28. Effect o f LIF in combination with various neurotrophic factors on the expression o f 
Navi. 7 mRNA in cultured adult mouse DRG neurons
Adult mouse DRG neurons were cultured in the presence or absence o f NGF (lOng/ml), MSP 
(50ng/ml), artemin (lOng/ml), LIF (50ng/ml) or LIF in combination with one of the fore 
mentioned neurotrophic factors. Expression of N avi.7 (A) mRNAs was quantified using real­
time QPCR. Significant differences in expression to that at ‘control 96 hours’ are indicated 
directly above bars, other relevant comparisons are outlined in B (Navi.7). * = p<0.05 ** =
p<0.01.
Error bars = +/- standard error, n = 4
P va lu e S ig n ifican ce
MSP, MSP + LIF 0.0310 *
NGF, NGF + LIF 0.0747
Art, Artemin + LIF 0.0082 **
LIF, MSP + LIF 0.0977
LIF, NGF + LIF 0.3119
LIF, Artemin + LIF 0.0129
Figure 4.29. Effect o f LIF in combination with various neurotrophic factors on the 
expression o f GAPDH mRNA in cultured adult mouse DRG neurons
Adult mouse DRG neurons were cultured in the presence or absence o f NGF (lOng/ml), MSP 
(50ng/ml), artemin (lOng/ml), LIF (50ng/ml) or LIF in combination with one o f the fore 
mentioned neurotrophic factors. Expression o f GAPDH mRNA was quantified using real­
time QPCR and all other results normalised against these values.
Error bars = +/- standard error, n = 4
4.4. Discussion
In this chapter, I have investigated whether the neurotrophic factors artemin, MSP, 
NGF and LIF can regulate the transcription of a number of functionally important 
genes within cultured adult mouse DRG neurons. Although extrapolating data from 
culture experiments and interpreting their physiological relevance has a number of 
caveats, in-vivo experimental approaches to investigating gene regulation also have 
drawbacks. Mice with null mutations of the artemin, NGF, MSP and LIF receptor 
genes are all available and would survive into adulthood if crossed with Bax null- 
mutant mice to produce double-null mutant lines. However, as discussed in the 
introduction to this chapter, investigating the regulation of gene expression in adult 
sensory neurons using double-null mutant mouse lines has a number of limitations. 
These factors should be borne in mind as may cause misleading interpretation of data. 
In addition, generating sufficient numbers of double-null mutant adult animals to 
produce statistically significant results would be an extremely time consuming and 
costly exercise that would lead to unacceptably high levels of animal wastage. The in- 
vivo administration of either neurotrophic factors or neurotrophic factor receptor 
blocking reagents to the peripheral or central target field of DRG neurons could also 
have been used to investigate the efficacy of neurotrophic factors in regulating 
neuronal gene expression. However, this approach also has a number of pitfalls that 
were discussed in the introduction to this chapter.
The DRG cultures used to investigate transcriptional gene regulation by NGF, 
artemin, MSP and LIF were mixed cultures containing both neurons and glial cells. In 
fact, non-neuronal cells typically significantly out numbered neurons at the start of the 
culture period. After 96 hours, there were many fewer non-neuronal cells in the adult 
DRG cultures than at the start of the culture period, presumably because the non­
neuronal cells did not survive very well in the minimal medium used for the cultures. 
However, despite the time-dependent decrease in the number of non-neuronal cells 
surviving in DRG cultures, significant numbers were still present after 96 hours of 
culture. The level of glial cell contamination in DRG cultures clearly varied from one 
set of cultures to another, but was uniform across all dishes in any one experiment. In-
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vivo, the majority of mRNAs that were assayed in this chapter are predominantly or 
exclusively expressed by neurons within DRG. Since the same is likely to be true in 
culture, the expression of the assayed mRNAs by contaminating glia is unlikely to 
significantly alter the interpretation of data. Neurons and glial cells both express 
GAPDH mRNA. However, the level of GAPDH mRNA expressed by neurons is 
several orders of magnitude greater than that expressed by glia, reflecting the size 
difference between the two cell types (discussed in previous chapters). Therefore, 
GAPDH mRNA expression by non-neuronal cells is unlikely to significantly affect 
the accuracy of neuronal mRNA quantification that is normalised to GAPDH mRNA 
levels. Especially since the level of non-neuronal cell contamination in each dish of 
any one set of cultures is likely to be similar. It is well established that glial cells, and 
Schwann cells in particular, can synthesise and secrete neurotrophic factors, both in- 
vivo and in-vitro. Therefore, it is possible that neurotrophic factors secreted by glia 
may either conceal or exacerbate the effects of exogenous neurotrophic factors in 
regulating transcriptional expression in some cultures. This is a possibility that must 
be borne in mind when interpreting the expression data presented in this chapter.
Below, I will discuss the transcriptional regulation of the mRNAs investigated in this 
chapter in turn, followed by summing up the significance of the data in terms of 
normal nociceptive thresholds and the response of sensory neurons to nerve lesion.
4.4.1. a- and P-CGRP
In chapter two of this thesis, an analysis of trigeminal and dorsal root ganglia from 
transgenic embryos demonstrated the differential regulation of a- and p- CGRP 
mRNAs by NGF/TrkA signalling in embryonic neural crest-derived sensory neurons. 
In chapter three, this research was extended to investigate the in-vitro and in-vivo 
regulation of a- and p- CGRP mRNAs by both NGF/TrkA and NT-3 dependent 
signalling in neonatal neural-crest and placode-derived sensory neurons. Results 
demonstrated that NGF/TrkA signalling was essential to achieve and maintain the 
correct expression levels of both a- and P- CGRP mRNAs in neonatal trigeminal, 
nodose and dorsal root ganglion neurons in-vivo. It was also revealed that NGF could 
maintain the expression of a-CGRP mRNA in cultured neonatal trigeminal neurons
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for 48 hours, preventing the marked drop in the expression of this neuropeptide 
mRNA that occured in control cultures. In contrast to a-CGRP mRNA, my data from 
chapter three showed that p-CGRP mRNA levels did not change significantly in 
neonatal trigeminal neurons cultured for 48 hours without neurotrophic factor support.
Figures 4.8, 4.14, and 4.22 reveal that the levels of a- and P-CGRP mRNAs, 
expressed by cultured adult mouse DRG neurons, fell 2- to 3-fold over 96 hours in the 
absence of neurotrophic factor support. The reduction in a-CGRP mRNA levels was 
consistently more pronounced than the fall in p-CGRP mRNA levels, an observation 
that is in agreement with the data obtained from neonatal trigeminal neuron cultures 
in the previous chapter. If one regards in-vitro culture as a model of nerve injury, then 
the culture data is in accordance with a number of previous publications 
demonstrating that CGRP mRNA and peptide expression falls sharply within 
damaged rat and mouse lumbar DRG neurons in-vivo following sciatic nerve 
transection (Noguchi et al., 1990; Verge et al, 1995; Mulder et al., 1997; Steme et al., 
1998; Shi et al., 2001; Shadiack et al., 2001). The studies by Noguchi et al and Verge 
et al are particularly relevant, since, like the data presented in this chapter, they 
discriminate between a- and p-CGRP mRNAs.
NGF, artemin and MSP were all able to significantly attenuate the culture-induced 
decrease in a- and P-CGRP mRNA expression in adult mouse DRG neurons (figures 
4.8, 4.14 and 4.22). NGF and artemin appeared to have similar efficacies in their 
ability to regulate the expression of a- and P-CGRP mRNAs, whilst MSP was slightly 
less effective in promoting CGRP mRNA expression than the other two neurotrophic 
factors. The ability of NGF to positively regulate the expression of CGRP mRNA and 
peptide within rodent sensory neurons, both in-vitro and in-vivo, has been previously 
well documented (e.g. Lindsay et al., 1989; Verge et al, 1995; Jiang and Smith, 1995; 
Price et al, 2005). Likewise, artemin has also been shown to partially reverse the 
down-regulation of CGRP peptide within adult rat DRG following sciatic nerve 
section or ligation.(Gardell et al, 2003). The demonstration that MSP was able to 
promote the expression of a- and p-CGRP mRNAs in cultured adult mouse DRG 
neurons, thereby partially reversing the axotomized phenotype, is a novel and 
potentially important observation that will be discussed more fully below. The data
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suggests that MSP may play a role in establishing the level of a- and p-CGRP 
mRNAs expressed by nociceptive sensory neurons in-vivo, although additional 
studies, preferably using conditional null-mutant transgenic mice, would be required 
to clarify this hypothesis.
The observations that MSP and artemin could regulate the expression of CGRP 
mRNAs in adult DRG cultures raises the possibility that these neurotrophic factors 
may play a role in the initial induction and developmental regulation of CGRP 
expression in developing sensory neurons, in a similar manner to NGF. An analysis of 
gene expression within sensory ganglia of embryonic and neonatal conditional null- 
mutants for the MSP receptor, RON, or the artemin receptor, GFR-a3, would help to 
determine whether this is the case. A similar approach would also to determine 
whether artemin and/or MSP are also involved in regulating the in-vivo 
developmental expression of the many other genes that were found in this chapter to 
be regulated by these neurotrophic factors in cultured adult DRG neurons (see below).
The combined addition of saturating concentrations of NGF and artemin to adult DRG 
cultures significantly increased the expression of both a- and p-CGRP mRNAs to 
higher levels than those found with either factor alone (figures 4.14 A and B). The 
levels of both CGRP mRNAs in cultures containing a combination of both 
neurotrophic factors was approximately 20% greater than cultures containing a single 
neurotrophic factor, and restored CGRP mRNA levels to time 0 {in-vivo) levels. The 
increase in CGRP mRNA expression may reflect the possibility that both 
neurotrophic factors use different intracellular signal transduction pathways to 
increase the expression of CGRP mRNAs within individual neurons that express 
CGRP and both neurotrophic factor receptors. However, the simplest interpretation of 
the data is that not all CGRP mRNA-positive DRG neurons express receptors for both 
NGF and artemin in culture. In adult rodents, approximately 35% of neurons in L4/L5 
DRG express TrkA. Most TrkA positive neurons are C- or A-5 fibre nociceptors that 
also express CGRP. Around 35% of this population also express the GDNF family 
signal transducing receptor, Ret (Averill et al, 1995; Molliver et al, 1997; Michael and 
Priestley, 1999; Orozco et al, 2001). GFR-a3 expression is restricted to 
approximately 20% of L4/L5 DRG neurons. GFR-a3-positive DRG neurons
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predominantly represent the sub-population of TrkA-positive, CGRP-positive, non­
myelinated C-fibre neurons that express Ret. However, 8% o f GFR-alpha 3 
expressing neurons (1.6% o f total neurons in L4/L5 DRG and approximately 5% of 
CGRP-positive neurons) are Ret- and CGRP-positive but TrkA-negative (Orozco et 
al, 2001). Thus, in the absence o f nerve injury, approximately 5% of CGRP-positive 
DRG neurons are responsive to artemin and not NGF, 60% are responsive to NGF but 
not artemin and 35% o f CGRP-positive DRG neurons are responsive to both factors. 
This is illustrated in figure 4.30.
CGRP-CGRP +
60 % 
TrkA+ 
GFRa.3 -
Figure 4.30. proportions o f  CGRPpositive DRG neurons that express 
NGF and artemin receptors
Based on the expression patterns o f NGF and artemin receptors in uninjured DRG, it 
may be predicted that NGF would be more effective than artemin at regulating CGRP 
mRNA expression in-vitro. It might also be anticipated that the addition o f artemin to 
cultures containing NGF would not significantly increase the expression of CGRP 
mRNAs compared to cultures containing NGF alone. However, peripheral nerve 
lesion and in-vitro culture induce many similar changes in neuronal gene expression, 
including changes in neurotrophic factor receptor expression. The number o f rat 
lumbar DRG neurons expressing detectable TrkA mRNA decreases by 50% at 7 days
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following sciatic nerve crush, ligation or transection (Krekoski et al, 1996; Kashiba et 
al, 1998; Shen et al, 1999). Conversely, the number of rat lumbar DRG neurons 
expressing GFR-a3 protein almost doubles by 14 days following spinal nerve 
ligation, so that virtually all C-fibre, peripherin-positive lumbar DRG neurons are 
GFR-a3-positive (Gardell et al, 2003). It is not clear whether similar changes in the 
expression of artemin and NGF receptors occur in DRG neurons at all levels of the rat 
spinal cord following sciatic nerve lesion. Similarly, it is not clear from the published 
literature whether changes in TrkA or GFR-a3 expression occur within mouse DRG, 
either in-vivo, following sciatic nerve lesion, or in-vitro. Unpublished work from 
within my laboratory has revealed a 20% decrease in the levels of TrkA mRNA 
expressed by adult mouse DRG neurons over a 96hour culture period. The culture- 
induced decrease in TrkA mRNA is accompanied by a similar increase in the levels of 
GFR-a3 mRNA (S Wyatt unpublished observation -  data not shown). The net result 
of these changes in receptor gene expression is likely to be a decrease in the 
proportion of DRG neurons expressing either both TrkA and GFR-a 3 together, or 
expressing TrkA alone. An increase in the number of neurons expressing GFR-a 3 in 
the absence of TrkA might also be anticipated. Unfortunately, immuno- 
cyctochemistry data is not available to substantiate this hypothesis. Nonetheless, this 
possibilty could account for the, better than expected, efficacy of artemin in regulating 
the expression of CGRP mRNAs in comparison to NGF. It may also explain the 
partially “additive” ability of NGF and artemin to increase CGRP mRNA expression.
In contrast to cultures containing both NGF and artemin, the addition of saturating 
levels of MSP to cultures containing saturating levels of either NGF or artemin did 
not increase the expression levels of either a- or p-CGRP mRNAs above those found 
in cultures containing just NGF or artemin alone. To date, the distribution of RON 
amongst adult DRG neurons in-vivo has not been determined. Likewise, the identity 
of the cultured adult mouse DRG neurons that express RON has not been established. 
The data presented here from the “additive” culture experiments suggests that the 
majority of cultured DRG neurons that express both RON and CGRP also express 
TrkA and GFR-a 3.
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The addition of 50ng/ml LIF to adult mouse DRG cultures affected the expression of 
a- and p-CGRP mRNAs in markedly different ways. Whilst LIF did not significantly 
alter the expression of a-CGRP mRNA, either alone or in combination with the other 
three neurotrophic factors (figure 4.22 A), it did have a marked effect on the 
expression of p-CGRP mRNA (figure 4.22B). The addition of LIF to cultures 
significantly reduced the expression of p-CGRP mRNA compared to control cultures. 
Moreover, LIF blocked the ability of MSP, artemin and NGF to ameliorate the culture 
induced down-regulation of p-CGRP mRNA expression. LIF mRNA and protein has 
been shown to be up-regulated, and functional LIF released, by de-differentiating 
Schwann cells at the site of nerve damage following nerve ligation, transection or 
crush (Banner and Paterson, 1994; Bolin et al., 1995; Sun and Zigmond, 1996; Hirota 
et al, 1996; Kurek et al., 1996; Ito et al., 1998; Thomson and Majithia, 1998). 
Functional LEF receptors are predominantly expressed by small nociceptive sensory 
neurons, the majority of which are CGRP-positive (Thompson et al, 1997). It has 
previously been postulated that the injury-induced release of LIF by Schwann cells 
may play a role in orchestrating some of the widespread changes in gene expression 
that occur in sensory neurons following peripheral nerve trauma. For example, LIF 
appears to play a role in the up-regulation of galanin and DINE expression following 
nerve injury (Comess et al., 1996; 1998; Ozturk and Tonge, 2001; Kerekes et al., 
1999; Sun and Zigmond, 1996; Kato et al, 2002). The data presented for P-CGRP 
mRNA in figure 4.22 B supports this hypothesis and is the first observation that LIF 
can regulate p-CGRP mRNA expression in dissociated DRG cultures.
Curiously, it has previously been reported that the addition of exogenous LIF to 
mouse lumbar DRG explants increases the expression of CGRP peptide compared to 
explants cultured in the absence of growth factors (Ozturk et al., 2002). However, 
neurons within explanted lumbar DRGs, behave very differently to those in 
dissociated cultures and do not appear to mimic changes in gene expression that occur 
following sciatic nerve lesion. For example, the number of CGRP immuno-positive 
neurons that are present within lumbar DRG explants do not decrease over time. This 
observation is in marked contrast to the rapid drop in CGRP mRNA and peptide 
expression in both dissociated DRG cultures and lumbar DRG subjected to in-vivo 
sciatic nerve lesion (e.g. Lindsay et al., 1989; Verge et al., 1995; Jiang and Smith,
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1995). Moreover, NGF does not appear to enhance CGRP expression in explanted 
DRG (Ozturk et al., 2002), despite the wealth of published data demonstrating that 
NGF can increase the expression of CGRP mRNA and peptide within DRG neurons 
both in culture and following in-vivo peripheral nerve lesion (for references see 
above).
The observation that exogenous LIF could decrease the expression of p-CGRP 
mRNA in adult mouse DRG cultures, whereas it did not affect the expression of a- 
CGRP mRNA, may reflect a genuine difference in the transcriptional regulation of the 
two different CGRP genes. Alternatively, it may reflect a difference in the sensitivity 
of each gene to regulation by LIF. Adult DRG cultures contain Schwann cells that are 
likely to begin synthesizing LEF after they have been removed from their normal in- 
vivo environment. This raises the possibility that LIF, released by Schwann cells 
within DRG cultures, plays a role in promoting some of the culture-induced changes 
in gene expression observed in this chapter. If the a-CGRP gene is very sensitive to 
regulation by LEF, the amounts of LEF present in control cultures may be saturating 
with regard to the regulation of a-CGRP mRNA expression. If the p-CGRP gene is 
less sensitive to regulation by LEF, the amount of LEF in control cultures might not 
have been high enough to significantly reduce p-CGRP mRNA expression. Indeed, 
this may explain why the drop in a-CGRP mRNA levels when DRG neurons were 
placed in culture was consistently greater than the drop in p-CGRP mRNA levels. 
Culturing DRG neurons with and without an antibody that either blocks the function 
of the signal- transducing component of the LEF receptor, gpl30, or sequesters and 
inactivates LEF would address this hypothesis. This approach may also shed further 
light on the ability of LIF to regulate the expression of other mRNAs within cultured 
DRG neurons. Unfortunately, time constraints prevented me from carrying out these 
experiments.
4.4.2. Substance P
Substance P (SP) mRNA showed a very similar pattern of regulation to that of a- and 
P-CGRP mRNAs in cultured adult mouse DRG neurons, reflecting the co-expression
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of SP in a sub-population (around 50%) of CGRP-positive, TrkA-positive, adult 
rodent DRG neurons (Lundberg et al., 1985; Lee et al., 1985; Skofitsch and 
Jacobowitz, 1985; Kashiba et al., 1996; Gardell et al., 2003).
SP mRNA expression levels dropped 8-to 10-fold fold over a 96 hour culture period 
in all cultures of adult mouse DRG neurons analysed (figures 4.7A, 4.8C, 4.15A and 
4.23A). This data is in accordance with previous studies on cultured adult rat DRG 
neurons (Mulderry, 1994; Lindsay et al., 1989). A marked drop in the expression of 
SP mRNA over time in culture was also observed in Chapter three for neonatal 
trigeminal neurons. Similarly, a marked reduction in the expression of SP mRNA and 
peptide within rat lumbar DRG has also been reported following sciatic or spinal 
nerve transection, ligation or crush (e.g. Nielsch et al., 1987; Zhang et al., 1995; Ji et 
al., 1996; Sterne et al., 1998; Gardell et al, 2003). The reduction in SP expression 
following peripheral nerve lesion has been directly attributed to a reduction in the 
supply of target field-derived NGF to neuronal cell bodies within DRG (Shadiack et 
al, 2001). The data presented in this chapter suggests that NGF may not be the only 
target field derived neurotrophin that regulates the steady state expression levels of SP 
within adult DRG neurons.
In chapters two and three of this thesis, I demonstrated that NGF is required for the 
induction and correct developmental regulation of SP mRNA in mouse sensory 
neurons. I also demonstrated that NGF can ameliorate the culture-induced down- 
regulation of SP mRNA in neonatal mouse trigeminal neurons. In accordance with 
this data, NGF could reduce the culture induced drop in SP mRNA expression within 
adult mouse DRG neurons by almost 50% (figure 4.8C). This finding is not novel, 
since NGF has previously been shown to promote the expression of SP in cultured 
adult mouse and rat DRG neurons (Lindsay et al., 1989; Mulderry, 1994; Zhang et al., 
1995; Skoff et al., 2006), and ameliorate the drop in SP expression within rat lumbar 
DRG neurons that occurs following sciatic nerve lesion (Zhang et al., 1995; Ji et al.,
1996). Moreover, transgenic mice ectopically expressing NGF in the spinal cord 
contain significantly more SP-positive neurons within DRG than wild type mice (Ma 
et al., 1995).
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Artemin could also significantly attenuate the culture-induced drop in SP mRNA 
levels in adult mouse DRG neurons (figures 4.7A, 4.8C, 4.15A and 4.23A). Perhaps 
surprisingly, given the relative distribution of artemin and NGF receptors within 
rodent DRG in-vivo (Averill et al., 1995; Molliver et al., 1997; Michael and Priestley, 
1999; Orozco et al., 2001, and illustrated in figure 4.30 above), artemin is 
significantly more effective than NGF in supporting the expression of SP mRNA in 
cultured adult mouse DRG neurons. However, as discussed above, it seems likely that 
the number of TrkA-positive mouse DRG neurons decreases over time in culture, 
whilst the number of neurons expressing the artemin receptor, GFR-a3, increases 
over time in culture. The data for SP, presented in this chapter, would tend to suggest 
that a proportion of SP-positive DRG neurons lose TrkA expression and gain GFR-a3 
expression during the culture period. The observation that artemin could positively 
regulate the expression of SP is also not novel, since it has previously been 
demonstrated that systemic artemin can ameliorate the fall in SP peptide within adult 
rat DRG neurons following spinal nerve ligation (Gardell et al., 2003). However, the 
observation that MSP was as effective as NGF in reducing the culture-induced down- 
regulation of SP mRNA expression in adult mouse DRG sensory neurons (figures 
4.7A, 4.8C, 4.15A and 4.23A) is a novel finding. This result suggests that a 
significant number of SP-positive mouse DRG neurons express functional MSP 
receptors in culture. Moreover, this data, together with the data from CGRP mRNA 
expression, suggests that MSP may play a role in regulating neuropeptide expression 
in adult DRG neurons in-vivo. Hence MSP may be involved in regulating sensory 
thresholds in nociceptive neurons.
Once again, as in the case of a- and P-CGRP mRNAs, the addition of saturating 
concentrations of NGF together with saturating concentrations of artemin to cultures 
increased the expression of SP mRNA to significantly higher levels than in cultures 
containing either NGF or artemin alone (figure 4.15 A). Moreover, culturing adult 
mouse DRG neurons with both these neurotrophic factors totally prevented the down- 
regulation of SP mRNA over time in culture. This raises the possibility that not all 
DRG neurons that express SP in culture express both TrkA and GFR-a3. Rather, 
since the effects of both factors on SP mRNA expression were not numerically the 
sum of each individual factor alone, it strongly suggests that adult mouse DRG
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neurons that express SP in culture can be divided into three sub-populations with 
regards to the expression of TrkA and GFR-a3. These populations being: A sub­
population that expresses SP together with TrkA and GFR-a3; a sub-population that 
expresses SP and just TrkA; a sub-population that expresses SP and just GFR-a3.
The addition of both artemin and MSP to DRG cultures also increased the expression 
of SP mRNA to higher levels than with either neurotrophic factor alone. In fact, this 
combination of neurotrophic factors was as effective as the combination of artemin 
and NGF together, totally preventing the culture-induced down-regulation of SP 
mRNA (figure 4.15 A). In contrast, the addition of MSP and NGF together, to adult 
mouse DRG cultures, only slightly increased the neuronal expression of SP mRNA in 
comparison to cultures containing either NGF or MSP alone. Moreover, the increase 
in SP mRNA expression with both NGF and MSP only reached statistical significance 
when compared to NGF alone. Significantly, the combination of NGF and MSP 
together is markedly less effective in promoting SP mRNA expression than the 
combinations of NGF or MSP with artemin. The most parsimonious explanation for 
this, especially since the efficacies of MSP and NGF individually in promoting SP 
mRNA expression are very similar, is that the majority of SP-positive neurons that 
express RON in culture also express TrkA. The hypothesis that RON expression is 
almost entirely restricted to a subset of NGF-responsive cultured adult mouse DRG 
neurons is supported by much of the other expression data presented in chapter 4 (see 
below).
The addition of 50ng/ml LIF to adult mouse DRG cultures did not alter the levels of 
SP mRNA compared to control cultures. However, LIF significantly attenuated the 
ability of NGF, artemin and MSP to promote the expression of SP (figure 4.23 A).
This data is in agreement with the previous observation that LIF can inhibit the NGF- 
induced up-regulation of SP mRNA in cultured adult rat DRG neurons (Mulderry, 
1994). Whilst my data, and the data from Mulderry, suggests that the release of LIF 
by Schwann cells partly underlies the nerve injury-induced reduction in SP 
expression, two previously published articles present data that opposes this 
hypothesis. First, it has been reported that the, sciatic nerve ligation-induced, down- 
regulation of SP mRNA expression occurs to the same extent in LIF*7* mice as wild-
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type mice, suggesting that nerve lesion-induced reductions in SP mRNA expression 
within DRG neurons are independent of LIF (Sun and Zigmond, 1996). However, LIF 
belongs to a family of cytokines that all signal through a common receptor 
component, gpl30 (reviewed in Taga, 1996; Murphy et al., 1997). This raises the 
possibility that other cytokines replace the functions of LIF in LIF7' mice. CNTF and 
IL-6 are two potential candidates for factors that may compensate for the lack of LIF 
in LIF7' mice. CNTF is expressed within Schwann cells surrounding peripheral 
nerves. Since CNTF lacks a signal peptide sequence it is only thought to be released 
from cells following nerve damage. Indeed, sciatic nerve lesion leads to the release of 
CNTF at the site of lesion resulting in increased retrograde transport in damaged 
sensory neurons (Curtis et al., 1993). IL-6, which like CNTF signals though a receptor 
complex containing gpl30, is rapidly up-regulated in peripheral nerves following 
nerve injury (Ito et al, 1998). Second, application of LIF to the proximal transected 
sciatic nerve stump reduces the axotomy-induced down-regulation of SP mRNA in rat 
lumber DRG neurons (Zhang et al., 1995). However, LIF is only effective in 
increasing the expression of SP within rat DRG neurons when very large amounts are 
applied to the transected nerve stump. Numerous previous unpublished observations 
within my laboratory demonstrate that many neurotrophic factors display a bell­
shaped dose response curve in relation to promoting neuronal surival, neurite 
outgrowth and modulating gene expression. This raises the possibility that the 
addition of super-saturating concentrations of LIF to the proximal stump of transected 
sciatic nerves partially reverses the down-regulation of SP mRNA that is induced by 
the release of lower, more physiologically relevant, amounts of LEF from de­
differentiating Schwann cells at the site of lesion. More research, perhaps using mice 
lacking functional gpl30 expression in sensory neurons, is required to clarify the role 
of injury released LIF in regulating SP expression in DRG neurons following nerve 
injury
4.4.3. VR1.
In chapter three of this thesis, I demonstrated that NGF/TrkA signalling did not 
appear to be required for the developmental regulation of VR1 mRNA expression in 
neural crest-derived sensory ganglia in-vivo. However, NGF was capable of totally
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preventing the culture-induced down-regulation of VR1 mRNA expression that 
occurs in neonatal trigeminal neurons. I also presented data suggesting that NT-3 
suppresses the expression of VR1 mRNA in developing neural crest-derived sensory 
neurons.
Adult mouse DRG neurons also exhibited a marked drop in VR1 mRNA expression 
over time in culture (figures 4.9 C, 4.15 B and 4.23 B). The culture-induced reduction 
in VR1 mRNA expression mirrors the changes that occur in rodent DRG neurons in- 
vivo following sciatic nerve injury (Michael and Priestly, 1999; Michael and Priestly 
2002; Fukuoka T et al., 2002; Wendland et al., 2003). Saturating concentrations of 
NGF reduced the culture-induced loss of VR1 mRNA expression by around 30% 
(figures 4.9 C, 4.15 B and 4.23 B). This observation is in accordance with previously 
published data demonstrating that exogenous NGF can promote VR1 mRNA 
expression in adult rodent DRG neurons in-vitro and in-vivo (Michael and Priestley, 
1999; Shu and Mendell, 1999; Winston et al., 2001). In addition, CFA-induced 
inflammation has been shown to increase the levels of VR1 protein expressed by 
TrkA-positive DRG neurons via an increase in the expression of NGF at the site of 
inflammation (Amaya et al., 2004). It is curious that NGF could completely prevent 
the culture-induced down-regulation of VR1 mRNA in neonatal trigeminal neurons 
(chapter three), but could only prevent 30% of the decrease in cultured adult mouse 
DRG neurons, especially since VR1 expression is almost entirely restricted to a sub­
population of TrkA- and CGRP- positive neurons in adult mouse L4/L5 DRG (Zwick 
et al., 2002). It is possible that the pattern of VR1 expression differs in mouse DRG at 
other axial levels (as represented in my DRG cultures) and/or in culture, being 
expressed in both TrkA-positive and TrkA-negative nociceptive neurons. Another 
explanation to account for the relatively poor ability of NGF to rescue the expression 
of VR1 mRNA in cultured adult mouse DRG neurons is that the proportion of TrkA- 
positive, and hence NGF-responsive, neurons decreases in adult DRG cultures over 
time (see above).
Artemin was also capable of preventing the culture-induced decrease in VR1 mRNA 
expression in adult mouse DRG cultures, with an efficacy slightly greater than NGF 
(figures 4.9 C, 4.15 B and 4.23 B). This would suggest, in culture at least, that VR1 
mRNA is expressed in a sub-population of neurons that predominantly express both
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TrkA and GFR-a3. Further evidence for this hypothesis is found in figure 4.15B. This 
figure demonstrates that the addition of saturating levels of both artemin and NGF to 
cultures did not significantly increase the expression of VR1 mRNA compared to 
cultures containing either NGF alone or artemin alone. The data presented in this 
chapter is the first demonstration that artemin can regulate the expression of VR1 in 
cultured sensory neurons, and raises the possibility that it modulates the neuronal 
expression of this important determinant of thermal and chemical nociceptive 
thresholds in-vivo.
MSP proved to be as effective as NGF in ameliorating the drop in VR1 mRNA levels 
in cultured DRG neurons (figures 4.9 C, 4.15 B and 4.23 B). This is the first 
demonstration that MSP can regulate the expression of VR1 in sensory neurons and 
adds to the number of functionally important sensory neuron mRNAs that can be 
transcriptionally regulated by this novel neurotrophic factor. Interestingly, the 
addition of saturating concentrations of NGF and MSP together to cultures did not 
enhance VR1 mRNA expression compared to either factor alone, suggesting that all 
DRG neurons that express TrkA and VR1 mRNA in culture also express RON. The 
combined effects of MSP and artemin on VR1 mRNA expression were also no greater 
than either of these two factors alone. In fact, the ability of all three neurotrophic 
factors combined to regulate the in-vitro expression of VR1 mRNA was no greater 
than any single neurotrophic factor on its own (figure 4.15 B). Since all three 
neurotrophic factors have a similar efficacy in terms of regulating the expression of 
VR1 mRNA, this raises the possibility that virtually all adult mouse DRG neurons, 
that express VR1 mRNA in culture, also express the receptors for all three 
neurotrophic factors.
The fact that the addition of all three neurotrophic factors together only prevented 
about 30% of the culture-induced reduction in VR1 mRNA expression raises the 
possibility that other neurotrophic factors may additionally regulate the expression of 
VR1 mRNA, both in-vitro and in-vivo. In the rat, VR1 is expressed in both the NGF- 
responsive, peptidergic sub-population of nociceptive neurons and the IB4-binding, 
non-peptidergic, sub-population of nociceptive neurons (Michael and Priestley, 1999; 
Guo et al., 1999). GDNF has been shown to play a role in the inflammation-induced
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up-regulation of VR1 expression in rat DRG (Amaya et al., 2004), and can also 
ameliorate the culture-induced down-regulation of VR1 mRNA in adult rat DRG 
neurons (Ogun-Muyiwa et al., 1999; Wendland et al., 2003). In the rat, the GDNF 
receptor, GFR-a 1 is expressed in 40% of lumbar DRG neurons, and this number 
increases to 60% following sciatic nerve transection (Kashiba et al., 1998; Bennett et 
al., 2000). It is not clear whether an up-regulation in GFR-a 1 expression occurs in 
cultures of rat DRG neurons. It is also not known whether it occurs in the mouse, 
either following peripheral nerve lesion, or in culture. However, it is possible that 
some VR1-positive cultured adult mouse DRG neurons expressing TrkA, lose NGF 
responsiveness over time in culture and gain expression of GFR-a 1, and hence GDNF 
responsiveness. It is interesting to speculate that the addition of GDNF to adult mouse 
DRG cultures containing NGF and/or artemin and/or MSP would restore the 
expression of VR1 mRNA to in-vivo levels. Another candidate for a neurotrophic 
factor that may positively regulate the expression of VR1 mRNA is NT4/5. NT4/5 has 
been shown to increase the capsaicin sensitivity of cultured adult rat DRG neurons 
(Shu and Mendell, 1999), presumably by increasing the expression of VR1 (although 
changes in the phosphorylation status of VR1 can alter its sensitivity to ligands, as 
discussed in the introduction to chapter 3). NT4/5 signals through the tyrosine kinase 
receptor TrkB (Klein et al., 1992; Ip et al., 1992), a receptor that is not normally 
expressed on most VR1-positive sensory neurons. However, NT4/5 can also activate 
TrkA, abeit with low efficiency (Berkemeier et al., 1991; Hallbook et al., 1991; Ip et 
al., 1992), and can also signal through the common neurotrophin receptor, p75 
(Rodriguez-Tebar et al., 1992), providing a theoretical mechanism whereby it could 
increase the expression of VR1 in cultured adult mouse DRG neurons.
The effects of LIF on the expression of VR1 mRNA were very similar to the effects 
of LIF on SP mRNA expression. The addition of LIF alone to cultures did not alter 
VR1 mRNA expression levels compared to controls. However, LIF could attenuate 
the ability of NGF, artemin and MSP to promote VR1 mRNA expression, although 
this is only statistically significant in the case of artemin (figure 4.23 B). This data 
supports the idea that injury-induced LIF production by Schwann cells may drive 
some of the changes in gene expression within DRG neurons that accompany 
peripheral nerve injury.
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LIF may not be the only injury-induced factor that drives changes in the expression of 
VR1 mRNA expression, both in-vivo and in-vitro. The in-vivo and in-vitro data 
presented in chapter three suggested that NT-3 may suppress the expression of VR1 
mRNA in neonatal neural crest-derived sensory neurons. This hypothesis is supported 
by the observation that NT-3 can reverse the thermal hyperalgesia-inducing increase 
in VR1 mRNA and protein expression that occurs following chronic constriction 
injury to the adult rat sciatic nerve (Wilson-Gerwing et al., 2005). Indeed, exogenous 
NT-3 can regulate the expression of a number of genes following axotomy, often in 
an antagonistic manner to NGF, and can prevent the loss of neurons and satellite cells 
within DRG following nerve lesion (Karchewski et al., 2002; Jongsma Wallin et al., 
2001; Park et al., 2003; Sterne et al., 1998; Wilson-Gerwing et al., 2006; Kuo et al., 
2005; Groves et al., 1999). Whilst sciatic nerve lesion reduces the expression of NT-3 
within peripheral nerves (Funakoshi et al., 1993; Cai et al., 1998), macrophages and 
activated T-cells invading the lesion site express NT-3 (Moalem et al, 2000; Sobue et 
al, 1998), raising the possibility that endogenous NT-3 may play a role in 
orchestrating the response of DRG neurons to injury. NT-3 may be particularly 
efficacious as an injury response agent, since it can activate all neurotrophic factor 
receptors to some degree and can thus exert effects on virtually all DRG neurons (see 
previous introductory sections for details). Schwann cells in culture express NT-3 
(Meier et al, 1999; Cai et al, 1999), as well as LIF, raising the possibility that NT-3 
may play a role in regulating the numerous culture-induced changes in gene 
expression observed in adult mouse DRG cultures.
4.4.4. TTX-resistant sodium channels
In chapter two of this thesis, I demonstrated that NGF/TrkA signalling was required 
for the initial induction of Navi.8 and Navi.9 mRNA expression in neural crest- 
derived sensory ganglia in-vivo. In chapter three, I showed that NGF is required for 
the correct developmental expression of both TTX-resistant sodium channel mRNAs 
in neural crest-derived sensory ganglia, but not placode-derived nodose ganglia. 
Moreover, I demonstrated that NGF could partially prevent the culture-induced drop 
in Navi.8 and Navi.9 mRNA expression in neonatal trigeminal and nodose neurons.
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In agreement with my previous data, NGF could ameliorate the reduction in TTX- 
resistant sodium channel mRNAs that also occured in cultured adult mouse DRG 
neurons, thereby partially restoring the “un-injured” phenotype to cultured 
nociceptive neurons (figures 4.9A and B, 4.16A and B and 4.24A and B). The culture 
induced drop in Navi.8 and Navi.9 expression mirrors the effects of peripheral nerve 
lesion in-vivo (Okuse et al., 1997; Cummins et al., 2000; Tate et al., 1998; Dib-hajj et 
al., 1998a, 1999; Sleeper et al., 2000; Decosterd et al., 2002). My data is in agreement 
with previously published data demonstrating that NGF can positively regulate the 
expression of Navi.8 mRNA and peptide both in adult rat DRG cultures (Black et al., 
1997; Fjell at al., 1999a) and in-vivo (Dib-Hajj et al., 1998b Fjell et al., 1999b and c). 
A previous publication failed to demonstrate that NGF could regulate the expression 
of Navi.9 mRNA (Fj ell et al, 1999a). However, the authors used a semi-quantitative 
method for measuring Navi.9 mRNA expression that does not have sufficient 
resolution to determine small changes in gene expression. In contrast, the same 
authors have demonstrated an increased expression of Navi.9 mRNA within DRG in 
mice over-expressing NGF in the skin (Fjell et al., 1999b).
NGF could almost completely prevent the culture-induced drop in Navi.8 mRNA 
expression in neonatal trigeminal neurons (chapter three of this thesis) In contrast, 
saturating levels of NGF were only capable of preventing 15% of the drop in Navi.8 
mRNA expression levels that occurs within cultured adult DRG neurons. The time 
course data that I presented in chapter three suggests that Navi.8 mRNA is 
significantly more widely expressed in neonatal neural-crest derived sensory ganglia 
compared to adult ganglia. P0 sensory ganglia also contain more NGF-responsive 
neurons than adult ganglia (Molliver and Snider, 1997; Molliver et al., 1997) 
suggesting a considerable overlap between TrkA- and Navi.8-positive neurons in 
neonatal sensory ganglia. In adult DRG, Navi.8 mRNA is expressed in virtually all 
A-6 and C-fibre (and some A-p fibre) nociceptive neurons in-vivo (around 65% of 
DRG neurons), whereas TrkA is only expressed in 35% of neurons. The majority of 
Navi.8-positive adult DRG neurons that do not express TrkA are IB4-positive, 
express Ret and are responsive to members of the GDNF family of neurotrophic 
factors (Djouhri et al., 2003; Fang et al., 2005; Averill et al., 1995; Molliver et al.,
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1997; Michael and Priestley, 1999; Fjell et al., 1999 (a); Amaya et al., 2000; Orozco 
et al., 2001). Indeed, GDNF has been shown to up-regulate the expression of Navi.8 
mRNA, both in-vitro and also in-vivo following sciatic nerve lesion (Fjell et al,
1999a; Cummins et al., 2000). Therefore, it is not surprising that NGF is unable to 
restore Navi.8 mRNA levels to in-vivo levels in adult mouse DRG cultures, 
especially in light of the changes in neurotrophic factor receptor expression that are 
likely to occur in culture. As outlined above such changes include a decrease in NGF 
responsive cells and an increase in GDNF responsive cells over the culture period. It 
is interesting to speculate that a combination of NGF and GDNF would maintain 
Navi.8 mRNA expression at in-vivo levels in cultured adult mouse DRG neurons.
NGF appeared to be even less effective in maintaining Navi.9 mRNA levels at time 0 
levels in culture than it was in maintaining Navi.8 mRNA expression. A situation that 
mirrors the data from neonatal trigeminal neurons, presented in chapter three. In 
contrast to Navi.8, Navi.9 is exclusively expressed in nociceptive C-fibre neurons 
within sensory ganglia, with no expression in either TrkA-positive, A-5 nociceptors or 
the rare A-P nociceptors (Fang et al., 2006). Within C-fibre nociceptive neurons, 
Navi.9 is expressed in both TrkA-positive and IB4-positive sub-populations (Amaya 
et al., 2000). However, Navi.9 expression is positively correlated with IB4 
expression, unlike Navi.8 whose expression is positively correlated with TrkA 
expression (Fang et al., 2005 and 2006). Thus, there are significantly less TrkA- 
positive neurons expressing high levels of Navi.9 mRNA than Navi.8 mRNA in- 
vivo. Conversely, many GDNF responsive, IB4-positive neurons express high levels 
of Navi.9 and are not responsive to NGF. The overlap between TrkA and Navi.9 
mRNA expression is likely to be further reduced in-vitro, accounting for the poor 
efficacy of NGF in promoting the expression of Navi.9 mRNA in adult mouse DRG 
cultures. Once again, as in the case of Navi. 8, GDNF has been previously shown to 
positively regulate the expression of Navi.9 (Fjell et al., 1999a; Cummins et al.,
2000), raising the possibility that a combination of saturating concentrations of NGF 
and GDNF added to cultures could fully maintain Navi.9 mRNA expression at in- 
vivo levels.
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Artemin was also able to partially attenuate the culture-induced drop in TTX-resistant 
sodium channel mRNAs (figures 4.9A and B, 4.16A and B and 4.24A and B). The 
efficacy of artemin and NGF in promoting Navi.8 and Navi.9 mRNA expression is 
similar, reflecting the broad overlap in expression between TrkA and GFR-a3 in 
adult mouse DRG neurons. Artemin has previously been shown to promote the 
expression of Navi.8 protein following spinal nerve ligation (Gardell et al., 2003), 
however, my data is the first demonstration that artemin can modulate the expression 
of Navi.9.
The demonstration that MSP could positively modulate the expression of both Navi. 8 
and Navi.9 mRNAs, is also a novel finding. On the whole MSP has a similar efficacy 
to NGF and artemin in regulating the expression of TTX-resistant sodium channel 
mRNAs, suggesting, as for previous genes above, that there is a fairly broad overlap 
in the expression of TrkA, GFR-a3 and RON by cultured adult mouse DRG neurons. 
This hypothesis is substantiated by the results from experiments where different 
combinations of saturating concentrations of neurotrophic factors were added to adult 
mouse DRG cultures (figures 4.16A and B). Whilst the combination of artemin and 
NGF could significantly increase the expression of both Navi.8 and Navi.9 mRNAs 
compared to either factor alone, the increase in expression of both mRNAs compared 
to cultures with a single factor was only around 20%, suggesting that only a small 
proportion of Navi.8- or Navi.9-positive neurons express either TrkA in the absence 
of GFR-a3 or GFR-a3 in the absence of TrkA. The data for cultures containing a 
combination of artemin and MSP is very similar to the data for cultures containing 
NGF and artemin. Once again, adding both MSP and NGF to cultures did not 
significantly increase the expression of Navi.8 or Navi.9 mRNAs above cultures 
containing either MSP or NGF alone. This data adds weight to the hypothesis that 
TrkA and RON are co-expressed in almost entirely overlapping sub-populations on 
cultured adult mouse DRG neurons.
LIF did not reduce the expression of Navi.8 or Navi.9 mRNAs in adult mouse DRG 
neurons compared to control cultures (figure 4.24 A). Whilst LIF did have a tendency 
to reduce the ability of NGF, artemin and MSP to promote the expression of both 
TTX-resistant sodium channel mRNAs, this was only statistically significant in the
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cases of Navi. 8 mRNA in cultures containing MSP and Navi.9 mRNA in cultures 
containing NGF. Nonetheless, the data raises the possibility that LIF may play a role 
in regulating the nerve lesion -induced drop in TTX-resistant sodium channel mRNA 
in-vivo. As discussed above, the effects of LIF in culture may be masked by LIF 
secreted from Schwann cells within the cultures, especially if Navi.8 and Navi.9 
mRNAs are very sensitive to regulation by LIF. Once again, culturing adult DRG 
neurons with a LIF or gpl30 function blocking antibody may shed more light on the 
role of Schwann cell-derived LIF in regulating the expression of TTX-resistant 
sodium channel mRNAs both in-vitro, and in-vivo, following peripheral nerve lesion.
4.4.5. Galanin
In chapter three, the analysis of transgenic mice produced data suggesting that NGF 
may promote the expression of galanin mRNA in neonatal neural-crest derived 
sensory neurons within trigeminal and dorsal root ganglia. This data was surprising, 
since it contradicted a number of publications demonstrating that a reduction in the 
availability of target field-derived NGF was at least partially responsible for the 
dramatic increase in galanin expression in adult DRG neurons following peripheral 
nerve lesion. Moreover, exogenous NGF has been shown to reduce galanin expression 
in adult DRG neurons, both in culture and in-vivo following peripheral nerve lesion 
(Verge et al., 1995; Kerekes et al., 1997; Ozturk and Tonge, 2001; Shadiack et al., 
2001).
In contrast to chapter three, the data presented in this chapter is in agreement with 
previously published data documenting the regulatory effects of NGF on galanin 
mRNA expression in adult DRG neurons. Galanin mRNA was expressed at very low 
levels in freshly dissociated adult mouse DRG (figures 4.10A, 4.17A and 4.25A), 
corresponding to the restricted expression of galanin in 2-5% of, mainly small- 
diameter, adult rodent DRG neurons in-vivo (Chang et al., 1985; Skotfitsch and 
Jacobowitz, 1985; Xu et al., 1996; Ma and Bisby, 1999). Galanin mRNA expression 
increased more than 20-fold in adult mouse DRG neurons over a 96 hour culture 
period. This is in accordance with previous in-vitro studies on adult mouse and rat 
DRG neurons (Kerekes et al., 1997; Ozturk and Tonge, 2001). A dramatic increase in
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galanin mRNA and peptide expression is also observed in adult rodent DRG 
following peripheral nerve injury (e.g. Hokfelt et al., 1987; Villar et al., 1989; Ma and 
Bisby, 1997, 1999; Zhang et al., 1998). The up-regulation of galanin expression in rat 
DRG following sciatic nerve injury occurs in both injured and “spared” neurons of all 
sizes and modalities (Ma and Bisby, 1997; 1999). A number of elegant transgenic 
studies suggest that lesion-induced galanin acts as a neuroprotective, anti-nociceptive 
agent (reviewed in Holmes et al, 2005).
The addition of lOng/ml NGF to cultures prevented about 40% of the culture-induced 
up-regulation of galanin mRNA (figures 4.10 A, 4.17 A and 4.25 A), an observation 
that is in agreement with previous literature documenting the regulation of galanin 
mRNA and peptide expression by NGF. The ability of NGF to prevent 40% of the 
culture-induced increase in galanin mRNA expression suggests that many of the 
small-diameter cells showing de-novo galanin expression in culture are TrkA-positive.
Artemin was also able to attenuate the increase in galanin mRNA expression in 
cultured DRG neurons, with an efficacy similar to NGF (figures 4.10A, 4.17A and 
4.25 A). The data suggests that most of the galanin-positive neurons that express TrkA 
and respond to NGF in culture also express GFR-a3 and respond to artemin. This 
hypothesis is supported by the observation that the addition of saturating 
concentrations of both artemin and NGF together to adult mouse DRG cultures only 
marginally decreases the expression of galanin mRNA compared to either factor 
alone. Moreover, the further decrease in galanin expression in cultures containing 
both NGF and artemin is only significant compared to cultures containing NGF alone. 
The observation that artemin can ameliorate the culture-induced increase in galanin 
mRNA expression is in accordance with recent data demonstrating that artemin can 
attenuate the increase in galanin peptide expression that occurs in rat DRG neurons 
following spinal nerve ligation (Gardell et al., 2003)
MSP was also able to partially prevent the culture-induced up-regulation in galanin 
mRNA in adult mouse DRG neurons (figures 4.10 A, 4.17 A and 4.25 A), although 
with a slightly lower efficacy than NGF or artemin. The combination of artemin and 
MSP was significantly more effective in reducing galanin mRNA expression than
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either factor alone, reducing the increase in galanin mRNA by around 75%. This 
suggests that a number of galanin mRNA-positive neurons exist in adult mouse DRG 
cultures that express either GFR-a3 or RON (figure 4.17 A). In contrast, MSP- 
responsive neurons expressing galanin would appear to be entirely a subset of NGF- 
responsive, galanin-positive neurons, since the addition of both factors together to 
cultures is no more effective than NGF alone in reducing galanin mRNA levels.
The addition of all three neurotrophic factors to cultures also inhibits the culture- 
induced increase in galanin mRNA by around 75%. The residual increase in galanin 
mRNA levels in the presence of all three neurotrophic factors is probably due to a 
combination of increased galanin mRNA expression in IB4-positive, TrkA-negative 
C-fibre neurons together with increased galanin mRNA expression in medium to 
large-diameter, myelinated neurons (Ma and Bisby, 1997; 1999). The former neuronal 
population expresses functional receptors for GDNF in-vivo (Molliver and Snider, 
1997; Molliver et al., 1997; Kashiba et al., 1998; Bennett et al., 2000) and may well 
respond to GDNF in culture by decreasing their expression of galanin mRNA. GFR- 
a l  expression is up-regulated in a sub-population of medium to large-diameter DRG 
neurons following nerve injury (Kashiba et al., 1998; Bennett et al., 2000). If GFR-al 
is also up-regulated in this neuronal sub-population in culture, GDNF may also be 
able to ameliorate the culture-induced increase in galanin mRNA in larger myelinated 
DRG neurons. Indeed, GDNF can attenuate the increase in galanin peptide that occurs 
in both large- and small-diameter rat DRG neurons following spinal nerve ligation 
(Wang et al., 2003).
Interestingly, BDNF has also been shown to ameliorate culture-induced increases in 
galanin mRNA expression in rat DRG neurons (Kerekes et al., 1997). The BDNF 
receptor, TrkB, is predominantly expressed by medium to large-diameter myelinated 
DRG neurons in the adult rodent (Karchewski et al., 1999; Kashiba et al., 2003), 
raising the possibility that BDNF attenuates increases in galanin mRNA expression in 
this population of neurons in-vitro.
NT-3 is also a candidate neurotrophic factor for attenuating the culture-induced 
increase in the expression of galanin mRNA in large, myelinated, TrkC-positive
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proprioceptive neurons, since it has been shown to reduce the expression of galanin 
mRNA in adult rat DRG neurons following chronic constriction injury (Wilson- 
Gerwing and Verge, 2006).
The presence of LIF significantly enhanced the culture-induced expression of galanin 
mRNA in adult mouse DRG cultures compared to control cultures (figure 4.25 A). LIF 
also significantly reduced the ability of NGF, artemin and MSP to attenuate the 
expression of galanin mRNA in culture. This data is in accordance with several 
previous publications that demonstrate that LIF increases the expression of galanin 
mRNA within adult DRG neurons, both in-vitro and in-vivo (Sun and Zigmond, 1996; 
Comess et al., 1996, 1998; Thompson et al., 1998; Kerekes et al., 1999; Ozturk and 
Tonge, 2001). Whilst these publications have demonstrated that LIF antagonises the 
effects of NGF in suppressing the expression of galanin, the data presented here is the 
first demonstration that LIF directly antagonises the ability of MSP and artemin to 
down-regulate the expression of galanin.
4.4.6. PACAP
The levels of PACAP mRNA expressed by adult mouse DRG neurons consistently 
increased more than ten-fold over 96 hours in culture (figures 4.1 OB, 4.17B and 
4.25B). The low level of PACAP mRNA in DRG neurons that was observed at time 0 
reflects the fact that PACAP is only expressed in 10% of adult rodent DRG neurons, 
predominantly in a sub-population of CGRP- and SP-positive small-diameter neurons 
(Moller et al., 1993; Mulder et al., 1994). The culture-induced increase in PACAP 
mRNA expression mirrors the effects of sciatic nerve transection and nerve 
compression injury (Zhang et al., 1995; Zhang et al., 1996; Jongsma-Wallin et al., 
2001; Pettersson et al., 2004). The former injury leads to a marked increase in the 
number of medium- to large-diameter L4/L5 DRG neurons expressing PACAP 
mRNA and protein, whilst sciatic nerve compression increases the expression of 
PACAP mRNA and protein in both large and small lumbar DRG neurons.
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The addition of lOng/ml NGF to cultures attenuated the culture-induced increase in 
PACAP mRNA expression. However, the efficacy of NGF in reducing PACAP 
expression was low, and was not statistically significant in all series of culture 
experiments (figure 4.17 B). The ability of NGF to partially prevent the culture- 
induced increase in PACAP mRNA expression within adult DRG neurons was an 
unexpected result, as NGF has previously been shown to play a role in the 
inflammation-induced increase in PACAP expression in TrkA-positive nociceptive 
neurons (Zhang et al., 1998; Jongsma-Wallin et al., 2003). Moreover, exogenous NGF 
increases the expression of PACAP mRNA and protein within rat TrkA-positive 
lumbar DRG neurons, both in the intact animal and following sciatic nerve transection 
(Jongsma-Wallin et al., 2001). However, NGF attenuates the increase in PACAP 
mRNA and peptide that occurs in TrkC-positive proprioceptive neurons of L4/L5 
DRG following sciatic nerve transection (Jongsma-Wallin et al., 2001). Presumably, 
NGF regulates PACAP expression in TrkC-positive neurons via the common 
neurotrophin receptor, p75, since there are no reports of de-novo TrkA expression 
within proprioceptive neurons following nerve injury. Alternatively, NGF may 
regulate PACAP mRNA expression within proprioceptive neurons by a paracrine 
mechanism. Whatever the mechanism, the fact that NGF down-regulates PACAP 
expression in proprioceptive neurons following nerve injury, explains the data 
presented in figures 4.10B, 4.17B and 4.25 B. It is likely that only 10% of DRG 
neurons express TrkA and PACAP mRNA in culture (Moller et al., 1993; Mulder et 
al., 1994), limiting the ability of NGF to increase the expression of PACAP mRNA 
within RNA samples extracted and purified from all cultured neurons. The increase in 
PACAP mRNA within TrkA-positive nociceptive neurons observed may be more 
than offset by the ability of NGF to attenuate the increase in PACAP mRNA within 
cultured proprioceptive neurons. A simple way to test this hypothesis would be to 
culture L4/L5 DRG neurons alongside DRG neurons from lower-thoracic axial levels. 
If the hypothesis is correct, PACAP mRNA levels should be increased by NGF in the 
cultures from thoracic DRG, containing few proprioceptive neurons, and decreased by 
NGF in cultures from L4/L5 DRG that contain relatively high numbers of 
proprioceptive neurons.
Artemin and MSP reduced PACAP mRNA expression in adult mouse DRG cultures 
by 15% compared to control cultures. This reduction, however, does not reach
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statistical significance in any set of cultures. The limited efficacy of MSP and artemin 
in reducing PACAP mRNA expression is in accordance with the observation that 
PACAP mRNA expression is restricted to a small subset of nociceptive neurons in 
adult rodent DRG and its expression is predominantly up-regulated within medium- to 
large-diameter myelinated neurons following peripheral nerve transection (Moller et 
al., 1993; Mulder et al., 1994; Zhang et al., 1995; Zhang et al., 1996; Jongsma-Wallin 
et al., 2001). The majority of larger myelinated neurons do not express GFR-a3 and 
the data presented in this chapter supports the idea that RON expression is also 
restricted to nociceptive neurons. The data suggests that a sub-population of small- 
diameter nociceptive neurons express PACAP mRNA and receptors for artemin and 
/or MSP in control DRG cultures, and that artemin and MSP can significantly 
attenuate PACAP mRNA expression within this sub-population of neurons. If this 
were the case, this would be the first example of artemin and MSP having a different 
effect to NGF on regulating gene expression within nociceptive sensory neurons. 
Whilst this hypothesis would require a detailed immuno-cyctochemistry study for 
verification, the data from the “additive” experiments gives it support. A combination 
of saturating concentrations of artemin and MSP reduced the culture-induced increase 
in PACAP mRNA expression by a statistically significant 30% (figure 4.17B). The 
additive effect of MSP and artemin suggests that most nociceptive DRG neurons 
expressing PACAP mRNA in culture express either GFR-a3 or RON, but not both 
(or, of course, neither receptor).
The addition of 50 ng/ml LIF to adult DRG cultures reduced the expression of 
PACAP mRNA by 25% compared to control cultures, a reduction that is statistically 
significant (figure 4.25B). Moreover, LIF enhances the limited ability of artemin and 
MSP, but not NGF, to attenuate the culture-induced up-regulation of PACAP mRNA, 
although this effect does not quite reach statistical significance. The ability of LIF to 
reverse the “axotomised phenotype” in the case of PACAP mRNA is markedly 
different to the effects that it exerts on the majority of other genes investigated in this 
chapter. Functional receptors for LIF are not expressed on the myelinated, larger- 
diameter DRG neurons that predominantly up-regulate PACAP mRNA expression 
following nerve transection (Zhang et al., 1995; Zhang et al., 1996; Jongsma-Wallin 
et al., 2001; Thompson et al., 1997). However, the data from cultures containing
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artemin and MSP suggests that a sub-population of small-diameter nociceptive 
neurons express PACAP mRNA in control DRG cultures. This raises the possibility 
that LIF decreases the expression of PACAP mRNA in this neuronal sub-population. 
The possibility also exists that LIF attenuates the culture-induced de-novo expression 
of PACAP mRNA within large-diameter myelinated DRG neurons via a paracrine 
mechanism involving the release of a second neurotrophic factor from small-diameter 
DRG neurons.
4.4.7. ATF3 and DINE
ATF3 and DINE are both ostensibly injury induced factors in the adult peripheral 
sensory nervous system. Both are expressed at extremely low levels in undamaged 
adult DRG neurons, but are rapidly induced following various peripheral nerve 
lesions. DINE mRNA is predominantly up-regulated in TrkA-positive, IB4-negative 
nociceptive neurons, and DINE expression is often coincident with de-novo galanin 
expression. No detectable DINE expression is found in glial cells following nerve 
injury (Kiryu-Seo et al., 2000; Kato et al., 2002; Ohba et al., 2004; Nagata et al., 
2006). In contrast, ATF3 mRNA and protein expression is induced within the 
majority of damaged neurons, of all sizes and modalities, following peripheral nerve 
damage (Tsujino et al., 2000; Tsuzuki et al., 2001; Obata et al., 2003; Wang et al., 
2003; Averill et al., 2004) ATF3 is also induced within Schwann cells following 
nerve lesion (Hunt et al., 2004).
The developmental time course data for ATF3 and DINE mRNAs reinforces the 
hypothesis that both factors play a negligible role in maintaining the functions and 
phenotype of healthy sensory neurons (figures 4. IB and C) Both mRNAs were barely 
detactable in either neural crest- or placode-derived sensory neurons at ages between 
E l6 and the adult.
In accordance with the in-vivo nerve injury data, ATF3 and DINE mRNAs were both 
markedly up-regulated in cultured adult mouse DRG neurons over a 96 hour culture 
period (figures 4.11A and B, 4.18A and B and 4.26A and B). This is the first data 
showing that these two genes are induced in adult DRG neurons by cell culture. The
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culture-induced increase in ATF3 mRNA over the 96 hour culture period (2- to 3- 
fold) was significantly less than the culture induced increase in DINE mRNA (30- 
fold). This observation is a little surprising, since, based on in-vivo nerve injury 
studies, DINE mRNA is only likely to be up-regulated in a relatively small sub­
population of cultured DRG neurons, whereas ATF3 is likely to be up-regulated in the 
majority of neurons and contaminating Schwann cells. Figure 4.7C provides a partial 
explanation for this observation. The rise in ATF3 mRNA levels appears to be short 
lived, peaking at 48 hours of culture and falling by 96 hours in culture. This is not the 
case for DINE mRNA (data not shown). Indeed, ATF3 mRNA was the only example 
amongst all of the mRNAs assayed showing a greater culture-induced change in gene 
expression at 48 hours than 96 hours (figures 4.7A and B and data not shown). ATF3 
mRNA was also the only mRNA assayed that showed significantly higher expression 
(> 5-fold) in freshly dissociated neurons compared to the intact DRG (data not 
shown), suggesting that the dissection and dissociation procedure initiates rapid ATF3 
mRNA induction. Thus, if the induction of ATF3 mRNA was assessed between intact 
DRG and neurons after 48 hours in culture the magnitude of the culture-induced 
induction would be greater than that of DINE mRNA.
NGF, artemin and MSP were all able to partially attenuate the culture-induced up- 
regulation of ATF3 and DINE mRNAs, although in the case of DINE mRNA the 
effects of the three neurotrophic factors are not always statistically significant (figures 
4.11A and B, 4.18A and B and 4.26A and B). Exogenous NGF has previously been 
shown to reduce ATF3 protein expression in small-diameter lumbar DRG neurons 
following sciatic nerve transection (Averill et al., 2004). My data is the first 
demonstration that NGF can regulate the expression of ATF3 mRNA in cultured adult 
rodent sensory neurons. Although it has not been established whether NGF can 
ameliorate DINE mRNA expression in nociceptive DRG neurons following 
peripheral nerve lesion, sequestering target field-derived NGF with an NGF blocking 
antibody is sufficient to induce DINE mRNA expression within small-diameter DRG 
neurons in the adult rat (Kato et al., 2002). Withdrawal of NGF from neonatal rat 
DRG explant cultures also induces DINE mRNA expression (Kato et al., 2002). 
Neither artemin nor MSP have been previously shown to regulate the expression of 
either ATF3 or DINE mRNAs in adult rodent DRG neurons in-vitro or in-vivo.
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Artemin was consistently the most effective of the three neurotrophic factors in 
reducing both DINE and ATF3 mRNA levels in all experiments here. Whilst both 
TrkA and GFR-a3 are predominantly expressed by small-diameter nociceptive 
neurons in-vivo, the number of DRG neurons expressing TrkA is double the number 
of neurons expressing GFR-a3. It might therefore be anticipated that NGF would be 
more effective than artemin in regulating the expression of neuronal genes (like 
DINE) whose expression is mainly restricted to nociceptive neurons (Averill et al., 
1995; Molliver et al., 1997; Michael and Priestley, 1999; Orozco et al., 2001). 
However, as discussed above, unpublished data from my laboratory suggests that the 
number of NGF responsive neurons decreases in adult mouse DRG cultures, whilst 
the number of artemin responsive neurons increases. This phenomenon may partially 
account for the better than expected efficacy of artemin in regulating DINE and ATF3 
mRNA compared to NGF. NGF and MSP appeared to show a similar efficacy in 
reversing culture-induced changes in ATF3 and DINE mRNA expression.
The addition of saturating combinations of either artemin and NGF or artemin and 
MSP to adult mouse DRG cultures did not significantly decrease the levels of ATF3 
mRNA or DINE mRNA beyond the levels found with artemin alone (figure 4.18A). 
Similarly, the addition of all three neurotrophic factors to cultures is no more effective 
in attenuating the culture induced increase in DINE and ATF3 mRNAs than artemin 
alone. This data suggests that more ATF3 and DINE expressing cells express GFR-a3 
than express TrkA or RON. It could be postulated therefore that NGF- and MSP- 
responsive cells expressing these two injury inducible factor mRNAs are a subset of 
artemin responsive cells. The addition of saturating concentrations of NGF and MSP 
to cultures was also no more effective at reducing ATF3 and DINE mRNA levels than 
either factor alone. The similar efficacy of NGF and MSP in regulating gene 
expression, and the lack of an additive effect of the two neurotrophic factors when 
added to cultures together, is a recurrent theme of the data presented in this chapter 
and suggests that NGF and MSP responsive adult mouse DRG neurons are a broadly 
over-lapping population, at least in culture.
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The addition of either artemin alone or artemin together with any combination of the 
other two neurotrophic factors reduced the levels of ATF3 mRNA to time 0 levels. 
However, based on in-vivo data, ATF3 is likely to be up-regulated in the majority of 
cultured adult mouse DRG neurons (Averill et al., 2004), whereas GFR-a3 
expression, and hence artemin responsiveness, is likely to be restricted to a sub­
population of small-diameter nociceptive neurons (Gardell et al, 2003). This raises the 
possibility that the apparent 100% efficacy of artemin in preventing the culture- 
induced up-regulation of ATF3 mRNA is an artifact of the fact that dissection and 
dissociation of DRG induces significant ATF3 mRNA expression, thereby giving an 
artificially high time 0 level of ATF3 mRNA expression. GDNF has been shown to 
reduce the levels of ATF3 in both small- and large-diameter DRG neurons following 
peripheral nerve lesion (Wang et al., 2003; Kato et al., 2004), and is therefore a good 
candidate neurotrophic factor for reducing ATF3 mRNA expression in cultured DRG 
neurons that are not responsive to NGF, artemin or MSP.
DINE mRNA has been reported to be induced in mainly TrkA-positive, nociceptive 
DRG neurons following peripheral nerve injury (Kato et al., 2002). Since this 
neuronal sub-population is responsive to NGF and artemin in culture (for example, 
see CGRP mRNA expression data in this chapter), it is curious that a combination of 
these neurotrophic factors were not more effective in reducing the culture-induced 
increase in DINE mRNA expression. It seems likely that the up-regulation in DINE 
mRNA is not entirely restricted to TrkA-positive nociceptive neurons in culture.
The addition of 50ng/ml LIF to adult mouse DRG cultures did not alter the levels of 
ATF3 mRNA compared to control cultures (figure 4.26 A). Similarly, the addition of 
LIF to cultures containing NGF, artemin or MSP did not alter ATF3 mRNA compared 
to cultures containing either of the three neurotrophic factors alone. The data suggests 
that LIF does not play a role in inducing ATF3 mRNA expression following nerve 
injury. This observation is not that surprising, since functional LIF receptors are 
restricted to small-diameter, nociceptive neurons in the adult rodent (Thompson et al.,
1997), whereas ATF3 is induced in neurons of all sizes and modalities following 
peripheral nerve lesion (Averill et al., 2004). In the absence of published data 
demonstrating that ATF3 expression is positively-regulated by another injury-induced
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neurotrophic factor following nerve lesion, it would seem that neurotrophic factor 
withdrawal drives ATF3 expression. However, this hypothesis does not fit easily with 
the extremely rapid onset of ATF3 mRNA induction compared to the other genes 
analysed in this chapter. Further work needs to be done to establish the factors that 
drive the expression of ATF3 in damaged neurons.
Surprisingly, the addition of LIF to adult mouse DRG cultures partially prevented the 
culture-induced up-regulation of DINE mRNA observed in control cultures.
Moreover, LIF significantly increased the effectiveness of artemin, NGF and MSP in 
ameliorating the increase in DINE mRNA expression (figure 4.26 B). This is the first 
data suggesting that LIF attenuates axotomy/culture induced changes in gene 
expression in nociceptive adult DRG neurons that express functional LIF receptors. 
This observation is a marked contrast to the apparent ability of LIF to enhance or 
drive the “axotomised phenotype” in nociceptive neurons that has been observed for 
many of the genes analysed in this chapter and has also been reported in several 
previous publications (Mulderry, 1994; Comess et al., 1996, 1998; Ozturk and Tonge, 
2001; Kerekes et al., 1999; Sun and Zigmond, 1996).
The data presented in figure 4.26 B conflicts with previous data demonstrating that 
the application of LIF to rat sciatic nerves induced DINE mRNA expression in lumbar 
DRG, as measured by semi-quantitative RT-PCR and in-situ hybridization (Kato et 
al., 2002). The application of a gp 130 blocking antibody was also shown to reduce 
DINE mRNA expression in DRG following sciatic nerve transection. Additionally, 
in-vitro experiments, using explanted lday old rat DRG, demonstrated that LIF could 
increase DINE mRNA expression and that the increased DINE mRNA expression 
could be antagonised by a gp 130 blocking antibody. The data in this publication was 
not convincing, since merely exposing the sciatic nerve to allow the application of 
LIF induced significant DINE mRNA expression and LIF only increased this 
expression 1.3-fold. Similarly, the application of a blocking gpl30 antibody to 
transected sciatic nerve only reduced DINE mRNA expression by 20% compared to 
controls. As discussed above, explant cultures are not a good model of axotomy and 
nerve injury in the adult compared to dissociated cultures, especially with neonatal 
ganglia. Moreover, the changes in DINE mRNA expression in explant cultures 
containing LIF were also only 1.2- to 1.3-fold, in accordance with the in-vivo
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experiments. Neither semi-quantitative RT-PCR nor in-situ hybridization are accurate 
enough techniques to measure the small changes in DINE mRNA expression that 
occurred in both the in-vivo and in-vitro studies presented in this publication.
The interpretation of the data presented in figure 4.26 B is complicated by the 
likelihood that control cultures will contain LIF as a result of contaminating Schwann 
cells. Clearly, further experiments are needed, using LIF together with anti-LIF and 
anti-gpl30 blocking antibodies, to determine whether LIF really does antagonise the 
culture-induced up-regulation of DINE mRNA in adult mouse DRG neurons.
4.4.8. P2X3
The time course of P2X3 mRNA expression revealed that P2X3 mRNA is expressed 
in a similar developmental pattern in nodose, trigeminal and dorsal root ganglia 
(figure 4.1 A). In all three ganglia, P2X3 mRNA levels were highest in the embryonic 
and neonatal period and a significant drop in expression occurred between P5 and the 
adult. The drop in the expression of P2X3 mRNA was most marked in the two neural- 
crest derived sensory ganglia. This data is in agreement with previously published 
observations of P2X3 mRNA and protein expression in the developing and adult 
peripheral sensory nervous system. P2X3 protein is found in the majority of sensory 
neurons within embryonic trigeminal, dorsal root and nodose ganglia (Boldogkoi et 
al., 2002; Ruan et al., 2004). In contrast, within lumbar DRG of the adult rodent, 
P2X3 protein and mRNA are localised to a sub-population of IB4-positive, small- 
diameter neurons. Additional P2X3 expression is also observed within a sub­
population TrkA- and CGRP-positive C- and A-5 fibre nociceptors in more rostral 
DRG. P2X3 expression is also restricted to predominantly small-diameter, IB4- 
positive neurons in the adult trigeminal and nodose ganglia (Vulchanova et al., 1998; 
Bradbury et al., 1998; Ramer et al., 2001; Boldogkoi et al., 2002; Ruan et al., 2004).
Cultured adult mouse DRG neurons showed no significant alteration in the levels of 
P2X3 mRNA expression over time in culture (figures 4.12 A, 4.19 A and 4.27A), 
suggesting that nerve injury does not affect the expression of this gene. However, 
peripheral nerve lesion has been shown to induce P2X3 mRNA and protein
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expression in “spared”, predominantly small-diameter, neurons and decrease P2X3 
mRNA and protein expression in damaged, ATF3-positive, neurons (Eriksson et al., 
1998; Novakovic e t ., 1999; Bradbury et al., 1998; Tsuzuki et al., 2001; Kage et al., 
2002; Gardell et al., 2003). Since dissection and dissociation of DRG for culture 
emulates axotomy, an injury paradigm that damages all DRG neurons, it would be 
anticipated that P2X3 mRNA expression would increase over time in culture. P2X3 
mRNA is unique in the context of this study, in that it is the only mRNA analysed that 
does not markedly change its levels of expression over time in control cultures to 
mirror the changes in gene expression that occur in-vivo following nerve lesion- 
induced neuronal damage. This would suggest that restricted access to target field- 
derived neurotrophic factors is not the major driving force behind the fall in 
expression of P2X3 mRNA in injured DRG neurons in-vivo. Rather, the data tends to 
suggest that lesion-induced production and release of an as yet unidentified 
neuroactive molecule/protein, that is not present in culture, is responsible for the 
injury-induced reduction in P2X3 expression.
Exogenous GDNF and artemin can both ameliorate the reduction in P2X3 expression 
in damaged adult DRG neurons (Bradbury et al., 1998; Wang et al., 2003; Gardell et 
al., 2003) and exogenous GDNF and NGF can induce P2X3 expression in adult DRG 
neurons in the absence of peripheral nerve injury (Ramer et al., 2001). This data raises 
the possibility that an increased availability of these three neurotrophic factors may 
induce the increase in P2X3 expression observed in “spared” neurons following 
peripheral nerve lesion. Curiously, NGF and artemin were unable to promote the 
expression of P2X3 mRNA in adult mouse DRG cultures (figures 4.12 A, 4.19 A and 
4.27 A), a rare example of the in-vivo regulation of gene expression within sensory 
neurons not being mirrored in-vitro. MSP was also ineffective in regulating the 
expression of P2X3 mRNA in cultured adult DRG neurons.
The addition of LIF to adult mouse DRG cultures did not significantly alter the 
expression of P2X3 mRNA, either in the presence or absence of the other three 
neurotrophic factors (figure 4.27A). This novel data strongly suggests that injury 
induced LIF is not responsible for the decrease in P2X3 expression that occurs in 
damaged, ATF3-positive, neurons following peripheral nerve lesion.
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4.4.9. TTX-sensitive sodium channels
Navi.6 mRNA expression levels increased between E l6 and P5 in trigeminal and 
dorsal root ganglia, before dropping to slightly lower levels in the adult. In nodose 
ganglia, Navi.6 mRNA expression peaked at PO and there was a more substantial fall 
in the levels of Navi.6 mRNA between neonatal and adult ages, so that the levels of 
Navi.6 mRNA in the adult ganglia were similar to those at E l6 (figure 4.2A). Navi.6 
is expressed at high levels at the nodes of Ranvier in mature myelinated sensory 
neurons where it is responsible for the high repetitive firing rates, lack of response to 
slow depolarising stimuli and resurgent sodium currents that are characteristic of 
myelinated sensory neurons (Cummins et al., 1998; Cummins et al., 2001; Herzog et 
al., 2003a; Cummins et al., 2005).Therefore, it is not surprising that Navi.6 was 
expressed at high levels in adult neural-crest derived sensory ganglia and that its 
expression pattern is in accordance with the functional development of myelinated 
sensory neurons. Navi.6 is also expressed at low levels in a uniform distribution 
along the axons of C-fibre non-myelinated sensory neurons (Black et al., 2002). The 
significantly lower levels of Navi.6 mRNA in nodose ganglia compared to trigeminal 
and dorsal root ganglia may reflect a greater number of nociceptive {unmyelinated) C- 
fibres and a smaller number of low threshold, A-p fibre mechanoreceptors in this 
ganglion compared to neural-crest derived sensory ganglia.
Navi. 7 is found in both large and small sensory neurons of the developing rodent 
DRG, whereas Navi.7 expression is predominantly localised to small-diameter, 
nociceptive sensory neurons in the adult DRG (Felts et al., 1997; Black et al., 1996; 
Gould et al., 2000; Djouhri et al., 2003). The increasingly restricted expression of 
Navi.7 is reflected in the developmental expression pattern of its mRNA (figure 
4.2B). Decreasing levels of Navi.7 mRNA were observed in all three ganglia as 
development proceeds, with expression levels in the adult approximately 50% of 
those at E l6.
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The levels of both TTX-sensitive sodium channel mRNAs expressed within adult 
mouse DRG neurons fell significantly over 96 hours in culture, with the drop being 5 
fold in most sets of cultures (figures 4.12A and B, 4.19B, 4.20A, 4.27B and 4.28 A). 
The levels of Navi.6 and Navi.7 mRNAs expressed by adult L5 DRG neurons also 
falls following L5 spinal nerve ligation (Kim et al., 2002). Interestingly, the drop in 
both TTX-sensitive mRNAs was restricted to damaged neurons, as “spared” L4 DRG 
neurons showed no alteration in their expression of either mRNA (Kim et al., 2002). 
Therefore, my results, showing a fall in the levels of Navi.6 and Navi. 7 mRNAs in 
“axotomised” cultured DRG neurons, agree with the previously published literature.
NGF, artemin and MSP were all ineffective at reproducibly attenuating the culture- 
induced decrease in Navi.6 and Navi.7 mRNA expression within DRG neurons in a 
statistically significant manner. Receptors for NGF and artemin are not expressed on 
the majority of myelinated neurons that show the highest levels of Navi.6 mRNA 
expression in-vivo (Cummins et al., 1998; Averill et al., 1995; Molliver et al., 1997; 
Michael and Priestley, 1999; Orozco et al., 2001; Cummins et al., 2001 Black et al., 
2002). If this in-vivo expression of TrkA, GFR-a3 and Navi.6 mRNAs is reflected in 
cultured DRG neurons, it would not be surprising that NGF and artemin were unable 
to regulate the in-vitro expression of Navi.6 mRNA in a statistically significant way. 
Infact, the medium- to large-diameter myelinated neurons expressing high levels of 
Navi.6 mRNA would be expected to respond to BDNF, NT-3, and to a certain extent 
GDNF, in culture, due to the neurotrophic factor receptors co-expressed on this 
subpopulation of neurons (Karchewski et al., 1999; Kashiba et al., 2003; Kashiba et 
al., 1998; Bennett et al., 2000). It is therefore possible that a reduced access to central 
and/or peripheral target field-derived BDNF, NT-3 and GDNF is the driving force 
behind the inury- and culture-induced decrease in Navi.6 mRNA expression. 
Accordingly, the addition of these neurotrophic factors to cultures may ameliorate the 
decrease in Navi.6 mRNA expression observed over time.
To date, no published data has emerged that describes the neurotrophic factor 
regulation of Navi. 6 mRNA or protein. In contrast, several publications have failed to 
demonstrate that NGF regulates Navi.7 expression in sensory neurons. For example, 
transgenic mice over-expressing NGF specifically in the peripheral target fields of
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DRG neurons do not show increased expression of Navi.7 mRNA (Fjell et al.,
1999b). Moreover, TTX-sensitive currents do not decrease in TrkA expressing 
nociceptive neurons (in which Navi.7 is the main TTX-sensitive sodium channel in 
the non-lesioned rodent) in animals that have reduced levels of target field NGF as a 
result of immunization-induced anti-NGF antibody production (Fjell et al., 1999 (b)).
The addition of LIF to cultured adult mouse DRG neurons did not significantly alter 
the levels of Navi.6 and Navi.7 mRNA compared to control cultures (figures 4.27B 
and 4.28A). However, LIF was able to reduce the expression of Navi.6 and Navi.7 
mRNAs in cultures containing MSP and NGF (although this only reached statistical 
significance in the case of Navi.6 mRNA and MSP and Navi.7 mRNA and NGF). 
This data raises the possibility that LIF may be at least partly responsible for the nerve 
injury- and culture-induced drop in the expression of these two sodium channel 
mRNAs in small-diameter DRG neurons expressing functional LIF receptors. The 
limited ability of exogenous LIF to reduce sodium channel mRNA expression raises 
the possibility that the expression of both mRNAs are almost maximally depressed by 
the low amounts of LIF released into the culture medium by Schwann cells 
contaminating DRG cultures.
Although the data presented in figures 4.27B and 4.28A suggest that LIF may play a 
role in orchestrating the culture- and injury-induced down-regulation of Navi.6 and 
Navi.7 mRNAs, the minimal efficacy of LIF raises the possibility that other 
mechanisms also act to decrease the expression of these mRNAs following neuronal 
damage. The inability of NGF, artemin and MSP to promote the expression of 
Navi.6 and Navi.7 mRNAs suggests that reduced access to peripheral target field- 
derived neurotrophic factors is not the primary reason behind the culture-induced 
down-regulation of TTX-sensitive sodium channel mRNA. This is especially true of 
Navi.7 mRNA, since a large percentage of Navi.7 mRNA-positive cells express 
receptors for NGF and artemin (and probably MSP, according to the data in this 
chapter), yet these neurotrophic factors are ineffective in maintaining Navi.7 mRNA 
expression. In-vivo experiments have demonstrated that Navi.7 plays a role in setting 
normal nociceptive thresholds to noxious mechanical stimuli. More importantly,
Navi. 7 is implicated in the generation of inflammatory mechanical and thermal 
hyperalgesia (Nassar et al., 2004 and 2005; Black et al., 2004; Yeomans et al., 2005).
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Therefore, determining the factors that regulate Navi.7 mRNA expression, both 
following nerve lesion and in inflammatory conditions, is important and warrants 
further research.
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4.5. Results in Brief
In chapter 4, the neurotrophic factor regulation of genes of interest in the adult mouse 
was studied using neuronal DRG cultures. The key results can be summarised as 
below:
a- and p-CGRP:
• Expression of both a- and p-CGRP mRNAs decreased over time in culture, 
reflecting effects observed in situations of nerve damage and axotomy.
• NGF, artemin and MSP were all able to significantly attenuate this culture- 
induced decrease in mRNA expression.
• Effects of NGF and artemin were additive, and may reflect culture induced 
alterations in receptors for NGF and artemin. A culture-induced decrease in 
TrkA mRNA has been observed and is accompanied by a similar increase in 
the levels of GFR-a3 mRNA (S Wyatt unpublished observation -  data not 
shown). The net result of these changes in receptor gene expression is likely to 
be a decrease in the proportion of DRG neurons expressing either both TrkA 
and GFR-a 3 together, or expressing TrkA alone. An increase in the number 
of neurons expressing GFR-a 3 in the absence of TrkA might also be 
anticipated. The partially additive effects of NGF and artemin in this 
experiment might be as a result of such changes.
• The addition of LEF to cultures had markedly different effects on a- and p- 
CGRP:
o LIF had no effect on the culture-induced down regulation of a-CGRP 
or its regulation by NGF, artemin or MSP. 
o Addition of LIF significantly reduced the expression of p-CGRP 
mRNA compared to control cultures. Moreover it significantly 
inhibited the ability of MSP artemin and NGF to reduce the culture- 
induced decrease in mRNA expression.
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SP:
• Expression of SP mRNA decreased over time in culture reflecting the injury- 
induced decrease observed previously in models of nerve injury.
• The presence of NGF, MSP or artemin significantly attenuated the culture- 
induced decease in SP.
• Additive effects of NGF and artemin were observed and are likely to reflect 
the alterations in receptor expression in such culture situations (as mentioned 
above).
• Addition of LIF alone had no effect on the culture-induced down regulation of 
SP mRNA, however it did significantly attenuate the positive effects of NGF, 
artemin and MSP
VR1:
• Expression of VR1 mRNA decreased over time in culture.
• The addition of NGF could partially prevent this decrease, and interestingly, 
both artemin and MSP could also significantly attenuate this decrease.
• No additive effects of any of the three factors was observed suggesting that 
those adult DRG neurons that express VR1 mRNA in culture, also express 
receptors for all three neurotrophic factors.
• Effects of LIF were very similar to those effects on SP. LIF alone had no 
effect on the culture induced down-regulation of VR1 mRNA, however it 
could attenuate the ability of NGF, artemin and MSP to promote VR1 mRNA 
expression.
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Nav1.8 and Nav1.9:
• A culture induced drop in both Navi .8 and Navi .9 mRNA expression was 
observed, mirroring the effects observed in peripheral nerve injury.
• NGF, artemin and MSP could all partially inhibit this downregulation, 
however levels were not returned to those at time 0.
• Additive effects of NGF and artemin were observed suggesting that there is a 
small proportion of TTX-R expressing neurons that express either TrkA in the 
absence of GFRa3 or GFRa3 in the absence of TrkA.
• LIF alone has no effect on the culture-induced downregulation of either TTX- 
R sodium channel, however it did appear to reduce the ability of NGF, artemin 
and MSP to promote the expression of Navi.8 and Navi.9.
Galanin:
• Galanin mRNA expression increased over time in culture in accordance with 
previous studies.
• This up-regulation was inhibited by the presence of NGF, artemin and/or 
MSP.
• Additive effects of MSP and artemin were observed suggesting a population 
of galanin expressing neurons express either RON or GFRa3, but not both.
• The presence of LIF significantly enhanced the culture-induced up-regulation 
of galanin mRNA as well as inhibiting the ability of NGF, artemin and MSP to 
attenuate its expression. This might suggest that the increase in LIF observed
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at sites of nerve injury may promote the subsequent alterations in gene 
expression that occur as a consequence of nerve damage.
PACAP:
• PACAP mRNA expression increased over 96 hours in culture.
• NGF could inhibit this upregulation, however the effect was small and not 
significant in all cultures. Effects of MSP and artemin were also apparent, but 
never reached statistical significance. These results reflect the idea that the 
upregulation in PACAP mRNA observed occurs predominantly in, TrkC 
expressing, medium to large diameter myelinated neurons that are not 
responsive to NGF.
• The additive effect of MSP and artemin observed suggests that most 
nociceptive DRG neurons expressing PACAP mRNA express either GFRa3 
or RON, but not both.
• Interestingly the presence of LIF appears to reverse the culture-induced 
upregulation in PACAP mRNA, and moreover enhances the limited ability of 
artemin and MSP (but not NGF) to attenuate the culture-induced upregulation 
of PACAP mRNA. This conflicts most of the previous data in which LIF 
appears to enhance the culture induced changes in gene expression.
ATF3 and DINE:
• Expression of both ATF3 and DINE mRNAs was markedly up-regulated over 
time in culture.
• NGF, artemin and MSP were all able to inhibit the culture-induced up­
regulation in ATF3 mRNA, and also to some extent DINE mRNA (although 
results were not always significant for NGF).
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• Artemin was consistently the most effective of the neurotrophic factors in 
reducing expression of both DINE and ATF3 mRNAs. This might be a 
reflection of the alteration in GFRa3 and TrkA receptors that occurs over time 
in culture (as mentioned previously).
• LIF had no effect on ATF3 mRNA expression, however its presence partially 
prevented the culture-induced up-regulation of DINE mRNA observed in 
control cultures. Furthermore LIF appeared to enhance effects of artemin,
NGF and MSP in attenuating the culture induced up-regulation in DINE 
mRNA.
P2X3:
• No alteration in P2X3 mRNA was observed over time in culture.
• NGF, artemin and MSP did not appear to regulate expression of P2X3 mRNA, 
and the addition of LIF also had no notable effects.
Nav1.6 and Nav1.7:
• Expression of both of these TTX-S sodium channels decreased over time in 
culture.
• No regulatory effects were observed for NGF, artemin or MSP.
• The presence of LIF alone had no effect on expression of Navi .6 or Navi .7 
mRNAs, however in cultures containing MSP or NGF, the addition of LEF was 
able to reduce the expression of Navi.6 and Navi.7 mRNAs further. This 
result might suggest that the increase in LIF following nerve injury is partially
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responsible for the associated alterations in the expression of these sodium 
channels.
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Chapter 5
General Discussion
In the aims and objectives of this thesis I outlined the main objective of this project, - 
to gain an insight and expand knowledge of the regulation and patterns of expression 
of particular genes, which are required for a number of key functional properties of 
subsets of sensory neurons.
In this thesis I have indeed gained much knowledge of the neurotrophic factor 
regulation of such genes. I have identified the differences in expression of the selected 
genes at different ages, in different ganglia and in different subpopulations of sensory 
neurons. I have used both in vitro and in vivo methods and as well as enhancing and 
expanding upon previous research, I have in some cases found conflicting results.
This is hardly surprising however, considering the number of variables involved -  
time, age, species and experimental approach to name just a few.
In chapter 3 of this thesis both in vivo and in vitro experiments were used, and on 
occasion, produced differing results. Likewise the in vitro cultures used in chapter 4, 
occasionally produced findings which conflicted with those from other published 
work in which in vivo approaches were utilised. This, however, is to be anticipated 
due to the different objectives underlying the two types of experiment. In vitro 
experiments tend to focus on organs, tissues, cells etc rather than the whole organism 
and are best suited at deducing the mechanism of action of a particular molecule. In in 
vitro experiments there are fewer variables, and reactions/effects are amplified 
making results more apparent. In contrast, experiments in vivo allow the observation 
of effects of an experiment on its living subject. As such, results from these two types 
of experiment can often be strikingly different, and should therefore be interpreted 
and compared with caution.
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Key Findings
Two of the key main outcomes of this thesis were the discovery of the difference in 
regulation of a  and p CGRP mRNAs, and the finding that MSP can regulate gene 
expression in the adult mouse.
a  and p CGRP share high sequence homology, differing by just one amino acid in the 
rat (and three in the mouse). They are however the products of separate genes and 
show different expression profiles, and as such functionally distinct roles, and 
regulation might therefore be anticipated. Despite this, very few studies have 
discriminated between the two isoforms of CGRP, mainly due to experimental 
difficulties in trying to individually detect such highly homologous molecules.
Real time Q-PCR has enabled me to accurately detect the expression of both isoforms 
and interestingly my results do indeed show that although regulation may be similar 
in some circumstances, in other situations contrasting patterns of regulation are 
apparent.
In the embryonic mouse, results show that the a  isoform of CGRP requires TrkA 
signalling for initial induction of expression within DRG, however p-CGRP shows no 
such requirement. By birth, NGF/TrkA signalling does seem to be important for the 
expression of both isoforms, since TrkA^'/Bax7' neonates showed a significant loss of 
a- and p~ CGRP mRNAs in both trigeminal ganglia and DRG compared to Bax7' 
neonates. NGF/TrkA signalling also appeared to be required for full expression of 
both a- and p-CGRP mRNAs by nodose neurons.
In the adult mouse mRNAs of both isoforms were down-regulated, over time in 
culture and both could be positively regulated by the addition of NGF, MSP or 
artemin. Interestingly however LIF affected the expression of a  and p CGRP in 
markedly different ways. LIF had no effect on the expression of a-CGRP mRNA, 
however its presence significantly reduced the expression of P-CGRP mRNA in
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comparison to control cultures. Furthermore it inhibited effects of NGF, MSP and 
artemin, which all act to attenuate the culture induced decrease in P-CGRP
A second key finding of this thesis was the demonstration that MSP can regulate the 
expression of a number of functionally important sensory neuron mRNAs (a-CGRP, 
p-CGRP, SP, Navi.8, Navi.9, VR1, PACAP, galanin, DINE, ATF3) as outlined in 
chapter 4. This is an entirely novel result. To date effects of this factor on gene 
regulation has only been addressed in the embryonic mouse. This is of particular 
importance, since changes in the expression of the genes under test, that occur during 
inflammation and following nerve trauma, may be causally related to pathological 
pain conditions. A role for MSP and the onset of such pain states is thus indicated.
Further Research
Obviously, had time and cost not been a factor, the thesis could have been expanded 
further, with additional experiments to confirm or disprove many of the theories put 
forward throughout this study.
Experiments using temporally and spatially controlled knockouts of neurotrophic 
factors receptors would be useful as would avoid the pitfalls of aberrant 
differentiation and/or target field innervation affecting the results. However such 
experiments are costly and time-consuming and some strains of mice that would be 
useful do not yet exist.
Immuno-histochemical study of sensory ganglia from TrkA'7'/Bax'7' and NT-3'7'/B ax'7' 
alongside those from temporally controlled TrkA'7' and NT-3'7' would also prove 
useful to determine the subpopulations of neurons within such mice and how the loss 
of TrkA or NT-3 from birth affects the subpopulations of neurons in the sensory 
ganglia.
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In vivo approaches involving injection of neurotrophic blocking reagents or 
neurotrophic factors would allow the study of effects of decreasing/increasing target 
field-derived neurotrophic factors on transcriptional regulation of the genes under test.
With the use of double null mutant adult mice I could explore in vivo effects in the 
adult, however this would be time consuming and costly and result in unnecessary 
animal wastage.
In summing up, this thesis provides further background to the role of neurotrophic 
factors within sensory neurons at different stages of development, providing insight 
into the regulation of some particularly important genes within different populations 
of sensory neurons of the mouse. Since many of the genes studied have roles both in 
determining normal nociceptive thresholds, and in the generation of inflammatory 
and neuropathic pain conditions, a through understanding of their expression and 
regulation is of importance for the therapeutic advancement of research in these 
fields.
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Appendix I
Abbreviations
AC Adenyl Cyclase
Ach Acetylcholine
AChR Acetylcholine receptor
AD Alzheimer’s disease
AM Adrenomedullin
AMY Amylin
ART Artemin
ASO Antisense oligonucleotide
ATF3 Activating transcription factor 3
ATP Adenosine triphosphate
BDNF Brain derived neurotrophic factor
bFGF basic fibroblast growth factor
CaP Prostate cancer
CFA Complete Freud’s Adjuvant
CGRP Calcitonin Gene Related Peptide
ChAT Choline acetyltransferase
CH Cyclohexamide
CHO cells Chinese hamster ovarian cells
CLC Cardiotrophin-like cytokine
CMF-HBSS Calcium and Magnesium Free Hank’s Balanced Salt Solution
CNS Central Nervous System
CNTF Ciliary neurotrophic factor
COX Cyclooxygenase
CT Calcitonin
CT-1 Cardiotrophin-1
DEPC di-ethyl-pyrocarbonate
DINE Damage-induced neuronal endopeptidase
dNTPS Deoxynucleotide triphosphate
DOPA Dihydroxyphenylalanine
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DRG Dichlorobenzimidazole riboside
DRG Dorsal root ganglion
ds Double Stranded
ECE Endothelin-converting enzyme
EDNRB Endothelin receptor B
EGF Epidermal growth factor
ERK Expression-signal related kinase
EST Expression sequence tag
ET-3 Endothelin-3
F12 Ham’s nutrient mixture F I2
F14 Ham’s nutrient mixture F14
IFNy Interferon-y
IR Immunoreactivity
JNK c-jun N-terminal kinase
GAPDH Glyceraldehyde phosphate dehyrogenase
GDNF Glial cell line derived neurotrophic factor
GFLs GDNF family ligands
GFRa GDNF family receptor a
GMAP Galanin Message-Associated Peptide
gpl30 glycoprotein 130
GPI gycosyl-phosphatidylinositol
HBSS Hanks balanced salt solution
HGF Hepatocyte growth factor
HIHS Heat-inactivated horse serum
EB4 Isolectin B4
IL-6 Interleukin-6
IP Inositol Phosphate
JNK c-Jun N-terminal kinases
kDA Kilo dalton
L-15 Liebowitz-15 medium
LA Local Anaesthetic
LC Locus Coeruleus
LIF Leukaemia inhibitory factor
LTP Long term potentiation
MAPK Mitogen-activated protein kinase
MCAO Middle cerebral artery occlusion
MPTP 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine
mRNA messenger ribonucleic acid
MS Multiple sclerosis
MSP Macrophage stimulating protein
NCAM Neural cell adhesion molecule
NEP Neural endopeptidase
NGF Nerve growth factor
NKA Neurokinin A
NKB Neurokinin B
NRIF Neurotrophin receptor interacting factor
NTN Neurturin
NTF Neurotrophic factor
NT-3 Neurotrophin-3
OE Over-expressing
OsM Oncostatin M
6-OHDA 6-hydroxydopamine
PACAP Pituitary adenylate cyclase-activating peptide
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PEPCK Phosphoenolpyruvate carboxy-kinase
p g e 2 Prostaglandin E2
PHN Post-herpetic neuralgia
PI3-K Phosphatidylinositol 3-kinase
PLC Phospholipase C
PNS Peripheral nervous system
PPT Preprotachykinin
PSP Persephin
PTB Phosphotyrosine binding domain
RH Random hexanucleotides
RT Reverse transcription
SCG Superior cervical ganglion
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SCN Suprachiasmatic nucleus
SE Status Epilepticus
SG SYBR Green
SNc Substantia nigra pars compacta
SNL Spinal nerve ligation
SP Substance P
SH2 Src homology domain-2
TAE Tris-acetate-EDT A
Taq Thermus aquaticus
TG Trigeminal
TH Tyrosine Hydroxylase
TTX Tetrodotoxin
TNF Tumour necrosis factor
Trk Tropomyosin-related kinase
TRP Transient receptor potential
VGSC Voltage gated sodium channel
VRC Vanadyl-ribonucleoside complex
VR1 Vanilloid Receptor 1
VRL Vanilloid Receptor-like
Appendix II
Tissue culture reagents and media
Liebowitz-15 (L-15) (Dissecting Medium):
Stored at 4°C and made up every 3-4 weeks
1 pot of LI 5 powder (GIBCO, Invitrogen), 60mg penicillin (Sigma) and lOOmg 
streptomycin (sigma) were dissolved in 1 litre deionised, distilled water. The pH was 
adjusted to 7.3 using HC1 and NaOH and the media sterilised by filtering through a 
0.22pm bell filter (PALL) in a laminar flow hood.
Ham’s F12:
Stored at 4°C. After addition of HIHS should be kept for approx. 2 weeks
1 pot of LI 5 powder (GIBCO, Invitrogen), 60mg penicillin (Sigma) and lOOmg 
streptomycin (sigma) were dissolved in 1 litre de-ionised, distilled water. The pH was 
adjusted to 7.3 using HC1 and NaOH and the media sterilised by filtering through a 
0.22pm bell filter in a laminar flow hood. For serum-supplemented media, 10% Heat 
inactivated horse serum (HIHS) was filtered in using a 50ml syringe and 0.22pm bell 
filter.
Ham’s F14 (Final Growing Medium):
Stored at 4°C and made up fortnightly
lOx stock was made up by dissolving a 51 unit of F-14 powder (Imperial) in 500ml of 
de-ionised, distilled water containing 500mg streptomycin (Sigma) and 300mg 
penicillin (Sigma). This lOx stock was stored as 25ml aliquots at -20°C until use. 
lx F14 solution was made by diluting an aliquot of F14 (25ml) in 225ml de-ionised 
distilled dH20. 0.5g sodium hydrogen carbonate was added and pH adjusted to 7 by 
bubbling through CO2 . The media was filter sterilised by passing through a 0.22pm
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bell filter. Whilst filtering, 2.5ml L-glutamine, 200mM (GIBCO, invitrogen) and 
5.5ml Albumax I solution (see below) was added.
Albumax I solution:
Stored at -20°C
20g/ml albumax I (GIBCO, invitrogen) was dissolved in 100ml dH20 and added to 
the solution below:
100ml dH20  
160mg putrescine
lml progesterone (0.625mg/ml in ethanol)
10ml L-thyroxine (0.4mg/ml in ethanol)
10ml sodium selenite (0.4mg/ml in PBS)
10ml tri-iodothyronine (0.34mg/ml in ethanol)
Laminin:
Murine Laminin (Sigma) was defrosted at 4°C and diluted in CMF-HBSS (Calcium 
and Magnesium free Hank’s Balanced Salt Solution), GIBCO, Invitrogen to a 
concentration of 20pg/ml. 120pl of laminin was then pipetted into the centre of each 
35mm dish and spread out using a pipette tip ensuring not to touch the sides of the 
dish. Laminined dishes were incubated at 37°C for a minimum of 4 hours before 
washing twice with F I2 + HIHS and then adding lml final medium.
Polv-DL-ornithine:
Stored at 4°C and made up fortnightly
0.5mg/ml poly-DL-omithine (Sigma) was prepared by dissolving**** in 0.15M 
borate buffer (4.6g boric acid (BDH) in 500ml de-ionised, distilled water, pH 8.4). 
The solution was sterilised by passing through 0.22pm bell filter.
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Trypsin:
1% stock solution was made by dissolving 50mg trypsin (Worthington) was added to 
5ml CMF-HBSS) and sterilised with 0.22pm filter (Nalgene). lOOpl aliquots were 
stored at -20°C until use.
0.05% working solution was made by diluting a 50pl aliquot in 950pl CMF-HBSS. 
Ganglia were incubated at 37°C in this solution to allow trypsinisation. Time varied 
according to age and type of ganglia.
Collaqenase
lOOmg/ml stock solution was made up by dissolving lOOmg in lml of HBSS 
supplemented with Calcium (0.097mg/ml) and Mg (0.185mg/ml). 20pl aliquots were 
stored at -20°C until use.
2mg/ml working solution was made by diluting a 20pl aliquot in 980pl HBSS. Adult 
ganglia were incubated in this solution prior to trypsinisation.
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Appendix III 
Real Time PCR
Reverse Transcription Mastermix:
REAGENT VOLUME MANUFACTURER
Buffer 4pl Stratagene
Random Hexanucleotides 2pl Pharmacia
dNTPS 2pl Stratagene
Stratascript Enzyme 0.38pl Stratagene
dH20 26.6pl GIBCO, Invitrogen
Added to 5 pi RNA
PCR Mastermix:
REAGENT VOLUME MANUFACTURER
lOx buffer 2.5pl Stratagene
MgCl2 1.5, 2 or 2.5pl to give final concn. of 
3, 4 or 5mM resp.
Stratagene
dNTPs (20mM) lpl Stratagene
Rox (1/500) 0.4pl Stratagene
Primers 0.5 pi MWG
Syber Green (1/4000) 0.25pl Molecular Probes
dH20 15.8, 15.3, 14.8pl to give final concn. 
of 3, 4 or 5mM resp.
GIBCO, Invitrogen
Added to 2.5pi cDNA
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